VASOPRESSIN V1A ANTAGONISTS

Abstract
The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
Description
FIELD OF THE INVENTION

The present invention relates to compounds with vasopressin V1a antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin V1a antagonists for the treatment of certain physiological disorders, such as Raynaud's disease and dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea).


BACKGROUND

The neurophyseal hormones vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides secreted by the posterior pituitary gland.


Only one OT receptor has so far been well characterised, while three VP receptors are known. These are designated the V1a, V1b and V2 receptors.


Vasopressin acts on the blood vessels, where it is a potent vasoconstrictor, and on the kidneys, where it promotes water reuptake leading to an antidiuretic effect.


The V1a, V1b, and V2, as well as the OT receptors, are members of the super-family of seven transmembrane receptors known as G-protein coupled receptors. The V1a receptor mediates phospholipase C activation and intracellular calcium mobilisation. Localisation of the receptors includes blood platelets, blood vessels, hepatocytes, brain and uterus-cervix. Thus a V1a antagonist may have effects on any or all of these tissues. For example, selective V1a antagonists have been cited as having clinical utility in dysmenorrhoea, pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.


With respect to dysmenorrhoea it has been proposed that myometrial activity is markedly increased in women with dysmenorrhoea during menstruation. It is proposed that the myometrial ischemia caused by increased uterine contractility might explain the menstrual pain. Furthermore, on the first day of menstruation, higher plasma concentrations of vasopressin have been measured in dysmenorroeic women than in controls.


In healthy women without dysmenorrhoea, intravenous infusion of lysine-vasopressin resulted in decreased uterine blood flow, increased uterine contractility and slight to moderate dysmenorrhoea-like pain, these effects being inhibited by a selective human V1a receptor antagonist. (Bossmar, T. et al., BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY (1997 April), 104(4), 471-7). Also, it is known that vasopressin contracts human uterine arteries in a dose-dependent and V1a-mediated fashion.


The above evidence suggests that a V1a antagonist would be an appropriate and effective treatment for dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea). Further evidence is taken from the clinical study carried out on the selective V1a antagonist SR49059 (“Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhea”. Brouard, R. et al., BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2000), 107(5), 614-619). It was found that there was a dose-related decrease in pain and a dose-related decrease in the amount of additional pain-killer taken compared to patients taking placebo.


The International Patent Application WO 03/016316 A1, published 27 Feb. 2003, discloses a number of compounds which are claimed to be oxytocin agonists and to find use in the treatment of male erectile dysfunction. No V1a antagonist activity is reported. The European Patent Application EP 1 449 844 A1, published 25 Aug. 2004, discloses a number of compounds which are claimed to be V1a antagonists and to find use in the treatment of primary dysmenorrhoea.


There exists a need for treatments for conditions which are associated with the V1a receptors. There further continues to exist a need for alternative V1a antagonists. Simple synthesis and oral availability are additional desirable characteristics.


DISCLOSURE OF THE INVENTION

According to an aspect, the present invention relates to compounds, preferably VP antagonists, and in particular specific antagonists of the V1a receptor, and pharmaceutically acceptable salts thereof.


According to another aspect, the present invention relates to pharmaceutical compositions comprising these compounds, which compositions are useful for the treatment of, inter alia, dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea).


According to another aspect, the present invention relates to the use of the compounds for the manufacture of a pharmaceutical composition for treatment of dysmenorrhoea.


According to further aspects, the present invention relates to the medical use and to the use of the above mentioned compounds and compositions in therapy and to therapeutic methods wherein the above mentioned compounds and compositions are used.







DETAILED DESCRIPTION OF THE INVENTION

According to an aspect the invention concerns a compound according to general formula 1a, or a compound which is a tautomer or a pharmaceutically acceptable salt thereof,




embedded image


wherein G is a group selected among general formula 2a, 3a, 4a, 5a, and 6a,




embedded image


wherein:


A1 is selected among CH2, CH(OH), NH, N-alkyl, O and S;


A2 is selected among CH2, CH(OH), C(═O) and NH;


A3 and A12 are independently selected among S, NH, N-alkyl, —C(R8)═CH—, —C(R8)═N—, —N═C(R8)— and —CH═C(R8)—;


A4 and A13 are independently selected among C(R9) and N;


A5 and A14 are independently selected among C(R10) and N;


A6 is selected among CH2, NH, N-alkyl and O;


A7 and A11 are independently selected among C and N;


A8 and A9 are independently selected among CH, N, NH, N(CH2)bR11 and S;


A10 is selected among —CH═CH—, CH, N, NH, N—(CH2)b—R11 and S;


wherein the ring constituted by A7, A8, A9, A10 and A11 is aromatic;


R1, R2 and R3 are independently selected among H, alkyl, O-alkyl, NO2, F, Cl and Br;


R4 is selected among H, alkyl, aryl, heteroaryl, —(CH2)c—R12, and




embedded image


R5 and R6 are independently selected among alkyl, aryl, —(CH2)f-aryl, and —(CH2)f-heteroaryl;


R7 is selected among H, alkyl, aryl, heteroaryl, and —(CH2)g—R14;


R8, R9 and R10 are independently selected among H, alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl), N(alkyl)2; with the provisos that when G is 3a, and R4 is H, alkyl, aryl, heteroaryl or —(CH2)c—R12, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N(alkyl)2; and


when G is 4a, R4 is H, alkyl, aryl, heteroaryl or —(CH2)c—R12, and A8 is NH, NCH3 or S, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N(alkyl)2;


R11 and R12 are independently selected among H, alkyl, aryl, heteroaryl, F, OH, O-alkyl, S-alkyl, O-acyl, NH2, NH-alkyl, N (alkyl)2 NH-acyl, N (alkyl)-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2, CN and CF3;


R13 is selected among H, alkyl, aryl, heteroaryl, —(CH2)h—R15 and Z—R16;


R14 and R15 are independently selected among H, alkyl, alkenyl, aryl, heteroaryl, F, OH, O-alkyl, S-alkyl, O-acyl, NH2, NH-alkyl, N(alkyl)2, NH-acyl, N(alkyl)-acyl, CO2H, CO2-alkyl, CO-alkyl, CO-aryl, CONH2, CONH-alkyl, CON(alkyl)2, alkenyl-CO2-alkyl, alkenyl-aryl, CN and CF3;


R16 is selected among H, alkyl, alkenyl, aryl, heteroaryl, O-aryl, —(CH2)i—R17, cyclopropyl-aryl and O—(CH2)i—R17;


R17 is selected among H, alkyl, aryl, heteroaryl, F, OH, O-alkyl, S-alkyl, O-acyl, NH2, NH-alkyl, N(alkyl)2, NH-acyl, N(alkyl)-acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON(alkyl)2 CN and CF3;


W is selected among O and NH;


X is selected among (CH2)m, C(═O) and S(═O)j

Y is selected among O, S, NH and N-alkyl;


Z is selected among —C(═O), —C(═O)—O and —S(═O)k;


a is selected among 1 and 2;


b and c are independently selected among 0, 1, 2 and 3;


d, e and f are independently selected among 1 and 2;


g, h and i are independently selected among 1, 2 and 3;


j and k are independently selected among 1 and 2; and


m and n are independently selected among 0, 1 and 2.


According to an aspect, R16 may further be selected among O-alkyl and O-alkenyl, and Z is different from —C(═O)—O.


It appears that the compounds of formula 1a of claim 1 are subject to the following constraints. When G is 3a, and R4 is H, alkyl, aryl, heteroaryl or —(CH2)c—R12, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N(alkyl)2. When G is 4a, R4 is H, alkyl, aryl, heteroaryl or —(CH2)c—R12, and A8 is NH, NCH3 or S. then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N(alkyl)2. The ring constituted by A7, A8, A9, A10 and A11 is aromatic, and accordingly the groups must satisfy certain requirements. When A10 is —CH═CH— the ring is a six membered ring. As such, it can only comprise atoms of the type —C(R)═ and —N═. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not —CH═CH— then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a “trigonal nitrogen” is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when A10 is not —CH═CH— then one (and only one) of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not —CH═CH— then one of A8, A9 and A10 is NH, N—(CH2)b-R11 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N—(CH2)b-R11 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N—(CH2)b-R11 or S.


According to aspects of the invention, additional and preferred embodiments of the invention are as set out below, in the description and the claims.


The term “alkyl” includes saturated hydrocarbon residues including:

    • linear groups up to 10 atoms (C1-C10). Examples of such alkyl groups include, but are not limited to, C1—methyl, C2—ethyl, C3—propyl and C4—n-butyl;
    • branched groups of between 3 and 10 atoms (C3-C10). Examples of such alkyl groups include, but are not limited to, C3—iso-propyl, C4—sec-butyl, C4—iso-butyl, C4—tert-butyl and C5—neo-pentyl;
    • cyclic groups of between 3 and 8 atoms (C3-C8). Examples of such groups include but are not limited to, C3—cyclopropyl, C4—cyclobutyl, C5—cyclopentyl and C6—cyclohexyl;
    • combinations of linear, branched and cyclic groups. Examples of such groups include, but are not limited to,




embedded image


The term “alkoxy” is used to denote O-alkyl groups.


The term “alkenyl” includes monounsaturated hydrocarbon residues including

    • linear groups of between two and six atoms (C2-C6). Examples of such alkenyl groups include, but are not limited to, C2—vinyl, C3—1-propenyl, C3—allyl and C4—2-butenyl;
    • branched groups of between 3 and 8 atoms (C3-C8). Examples of such alkenyl groups include, but are not limited to, C4—2-methyl-2-propenyl and C6—2,3-dimethyl-2-butenyl;
    • cyclic groups of between 3 and 8 atoms (C3-C8). Examples of such groups include, but are not limited to, C5—3-cyclopentenyl and C6—1-cyclohexenyl.


The term “aryl” includes optionally substituted phenyl and optionally substituted naphthyl. Examples of such aryl groups include, but are not limited to, phenyl, 2-tolyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,5-difluorophenyl, 1-naphthyl and 2-naphthyl.


The term “heteroaryl” includes optionally substituted heterocycles. Such heteroaryl groups include, but are not limited to, pyridyl, 2-chloropyridyl, 4-methylpyridyl, thienyl, 3-chlorothienyl, 2,3-dimethylthiophenyl, furyl, 2-methylfuryl, pyrrole, N-methylpyrrole, oxazole, imidazole, pyrazole and triazole.


The term “acyl” denotes a group R—C(═O), where R is H, a saturated or unsaturated hydrocarbon moiety of up to seven carbon atoms or an optionally substituted phenyl, optionally substituted pyridyl or optionally substituted thienyl group. Examples of acyl groups include, but are not limited to: formyl, acetyl, pivaloyl, benzoyl and nicotinoyl.


Certain compounds of the present invention are capable of forming salts with acids or bases. For example, compounds containing one or more basic nitrogen atoms can form addition salts with mineral and organic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, methanesulphonic acid, citric acid and benzoic acid. Compounds containing acidic groups can form salts with bases. Examples of such salts include the sodium, potassium, calcium, triethylammonium and tetraethylammonium salts. Furthermore, compounds that have both acidic and basic groups can form internal salts (zwitterions). Insofar as these salts are pharmaceutically acceptable, they are included within the scope of the invention.


Certain compounds within the scope of the present invention may exist as tautomers. For example, where G1 is general formula 4a (4b, 4c, 4d) and X2 is NH the resulting imidazole can exist as its tautomer which is defined by G1 as general formula 5a (5b, 5c, 5d) and X2 as NH. All such tautomers are considered to be within the scope of the present invention.


The compounds according to the present invention may have one or more stereogenic centres (“asymmetric carbon atoms”) and so may exhibit optical isomerism. The scope of the present invention includes all epimers, enantiomers and diastereomers of compounds according to the present invention, including single isomers, mixtures and racemates.


According to an aspect, it is preferred that G is selected among:




embedded image


According to an aspect, it is further preferred that G is selected among:




embedded image


embedded image


According to an aspect, it is preferred that at least one of R1, R2 and R3 is other than hydrogen; preferably one of R1, R2 and R3 is selected among methyl, chlorine and fluorine, and the others are hydrogen.


According to different aspects, it is preferred that W is NH; R4 is alkyl; d is 2 and e is 2; R13 is alkyl; and/or n is 0.


According to an aspect, it is preferred that R2 is H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(═O) and n is 0, as shown in formula 18a:




embedded image


wherein R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine, and R13 is alkyl.


According to an aspect, it is preferred that X is C(═O), n is 0 and R4 is a piperidine where d is 2 and e is 2, as shown in formula 19a:




embedded image


wherein G is selected among general formulae 7a to 17a, and R13 is alkyl.


According to an aspect, it is preferred that R2 is H and W is NH as shown in formula 20a:




embedded image


wherein either R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine; and G is selected from general formulae 7a to 17a.


According to an aspect, it is preferred that R2 is H, W is NH and X is C(═O) as shown in formula 21a:




embedded image


wherein R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine; and R4 is alkyl.


According to an aspect, it is preferred that X is C(═O) as shown in formula 22a:




embedded image


wherein G is selected among general formulae 7a to 17a, and R4 is alkyl.


According to an aspect, it is preferred that R2 and R3 are both H, W is NH and X is C(═O) as shown in formula 23a:




embedded image


wherein G is selected among general formulae 9a, 10a, 15a, 16a and 17a, R1 is selected among methyl, chlorine and fluorine, and R4 is alkyl.


According to an aspect, it is preferred that R2 and R3 are both H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(═O) and n is 0 as shown in formula 24a:




embedded image


wherein G is selected among general formulae 9a, 10a, 15a, 16a and 17a, R1 is selected among methyl, chlorine and fluorine, and R13 is alkyl.


According to an aspect, particularly preferred compounds are provided in claim 17.


According to an aspect of the present invention, it relates to the compounds of claim 18. According to an aspect, the ring containing A3, A4 and A5 according to general formulae 2b and 3b is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N(alkyl)2.


It appears that the compounds of formula 1b of claim 18 are subject to following constraints. As the ring constituted by A7, A8, A9, A10 and A11 is aromatic, the groups must satisfy certain requirements. When A10 is —CH═CH— the ring is a six membered ring. As such, it can only comprise atoms of the type —C(R)═ and —N═. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not —CH═CH— then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a “trigonal nitrogen” is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when A10 is not —CH═CH— then one, and only one, of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not —CH═CH— then one of A8, A9 and A10 is NH, N—(CH2)d—R5 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N—(CH2)d—R5 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N—(CH2)d—R5 or S.


According to an aspect, particularly preferred compounds are provided in claim 30.


According to an aspect of the present invention, it relates to the compounds of claim 31. It appears that the compounds of formula 1c of claim 31 are subject to following constraints. The ring constituted by A7, A8, A9, A10 and A11 is aromatic, and accordingly the groups must satisfy certain requirements. When A10 is —CH═CH— the ring is a six membered ring. As such, it can only comprise atoms of the type —C(R)═ and —N═. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not —CH═CH— then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a “trigonal nitrogen” is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when A10 is not —CH═CH— then one (and only one) of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not —CH═CH— then one of A8, A9 and A10 is NH, N—(CH2), —R6 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N—(CH2)c—R6 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N—(CH2)c—R6 or S.


According to an aspect, particularly preferred compounds are provided in claim 45.


According to an aspect of the present invention, it relates to the compounds of claim 46. It appears that the compounds of formula 1d of claim 46 are subject to the following constraints. The ring constituted by A7, A8, A9, A10 and A11 is aromatic, and accordingly the groups must satisfy certain requirements. When A10 is —CH═CH— the ring is a six membered ring. As such, it can only comprise atoms of the type —C(R)═ and —N═. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not —CH═CH— then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a “trigonal nitrogen” is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when A10 is not —CH═CH— then one (and only one) of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not —CH═CH— then one of A8, A9 and A10 is NH, N—(CH2), —R11 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N—(CH2)c—R11 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N—(CH2)c—R11 or S.


According to an aspect, particularly preferred compounds are provided in claim 69.


The particularly preferred compounds of the invention are V1a antagonists of high activity.


According to an aspect, at least one of the compounds, identified as follows, is not part of the present invention: claim 1 and ex. 286 (3-Pyridin-3-yl-4,5-dihydro-isoxazole-5-carboxylic acid [4-(4-dimethylamino-benzylcarbamoyl)-phenyl]-amide) of U.S. Pat. No. 6,583,141; ex. 5 and 6 of WO 02/04403 (N-[4-(N-Methyl-N-phenylaminocarbonyl)-phenylmethyl]-3-(4′-trifluormethylbiphenyl-2-carbonylamino)benzoic acid amide and N-[4-(N-Methyl-N-phenylaminocarbonyl)-phenylmethyl]-3-(biphenyl-2-carbonylamino)benzoic acid amide); abstract, J. Org. Chem. USSR, vol. 18, no. 6, 1982, p. 1115-1119 (p-(N,N-diethylcarbamoyloxy)-N,N-diethylbenzamide); p. 3, 1. 16-p. 4, 1. 11, ex. 1-4, 11, and 14-19 of WO 01/29005; p. 3, 1. 9-p. 5, 1. 23, ex. 11, 28-31, 38, and 71-77 of WO 02/00626; and p. 3, 1. 1-p. 4, 1. 17, ex. 12-18 of WO 03/016316.


According to an aspect, the invention concerns a pharmaceutical composition comprising a compound according to the invention as an active agent.


The invention is further related to pharmaceutical compositions incorporating a compound according to the invention used as a V1a antagonist, which compositions are particularly useful for medical indications such as the treatment of dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea), pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.


Any excipients used will depend on the intended nature of the formulation, which will, in turn, depend on the intended route of administration. Administration may be oral, transmucosal (such as sublingual, buccal, intranasal, vaginal and rectal), transdermal or by injection (such as subcutaneous, intramuscular and intravenous). Oral administration is generally preferred. For oral administration, the formulation may be a tablet, a capsule or a sachet. Other formulations include dry powders, solutions, suspensions, suppositories and the like.


According to an aspect, the invention concerns the use of a compound of the invention for the manufacture of a medicament for the treatment of a disease selected among dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea), pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.


The compounds according to the present invention may be useful for treatment of several diseases, disorders or conditions. The term “treatment” used herein relates to both treatment in order to cure or alleviate a disease, disorder or a condition, and to treatment in order to prevent the development of a disease, disorder or a condition. The treatment may either be performed in an acute or in a chronic way. The human or animal to be treated, i.e. the patient, may be any human or non-human mammal in need of treatment according to the invention.


The administration of the compositions of the present invention will generally be under the control of a physician. The physician will determine the amount of composition to be administered and the dosing schedule, taking into account the patient's physical condition and the therapeutic goals.


Further aspects of the invention relates to methods of treatment of the above mentioned diseases, disorders or conditions. According to a method according to the invention a therapeutically effective amount of the compound, or of the pharmaceutical composition described above, is administered to a patient in need of this treatment. According to different aspects of the invention, it concerns a method of treatment of a disorder selected among dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea), pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.


The term “therapeutically effective amount” relates to an amount that will lead to the desired therapeutical effect. The therapeutically effective amount will be determined by the attending physician taking into consideration all appropriate factors. Generally a single dose will comprise between 0.1 mg and 1000 mg, preferably between 1 mg and 250 mg, of the active compound according to the invention. The dose may be given on a single occasion or repeatedly. When given repeatedly, it may be given at regular intervals, such as once, twice or three times daily, or on demand, according to the condition being treated.


The pharmaceutical composition according to the present invention may be presented in any form that is known in the art. For example, the formulation may be presented as a tablet, capsule, powder, suppository, cream, solution or suspension, or in a more complex form such as an adhesive patch. The formulation will generally include one or more excipients, such as diluents, bulking agents, binding agents, dispersants, solvents, preservatives, flavouring agents and the like. The formulation may also include one or more additional pharmacologically active species. Preferably the formulation includes no such additional active agents.


When used as therapeutic agents, the compositions of the present invention may be administered by any appropriate route that is known in the art. For example, they may be administered by the oral, buccal, sublingual, rectal, intra-vaginal, nasal, pulmonary or transdermal routes. Alternatively, they may be given by injection, including intravenous, subcutaneous and intramuscular injection.


The compounds of the present invention can be prepared using standard chemical manipulations. These are described in detail in WO 03/016316 A1, pages 12-17. (Hudson, P. J. et al., “Diazacycloalkanes as Oxytocin Agonists”).


The following examples are to be considered as enabling and not limiting for the invention.


EXAMPLES

The following abbreviations are used:

  • AIBN 2,2′-azobisisobutyronitrile
  • Boc carboxylic acid tert-butyl ester or tert-butoxycarbonyl amino
  • Bu butyl-alkyl residues may be further denoted as n (normal, i.e. unbranched), i (iso) and t (tertiary)
  • DIEA N,N-diisopropylethylamine
  • DMAP 4-(dimethylamino)pyridine
  • DMF dimethylformamide
  • Et ethyl
  • EtOAc ethyl acetate
  • HOBt 1-hydroxybenzotriazole
  • HPLC High performance liquid chromatography H hour(s)
  • Me methyl
  • Min minute(s)
  • MS mass spectrum
  • NMR nuclear magnetic resonance spectrum—NMR spectra were recorded in CDCl3 at a frequency of 270 MHz unless otherwise indicated
  • OVA ornithine vasotocin analogue
  • pet. petroleum ether boiling in the range 60-80° C.
  • Ether
  • Ph phenyl
  • Pn pentyl
  • Pr propyl
  • THF tetrahydrofuran
  • Tos toluene-4-sulphonyl
  • WSCD water-soluble carbodiimide (N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride


Examples E1-E125 describe the synthesis of intermediates and compounds of the present invention. Example A describes how compounds can be assayed based on their ability to inhibit the cellular consequences of AVP stimulation on intact cells. Example B describes tablets for oral administration comprising a compound according to the invention.


Example E1
6-Chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene
Example E1.1
5-(4-Chloro-2-nitro-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester

Sodium hydride (60% dispersion in oil, 7.28 g, 180 mmol) was added portionwise to a solution of ethyl 5-amino-1-methylpyrazole-4-carboxylate (21.8 g, 148 mmol) in anhydrous THF at 0° C. The mixture was allowed to warm to room temperature and stirred for 1 h. A solution of 4-chloro-2-fluoronitrobenzene (22.6 g, 129 mmol) in anhydrous THF (50 ml) was added dropwise. The resultant deep purple solution was stirred at room temperature for 18 h then poured into ice-cold 1N hydrochloric acid. The resulting mixture was extracted with dichloromethane (200 ml×2), and the combined organic extracts were washed with brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 60% pet ether:40% EtOAc) to yield the title compound (27.5 g, 62%).


Example E1.2
5-(2-Amino-4-chloro-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester

Zinc powder (26.17 g, 400 mmol) was added to a suspension of 5-(4-chloro-2-nitro-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester from Example E1.1 (26.0 g, 80 mmol) in methanol/acetic acid (10:1, 330 ml) at room temperature. After the exothermic reaction which followed, the resulting suspension was stirred at room temperature for 18 h before being filtered through Celite® filter agent. The filtrate was concentrated in vacuo. The residue was dissolved in EtOAc, and the solution was washed with saturated NaHCO3 and brine, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 65% EtOAc:35% pet ether to 80% EtOAc:20% pet ether) to yield the title compound (18.41 g, 78.0%).


Example E1.3
6-Chloro-3-methyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one

Sodium(methylsulphinyl)methanide (53.4 mmol) was prepared from sodium hydride (60% dispersion in oil, 2.14 g, 53.4 mmol) and anhydrous dimethyl sulphoxide (35 ml) by heating at 65° C. until a solution was observed. To this was added a solution of 5-(2-amino-4-chloro-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester from Example E1.2 (9.02 g, 30.5 mmol) in anhydrous dimethyl sulphoxide (20 ml), and stirring continued at 65° C. for 30 min. The mixture was poured into ice (200 ml), and the resulting solid collected and purified by recrystallisation from methanol/EtOAc to yield the title compound (5.56 g, 73.3%).


Example E1.4
6-Chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene

To a suspension of 6-chloro-3-methyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one from Example E1.3 (5.56 g, 22.4 mmol) in anhydrous THF (200 ml) at 0° C. was added lithium aluminium hydride (4.24 g, 112 mmol), and the resulting suspension was heated at reflux for 18 h, then allowed to cool to room temperature. A further portion of lithium aluminium hydride (4.24 g, 112 mmol) was added, and the mixture was heated at reflux for 18 h. The mixture was cooled to 0° C., 35% ammonia solution (10 ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30 min. The resulting suspension was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 0.5% 35% ammonia:5% methanol:dichloromethane) to yield the title compound (3.88 g, 74%).


Example E2
3,6-Dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene
Example E2.1
1-Methyl-5-(4-methyl-2-nitro-phenylamino)-1H-pyrazole-4-carboxylic acid ethyl ester

Sodium hydride (60% dispersion in oil, 7.28 g, 180 mmol) was added portionwise to a solution of ethyl 5-amino-1-methylpyrazole-4-carboxylate (21.8 g, 148 mmol) in anhydrous THF at 0° C. The mixture was allowed to warm to room temperature and stirred for 1 h then a solution of 3-fluoro-4-nitrotoluene (20 g, 129 mmol) in anhydrous THF (50 ml) was added dropwise. The resultant deep purple solution was stirred at room temperature for 18 h then poured into ice-cold 1N hydrochloric acid. The resulting mixture was extracted with dichloromethane (200 ml×2), and the combined organic extracts were washed with brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 60% pet ether:40% EtOAc) to yield the title compound (28.00 g, 61%).


Example E2.2
5-(2-Amino-4-methyl-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester

Tin (II) chloride (86.65 g, 457.0 mmol) was added to a solution of 1-methyl-5-(4-methyl-2-nitro-phenylamino)-1H-pyrazole-4-carboxylic acid ethyl ester from Example E2.1 (28.00 g, 91.4 mmol) in methanol and the mixture heated at reflux for 3 days. The solvent was removed in vacuo and the residue taken up in EtOAc (400 ml) and cooled to 0° C. 35% Ammonia solution was added to pH 14, and the mixture was stirred for 15 min before being filtered through Celite® filter agent. The filtrate was washed with 2M NH3 and brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 6% methanol:94% dichloromethane rising to 10% methanol:90% dichloromethane) to yield the title compound (12.8 g, 52%).


Example E2.3
3,6-Dimethyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one

Sodium(methylsulphinyl)methanide (22.7 mmol) was prepared from sodium hydride (60% dispersion in oil, 912 mg, 22.7 mmol) and anhydrous dimethyl sulphoxide (5.5 ml) by heating at 65° C. until a solution was observed. To this was added a solution of 5-(2-amino-4-methyl-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester from Example E2.2 (3.56 g, 13.0 mmol) in anhydrous dimethyl sulphoxide (10 ml), and stirring continued at 65° C. for 30 min. The mixture was then poured into ice (200 ml), the resulting solid collected and purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to yield the title compound (1.12 g, 38%).


Example E2.4
3,6-Dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene

To a suspension of 3,6-dimethyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one from Example E2.3 (2.35 g, 10.3 mmol) in anhydrous THF (100 ml) at 0° C. was added lithium aluminium hydride (1.56 g, 41.2 mmol), and the resulting suspension was heated at reflux for 18 h then allowed to cool to room temperature. A further portion of lithium aluminium hydride (781 mg, 20.6 mmol) was added, and the mixture was heated at reflux for 3 h. The mixture was cooled to 0° C., 35% ammonia solution (10 ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30 min. The resulting suspension was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to yield the title compound (1.60 g, 72%).


Examples E2a-g are described in WO 03/016316 A1, (Hudson, P. et al. “Diazacycloalkanes as Oxytocin Agonists”), pages 26-31.


Example E2h
4-(tert-Butoxycarbonylamino-methyl)-3-methyl-benzoic acid
Example E2h.1
4-Cyano-3-methyl-benzoic acid methyl ester

A mixture of 4-cyano-3-methyl-benzoic acid from Example E2d (1.5 g, 9.3 mmol) and thionyl chloride (5 ml, 68.5 mmol) in dichloromethane (20 ml) was heated at reflux for 2 h then solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (25 ml). Methanol (10 ml) was added and the solution was stirred at room temperature for 2 h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield the title compound (1.6 g, 100%).


Example E2h.2
4-Aminomethyl-3-methyl-benzoic acid methyl ester

A solution of 4-cyano-3-methyl-benzoic acid methyl ester from Example E2h.1 (1.6 g, 9.3 mmol) in methanol (50 ml) to 0° C. was treated with cobalt(II) chloride hexahydrate (5.1 g, 18.6 mmol). The mixture was stirred for 15 min at room temperature then sodium borohydride (3.5 g, 93 mmol) was added portionwise. The reaction mixture was stirred for 90 min then concentrated NH3 (5 ml) was added dropwise. The mixture was warmed up to room temperature over 30 min, filtered through Celite® filter agent, washed with methanol and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:10% methanol:89% dichloromethane) to yield the title compound (670 mg, 37%).


Example E2h.3
4-(tert-Butoxycarbonylamino-methyl)-3-methyl-benzoic acid methyl ester

Di-tert-butyl dicarbonate (900 mg, 4.1 mmol) was added to a solution of 4-aminomethyl-3-methyl-benzoic acid methyl ester from Example E2h.2 (670 mg, 3.7 mmol) in dichloromethane (50 ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 1 h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with 0.3N KHSO4 then brine, dried and concentrated in vacuo to yield the title compound (1.04 g, 100%).


Example E2h.4
4-(tert-Butoxycarbonylamino-methyl)-3-methyl-benzoic acid

4-(tert-Butoxycarbonylamino-methyl)-3-methyl-benzoic acid methyl ester from Example E2h.3 (1.04 g, 3.7 mmol) was dissolved in dioxan (20 ml). 1N NaOH solution (5.6 ml, 5.6 mmol) was added and the mixture was stirred for 18 h at room temperature then concentrated in vacuo. The residue was redissolved in EtOAc, washed with 1N KHSO4 then brine, dried and concentrated in vacuo to yield the title compound (800 mg, 81%).


Example E3
4-(tert-Butoxycarbonylamino-methyl)-3-fluoro-benzoic acid
Example E3.1
3-Fluoro-4-methylbenzoic acid methyl ester

Thionyl chloride (9.62 g, 81 mmol) was added to a solution of 3-fluoro-4-methylbenzoic acid (5.0 g, 32.4 mmol) in toluene (50 ml). The mixture was stirred at room temperature for 1.5 h and heated at reflux for 3 h. The solvent was removed in vacuo and the residue was taken up in methanol (30 ml) and CH2Cl2 (30 ml) and stirred for 18 h. The mixture was evaporated in vacuo and the residue was taken up in EtOAc (50 ml), washed with saturated NaHCO3 solution (3×75 ml), dried and evaporated in vacuo to yield the title compound (4.5 g, 83%).


Example E3.2
4-Bromomethyl-3-fluorobenzoic acid methyl ester

3-Fluoro-4-methylbenzoic acid methyl ester from Example E3.1 (4.5 g, 26.6 mmol) was dissolved in carbon tetrachloride (150 ml). AIBN (457 mg, 2.7 mmol) and N-bromosuccinimide (5.2 g, 29.3 mmol) were added and the mixture was heated at reflux for 18 h. The mixture was allowed to cool and further portions of AIBN (457 mg, 2.7 mmol) and N-bromosuccinimide (5.2 g, 29.3 mmol) were added. The mixture was heated at reflux for 56 h. The mixture was allowed to cool and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% EtOAc:90% pet ether) to yield the title compound (2.7 g, 41%).


Example E3.3
4-Azidomethyl-3-fluorobenzoic acid methyl ester

Sodium azide (609 mg) was added to a solution of 4-bromomethyl-3-fluorobenzoic acid methyl ester from Example E3.2 (2.1 g, 8.5 mmol) in DMF (30 ml). The mixture was stirred for 18 h, diluted with EtOAc, washed with water and brine and concentrated in vacuo to give a colourless oil identified as the title compound (1.8 g, 100%).


Example E3.4
4-Aminomethyl-3-fluorobenzoic acid methyl ester

Hydrogen was passed through a degassed solution of 4-azidomethyl-3-fluorobenzoic acid methyl ester from Example E3.3 (2.11 g, 10 mmol) in methanol containing 10% palladium on carbon for 2 h. The reaction mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a colourless oil identified as the title compound (1.51 g, 83%).


Example E3.5
4-(tert-Butoxycarbonylamino-methyl)-3-fluorobenzoic acid methyl ester

To a solution of 4-aminomethyl-3-fluorobenzoic acid methyl ester from Example E3.4 (1.5 g, 8.2 mmol) in dichloromethane (20 ml) were added di-tert-butyl Bicarbonate (2.3 g, 11 mmol) and triethylamine (1.4 ml, 10 mmol). The mixture was stirred for 18 h, washed with 0.3M KHSO4 and brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% EtOAc:90% pet. ether) to give a white solid identified as the title compound (1.4 g, 60%).


Example E3.6
4-(tert-Butoxycarbonylamino-methyl)-3-fluorobenzoic acid

To a solution of 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid methyl ester from Example E3.5 (640 mg, 2.25 mmol) in dioxan (40 ml) was added 1N NaOH (4.5 ml, 4.5 mmol). The mixture was stirred for 18 h, diluted with EtOAc, washed with 1N KHSO4, water and brine and concentrated in vacuo to give a white solid identified as the title compound (608 mg, 100%).


Example E4
1-(3,3-Dimethyl-butyl)-piperazine dihydrochloride
Example E4.1
4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid tert-butyl ester

To a solution of 1-boc-piperazine (8.19 g, 43.9 mmol) in methanol/acetic acid (99:1, v/v, 100 ml) was added 3,3-dimethylbutyraldehyde (4.0 g, 40.0 mmol) and the resulting mixture was stirred at room temperature for 1 h. Sodium cyanoborohydride (3.27 g, 51.9 mmol) was added, and the resulting mixture was stirred at room temperature for 18 h then concentrated in vacuo. The residue was dissolved in EtOAc and the resulting solution was washed with saturated NaHCO3, water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% EtOAc) to yield the title compound (9.1 g, 84%).


Example E4.2
1-(3,3-Dimethyl-butyl)-piperazine dihydrochloride

A solution of 4-(3,3-dimethyl-butyl)-piperazine-1-carboxylic acid tert-butyl ester from Example E4.1 (9.1 g, 31.8 mmol) in methanol (100 ml) was treated with 4N HCl/dioxan (100 ml) and the mixture was stirred at room temperature for 30 min then concentrated in vacuo. The residue was triturated with diethyl ether and the resulting solid recrystallised from methanol/diethyl ether to yield 1-(3,3-dimethyl-butyl)-piperazine dihydrochloride (7.4 g, 90%).


Example E5
2-Methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene
Example E5.1
2-(Toluene-4-sulfonylamino)-benzoic acid methyl ester

Methyl anthranilate (110 g, 0.73 mol) was dissolved in dichloromethane (1 litre) at 0° C. and triethylamine (115 ml, 0.8 mol) was added. Tosyl chloride (133 g, 0.745 mol) was added portionwise at 0° C. The reaction mixture was stirred for 30 min at 0° C. and 64 h at room temperature. The mixture was reduced in vacuo. The residue was dissolved in EtOAc and the organic layer was washed with 5% KHCO3(aq) solution, 1N HCl solution and brine, dried, filtered and concentrated in vacuo. The residue was crystallised from EtOAc/hexane to yield the title compound (181 g, 81%).


Example E5.2
2-[(3-Ethoxycarbonyl-propyl)-(toluene-4-sulfonyl)-amino]-benzoic acid methyl ester

2-(Toluene-4-sulfonylamino)-benzoic acid methyl ester from Example E5.1 (100 g) was dissolved in DMF (250 ml). Potassium carbonate (125 g) and ethyl 4-bromobutanoate (60 g) were added and the mixture was heated at 80° C. for 18 h. The mixture was cooled to room temperature, filtered and reduced in vacuo. The residue was partitioned between chloroform and 1M HCl solution. The aqueous layer was extracted with chloroform. The organic layers were combined, washed with brine, dried, filtered and concentrated in vacuo. The material was crystallised from EtOAc/hexane and dried in a vacuum oven at 60° C. for 3 hours to yield the title compound (98.6 g, 72%).


Example E5.3
5-Hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester and 5-hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid ethyl ester

2-[3-Ethoxycarbonyl-propyl)-(toluene-4-sulfonyl)-amino]-benzoic acid methyl ester from Example E5.2 (98.6 g, 0.235 mol) was taken up in warm toluene (600 ml) and was added dropwise to a mixture of potassium tert-butoxide (40 g) in toluene (1 litre) refluxing under Dean-Stark conditions. The mixture was heated at reflux under Dean-Stark conditions for 1 h further and cooled to room temperature. It was diluted with EtOAc (500 ml) and washed with 1M HCl solution, saturated NaHCO3(aq) and brine. The organic layer was dried, filtered and reduced in vacuo. The residue was precipitated from EtOAc/hexane and dried in a vacuum oven to yield a mixture of 5-hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester and 5-hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid ethyl ester (53.5 g).


Example E5.4
1-(Toluene-4-sulfonyl)-1,2,3,4-tetrahydro-benzo[b]azepin-5-one

A mixture of 5-hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester and 5-hydroxy-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylic acid ethyl ester from Example E5.3 were heated at reflux in a mixture of ethanol (100 ml), acetic acid (300 ml), concentrated HCl (100 ml) and water (50 ml) for 18 h. The mixture was cooled to room temperature, diluted with water (800 ml) and extracted with chloroform. The combined organic extracts were dried, filtered and reduced in vacuo. The residue was crystallised twice from methanol to yield the title compound (44 g, 60% over two steps).


Example E5.5
1,2,3,4-Tetrahydro-benzo[b]azepin-5-one

Polyphosphoric acid (25 g) was heated at 100° C. under nitrogen until it could be stirred. 1-(Toluene-4-sulfonyl)-1,2,3,4-tetrahydro-benzo[b]azepin-5-one from Example E5.4 (2.6 g, 8.26 mmol) was added portionwise and the reaction mixture was heated at 100° C. for 1.5 h. It was poured into ice and basified with 2M NaOH(aq). The aqueous layer was extracted twice with dichloromethane. The organic extracts were combined, washed with brine, dried and reduced in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc:60% hexane) to yield the title compound (1.05 g, 79%).


Example E5.6
1-Benzoyl-1,2,3,4-tetrahydro-benzo[b]azepin-5-one

1,2,3,4-Tetrahydro-benzo[b]azepin-5-one from Example E5.5 (480 mg, 2.98 mmol) was dissolved in a mixture of dichloromethane (30 ml) and triethylamine (1.3 ml). Benzoyl chloride (0.46 g, 3.28 mmol) was added and the reaction mixture was heated for at reflux for 2 h. The mixture was cooled and reduced in vacuo. The residue was dissolved in EtOAc and washed with 1M KHSO4(aq), water and brine. The organic layer was dried, filtered and reduced in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% hexane) to yield the title compound (440 mg, 56%).


Example E5.7
1-Benzoyl-4-bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one

1-Benzoyl-1,2,3,4-tetrahydro-benzo[b]azepin-5-one from Example E5.6 (54.2 g, 205 mmol), N-bromosuccinimide (3.6 g, 20.4 mmol) and bromine (11.1 ml, 214.7 mmol) were dissolved in dichloromethane (1.0 litre). Triethylamine (30 ml, 215 mmol) was added dropwise over 30 minutes then the reaction mixture was heated at reflux for 4 h. Additional bromine (1.1 ml, 21.5 mmol) and triethylamine (3.0 ml, 21.5 mmol) were added and the reaction mixture was heated at reflux for a further 4 h. Additional bromine (1.1 ml, 21.5 mmol) and triethylamine (3.0 ml, 21.5 mmol) were added again and the reaction mixture was heated at reflux for a further 4 h. On cooling to room temperature, the reaction solution was washed with 5% aqueous sodium metabisulfate solution (150 ml) and the aqueous phase was diluted with water (600 ml). The organic phase was separated, washed with saturated Na—HCO3(aq), dried over sodium sulphate and filtered. The filtrate was diluted with EtOAc (100 ml), filtered through a silica pad (eluant; CH2Cl2) and reduced in vacuo to yield the title compound (73.6 g) which was used without further purification.


Example E5.8
6-Benzoyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene

1-Benzoyl-4-bromo-1,2,3,4-tetrahydro-benzo[b]azepin-5-one (67.5 g, 200 mmol) from Example E5.7, acetamidine hydrochloride (92.7 g, 980 mmol) and potassium carbonate (136.0 g, 980 mmol) were suspended in acetonitrile (2.0 litres) and heated at reflux for 17 h under nitrogen. Additional acetamidine hydrochloride (18.5 g, 200 mmol) and potassium carbonate (27.7 g, 200 mmol) were added and the reaction mixture was heated at reflux for a further 6 h. Additional acetamidine hydrochloride (18.5 g, 200 mmol) and potassium carbonate (27.7 g, 200 mmol) were added again and the reaction mixture was heated at reflux for a further 6 h. On cooling to room temperature, the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was taken up in dichloromethane (1.4 litres), washed with water (500 ml), dried over sodium sulfate, filtered and reduced in vacuo. The crude products were purified by flash chromatography on silica gel, (eluant; 45% EtOAc:45% acetonitrile:10% methanol) to yield the title compound (26.7 g, 34%) and 6-benzoyl-2-methyl-5,6-dihydro-4H-1-oxa-3,6-diaza-benzo[e]azulene (3.3 g, 4%).


Example E5.9
2-Methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene

6-Benzoyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5.8 (160 mg, 0.53 mmol) was dissolved in a 6M HCl/dioxan solution (50 ml) and heated at reflux for 18 h. The reaction mixture was cooled to room temperature and reduced in vacuo. The residue was partitioned between EtOAc and saturated NaHCO3(aq) and the layers were separated. The organic layer was washed with brine, dried, filtered and reduced in vacuo to yield the title compound (69 mg, 66%).


Example E5a 1-Benzyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene
Example E5a.1
(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-phenyl-methanone

Sodium hydride (60% dispersion in oil, 905 mg, 22.5 mmol) was placed in anhydrous THF (200 ml) and cooled down to 0° C. 6-Benzoyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5.8 (4.9 g, 16.1 mmol) was added dropwise and the mixture was stirred for 1 h at room temperature. Benzyl bromide (2.31 ml, 19.3 mmol) and potassium iodide (1.34 g, 8.0 mmol) were added and the mixture was stirred for 16 h. The solution was diluted with EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (5.73 g, 90%).


Example E5a.2
1-Benzyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene

(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-phenyl-methanone from Example E5a.1 (5.73 g, 14.6 mmol) was placed in methanol (50 ml) and a 6M HCl aqueous solution (200 ml) was added. The reaction mixture was heated at reflux for 18 h then concentrated in vacuo. The residue was dissolved in dichloromethane, basified with saturated NaHCO3 then washed with brine, dried and concentrated in vacuo to yield the title compound (3.30 g, 78%).


Example E6
2-Methyl-5,6-dihydro-4H-1-oxa-3,6-diaza-benzo[e]azulene

6-Benzoyl-2-methyl-5,6-dihydro-4H-1-oxa-3,6-diaza-benzo[e]azulene from Example E5.8 (1.0 g, 3.25 mmol) was reacted with a 6M HCl/dioxan solution (100 ml) using an analogous procedure to that described for Example E5.9 to yield the title compound (540 mg, 82%).


Example E7
2-Methyl-5,6-dihydro-4H-3-thia-1,6-diaza-benzo[e]azulene
Example E7.1
(2-Methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulen-6-yl)-phenyl-methanone

To a solution of 1-benzoyl-4-bromo-1,2,3,4-tetrahydrobenzo[b]azepin-5-one (1.0 g, 2.9 mmol) from Example E5.7 in ethanol (50 ml) was added thioacetamide (0.75 g, 10=01). The solution was stirred for 16 h. The resultant suspension was reduced in volume by evaporation and cooled. The precipitate was collected by filtration and the solid was washed with cold ethanol and dried to yield the title compound as a white solid (0.65 g, 70%).


Example E7.2
2-Methyl-5,6-dihydro-4H-3-thia-1,6-diaza-benzo[e]azulene

A suspension of (2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulen-6-yl)-phenyl-methanone from Example E7.1 (0.42 g, 1.3 mmol) in 6M hydrochloric acid (45 ml) was heated at reflux for 16 h. The solution was cooled and treated with saturated NaHCO3(aq) (100 ml). Additional solid NaHCO3 was added until the solution was basic. The mixture was extracted with dichloromethane and the organic extracts were dried and reduced in vacuo to yield the title compound as a yellow oil (0.21 g, 76%).


Example E8
4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide
Example E8.1
[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester

A solution of 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid from Example E3.1 (538 mg, 2.0 mmol) and DMAP (220 mg, 1.8 mmol) in dichloromethane (20 ml) at room temperature was treated with DIEA (0.93 ml, 5.4 mmol) and WSCD (460 mg, 2.4 mmol), and the resulting solution was stirred at room temperature for 1 h. 3,6-Dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E2 (385 mg, 1.8 mmol) was added and the resulting solution was heated at reflux for 20 h and allowed to cool to room temperature. The solution was diluted with dichloromethane, washed with saturated NaHCO3 and brine and concentrated in vacuo. The residue was purified by preparative HPLC (eluant 10% methanol:90% dichloromethane) to yield the title compound (265 mg, 32%).


Example E8.2
(4-Aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester from Example E8.1 (237 mg, 0.51 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (205 mg, 100%).


Example E8.3
4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide

DIEA (0.10 ml, 0.60 mmol) and 1,1′-carbonyldiimidazole (28 mg, 0.17 mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E8.2 (57 mg, 0.14 mmol) in DMF (5.0 ml) and the mixture was stirred at room temperature for 4 h. 1-(3,3-Dimethyl-butyl)-piperazine dihydrochloride from Example E4 (38 mg, 0.16 mmol) was added and the mixture was stirred at room temperature for 24 h and concentrated in vacuo. The residue was dissolved in EtOAc and the resulting solution was washed with brine and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 10% methanol:90% dichloromethane) to give a white solid identified as the title compound (45 mg, 56%).


Example E9
4-(tert-Butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid

To a solution of 4-aminomethyl-cyclohexanecarboxylic acid (20.0 g, 127.39 mmol) in dioxan (400 ml) was added 1N KHCO3 (300 ml, 300=01) and di-tert-butyl dicarbonate (33.3 g, 129.57 mmol). The mixture was stirred for 18 h and concentrated in vacuo. The aqueous residue was washed with ether, then acidified with 1N KHSO4 and extracted with EtOAc (×3). The combined organic extracts were washed with water and brine and concentrated in vacuo to give a white solid identified as the title compound (31.9 g, 98%).


Example E10
Cyclopropanecarboxylic acid [4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide
Example E10.1
[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester

A solution of 4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid from Example E9 (510 mg, 2.0 mmol) in dichloromethane (25 ml) at room temperature was treated with DIEA (0.70 ml, 4.0 mmol), PyBrop (2.40 g, 5.1 mmol), and 6-chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E1 (422 mg, 1.8 mmol) and the resulting solution was heated at reflux for 20 h and allowed to cool to room temperature. The solution was diluted with dichloromethane, washed with brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant EtOAc) to yield the title compound (775 mg, 91%).


Example E10.2
(4-Aminomethyl-cyclohexyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

A solution of [4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester from Example E10.1 (775 mg, 1.63 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (655 mg, 100%).


Example E10.3
Cyclopropanecarboxylic acid [4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide

DIEA (0.50 ml, 2.90 mmol) and cyclopropanecarbonyl chloride (0.045 ml, 0.50 mmol) were added to a solution of (4-aminomethyl-cyclohexyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E10.2 (220 mg, 0.53 mmol) in dichloromethane (5 ml). The mixture was stirred for 2 h then diluted with dichloromethane, washed with water and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia/10% methanol/90% dichloromethane) to give a white solid identified as the title compound (132 mg, 60%).


Example E11
3-Methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene
Example E11.1
1-Methyl-5-(2-nitro-phenylamino)-1H-pyrazole-4-carboxylic acid ethyl ester

Sodium hydride (60% dispersion in oil, 7.0 g, 170 mmol) was added portionwise to a suspension of 5-amino-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester (21.1 g, 125 mmol) in anhydrous THF (300 ml) at 0° C. The mixture was allowed to warm to room temperature and stirred for 0.75 h then cooled to 0° C. 1-fluoro-2-nitrobenzene (17.6 g, 125 mmol) was added and the resultant suspension was stirred at room temperature for 18 h. EtOAc and 0.3M KHSO4 were added and separated. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 50% hexanes/50% ethyl acetate) to yield the title compound (20.8 g, 58%).


Example E11.2
5-(2-Amino-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester

1-Methyl-5-(2-nitro-phenylamino)-1H-pyrazole-4-carboxylic acid ethyl ester (20.8 g, 72 mmol) from Example E11.1 was dissolved in methanol (330 ml) and hydrogenated over 10% Pd/C catalyst for 4 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a white solid identified as the title compound (16.2 g, 87%).


Example E11.3
3-Methyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one

Sodium(methylsulphinyl)methanide (29.7 mmol) was prepared from sodium hydride (60% dispersion in oil, 1.19 g, 29.7 mmol) and anhydrous dimethyl sulphoxide (7 ml) by heating at 65° C. until a solution was observed. To this was added a solution of 5-(2-amino-phenylamino)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester from Example E11.2 (3.63 g, 16.9 mmol) in anhydrous dimethyl sulphoxide (10 ml), and stirring continued at 65° C. for 2.5 h. The mixture was poured into ice (100 ml), and the resulting solid collected and purified by recrystallisation from methanol/EtOAc/60-80 pet ether to yield the title compound (1.46 g, 40%).


Example E11.4
3-Methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene

To a suspension of 3-methyl-4,9-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-10-one from Example E11.3 (3.01 g, 14.1 mmol) in anhydrous THF (100 ml) at 0° C. was added lithium aluminium hydride (2.13 g, 56.2 mmol), and the resulting suspension was heated at reflux for 18 h, then allowed to cool to room temperature. The mixture was cooled to 0° C., 35% ammonia solution (10 ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30 min. The resulting suspension was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% methanol:chloroform rising to 5% methanol:chloroform) to yield the title compound (1.60 g, 57%).


Example E12
[4-(Isobutylamino-methyl)-cyclohexyl]-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

A solution of isobutyraldehyde (0.36 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of (4-Aminomethyl-cyclohexyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E10.2 (1.88 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and DIEA (0.0026 ml). The mixture was stirred at room temperature for 1 h then a solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=396.4


Example E13
[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (1.08 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of (4-Aminomethyl-cyclohexyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride (Compound number 149) (1.95 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=533.3


Example E14
(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-(4-hexylaminomethyl-cyclohexyl)-methanone

A solution of 1-bromohexane (0.83 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of (4-Aminomethyl-cyclohexyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E10.2 (2.05 mg, 0.005 mmol) in DMF (0.05 ml) and triethylamine (0.0021 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=458.4


Example E15
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid
Example E15.1
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid ethyl ester

3,3-Dimethylbutyraldehyde (5.26 ml, 42.0 mmol) was added to a solution of ethyl isonipecotate (6.6 g, 42.0 mmol) in methanol/acetic acid (99:1, v/v, 50 ml) and the mixture was stirred at room temperature for 1 h. Sodium cyanoborohydride (3.43 g, 54.6 mmol) was added, and the mixture was stirred at room temperature for 4 days then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 25% EtOAc:75% cyclohexane) to yield the title compound (7.16 g, 71%).


Example E15.2
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid

Lithium hydroxide monohydrate (1.37 g, 32.6 mmol) was added to a solution of 1-(3,3-dimethyl-butyl)-piperidine-4-carboxylic acid ethyl ester from Example E15.1 (7.16 g, 29.7 mmol) in THF (50 ml) and water (5 ml). The mixture was stirred at room temperature for 18 h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 90% dichloromethane:9% methanol:1% acetic acid) to yield the title compound (5.51 g, 87%).


Example E15a
1-Cyclopropylmethyl-piperidine-4-carboxylic acid

The title compound was prepared from cyclopropanecarboxaldehyde and ethyl isonipecotate using similar procedures to those described for Example E15.


Example E16
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid [4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide
Example E16.1
4-(3,3-Dimethyl-butyl)-piperazine-4-carboxylic acid [4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide

HBTU (84 mg, 0.22 mmol) was added to a solution of 1-(3,3-dimethyl-butyl)-piperidine-4-carboxylic acid from Example E15 (42 mg, 0.17 mmol) in DMF (5 ml) and DIEA (to pH9). The mixture was stirred at room temperature for 1 h. (4-Aminomethyl-cyclohexyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride (Compound Number 150) (42 mg, 0.11 mmol) was added and the mixture was stirred at room temperature for 18 h. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 10% methanol:90% dichloromethane) to give a white solid identified as the title compound (34 mg, 57%).


Example E17
N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-2-piperidin-4-yl-acetamide hydrochloride

A solution of 4-({[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamoyl}-methyl)-piperidine-1-carboxylic acid tert-butyl ester (Compound Number 228) (259 mg, 0.45 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (230 mg, 93%).


Example E18
N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-methanesulfonamide

A solution of methanesulfonyl chloride (0.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of (4-aminomethyl-cyclohexyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone (Compound number 149) (1.95 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=432.1


Example E19
N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-2-(1-methanesulfonyl-piperidin-4-yl)-acetamide

A solution of methanesulfonyl chloride (0.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-2-piperidin-4-yl-acetamide hydrochloride from Example E17 (2.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=557.4


Example E20
2-(1-Acetyl-piperidin-4-yl)-N-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-acetamide

A solution of acetyl chloride (0.39 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-2-piperidin-4-yl-acetamide hydrochloride from Example E17 (2.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=521.5


Example E21
1-Isobutyl-piperidine-4-carboxylic acid [4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide

A solution of isobutyraldehyde (0.36 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of piperidine-4-carboxylic acid [4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide hydrochloride (Compound number 238) (2.43 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and DIEA (0.0026 ml). The mixture was stirred at room temperature for 1 h then a solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=507.4


Example E22
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-3-(1-hexyl-piperidin-4-yl)-propionamide

A solution of 1-bromohexane (0.83 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of N-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-3-piperidin-4-yl-propionamide hydrochloride (Compound number 237) (2.57 mg, 0.005 mmol) in DMF (0.05 ml) and triethylamine (0.0021 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=597.6/599.6


Example E23
4-({[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamoyl}-methyl)-piperidine-1-carboxylic acid 4-nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (1.08 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-2-piperidin-4-yl-acetamide hydrochloride from Example E17 (2.58 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=658.5


Example E24
4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid [4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-amide

DIEA (0.30 ml, 1.7 mmol) and 1,1′-carbonyldiimidazole (39 mg, 0.24 mmol) were added to a solution of (4-aminomethyl-cyclohexyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride (Compound number 149) (78 mg, 0.20 mmol) in DMF (4.0 ml) and the mixture was stirred at room temperature for 2 h. 1-(3,3-Dimethyl-butyl)-piperazine dihydrochloride from Example E4 (56 mg, 0.23 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 10% methanol:90% dichloromethane) to give a white solid identified as the title compound (32 mg, 29%).


Example E25
3-Chloro-6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycloheptene
Example E25.1
N-(4-Chloro-2-hydroxy-phenyl)-benzamide

2-Amino-5-chlorophenol (1.45 g, 10 mmol) was dissolved in EtOAc (30 ml) and water (20 ml). Sodium bicarbonate (1.25 g, 15 mmol) then benzoyl chloride (1.42 g, 10 mmol) were added and the mixture was stirred at room temperature for 1 h. The layers were partitioned and the organic layer was washed with brine, dried and concentrated in vacuo. The residue was triturated with diethyl ether to yield the title compound (2.05 g, 82%).


Example E25.2
(3-Chloro-7,8-dihydro-6H-5-oxa-9-aza-benzocyclohepten-9-yl)-phenyl-methanone

N-(4-Chloro-2-hydroxy-phenyl)-benzamide from Example E25.1 (1.0 g, 4 mmol) was dissolved in acetonitrile (10 ml) and dichloromethane (15 ml). 1,3-Dibromopropane (3.26 g, 16 mmol), aliquat 336 (170 mg, 0.4 mmol) and sodium hydroxide (750 mg, 16 mmol) were added and the mixture was heated at 60° C. for 3 h. The solid was filtered off and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc:70% hexane) to yield the title compound (783 mg, 83%).


Example E25.3
3-Chloro-6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycloheptene

(3-Chloro-7,8-dihydro-6H-5-oxa-9-aza-benzocyclohepten-9-yl)-phenyl-methanone from Example E25.2 (783 mg, 2.7 mmol) was dissolved in dioxan (10 ml) and 6M HCl aqueous solution (50 ml) was added. The mixture was heated at reflux for 20 h then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in diethyl ether and water, basified with NaHCO3 and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo to yield the title compound (280 mg, 47%).


Example E26
N-Cyclohexyl-N′-methyl-benzene-1,2-diamine
Example E26.1
Cyclohexyl-(2-nitro-phenyl)-amine

A mixture of 2-fluoronitrobenzene (5.0 g, 35.4 mmol), cyclohexylamine (4.5 ml, 39.0 mmol) and potassium carbonate (17.1 g, 124 mmol) in acetonitrile (100 ml) was heated at reflux for 2 days. The mixture was diluted with EtOAC, washed with water then brine, dried and partially concentrated in vacuo. The solid which precipitated was collected and washed with hexane to yield the title compound (6.7 g, 86%).


Example E26.2
N-Cyclohexyl-benzene-1,2-diamine

Cyclohexyl-(2-nitro-phenyl)-amine from Example E26.1 (3.0 g, 13.6 mmol) was dissolved in methanol (100 ml) and tin (II) chloride (12.9 g, 68.1 mmol) was added. The mixture was stirred for 20 h at room temperature then heated at reflux for 18 h and concentrated in vacuo. The residue was placed in EtOAC (100 ml), cooled down to 0° C. and pH was adjusted to 14 with conc. NH3. The precipitate was filtered off and washed with EtOAc. The filtrate was washed with 2M NH3, water then brine, dried and concentrated in vacuo to yield the title compound (2.25 g, 86%).


Example E26.3
N-Cyclohexyl-N′-methyl-benzene-1,2-diamine

Potassium carbonate (2.45 g, 17.7 mmol) and iodomethane (0.81 ml, 13.0 mmol) were added to a solution of N-cyclohexyl-benzene-1,2-diamine from Example E26.2 (2.25 g, 11.8 mmol) in DMF (10 ml). The mixture was stirred for 6 h at room temperature then poured into water and extracted with EtOAc. The organic layer was washed with water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% EtOAc:95% hexane) to yield the title compound (950 mg, 39%).


Example E27
3-Fluoro-4-hydroxy-benzoic acid ethyl ester

A solution of 3-fluoro-4-hydroxy-benzoic acid (5.16 g, 33.1 mmol) in ethanol (100 ml) was treated with conc. sulphuric acid (5 ml), and the mixture heated at reflux for 4 days. The volatiles were removed in vacuo, and the aqueous residue was basified with saturated NaHCO3 and extracted twice with diethyl ether. The combined organic extracts were dried and concentrated in vacuo to yield the title compound (5.16 g, 85%).


Example E28
2-Chloro-4-hydroxy-benzoic acid ethyl ester

A solution of 2-chloro-4-hydroxy-benzonitrile (5.0 g, 32.6 mmol) in ethanol (125 ml) was treated with conc. sulphuric acid (25 ml) and the mixture heated at reflux for 3 days. Conc. sulphuric acid (25 ml) was added and the mixture was heated at reflux for another 2 days. The volatiles were removed in vacuo, and the aqueous residue was basified with saturated NaHCO3 and extracted 4 times with diethyl ether. The combined organic extracts were dried and concentrated in vacuo to yield the title compound (2.5 g, 38%).


Example E29
4-Hydroxy-3-methyl-benzoic acid methyl ester

4-Amino-3-methyl-benzoic acid methyl ester (5.25 g, 32.0 mmol) was treated with a 35% solution of sulphuric acid (50 ml) and the mixture was stirred and heated until dissolution then cooled to 0° C. Sodium nitrite (2.82 g, 41.6 mmol) in water (50 ml) was added dropwise and the mixture was stirred for 5 min at 0° C. Urea was added to destroy the excess nitrite. Copper nitrate (121 g, 320 mmol) in water (11) was added then copper oxide (4.25 g, 32.0 mmol). The mixture was warmed up to room temperature over 30 min and extracted with EtOAc (×3). The organics were combined, washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc:70% hexane) to yield the title compound (2.2 g, 42%).


Example E30
4-(3-Carboxy-propyl)-3-methyl-benzoic acid methyl ester
Example E30.1
4-((E)-2-tert-Butoxycarbonyl-vinyl)-3-methyl-benzoic acid methyl ester

Tetrakis(triphenylphosphine)palladium (0) (5.0 g, 4.33 mmol) was added to a stirred solution of methyl 4-bromo-3-methylbenzoate (9.93 g, 43.3 mmol), tert-butyl acrylate (50 ml, 341.3 mmol) and sodium acetate (35.8 g, 436.4 mmol) in DMA (350 ml). The mixture was heated at 140° C. for 5 h, filtered through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was redissolved in EtOAc, washed with 0.3M KHSO4 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc:85% hexane to 20% EtOAc:80% hexane) to yield the title compound (4.81 g, 40%).


Example E30.2
4-(2-tert-Butoxycarbonyl-ethyl)-3-methyl-benzoic acid methyl ester

4-((E)-2-tert-Butoxycarbonyl-vinyl)-3-methyl-benzoic acid methyl ester from Example E30.1 (4.00 g, 14.5 mmol) was dissolved in methanol (100 ml) and hydrogenated over 10% Pd/C catalyst (480 mg) for 5 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (3.41 g, 84%).


Example E30.3
4-(2-Carboxy-ethyl)-3-methyl-benzoic acid methyl ester

Trifluoroacetic acid (40 ml) was added slowly to a stirred solution of 4-(2-tert-butoxycarbonyl-ethyl)-3-methyl-benzoic acid methyl ester from Example E30.2 (4.9 g, 17.6 mmol) in dichloromethane (80 ml) at room temperature. The mixture was stirred for 2 h then concentrated in vacuo and azeotroped with dichloromethane. The residue was recrystallised in EtOAc to yield the title compound (2.77 g, 71%).


Example E30.4
4-(3-Carboxy-propyl)-3-methyl-benzoic acid methyl ester

4-(2-Carboxy-ethyl)-3-methyl-benzoic acid methyl ester from Example E30.3 (500 mg, 2.25 mmol) was dissolved in dry dichloromethane (10 ml) and a few drops of DMF. Oxalyl chloride (0.393 ml, 4.5 mmol) was added dropwise and the mixture was stirred for 1 h at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in acetonitrile (20 ml) and cooled to 0° C. A solution of 2M (trimethylsilyl)diazomethane in hexanes (2.25 ml, 4.5 mmol) was added dropwise and the reaction mixture was stirred for 5 h at 0° C. then 20 h at room temperature. Ethyl acetate then 10% citric acid solution were added and the layers were partitioned. The organic layer was washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% ethyl acetate:50% cyclohexane). The product obtained was dissolved in a mixture of acetonitrile and water. A solution of silver benzoate (103 mg, 0.45 mmol) in triethylamine (1.25 ml, 9 mmol) was added gradually while the mixture was sonicated in an ultrasound bath. After 30 min at room temperature, solvents were removed in vacuo. Ethyl acetate and 10% aqueous citric acid solution were added and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% cyclohexane) to yield the title compound (378 mg, 71%).


Example E31
4-(4-Methoxycarbonyl-butyl)-3-methyl-benzoic acid
Example E31.1
4-Bromo-3-methyl-benzoic acid tert-butyl ester

4-Bromo-3-methyl-benzoic acid (2.06 g, 9.6 mmol) and thionyl chloride (2.2 ml, 30.2 mmol) in toluene (50 ml) were heated at reflux for 2 h then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in THF (100 ml) and triethylamine (2.8 ml, 20.1 mmol), cooled down to 0° C. and lithium tert-butoxide (1.24 g, 15.5 mmol) was added portionwise. The mixture was stirred for 18 h at room temperature then concentrated in vacuo. The residue was dissolved in EtOAc, washed with 1M HCl, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% EtOAc:95% pet. ether) to yield the title compound (1.86 g, 71%).


Example E31.2
4-((1E,3E)-4-Methoxycarbonyl-buta-1,3-dienyl)-3-methyl-benzoic acid tert-butyl ester

Tetrakis(triphenylphosphine)palladium (0) (852 mg, 0.7 mol) was added to a stirred solution of 4-bromo-3-methyl-benzoic acid tert-butyl ester from Example E31.1 (1.86 g, 6.8 mmol), 1-acetoxy-1,3-butadiene (7.5 ml, 64.5 mmol) and sodium acetate (5.69 g, 69.4 mmol) in DMA (75 ml). The mixture was heated at 140° C. for 3 h, filtered through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc:80% pet. ether) to yield the title compound (1.54 g, 74%).


Example E31.3
4-(4-Methoxycarbonyl-butyl)-3-methyl-benzoic acid tert-butyl ester

4-((1E,3E)-4-Methoxycarbonyl-buta-1,3-dienyl)-3-methyl-benzoic acid tert-butyl ester from Example E31.2 (1.54 g, 5.1 mmol) was dissolved in methanol (40 ml) and hydrogenated over 10% Pd/C catalyst (200 mg) for 5 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (1.43 g, 92%).


Example E31.4
4-(4-Methoxycarbonyl-butyl)-3-methyl-benzoic acid

Trifluoroacetic acid (20 ml) was added to a solution of 4-(4-methoxycarbonyl-butyl)-3-methyl-benzoic acid tert-butyl ester from Example E31.3 (1.43 g, 4.7 mmol) in dichloromethane (40 ml) and the mixture was stirred for 2 h at room temperature. Solvents were concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (1.07 g, 92%).


Example E32
4-Carboxymethyl-3-methyl-benzoic acid methyl ester
Example E32.1
4-tert-Butoxycarbonylmethyl-3-methyl-benzoic acid methyl ester

Copper (II) fluoride (4.08 g, 40.1 mmol) and bis-[tri-(o-tolyl)phosphine]palladium dichloride (473 mg, 0.6 mmol) were added to a solution of methyl 4-bromo-3-methyl benzoate (4.60 g, 20.1 mmol) in THF (30 ml). The mixture was heated at reflux before silyl ketene acetal (18.5 g, 80.3 mmol) was added. The mixture was heated at reflux for 2 days then diluted with Et2O. Aqueous NH4Cl solution (250 ml) was added and the mixture was stirred for 30 min at room temperature. The layers were partitioned and the aqueous layer extracted twice with Et2O. The organics were combined, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% EtOAc:95% hexane) to yield the title compound (2.84 g, 53%).


Example E32.2
4-Carboxymethyl-3-methyl-benzoic acid methyl ester

Trifluoroacetic acid (15 ml) was added to a solution of 4-tert-butoxycarbonylmethyl-3-methyl-benzoic acid methyl ester from Example E32.1 (2.84 g, 10.7 mmol) in dichloromethane (15 ml). The mixture was stirred for 90 min at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was recrystallised from EtOAc and hexane to yield the title compound (1.81 g, 81%).


Example E33
4-[1,3]-Dioxolan-2-yl-piperidine
Example E33.1
4-Hydroxymethyl-piperidine-1-carboxylic acid benzyl ester

4-Piperidinemethanol (5.0 g, 43 mmol) was dissolved in dichloromethane (100 ml) and triethylamine (12 ml, 86 mmol) at 0° C. Benzylchloroformate (6.8 ml, 47.3 mmol) was added and the mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was redissolved in EtOAc, washed with 1M KHSO4, water then brine, dried and concentrated in vacuo to yield the title compound (8.33 g, 77%).


Example E33.2
4-Formyl-piperidine-1-carboxylic acid benzyl ester

Dess-Martin reagent (17 g, 39.6 mmol) was added portionwise to a solution of 4-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester from Example E33.1 (8.33 g, 33 mmol) in dichloromethane (100 ml) at room temperature. The mixture was stirred for 3 h under an inert atmosphere then diluted with chloroform and water and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc:60% hexane) to yield the title compound (5.5 g, 66%).


Example E33.3
4-[1,3]Dioxolan-2-yl-piperidine-1-carboxylic acid benzyl ester

Ethylene glycol (5 ml) and a catalytic amount of p-toluenesulfonic acid were added to 4-formyl-piperidine-1-carboxylic acid benzyl ester from Example E33.2 (5.6 g, 22.6 mmol) in toluene (100 ml) and the mixture was heated at reflux under Dean and Stark conditions for 2.5 h. Solvents were removed in vacuo and the residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% pet. ether) to yield the title compound (5.14 g, 78%).


Example E33.4
4-[1,3]Dioxolan-2-yl-piperidine

4-[1,3]Dioxolan-2-yl-piperidine-1-carboxylic acid benzyl ester from Example E33.3 (5.14 g, 17.7 mmol) was dissolved in methanol (100 ml) and hydrogenated over 10% Pd/C catalyst (551 mg) for 4 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (2.84 g, 100%).


Example E34
4-(3-Hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester

A solution of piperazine-1-carboxylic acid tert-butyl ester (26.5 g, 142 mmol) in acetone (300 ml) at room temperature was treated with 3-bromo-propan-1-ol (14.5 ml, 156.2 mmol), potassium carbonate (50 g, 361.8 mmol) and potassium iodide (2.4 g, 14.2 mmol), and the mixture was heated at reflux for 18 h then allowed to cool to room temperature. The suspension was filtered and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane) to yield the title compound (27.7 g, 80%).


Example E35
1-Cyclopropylmethyl-imidazolidine ditrifluoroacetate
Example E35.1
[2-(Cyclopropylmethyl-amino)-ethyl]-carbamic acid tert-butyl ester

Potassium hydrogen carbonate (220 mg, 2.2 mmol) and (bromoethyl)cyclopropane (270 mg, 2.0 mmol) were added to a solution of tert-butyl-N-(2-aminoethyl)carbamate (320 mg, 2.0 mmol) in THF (10 ml). The mixture was heated at 66° C. for 20 h and solvents were concentrated in vacuo. The residue was dissolved in chloroform, washed with water, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% triethylamine:4% methanol:95% chloroform) to yield the title compound (130 mg, 30%).


Example E35.2
1-Cyclopropylmethyl-imidazolidine ditrifluoroacetate

Trifluoroacetic acid (5 ml) was added to a solution of [2-(cyclopropylmethyl-amino)-ethyl]-carbamic acid tert-butyl ester from Example E35.1 (180 mg, 0.84 mmol) in dichloromethane (3 ml) and the mixture was stirred for 75 min at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was placed in water (10 ml) and formaldehyde (37% w/w solution, 0.10 ml, 1.36 mmol) was added. The mixture was stirred for 6 days at room temperature, concentrated in vacuo, azeotroped with toluene then pet. ether to yield the title compound (255 mg, 86%).


Example E36
2-piperazin-1-yl-1-p-tolyl-ethanone dihydrochloride
Example E36.1
4-(2-Oxo-2-p-tolyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester

2-Bromo-4-methylacetophenone (572 mg, 2.68 mmol) was added to a solution of piperazine-1-carboxylic acid tert-butyl ester (500 mg, 2.68 mmol) in dichloromethane (5 ml) and triethylamine (0.45 ml, 3.22 mmol). The mixture was stirred for 3 days at room temperature and solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% hexane:60% EtOAc) to yield the title compound (661 mg, 77%).


Example E36.2
2-piperazin-1-yl-1-p-tolyl-ethanone dihydrochloride

4-(2-Oxo-2-p-tolyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester from Example E36.1 (661 mg, 2.08 mmol) was dissolved in 4M HCl solution in dioxan (25 ml) at 0° C. and the mixture was stirred for 45 min at room temperature. Solvents were concentrated in vacuo and azeotroped with diethyl ether to yield the title compound (536 mg, 88%).


Example E37
2-Bromo-1-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-ethanone

Bromoacetyl bromide (0.52 ml, 6.0 mmol) was added to a solution of 1-(3,3-dimethyl-butyl)-piperazine hydrochloride from Example E4 (1.5 g, 5.7 mmol) in dichloromethane (20 ml) and triethylamine (3.57 ml, 25.6 mmol) at 0° C. The mixture was stirred for 20 h at room temperature, washed with saturated NaHCO3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane) to yield the title compound (220 mg, 13%).


Example E38
Cyclopropyl-piperidin-4-ylmethyl-carbamic acid tert-butyl ester
Example E38.1
4-Cyclopropylaminomethyl-piperidine-1-carboxylic acid benzyl ester

Cyclopropylamine (1.4 g, 24.4 mmol) and acetic acid (0.5 ml) were added to a solution of 4-formyl-piperidine-1-carboxylic acid benzyl ester from Example E33.2 (5.5 g, 22.2 mmol) in methanol (49.5 ml) and the mixture was stirred for 1 h at room temperature. Sodium cyanoborohydride (1.84 g, 28.9 mmol) was added and the mixture was stirred for 20 h at room temperature under an inert atmosphere. Solvents were removed in vacuo and azeotroped with toluene. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to yield the title compound (3.0 g, 47%).


Example E38.2
4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidine-1-carboxylic acid benzyl ester

DMAP (127 mg, 1.04 mmol) and di-tert-butyl dicarbonate (3.4 g, 12.5 mmol) were added to a solution of 4-cyclopropylaminomethyl-piperidine-1-carboxylic acid benzyl ester from Example E38.1 (3.0 g, 10.4 mmol) in dichloromethane (50 ml) and triethylamine (to pH9). The mixture was stirred for 20 h at room temperature then concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc:60% hexane) to yield the title compound (3.67 g, 92%).


Example E38.3
Cyclopropyl-piperidin-4-ylmethyl-carbamic acid tert-butyl ester

4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidine-1-carboxylic acid benzyl ester from Example E38.2 (3.67 g, 9.4 mmol) was dissolved in methanol (100 ml) and hydrogenated over 10% Pd/C catalyst (3 g) for 1 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (2.07 g, 87%).


Example E39
4-[3-(4-Carboxy-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester
Example E39.1
4-[3-(4-Ethoxycarbonyl-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester

Triphenylphosphine polystyrene (loading 1.0 mmol/g, 11 g, 11.0 mmol) and DEAD (2.45 g, 11.0 mmol) were added to a solution of 3-fluoro-4-hydroxy-benzoic acid ethyl ester from Example E27 (1.3 g, 7.4 mmol) and 4-(3-hydroxypropyl)-piperazine-1-carboxylic acid tert-butyl ester from Example E34 (1.8 g, 7.4 mmol) in tetrahydrofuran (100 ml) at 0° C. The suspension was allowed to warm to room temperature and stirred for 18 h. The mixture was filtered and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAC) to yield the title compound (1.7 g, 57%).


Example E39.2
4-[3-(4-Carboxy-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester

A solution of 4-[3-(4-ethoxycarbonyl-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E39.1 (1.7 g, 4.1 mmol) in dioxan (25 ml) was treated with 2N NaOH (3 ml) and the mixture stirred at 50° C. for 18 h. A further aliquot of 2N NaOH was added (2 ml), and stirring continued at 50° C. for 3 h. Solvents were removed in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 1% acetic acid:9% methanol:90% chloroform) to yield the title compound (1.45 g, 92%).


Example E40
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-ethoxy}-3-methyl-benzoic acid
Example E40.1
4-[2-(4-Methoxycarbonyl-2-methyl-phenoxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester

4-(2-Hydroxy-ethyl)-piperazine-1-carboxylic acid tert-butyl ester (500 mg, 2.2 mmol) was dissolved in THF (30 ml) and cooled down to 0° C. Polymer-supported triphenylphosphine (2.2 g, 2.2 mmol), DEAD (378 mg, 2.2 mmol) and 4-hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (361 mg, 2.2 mmol) were added and the mixture was stirred for 20 h at room temperature. The resin was filtered off and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (495 mg, 60%).


Example E40.2
3-Methyl-4-(2-piperazin-1-yl-ethoxy)-benzoic acid methyl ester dihydrochloride

4-[2-(4-Methoxycarbonyl-2-methyl-phenoxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E40.1 (200 mg, 0.53 mmol) was dissolved in 4M HCl solution in dioxan (5 ml). The mixture was stirred for 30 min at room temperature, concentrated in vacuo and azeotroped with toluene to yield the title compound (185 mg, 100%).


Example E40.3
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-ethoxy)}-3-methyl-benzoic acid methyl ester

3,3-Dimethylbutyraldehyde (54 mg, 0.53 mmol) was added to a solution of 3-methyl-4-(2-piperazin-1-ylethoxy)-benzoic acid methyl ester dihydrochloride from Example E40.2 (146 mg, 0.42 mmol) in methanol/acetic acid (99:1, v/v, 10 ml) and the mixture was stirred at room temperature for 1 h. Sodium cyanoborohydride (42 mg, 0.69 mmol) was added, and the mixture was stirred at room temperature for 18 h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (64 mg, 34%).


Example E40.4
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-ethoxy}-3-methyl-benzoic acid

4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-ethoxy}-3-methyl-benzoic acid methyl ester from Example E40.3 (42 mg, 0.12 mmol) was dissolved in dioxan (5 ml) and 1M NaOH (1 ml) was added. The mixture was heated at reflux for 2 h then solvents were concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3, water then brine, dried and concentrated in vacuo to yield the title compound (40 mg, 100%).


Example E41
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-oxo-ethoxy}-3-methyl-benzoic acid
Example E41.1
4-tert-Butoxycarbonylmethoxy-3-methyl-benzoic acid methyl ester

Potassium carbonate (4.6 g, 33 mmol), potassium iodide (0.25 g, 1.5 mmol) and tert-butylbromoacetate (2.5 ml, 16.5 mmol) were added to a solution of 4-hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (2.5 g, 15 mmol) in acetone (150 ml) and the mixture was heated at reflux for 20 h. The solid was filtered off and the filtrate concentrated in vacuo. The residue was dissolved in EtOAc, washed with 1N KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc:85% hexane) to yield the title compound (3.8 g, 90%).


Example E41.2
4-Carboxymethoxy-3-methyl-benzoic acid methyl ester

Trifluoroacetic acid (20 ml) was added to a solution of 4-tert-butoxycarbonylmethoxy-3-methyl-benzoic acid methyl ester from Example E41.1 (3.8 g, 13.6 mmol) in dichloromethane (40 ml) and the mixture was stirred for 1 h at room temperature. Volatiles were removed in vacuo and azeotroped with dichloromethane to yield the title compound (3.04 g, 100%).


Example E41.3
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-oxo-ethoxy}-3-methyl-benzoic acid methyl ester

WSCD (5.14 g, 27.2 mmol) and DMAP (1.64 g, 13.6 mmol) were added to a solution of 4-carboxymethoxy-3-methyl-benzoic acid methyl ester from Example E41.2 (3.04 g, 13.6 mmol) in dichloromethane (100 ml) and triethylamine (5 ml). The mixture was stirred for 1 h at room temperature then 1-(3,3-dimethyl-butyl)-piperazine dihydrochloride from Example E4 (3.67 g, 14.9 mmol) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (2.8 g, 55%).


Example E41.4
4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-oxo-ethoxy}-3-methyl-benzoic acid

1M Boron tribromide solution (2.66 ml, 2.66 mmol) was added dropwise to a solution of 4-{2-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-2-oxo-ethoxy}-3-methyl-benzoic acid methyl ester from Example E41.3 (500 mg, 1.33 mmol) in dichloromethane (20 ml) at 0° C. under an inert atmosphere. The mixture was stirred for 20 h at room temperature then cooled down to 0° C. 1M Boron tribromide solution (1.33 ml, 1.33 mmol) was added and the mixture was stirred for 2 h at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 1% acetic acid:5% methanol:94% chloroform) to yield the title compound (350 mg, 72%).


Example E41a 4-(2-Bromo-acetyl)-piperazine-1-carboxylic acid tert-butyl ester

A solution of bromoacetyl bromide (8.5 ml, 97 mmol) in DCM (250 ml) at 0° C. was treated dropwise with a solution of 1-Boc-piperazine (15.9, 85.3 mmol) and triethylamine (18.0 ml, 130 mmol) in DCM (150 ml). After addition was complete, the mixture was stirred at room temperature for 4 h. The solution was washed with ice-cold 1M HCl, sat. aq. NaHCO3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc:80% cyclohexane to 50% EtOAc:50% cyclohexane) to yield the title compound (15.7 g, 60.0%).


Example E41b
2-Chloro-4-hydroxy-benzoic acid methyl ester
Example E41b.1
4-Amino-2-chloro-benzoic acid methyl ester

A solution of 4-Amino-2-chloro-benzoic acid (5.3 g, 31 mmol) in methanol (100 ml) was treated with acetyl chloride (5 ml) and then heated at reflux for 16 hours. The solvents were evaporated in vacuo. The residue was dissolved in EtOAc, washed with saturated sodium hydrogen carbonate, dried and concentrated in vacuo to yield the title compound as a purple solid, 5.45 g, 95%.


Example E41b.2
2-Chloro-4-hydroxy-benzoic acid

4-Amino-2-chloro-benzoic acid methyl ester from Example E41b.1 (5.45 g, 29.4 mmol) was treated with a 35% solution of sulphuric acid (120 ml) and the mixture was stirred and heated until dissolution then cooled to 0° C. Sodium nitrite (4.30 g, 62.5 mmol) in water (25 ml) was added dropwise and the mixture was stirred for 15 min at 0° C. Urea was added to destroy the excess nitrite. Copper nitrate (200 mg, 0.83 mmol) was added and heated to 90° C. The reaction mixture was cooled to room temperature, extracted into ethyl acetate ×3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc:70% hexane to 50% EtOAc:49% hexane:1% AcOH) to yield the title compound (3.7 g, 73%).


Example E41b.3
2-Chloro-4-hydroxy-benzoic acid methyl ester

A solution of 2-chloro-4-hydroxy-benzoic acid (3.70 g, 21.4 mmol)) in methanol (50 ml) was treated with thionyl chloride (2.4 ml, 32 mmol) dropwise and stirred for 24 hours and the solvents were removed in vacuo. The residue was dissolved in ethyl acetate and washed with sat. sodium hydrogen carbonate, dried and solvents were removed in vacuo. The residue was purified by column chromatography on silica gel (eluant with 30% EtOAc:70% cyclohexane) to yield the desired product as a yellow solid, 3.68 g, 92%.


Example E41c
4-[2-(4-Carboxy-3-chloro-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester
Example E41c.1
4-[2-(3-Chloro-4-methoxycarbonyl-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester

2-Chloro-4-hydroxy-benzoic acid methyl ester from example E41b (2.0 g, 10.9 mmol) and 4-(2-Bromo-acetyl)-piperazine-1-carboxylic acid tert-butyl ester from Example E41a (3.68 g, 12.0 mmol) in acetonitrile (30 ml) were treated with potassium carbonate (1.6 g, 11.5 mmol), and the mixture heated at reflux 18 h. before the solvents were removed in vacuo. The residue was adsorbed onto silica gel and purified by flash chromatography on silica gel (eluant; 20% EtOAc:80% cyclohexane to 50% EtOAc:50% cyclohexane to 70% EtOAc:30% cyclohexane) to yield the title compound (4.5 g, 100%).


Example E41c.2
4-[2-(4-Carboxy-3-chloro-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester

A solution of 4-[2-(3-Chloro-4-methoxycarbonyl-phenoxy)-acetyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E41c.1 (4.5 g, 10.8 mmol) in THF at 0° C. was treated with potassium trimethylsilanolate (1.6 g, 10.9 mmol), and the mixture stirred at room temperature for 18 h. A further 1.6 g (10.9 mmol) potassium silanolate was added, and stirring continued at room temperature for 2 h. A further 1.6 g (10.9 mmol) potassium silanolate was added, and the mixture was stirred at 45° C. for 2 h. The mixture was then diluted with water and THF was removed in vacuo. The residue was washed with ether, cooled in an ice-bath and adjusted to pH5 with solid KHSO4 whereupon it was extracted with CHCl3 and CHCl3/isopropanol (90:10 v/v). The combined organics were dried and solvents were removed in vacuo to yield the title compound (3.7 g, 85%).


Example E42
4-(3-tert-Butoxycarbonyl-propoxy)-3-methyl-benzoic acid
Example E42.1
4-Bromo-butyric acid tert-butyl ester

1M Boron tribromide (39 ml, 39 mmol) was added to a solution of butyrolactone (3 ml, 39 mmol) in dichloromethane (30 ml). The mixture was stirred for 20 h at room temperature then quenched with an excess of tert-butylalcohol. The mixture was stirred for 2 h at room temperature, diluted with dichloromethane, washed with saturated NaHCO3, saturated Na2S2O3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 5% EtOAc:95% hexane) to yield the title compound (3 g, 34%).


Example E42.2
4-(3-tert-Butoxycarbonyl-propoxy)-3-methyl-benzoic acid methyl ester

Potassium carbonate (580 mg, 4.20 mmol) and potassium iodide (72 mg, 0.43 mmol) were added to a solution of 4-hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (293 mg, 1.76 mmol) and 4-bromo-butyric acid tert-butyl ester from Example E42.1 (397 mg, 1.78 mmol) in acetone (50 ml). The mixture was heated at reflux for 18 h then the solid was filtered off and the filtrate concentrated in vacuo. The residue was dissolved in EtOAc, washed with water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc:80% pet. ether) to yield the title compound (414 mg, 76%).


Example E42.3
4-(3-tert-Butoxycarbonyl-propoxy)-3-methyl-benzoic acid

Lithium hydroxide monohydrate (137 mg, 3.26 mmol) was added to a solution of 4-(3-tert-butoxycarbonyl-propoxy)-3-methyl-benzoic acid methyl ester from Example E42.2 (414 mg, 1.34 mmol) in THF (10 ml) and water (5 ml). The mixture was stirred for 48 h at room temperature and concentrated in vacuo. The residue was dissolved in chloroform, acidified with 1M HCl then washed with brine, dried and concentrated in vacuo to yield the title compound (275 mg, 70%).


Example E43
4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid
Example E43.1
4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid methyl ester

HBTU (910 mg, 2.4 mmol) was added to a solution of 4-(3-carboxy-propyl)-3-methyl-benzoic acid methyl ester from Example E30 (378 mg, 1.6 mmol) and 1-(3,3-dimethyl-butyl)-piperazine hydrochloride from Example E4 (467 mg, 1.9 mmol) in dichloromethane (15 ml) and DIEA (0.836 ml, 4.8 mmol). The mixture was stirred for 20 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 5% methanol:95% dichloromethane) to yield the title compound (582 mg, 94%).


Example E43.2
4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid

Lithium hydroxide monohydrate (108 mg, 2.6 mmol) was added to a solution of 4-{4-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid methyl ester from Example E43.1 (500 mg, 1.3 mmol) in THF (12 ml) and water (6 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% acetic acid:4% methanol:94% dichloromethane) then recrystallised from chloroform and pet. ether to yield the title compound (439 mg, 91%).


Example E44
4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid
Example E44.1
4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid methyl ester

Oxalyl chloride (2.6 ml, 30 mmol) was added slowly to a solution of 4-(2-carboxy-ethyl)-3-methyl-benzoic acid methyl ester from Example E30.3 (5.33 g, 24 mmol) in dichloromethane (60 ml) and few drops of DMF at 0° C. The mixture was stirred for 2 h at room temperature then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (30 ml) and added to a solution of 1-(3,3-dimethyl-butyl)-piperazine hydrochloride from Example E4 (6.3 g, 26 mmol) in dichloromethane (45 ml) and DIEA (17 ml, 96 mmol) at 0° C. The mixture was stirred for 1 h at room temperature then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane) to yield the title compound (8.5 g, 96%).


Example E44.2
4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid

Lithium hydroxide monohydrate (2.4 g, 56.7 mmol) was added to a solution of 4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid methyl ester from Example E44.1 (8.5 g, 22.7 mmol) in THF (200 ml) and water (100 ml). The mixture was stirred for 24 h at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% acetic acid:4% methanol:94% dichloromethane) to yield the title compound (8.1 g, 99%).


Example E45
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid
Example E45.1
4-((E)-2-tert-Butoxycarbonyl-vinyl)-3-methyl-benzoic acid

Lithium hydroxide monohydrate (384 mg, 9.2 mmol) was added to a solution of 4-((E)-2-tert-butoxycarbonyl-vinyl)-3-methyl-benzoic acid methyl ester from Example E30.1 (1.27 g, 4.6 mmol) in THF (50 ml) and water (20 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was dissolved in EtOAc, washed with 1M KHSO4, water then brine, dried and concentrated in vacuo to yield the title compound (1.1 g, 92%).


Example E45.2
(E)-3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-acrylic acid tert-butyl ester

4-((E)-2-tert-Butoxycarbonyl-vinyl)-3-methyl-benzoic acid from Example E45.1 (1.1 g, 4.2 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (720 mg, 3.6 mmol) were dissolved in dichloromethane (50 ml) and triethylamine (0.75 ml). DMAP (4.45 g, 3.6 mmol) and WSCD (1.36 g, 7.1 mmol) were added and the mixture was heated at reflux for 2 days. The solution was diluted with dichloromethane, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (1.35 g, 82%).


Example E45.3
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid tert-butyl ester

(E)-3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-acrylic acid tert-butyl ester from Example E45.2 (436 mg, 0.99 mmol) was dissolved in methanol (40 ml) and hydrogenated over 10% Pd/C catalyst (91 mg) for 5 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (426 mg, 96%).


Example E45.4
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid

Trifluoroacetic acid (5 ml) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid tert-butyl ester from Example E45.3 (413 mg, 0.92 mmol) in dichloromethane (10 ml) and the mixture was stirred for 45 min at room temperature. Solvents were removed in vacuo and azeotroped with dichloromethane. The residue was crystallised with MeOH/Et2O to yield the title compound (322 mg, 90%).


Example E46
(E)-3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-acrylic acid

Trifluoroacetic acid (5 ml) was added to a solution of (E)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-acrylic acid tert-butyl ester from Example E45.2 (338 mg, 0.76 mmol) in dichloromethane (10 ml) and the mixture was stirred for 45 min at room temperature. Solvents were removed in vacuo and azeotroped with dichloromethane to yield the title compound (337 mg, 80%).


Example E47
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-1-piperazin-1-yl-propan-1-one
Example E47.1
4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperazine-1-carboxylic acid tert-butyl ester

PyBroP (1.54 g, 3.3 mmol) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid from Example E45 (850 mg, 2.25 mmol) and DMAP (275 mg, 2.25 mmol) in dichloromethane (20 ml) and DIEA (0.90 ml, 5.2 mmol). The mixture was stirred for 15 mins at room temperature then 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (450 mg, 2.25 mmol) was added. The mixture was heated at reflux for 18 h, diluted with dichloromethane, washed with 0.3M KHSO4 solution then saturated NaHCO3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% EtOAc) to yield the title compound (1.09 g, 87%).


Example E47.2
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-1-piperazin-1-yl-propan-1-one

4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperazine-1-carboxylic acid tert-butyl ester from Example E47.1 (1.09 g, 1.95 mmol) was dissolved in methanol (20 ml) and 4M HCl/dioxan solution (20 ml) was added. The mixture was stirred for 3 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in methanol (30 ml) and ammonia (5 ml) then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 0.5% 35% ammonia:4.5% methanol:95% dichloromethane to 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (759 mg, 73%).


Example E48
{4-[3-(4-Cyclopropyl-piperazin-1-yl)-propoxy]-3-fluorophenyl}-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone
Example E48.1
4-(3-Bromo-propoxy)-3-fluoro-benzoic acid ethyl ester

1,3-Dibromopropane (2.2 g, 11.0 mmol), potassium carbonate (1.86 g, 13.6 mmol) and potassium iodide (90 mg, 0.5 mmol) were added to 3-fluoro-4-hydroxy-benzoic acid ethyl ester from Example E27 (1.0 g, 5.4 mmol) in acetone (25 ml) and the mixture was heated at reflux for 20 h. The solid was filtered off and washed with EtOAc. The filtrate was concentrated in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc:80% hexane) to yield the title compound (1.18 g, 71%).


Example E48.2
4-[3-(4-Cyclopropyl-piperazin-1-yl)-propoxy]-3-fluoro-benzoic acid ethyl ester

1-Cyclopropyl-piperazine dihydrochloride (642 mg, 3.2 mmol, according to the procedure described by G. S. Poindexter, M. A. Bruce, K. L. Le Boulluec, I. Monkovic, Tet. Lett., 35(44), 7331-7334, 1994), potassium carbonate (2.1 g, 15.2 mmol) and potassium iodide (50 mg, 0.3 mmol) were added to 4-(3-bromo-propoxy)-3-fluorobenzoic acid ethyl ester from Example E48.1 (1.2 g, 3.9 mmol) in acetone (25 ml). The mixture was heated at reflux for 20 h. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc then 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (1.0 g, 89%).


Example E48.3
4-[3-(4-Cyclopropyl-piperazin-1-yl)-propoxy]-3-fluoro-benzoic acid

4-[3-(4-Cyclopropyl-piperazin-1-yl)-propoxy]-3-fluoro-benzoic acid ethyl ester from Example E48.2 (1.0 g, 2.9 mmol) was dissolved in dioxan (10 ml) and 2N NaOH solution (3 ml, 6.0 mmol) was added. The mixture was heated at 60° C. for 18 h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:19% methanol:80% dichloromethane) to yield the title compound (920 mg, 100%).


Example E48.4
{4-[3-(4-Cyclopropyl-piperazin-1-yl)-propoxy]-3-fluoro-phenyl}-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

HBTU (325 mg, 0.9 mmol) and 4M HCl in dioxan (0.45 ml, 1.8 mmol) were added to a solution of 4-[3-(4-cyclopropyl-piperazin-1-yl)-propoxy]-3-fluoro-benzoic acid from Example E48.3 (230 mg, 0.7 mmol) in DMF (5 ml). The mixture was stirred at room temperature for 30 min. 3-Methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E65 (186 mg, 0.9 mmol) and DIEA (pH=9) were added and the mixture was stirred at room temperature for 18 h. The mixture was heated at 60° C. for 3 h then HBTU (300 mg, 0.8 mmol) was added. The mixture was heated at 60° C. for 2 days then solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with saturated Na—HCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a brown solid identified as the title compound (55 mg, 15%).


Example E49
[3-Fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone dihydrochloride
Example E49.1
4-{3-[2-Fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester

A solution of 4-[3-(4-carboxy-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E39 (865 mg, 2.3 mmol) in dichloromethane (50 ml) was treated with triethylamine (to pH9), WSCD (865 mg, 4.5 mmol) and DMAP (276 mg, 2.3 mmol), and the mixture was stirred at room temperature for 10 min. 3-Methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (541 mg, 2.7 mmol) was added. The mixture was heated at reflux for 18 h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3 then brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to yield the title compound (615 mg, 48%).


Example E49.2
[3-Fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone dihydrochloride

A solution of 4-{3-[2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester from Example E49.1 (615 mg, 1.09 mmol) in methanol (2 ml) at 0° C. was treated with 4N HCl in dioxan (5 ml). The solution was allowed to warm to room temperature and stirred for 1 h. Solvents were removed in vacuo to give a white foam identified as the title compound (585 mg, 100%).


Example E50
(4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone bis(trifluoroacetate)

3,3-Dimethylbutyraldehyde (120 mg, 1.20 mmol) and triethylamine (to pH9) were added to a solution of [3-fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone dihydrochloride from Example E49 (585 mg, 1.09 mmol) in methanol/acetic acid (99:1, v/v, 20 ml) and the mixture was stirred at room temperature for 1 h. Sodium cyanoborohydride (103 mg, 1.30 mmol) was added and the mixture was stirred at room temperature for 18 h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to yield (4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluorophenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone, which was lyophilised from aqueous trifluoroacetic acid to give a white solid identified as the title compound (700 mg, 83%).


Example E51
(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-{4-[3-(1-isobutyl-piperidin-4-yl)-propoxy]-3-methyl-phenyl}-methanone

A solution of isobutyraldehyde (0.36 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of (3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-[3-methyl-4-(3-piperidin-4-yl-propoxy)-phenyl]-methanone hydrochloride (2.6 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and DIEA (0.0026 ml). The mixture was stirred at room temperature for 1 h then a solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=530.5


Example E52
(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-{2-fluoro-4-[3-(4-hexyl-piperazin-1-yl)-propoxy]-phenyl}-methanone

A solution of 1-bromohexane (0.83 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of (6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-[2-fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride from Example E5a (2.85 mg, 0.005 mmol) in DMF (0.05 ml) and triethylamine (0.0021 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=583.6


Example E53
1-(4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-propyl}-piperazin-1-yl)-ethanone

A solution of acetyl chloride (0.39 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)=[3-methyl-4-(3-piperazin-1-yl-propoxy)-phenyl]-methasone dihydrochloride (Compound number 408) (2.67 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=503.2


Example E54
{4-[3-(4-Methanesulfonyl-piperazin-1-yl)-propoxy]-3-methyl-phenyl}-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

A solution of methanesulfonyl chloride (0.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-[3-methyl-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride (Compound number 408) (2.67 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=539.2


Example E55
1-(4-[1,3]Dioxolan-2-yl-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

HBTU (327 mg, 0.86 mmol) was added to a solution of 4-[1,3]dioxolan-2-yl-piperidine from Example E33 (143 mg, 0.91 mmol) and 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid from Example E45 (320 mg, 0.82 mmol) in dichloromethane (20 ml) and DIEA (0.7 ml, 4.02 mmol) and the mixture was stirred for 20 h at room temperature. Dichloromethane was added and the solution was washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 4% methanol:96% dichloromethane to 8% methanol:92% dichloromethane) to give a white solid identified as the title compound (359 mg, 83%).


Example E56
1-[4-(Furan-2-carbonyl)-piperazin-1-yl]-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

A solution of HBTU (1.90 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid from Example E45 (1.95 mg, 0.005 mmol) in DMF (0.05 ml) and DIEA (0.0022 ml). The mixture was stirred at room temperature for 30 min then a solution of 1-(2-furoyl)piperazine (0.90 mg, 0.005 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 18 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=553.4


Example E57
(E)-3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-1-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-propenone

A solution of HBTU (1.90 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of(E)-3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-acrylic acid from Example E46 (1.95 mg, 0.005 mmol) in DMF (0.05 ml) and DIEA (0.0022 ml). The mixture was stirred at room temperature for 30 min then a solution of 1-(2-Piperidin-1-yl-ethyl)-piperazine (0.99 mg, 0.005 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 18 h at room temperature then solvents were removed in vacuo to yield the title compound.


Example E58
1-{4-[(Butyl-methyl-amino)-methyl]-piperidin-1-yl}-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one
Example E58.1
1-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidine-4-carbaldehyde

Pyridinium p-toluenesulfonate (85 mg, 0.34 mmol) was added to a solution of 1-(4-[1,3]dioxolan-2-yl-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one from Example E55 (614 mg, 1.16 mmol) in acetone (20 ml) and water (20 ml). The mixture was heated at reflux for 7 days then solvents were removed in vacuo. The residue was redissolved in EtOAc, washed with 0.3M KHSO4 then brine, dried, concentrated in vacuo then crystallised with chloroform and pet. ether to yield the title compound (451 mg, 80%).


Example E58.2
1-{4-[(Butyl-methyl-amino)-methyl]-piperidin-1-yl}-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

A solution of 1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidine-4-carbaldehyde from Example E58.1 (2.43 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of butyl-methyl-amine (0.43 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and the mixture was heated at 50° C. for 3 h then stirred at room temperature for 2 days. A solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added and the mixture was stirred for 20 h at room temperature. Solvents were removed in vacuo to yield the title compound. MS: (ESI)+: [M+H]+=557.6


Example E59
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-1-[4-(2-morpholin-4-yl-ethylamino)-piperidin-1-yl]-propan-1-one

A solution of 1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidin-4-one (Compound number 701) (2.36 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of 2-morpholin-4-yl-ethylamine (0.65 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and the mixture was heated at 50° C. for 3 h then stirred at room temperature for 2 days. A solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added and the mixture was stirred for 20 h at room temperature. Solvents were removed in vacuo to yield the title compound. MS: (ESI)+: [M+H]+=586.6


Example E60
1-(4-Hexyl-piperazin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

A solution of 1-bromohexane (0.83 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-1-piperazin-1-yl-propan-1-one from Example E47 (2.29 mg, 0.005 mmol) in DMF (0.05 ml) and triethylamine (0.0021 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=543.4


Example E61
3-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1-(4-propyl-piperazin-1-yl)-propan-1-one

A solution of propionaldehyde (0.29 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of 3-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1-piperazin-1-yl-propan-1-one (2.36 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and DIEA (0.0026 ml). The mixture was stirred at room temperature for 1 h then a solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=515.5


Example E62
1-(4-Acetyl-piperazin-1-yl)-3-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propan-1-one

A solution of acetyl chloride (0.39 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of 3-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1-piperazin-1-yl-propan-1-one (2.47 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 20 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=535.5


Example E63
3-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1-(4-methanesulfonyl-piperazin-1-yl)-propan-1-one

A solution of methanesulfonyl chloride (0.57 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of 3-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1-piperazin-1-yl-propan-1-one (2.36 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 20 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=551.3


Example E64
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-butan-1-one

4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid from Example E43 (139 mg, 0.37 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (75 mg, 0.37 mmol) were dissolved in dichloromethane (5 ml) and DIEA (0.195 ml, 1.11 mmol). WSCD (93 mg, 0.48 mmol) and DMAP (9 mg, 0.07 mmol) were added and the mixture was heated at reflux for 3 days, then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (11 mg, 5%).


Example E65
N-Benzyl-3-[4-(2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionamide
Example E65.1
4-((E)-2-Methoxycarbonyl-vinyl)-benzoic acid

Sodium hydride (60% dispersion in oil, 1.46 g, 36.6 mmol) was added to a solution of 4-formylbenzoic acid (5.0 g, 33.3 mmol) in toluene (200 ml) and the mixture was stirred for 2 h at room temperature. Methyl (triphenyl-phosphoranylidene)acetate (11.69 g, 35.0 mmol) was added and the mixture was heated at reflux for 20 h. Solvents were removed in vacuo and the residue was redissolved in dichloromethane and 1M NaHCO3. The layers were partitioned and the aqueous layer was acidified with 1M HCl solution then extracted with chloroform. The organic layer was dried and concentrated in vacuo to yield the title compound (3.65 g, 53%).


Example E65.2
(E)-3-[4-(2,3,4,5-Tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-acrylic acid methyl ester

WSCD (1.17 g, 6.16 mmol) was added to a solution of 4-((E)-2-methoxycarbonyl-vinyl)-benzoic acid from Example E65.1 (740 mg, 3.59 mmol), 2,3,4,5-tetrahydro-1H-benzo[b]azepine (445 mg, 3.02 mmol) and DMAP (370 mg, 3.02 mmol) in dichloromethane (40 ml) and triethylamine (0.7 ml, 5.02 mmol). The mixture was heated at reflux for 42 h then solvents were concentrated in vacuo. The residue was dissolved in EtOAc, washed with 1M KHSO4 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc:70% pet. ether) to yield the title compound (484 mg, 48%).


Example E65.3
3-[4-(2,3,4,5-Tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionic acid methyl ester

(E)-3-[4-(2,3,4,5-Tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-acrylic acid methyl ester from Example E65.2 (485 mg, 1.44 mmol) was dissolved in methanol (60 ml) and hydrogenated over 10% Pd/C catalyst (214 mg) for 2 h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (415 mg, 85%).


Example E65.4
3-[4-(2,3,4,5-Tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionic acid

Lithium hydroxide monohydrate (114 mg, 2.72 mmol) was added to a solution of 3-[4-(2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionic acid methyl ester from Example E65.3 (415 mg, 1.23 mmol) in water (5 ml) and dioxan (20 ml). The mixture was stirred for 18 h at room temperature then concentrated in vacuo. The residue was dissolved in chloroform, washed with 1M HCl solution then brine, dried and concentrated in vacuo to yield the title compound (241 mg, 61%).


Example E65.5
N-Benzyl-3-[4-(2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionamide

A mixture of 3-[4-(2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-propionic acid from Example E65.4 (57 mg, 0.18 mmol) and thionyl chloride (0.2 ml, 2.74 mmol) in dichloromethane (6 ml) was heated at reflux for 2 h then volatiles were removed in vacuo. The residue was dissolved in dichloromethane (8 ml) then benzylamine (0.022 ml, 0.20 mmol) and triethylamine (0.05 ml, 0.36 mmol) were added. The mixture was stirred for 3 h at room temperature then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% pet. ether:70% EtOAc) to give a white fluffy solid identified as the title compound (36.5 mg, 50%).


Example E66
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-[2-methyl-4-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-phenyl]-propan-1-one

Oxalyl chloride (0.049 ml, 0.55 mmol) was added slowly to a solution of 4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid from Example E44 (100 mg, 0.28 mmol) in dichloromethane (10 ml) and few drops of DMF. The mixture was stirred for 1 h at room temperature then concentrated in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (10 ml) and DIEA (0.144 ml, 0.84 mmol) then 2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5 (55 mg, 0.28 mmol) was added. The mixture was stirred for 20 h at room temperature then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white fluffy solid identified as the title compound (42 mg, 28%).


Example E67
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-[2-methyl-4-(6-methyl-3,4-dihydro-2E-quinoline-1-carbonyl)-phenyl]-propan-1-one

DMAP (51 mg, 0.42 mmol) and WSCD (161 mg, 0.84 mmol) were added to a solution of 4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid from Example E44 (150 mg, 0.42 mmol) in dichloromethane (10 ml) and triethylamine (0.176 ml, 1.26 mmol) and the mixture was stirred for 30 min at room temperature. 6-Methyl-1,2,3,4-tetrahydro-quinoline (67 mg, 0.46 mmol) was added and the mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was redissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (12 mg, 6%).


Example E68
(4-{3-[1-(3,3-Dimethyl-butyl)-piperidin-4-yl]-propoxy}-3-methyl-phenyl)-(3-methyl-4,10-dihydro-3E-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone
Example E68.1
4-(3-Hydroxy-propyl)-piperidine-1-carboxylic acid tert-butyl ester

4-(2-Carboxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 3.9 mmol, according to the procedure described in J. Med. Chem., 41(14), 2492, 1998) was dissolved in THF (50 ml) and cooled down to 0° C. 2M Borane solution in THF (3.9 ml, 7.8 mmol) was added slowly and the mixture was stirred for 20 h at room temperature. Water was added and solvents were concentrated in vacuo. The residue was dissolved in EtOAC, basified with NaHCO3, washed with brine, dried and concentrated in vacuo to yield the title compound (938 mg, 99%).


Example E68.2
4-[3-(4-Methoxycarbonyl-2-methyl-phenoxy)-propyl]-piperidine-1-carboxylic acid tert-butyl ester

4-(3-Hydroxy-propyl)-piperidine-1-carboxylic acid tert-butyl ester from Example E68.1 (400 mg, 1.64 mmol) and 4-hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (274 mg, 1.64 mmol) were dissolved in THF (30 ml) and cooled down to 0° C. Polymer-supported triphenylphosphine (1.7 g, 2.46 mmol) then DEAD (0.387 ml, 2.46 mmol) were added and the mixture was heated at reflux for 20 h. The resin was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 20% EtOAC:80% cyclohexane) to yield the title compound (340 mg, 53%).


Example E68.3
4-[3-(4-Carboxy-2-methyl-phenoxy)-propyl]-piperidine-1-carboxylic acid tert-butyl ester

2M NaOH solution (1.25 ml, 2.5 mmol) was added to 4-[3-(4-methoxycarbonyl-2-methyl-phenoxy)-propyl]-piperidine-1-carboxylic acid tert-butyl ester from Example E68.2 (340 mg, 0.87 mmol) in dioxan (10 ml) and the mixture was heated at 60° C. for 20 h. 2M NaOH solution (5 ml, 10 mmol) was added and the mixture was heated at 60° C. for 20 h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1% acetic acid:9% methanol:90% dichloromethane) to yield the title compound (303 mg, 92%).


Example E68.4
4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester

PyBroP (224 mg, 0.48 mmol) and DMAP (39 mg, 0.32 mmol) were added to a solution of 4-[3-(4-carboxy-2-methyl-phenoxy)-propyl]-piperidine-1-carboxylic acid tert-butyl ester from Example E68.3 (120 mg, 0.32 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (70 mg, 0.35 mmol) in dichloromethane (5 ml) and DIEA (0.111 ml, 0.64 mmol). The mixture was heated at reflux for 2 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to yield the title compound (71 mg, 40%).


Example E68.5
(3-Methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-[3-methyl-4-(3-piperidin-4-yl-propoxy)-phenyl]-methanone hydrochloride

4M HCl solution in dioxan (1 ml) was added to a solution of 4-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester from Example E68.4 (71 mg, 0.13 mmol) in methanol (3 ml). The mixture was stirred for 20 h at room temperature then solvents were concentrated in vacuo. The residue was triturated with diethyl ether to yield the title compound (61 mg, 97%).


Example E68.6
(4-{3-[1-(3,3-Dimethyl-butyl)-piperidin-4-yl]-propoxy}-3-methyl-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

Acetic acid (0.05 ml) and 3,3-dimethylbutyraldehyde (0.024 ml, 0.19 mmol) were added to a solution of (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-[3-methyl-4-(3-piperidin-4-yl-propoxy)-phenyl]-methanone hydrochloride from Example E68.5 (60 mg, 0.12 mmol) in methanol (2.45 ml) and triethylamine (0.026 ml, 0.19 mmol). The mixture was stirred at room temperature for 1 h then sodium triacetoxyborohydride (40 mg, 0.19 mmol) was added. The mixture was stirred at room temperature for 18 h, diluted with dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white fluffy solid identified as the title compound (33 mg, 48%).


Example E69
(4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-phenyl)-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone
Example E69.1
4-{3-[4-(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-fluoro-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester

4-[3-(4-Carboxy-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E39 (130 mg, 0.34 mmol) was dissolved in dichloromethane (5 ml) and a few drops of DMF. Oxalyl chloride (0.059 ml, 0.68 mmol) was added slowly and the mixture was stirred, for 30 min at room temperature. Solvents were concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (5 ml) and 1-benzyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5a (100 mg, 0.34 mmol) then DIEA (0.176 ml, 1.02 mmol) were added. The mixture was stirred for 2 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to yield the title compound (110 mg, 50%).


Example E69.2
(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-[3-fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride

4-{3-[4-(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-fluoro-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester from Example E69.1 (110 mg, 0.17 mmol) was dissolved in methanol (5 ml) and 4M HCl in dioxan (2 ml) was added. The mixture was stirred for 20 h at room temperature then concentrated in vacuo to yield the title compound (105 mg, 100%).


Example E69.3
(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-(4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-phenyl)-methanone

(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-[3-fluoro-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride from Example E69.2 (105 mg, 0.17 mmol) was dissolved in methanol (2.45 ml) and triethylamine (0.07 ml, 0.50 mmol). Acetic acid (0.05 ml) then 3,3-dimethylbutyraldehyde (0.032 ml, 0.25 mmol) were added and the mixture was stirred for 1 h at room temperature. Sodium cyanoborohydride (16 mg, 0.25 mmol) was added and the mixture was stirred for 3 h at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane) to yield the title compound (102 mg, 95%).


Example E69.4
(4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-phenyl)-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone

(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-(4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-phenyl)-methanone from Example E69.3 (90 mg, 0.14 mmol) was dissolved in methanol (5 ml) and acetic acid (1 ml) and hydrogenated over 20 wt. % palladium hydroxide catalyst (90 mg) for 8 h. The mixture was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (39 mg, 51%).


Example E70
(4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-methyl-phenyl)-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone
Example E70.1
4-{3-[4-(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester

4-[3-(4-Carboxy-2-methyl-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester (350 mg, 0.92 mmol) was dissolved in dichloromethane (5 ml) and a few drops of DMF. Oxalyl chloride (0.162 ml, 1.84 mmol) was added slowly and the mixture was stirred for 30 min at room temperature. Solvents were concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (10 ml) and 1-benzyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5a (268 mg, 0.92 mmol) then DIEA (0.48 ml, 2.77 mmol) were added. The mixture was stirred for 2 days at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to yield the title compound (230 mg, 38%).


Example E70.2
(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-[3-methyl-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride

4-{3-[4-(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-phenoxy]-propyl}-piperazine-1-carboxylic acid tert-butyl ester from Example E70.1 (230 mg, 0.35 mmol) was dissolved in methanol (5 ml) and 4M HCl in dioxan (2 ml) was added. The mixture was stirred for 2 h at room temperature then concentrated in vacuo and triturated with diethyl ether to yield the title compound (215 mg, 98%).


Example E70.3
(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-(4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-methyl-phenyl)-methanone

(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-[3-methyl-4-(3-piperazin-1-yl-propoxy)-phenyl]-methanone dihydrochloride from Example E70.2 (100 mg, 0.16 mmol) was dissolved in methanol (2.45 ml) and triethylamine (0.068 ml, 0.48 mmol). Acetic acid (0.05 ml) then 3,3-dimethylbutyraldehyde (0.031 ml, 0.24 mmol) were added and the mixture was stirred for 1 h at room temperature. Sodium cyanoborohydride (16 mg, 0.24 mmol) was added and the mixture was stirred for 20 h at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield the title compound (98 mg, 96%).


Example E70.4
(4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-methyl-phenyl)-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone

(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-(4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-methyl-phenyl)-methanone from Example E70.3 (98 mg, 0.15 mmol) was dissolved in methanol (5 ml) and acetic acid (1 ml) and hydrogenated over 20 wt. % palladium hydroxide catalyst (98 mg) for 8 h. The mixture was filtered through glass-fibre paper and the filtrate was concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (17 mg, 20%).


Example E71

N-(4-Chloro-phenyl)-4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-N-methyl-benzamide


Example E71.1
4-(3-{4-[(4-Chloro-phenyl)-methyl-carbamoyl]-2-fluoro-phenoxy}-propyl)-piperazine-1-carboxylic acid tert-butyl ester

PyBroP (606 mg, 1.3 mmol) was added to a solution of 4-[3-(4-carboxy-2-fluoro-phenoxy)-propyl]-piperazine-1-carboxylic acid tert-butyl ester from Example E39 (382 mg, 1.0 mmol) in dichloromethane (20 ml) and DIEA (to pH9). The mixture was stirred for 1 h at room temperature then (4-chloro-phenyl)-methyl amine (156 mg, 1.1 mmol) was added. The mixture was stirred for 2 days at room temperature then solvents were concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (210 mg, 41%).


Example E71.2
N-(4-Chloro-phenyl)-3-fluoro-N-methyl-4-(3-piperazin-1-yl-propoxy)-benzamide dihydrochloride

4-(3-{4-[(4-Chloro-phenyl)-methyl-carbamoyl]-2-fluoro-phenoxy}-propyl)-piperazine-1-carboxylic acid tert-butyl ester from Example E71.1 (210 mg, 0.4 mmol) was dissolved in 4M HCl in dioxan (5 ml) and stirred for 1 h at room temperature. Solvents were concentrated in vacuo and azeotroped with toluene to yield the title compound (184 mg, 100%).


Example E71.3
N-(4-Chloro-phenyl)-4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-propoxy}-3-fluoro-N-methyl-benzamide

N-(4-Chloro-phenyl)-3-fluoro-N-methyl-4-(3-piperazin-1-yl-propoxy)-benzamide dihydrochloride from Example E71.2 (184 mg, 0.4 mmol) was dissolved in methanol (4.95 ml) and triethylamine (0.167 ml, 1.2 mmol). Acetic acid (0.05 ml) then 3,3-dimethylbutyraldehyde (46 mg, 0.44 mmol) were added and the mixture was stirred for 1 h at room temperature. Sodium cyanoborohydride (31 mg, 0.5 mmol) was added and the mixture was stirred for 20 h at room temperature then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to give a white foam identified as the title compound (77 mg, 37%).


Example E72
(4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone
Example E72.1
4-(4-Bromo-butoxy)-3-fluoro-benzoic acid ethyl ester

1,4-Dibromobutane (2.34 g, 10.8 mmol), potassium carbonate (1.86 g, 13.5 mmol) and potassium iodide (90 mg, 0.5 mmol) were added to a solution of 3-fluoro-4-hydroxy-benzoic acid ethyl ester from Example E27 (1.0 g, 5.4 mmol) in acetone (25 ml) and the mixture was heated at reflux for 20 h. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc:85% hexane) to yield the title compound (1.38 g, 80%).


Example E72.2
4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-benzoic acid ethyl ester

1-(3,3-Dimethyl-butyl)-piperazine hydrochloride from Example E4 (874 mg, 3.7 mmol), potassium carbonate (2.5 g, 18.0 mmol) and potassium iodide (60 mg, 0.4 mmol) were added to a solution of 4-(4-bromo-butoxy)-3-fluoro-benzoic acid ethyl ester from Example E72.1 (1.4 g, 4.4 mmol) in acetone (35 ml) and the mixture was heated at reflux for 20 h. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 1% 35% ammonia:10% methanol:89% EtOAc) to yield the title compound (1.35 g, 90%).


Example E72.3
4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-benzoic acid

Sodium hydroxide (0.5 g, 13.2 mmol) and water (5 ml) were added to a solution of 4-{4-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-benzoic acid ethyl ester from Example E72.2 (1.35 g, 3.3 mmol) in dioxan (20 ml). The mixture was stirred for 1 h at room temperature then heated at 60° C. for 20 h. Solvents were concentrated in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:19% methanol:80% chloroform) to yield the title compound (0.85 g, 67%).


Example E72.4
(4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

A mixture of 4-{4-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-butoxy}-3-fluoro-benzoic acid from Example E72.3 (190 mg, 0.5 mmol) and thionyl chloride (2 ml) in dichloromethane (5 ml) was heated at reflux for 1 h. Solvents were concentrated in vacuo and the residue was dissolved in dichloromethane (10 ml). 3-Methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (110 mg, 0.55 mmol) and DIEA (to pH9) were added. The mixture was stirred at room temperature for 2 days and concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a colourless oil identified as the title compound (48 mg, 17%).


Example E73
(4-{2-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-ethoxy}-3-methyl-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

WSCD (58 mg, 0.30 mmol) and DMAP (20 mg, 0.15 mmol) were added to a solution of 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (37 mg, 0.20 mmol) and 4-{2-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-ethoxy}-3-methyl-benzoic acid from Example E40 (53 mg, 0.15 mmol) in dichloromethane (5 ml) and triethylamine (to pH9). The mixture was heated at reflux for 2 days then concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% chloroform) to give an off-white solid identified as the title compound (3.5 mg, 4%).


Example E74
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-ethanone

Oxalyl chloride (42 mg, 0.34 mmol) and 2 drops of DMF were added to a solution of 4-{2-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-2-oxo-ethoxy}-3-methyl-benzoic acid from Example E41 (100 mg, 0.28 mmol) in dichloromethane (5 ml) at 0° C. The mixture was stirred for 1 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (5 ml) and a solution of 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (61 mg, 0.31 mmol) in dichloromethane (1 ml) and triethylamine (to pH9) was added. The mixture was stirred for 2 days at room temperature then concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified twice by flash chromatography on silica gel (eluant; 5% methanol:95% chloroform to 10% methanol:90% chloroform then 5% methanol:95% EtOAc to 10% methanol:90% EtOAc) to give a white solid identified as the title compound (25 mg, 17%).


Example E75
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-[4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-ethanone
Example E75.1
(4-Benzyloxy-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

Oxalyl chloride (0.41 ml, 4.7 mmol) and a few drops of DMF were added to a solution of 4-(benzyloxy)benzoic acid (855 mg, 3.7 mmol) in dichloromethane (15 ml). The mixture was stirred for 2 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (10 ml) and a solution of 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (500 mg, 2.5 mmol) in dichloromethane (10 ml) and triethylamine (0.87 ml, 6.2 mmol) was added. The mixture was stirred for 20 h at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 3% methanol:97% EtOAc) to yield the title compound (820 mg, 80%).


Example E75.2
(4-Hydroxy-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

(4-Benzyloxy-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone from Example E75.1 (800 mg, 1.95 mmol) was dissolved in methanol (100 ml) and hydrogenated over 10% Pd/C catalyst (400 mg) for 7 h. The mixture was filtered through Celite® filter agent, washed with chloroform and methanol and the filtrate was concentrated in vacuo to yield the title compound (140 mg, 22%).


Example E75.3
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-2-[4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-ethanone

Potassium carbonate (104 mg, 0.76 mmol) was added to a mixture of 2-bromo-1-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-ethanone from Example E37 (110 mg, 0.38 mmol) and (4-hydroxy-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone from Example E75.2 (90 mg, 0.28 mmol) in acetonitrile (5 ml). The mixture was heated at reflux for 20 h then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with 5% KHCO3 solution, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (21 mg, 11%).


Example E76
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butan-1-one
Example E76.1
4-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butyric acid tert-butyl ester

WSCD (391 mg, 2.06 mmol) and DMAP (133 mg, 1.09 mmol) were added to a solution of 4-(3-tert-butoxycarbonyl-propoxy)-3-methyl-benzoic acid from Example E42 (275 mg, 0.94 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (191 mg, 0.95 mmol) in dichloromethane (30 ml) and triethylamine (0.28 ml, 2.01 mmol). The mixture was heated at reflux for 72 h, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (80 mg, 18%).


Example E76.2
4-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butyric acid

Trifluoroacetic acid (5 ml) was added to a solution of 4-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butyric acid tert-butyl ester from Example E76.1 (80 mg, 0.17 mmol) in dichloromethane (10 ml). The mixture was stirred for 2 h at room temperature, concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (71 mg, 100%).


Example E76.3
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butan-1-one

HBTU (101 mg, 0.27 mmol) was added to a solution of 4-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy]-butyric acid from E76.2 (71 mg, 0.17 mmol) and 1-(3,3-dimethyl-butyl)-piperazine dihydrochloride from Example E4 (54 mg, 0.22 mmol) in dichloromethane (10 ml) and DIEA (0.15 ml, 0.86 mmol). The mixture was stirred for 20 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 6% methanol:94% dichloromethane) to give a white powder identified as the title compound (52 mg, 53%).


Example E77
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid piperidin-4-ylmethyl ester
Example E77.1
4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyloxymethyl}-piperidine-1-carboxylic acid benzyl ester

WSCD (107 mg, 0.54 mmol) and DMAP (33 mg, 0.27 mmol) were added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid from Example E45 (106 mg, 0.27 mmol) and 4-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester (81 mg, 0.32 mmol) in dichloromethane (5 ml) and DIEA (0.095 ml, 0.54 mmol). The mixture was stirred for 3 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (44 mg, 26%).


Example E77.2
3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid piperidin-4-ylmethyl ester

4-{3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyloxymethyl}-piperidine-1-carboxylic acid benzyl ester from Example E77.1 (44 mg, 0.07 mmol) was dissolved in methanol (5 ml) and hydrogenated over 10% Pd/C catalyst (5 mg) for 2 h. The mixture was filtered through Celite® filter agent and the filtrate concentrated in vacuo to give a white powder identified as the title compound (34 mg, 98%).


Example E78
Methyl (3-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenoxy)acetate

Diisopropylethylamine (2.1 ml, 12.0 mmol), dimethylamino-pyridine (0.74 g, 6.0 mmol), PyBroP® (4.20 g, 9.0 mmol) and 3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene from Example E2 (1.28 g, 6.0 mmol) were added to a solution of tert-butyl 4-(2-(4-carboxy-3-chloro-phenoxy)-acetyl)-piperazine-1-carboxylate from Example E41c (2.39 g, 6.0 mmol) in dichloromethane (50 ml) and the mixture was heated at reflux for 20 h. The reaction mixture was cooled, diluted with dichloromethane (50 ml), washed with saturated aqueous sodium hydrogen carbonate, dried and concentrated in vacuo. The residue was dissolved in methanol (150 ml) and treated with a 4M solution of hydrogen chloride in dioxan (50 ml), with cooling in an ice bath. The solution was stirred at room temperature for 16 h. The reaction mixture was evaporated and the residue taken up in water and washed with chloroform. The aqueous was treated with solid sodium hydrogen carbonate until basic pH, extracted into chloroform, dried and evaporated. The residue was purified by flash chromatography on silica gel (eluant; EtOAc followed by a 2% to 10% methanol:98% to 90% EtOAc gradient) to yield a white solid identified as the title compound (0.53 g, 20%).


Example E79
1-(4-Hydroxymethyl-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

Sodium borohydride (12 mg, 0.32 mmol) was added to a solution of 1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidine-4-carbaldehyde from Example E58.1 (74 mg, 0.15 mmol) in methanol (6 ml). The mixture was stirred for 1 h at room temperature, acidified with 1M HCl and concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was crystallised from chloroform and pet. ether to give a white powder identified as the title compound (28 mg, 38%).


Example E80
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-[4-(3,4-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propan-1-one
Example E80.1
3-[4-(3,4-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propionic acid tert-butyl ester

Sodium hydride (14 mg, 0.34 mmol) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid tert-butyl ester from Example E45 (125 mg, 0.28 mmol) in DMF (2 ml) at 0° C. The mixture was stirred for 20 min at room temperature then cooled down to 0° C. Methyl iodide (0.09 ml, 1.4 mmol) was added and the mixture was stirred for 20 h at room temperature. EtOAc was added and the mixture was washed with 0.3M KHSO4 then brine, dried, concentrated in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (46 mg, 36%).


Example E80.2
3-[4-(3,4-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propionic acid

Trifluoroacetic acid (2 ml) was added to 3-[4-(3,4-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propionic acid tert-butyl ester from Example E80.1 (46 mg, 0.10 mmol) in dichloromethane (5 ml). The mixture was stirred for 2 h at room temperature then concentrated in vacuo to yield the title compound (40 mg, 100%).


Example E80.3
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-[4-(3,4-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propan-1-one

Oxalyl chloride (0.018 ml, 0.20 mmol) was added to a solution of 3-[4-(3,4-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-propionic acid from Example E80.2 (40 mg, 0.10 mmol) in dichloromethane (5 ml) and a few drops of DMF. The mixture was stirred for 1 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (5 ml) and 1-(3,3-dimethyl-butyl)-piperazine dihydrochloride from Example E4 (30 mg, 0.12 mmol) and DIEA (0.052 ml, 0.30 mmol) were added. The mixture was stirred for 20 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (36 mg, 65%).


Example E81
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-[2-methyl-4-(2,3,4,5-tetrahydro-benzo[e][1,4]diazepine-1-carbonyl)-phenyl]-butan-1-one
Example E81.1
1-(4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoyl)-1,2,3,5-tetrahydro-benzo[e][1,4]diazepine-4-carboxylic acid tert-butyl ester

WSCD (58 mg, 0.30 mmol) and DMAP (18 mg, 0.15 mmol) were added to a solution of 4-{4-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid from Example E43 (55 mg, 0.15 mmol) and 1,2,3,5-tetrahydro-benzo[e][1,4]diazepine-4-carboxylic acid tert-butyl ester (73 mg, 0.30 mmol) in dichloromethane (3 ml) and DIEA (0.052 ml, 0.30 mmol). The mixture was heated at reflux for 5 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to yield the title compound (25 mg, 28%).


Example E81.2
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-[2-methyl-4-(2,3,4,5-tetrahydro-benzo[e][1,4]diazepine-1-carbonyl)-phenyl]-butan-1-one

1-(4-{4-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoyl)-1,2,3,5-tetrahydro-benzo[e][1,4]diazepine-4-carboxylic acid tert-butyl ester from Example E81.1 (25 mg, 0.04 mmol) was dissolved in methanol (2 ml) and 4M HCl in dioxan (2 ml) was added. The mixture was stirred for 1 h at room temperature then concentrated in vacuo to give a white powder identified as the title compound (6 mg, 28%). (ESI)+: [M+H]+=505.5


Example E82
4-[4-(7,8-Dihydro-6H-5-oxa-9-aza-benzocycloheptene-9-carbonyl)-2-methyl-phenyl]-1-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-butan-1-one

WSCD (58 mg, 0.30 mmol) and DMAP (18 mg, 0.15 mmol) were added to a solution of 4-{4-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-4-oxo-butyl}-3-methyl-benzoic acid from Example E43 (55 mg, 0.15 mmol) and 6,7,8,9-tetrahydro-5-oxa-9-aza-benzocycloheptene (44 mg, 0.30 mmol) in dichloromethane (3 ml) and DIEA (0.052 ml, 0.30 mmol). The mixture was heated at reflux for 5 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (6 mg, 10%).


Example E83
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-5-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentan-1-one
Example E83.1
5-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentanoic acid methyl ester

WSCD (822 mg, 4.3=01) and DMAP (273 mg, 2.2 mmol) were added to a solution of 4-(4-methoxycarbonyl-butyl)-3-methyl-benzoic acid from Example E31 (571 mg, 2.3 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (424 mg, 2.1 mmol) in dichloromethane (50 ml) and triethylamine (0.6 ml, 4.3 mmol). The mixture was heated at reflux for 72 h, diluted with dichloromethane, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 5% triethyamine:95% EtOAc) to yield the title compound (424 mg, 46%).


Example E83.2
5-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentanoic acid

Lithium hydroxide monohydrate (120 mg, 2.86 mmol) was added to a solution of 5-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentanoic acid methyl ester from Example E83.1 (410 mg, 0.95 mmol) in THF (10 ml) and water (5 ml). The mixture was stirred for 24 h at room temperature and concentrated in vacuo. The residue was acidified with 1M HCl and extracted with chloroform. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% acetic acid:7% methanol:90% chloroform) to yield the title compound (105 mg, 26%).


Example E83.3
1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-5-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentan-1-one

HBTU (104 mg, 0.27 mmol) was added to a solution of 5-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-pentanoic acid from E83.2 (105 mg, 0.25 mmol) and 1-(3,3-dimethyl-butyl)-piperazine dihydrochloride from Example E4 (69 mg, 0.28 mmol) in DMF (10 ml) and DIEA (0.2 ml, 1.15 mmol). The mixture was stirred for 24 h at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 4% methanol:96% dichloromethane to 8% methanol:92% dichloromethane) to give a white solid identified as the title compound (88 mg, 62%).


Example E84
1-(4-Hydroxy-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

Sodium borohydride (4 mg, 0.1 mmol) was added to a solution of 1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidin-4-one (Compound number 701) (50 mg, 0.11 mmol) in methanol/acetic acid (99:1, v/v, 100 ml) and the mixture was stirred at room temperature for 1 h. Sodium borohydride (4 mg, 0.11 mmol) was added again and the mixture was stirred for 1 h at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to give a white powder identified as the title compound (28 mg, 56%).


Example E85
1-(4-Cyclobutylmethyl-piperazin-1-yl)-2-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-ethanone
Example E85.1
4-[2-(4-Cyclobutylmethyl-piperazin-1-yl)-2-oxo-ethyl]-3-methyl-benzoic acid methyl ester

Oxalyl chloride (0.36 ml, 3.3 mmol) was added to a solution of 4-carboxymethyl-3-methyl-benzoic acid methyl ester from Example E32 (687 mg, 3.3 mmol) in dichloromethane (20 ml) and few drops of DMF. The mixture was stirred for 3 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (10 ml) and added to a solution of 1-cyclobutylmethyl-piperazine dihydrochloride (750 mg, 3.3 mmol) in dichloromethane (10 ml) and DIEA (1.73 ml, 9.9 mmol) at 0° C. The mixture was stirred for 20 h at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% methanol:97% dichloromethane) to yield the title compound (528 mg, 46%).


Example E85.2
4-[2-(4-Cyclobutylmethyl-piperazin-1-yl)-2-oxo-ethyl]-3-methyl-benzoic acid

Lithium hydroxide monohydrate (122 mg, 2.9 mmol) was added to a solution of 4-[2-(4-cyclobutylmethyl-piperazin-1-yl)-2-oxo-ethyl]-3-methyl-benzoic acid methyl ester from Example E85.1 (500 mg, 1.4 mmol) in THF (10 ml) and water (5 ml). The mixture was stirred for 20 h at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% acetic acid:7% methanol:90% chloroform) to yield the title compound (300 mg, 63%).


Example E85.3
1-(4-Cyclobutylmethyl-piperazin-1-yl)-2-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-ethanone

WSCD (76 mg, 0.39 mmol) and DMAP (7 mg, 0.06 mmol) were added to a solution of 4-[2-(4-cyclobutylmethyl-piperazin-1-yl)-2-oxo-ethyl]-3-methyl-benzoic acid from Example E85.2 (100 mg, 0.30 mmol) and 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (61 mg, 0.30 mmol) in dichloromethane (20 ml) and DIEA (0.16 ml, 0.91 mmol). The mixture was heated at reflux for 20 h and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 4% methanol:96% dichloromethane to 6% methanol:94% dichloromethane to 1% 35% ammonia:7% methanol:92% dichloromethane) to give an off-white solid identified as the title compound (50 mg, 32%).


Example E86
1-(4-Cyclopropylaminomethyl-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one
Example E86.1
4-(3-{4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidin-1-yl}-3-oxo-propyl)-3-methyl-benzoic acid methyl ester

Oxalyl chloride (1.26 ml, 14.4 mmol) was added to a solution of 4-(2-carboxy-ethyl)-3-methyl-benzoic acid methyl ester from Example E30.3 (1.60 g, 7.2 mmol) in dichloromethane (50 ml) and few drops of DMF. The mixture was stirred for 1 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (50 ml) and DIEA (2.5 ml, 14.4 mmol) and cyclopropyl-piperidin-4-ylmethyl-carbamic acid tert-butyl ester from Example E38 (1.83 g, 7.2 mmol) in dichloromethane (5 ml) was added. The mixture was stirred for 2 h at room temperature, diluted with dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% cyclohexane) to yield the title compound (1.42 g, 43%).


Example E86.2
4-(3-{4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidin-1-yl}-3-oxo-propyl)-3-methyl-benzoic acid

Lithium hydroxide monohydrate (142 mg, 3.4 mmol) was added to a solution of 4-(3-{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidin-1-yl}-3-oxo-propyl)-3-methyl-benzoic acid methyl ester from Example E86.1 (1.41 g, 3.1 mmol) in THF (20 ml) and water (2 ml). The mixture was stirred for 16 h at room temperature then 1M NaOH solution (5 ml) was added. The mixture was heated at 60° C. for 3 h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with 1M HCl then brine, dried and concentrated in vacuo to yield the title compound (1.25 g, 91%).


Example E86.3
Cyclopropyl-(1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester

WSCD (1.08 g, 5.6 mmol) and DMAP (343 mg, 2.8 mmol) were added to a solution of 4-(3-{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-piperidin-1-yl}-3-oxo-propyl)-3-methyl-benzoic acid from Example E86.2 (1.25 g, 2.8 mmol) in dichloromethane (100 ml) and triethylamine (0.783 ml, 5.6 mmol). The mixture was stirred for 1 h at room temperature then 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (676 mg, 3.4 mmol) was added. The mixture was heated at reflux for 2 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% methanol:98% EtOAc to 5% methanol:95% EtOAc) to yield the title compound (1.1 g, 62%).


Example E86.4
1-(4-Cyclopropylaminomethyl-piperidin-1-yl)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

Cyclopropyl-(1-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester from Example E86.3 (220 mg, 0.35 mmol) was dissolved in methanol (5 ml) and 4M HCl solution in dioxan (5 ml) was added. The mixture was stirred for 2 h at room temperature then concentrated in vacuo to give an off-white solid identified as the title compound (189 mg, 95%).


Example E87
N-Cyclopropyl-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-N-piperidin-4-ylmethyl-propionamide hydrochloride
Example E87.1
4-[(Cyclopropyl-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester

PyBroP (238 mg, 0.51 mmol) was added to a solution of 3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionic acid from Example E45 (200 mg, 0.51 mmol) and 4-cyclopropylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester (130 mg, 0.51 mmol) in dichloromethane (10 ml) and DIEA (0.18 ml, 1.02 mmol). The mixture was stirred for 4 days at room temperature, diluted with EtOAc, washed with 5% KHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane) to yield the title compound (235 mg, 73%).


Example E87.2
N-Cyclopropyl-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-N-piperidin-4-ylmethyl-propionamide hydrochloride

4-[(Cyclopropyl-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-phenyl]-propionyl}-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester from Example E87.1 (235 mg, 0.37 mmol) was dissolved in 4M HCl solution in dioxan (5 ml). The mixture was stirred for 1 h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in 1M HCl, washed twice with dichloromethane and freeze-dried to give an off-white solid identified as the title compound (82 mg, 39%).


Example E88
1-Methyl-5-(3-methyl-2-nitro-phenylamino)-1H-pyrazole-4-carboxylic acid ethyl ester

Cesium carbonate (35.2 g, 108 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.4 g, 0.7 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.2 g, 0.2 mmol) were added to a solution of ethyl 5-amino-1-methylpyrazole-4-carboxylate (15.3 g, 90 mmol) in dioxan (50 ml) under an inert atmosphere. A solution of 3-bromo-2-nitrotoluene (16.2 g, 75 mmol) in dioxane (10 ml) was added and the mixture was stirred for 30 min at room temperature then heated at reflux for 72 h. The suspension was filtered through Celite® filter agent, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% pet. ether) then recrystallised from EtOAc/pet. ether to yield the title compound (12.5 g, 45%).


Example E89
5-Amino-1-ethyl-1H-pyrazole-4-carboxylic acid ethyl ester

Triethylamine (19.6 ml, 144 mmol) was added cautiously to a solution of ethyl (ethoxymethylene)cyanoacetate (10.1 g, 60 mmol) and ethyl hydrazine oxalate (9.9 g, 66 mmol) in ethanol (200 ml). The mixture was heated at reflux for 24 h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with 5% KHCO3 solution then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 25% pet. ether:75% EtOAc) to yield the title compound (8.8 g, 80%).


Example E90
1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide
Example E90.1
[3-Fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-carbamic acid tert-butyl ester

A mixture of 4-(tert-butoxycarbonylamino-methyl)-2-fluoro-benzoic acid from Example E2 (1.35 g, 5.0 mmol), 3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E11 (1.0 g, 5.0 mmol) and PyBroP (3.03 g, 6.5 mmol) in dichloromethane (25 ml) and DIEA (1.31 ml, 7.5 mmol) was heated at reflux for 18 h. After cooling to room temperature, the mixture was washed with 5% KHCO3, 1M HCl then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (1.25 g, 56%).


Example E90.2
(4-Aminomethyl-2-fluoro-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

[3-Fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-carbamic acid tert-butyl ester from Example E90.1 (1.25 g, 2.8 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (1.0 g, 97%).


Example E90.3
1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

HBTU (227 mg, 0.6 mmol) was added to a solution of 1-cyclopropylmethyl-piperidine-4-carboxylic acid from Example E15a (99 mg, 0.45 mmol) in DMF (5 ml) and DIEA (to pH9). The mixture was stirred at room temperature for 1 h. (4-Aminomethyl-2-fluoro-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E90.2 (116 mg, 0.3 mmol) was added and the mixture was stirred at room temperature for 18 h. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:19% methanol:80% dichloromethane) to give a white solid identified as the title compound (71.5 mg, 46%).


Example E91

N-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-2-piperidin-4-yl-acetamide hydrochloride


A solution of 4-{[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylcarbamoyl]-methyl}-piperidine-1-carboxylic acid tert-butyl ester (Compound number 1067) (156 mg, 0.27 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (135 mg, 97%).


Example E92
2-[1-(3,3-Dimethyl-butyl)-piperidin-4-yl]-N-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-acetamide

3,3-Dimethylbutyraldehyde (0.048 ml, 0.38 mmol) was added to a solution of N-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-2-piperidin-4-yl-acetamide from Example E91 (130 mg, 0.25 mmol) in methanol/acetic acid (49:1, v/v, 2.5 ml) and the mixture was stirred at room temperature for 1 h. Sodium cyanoborohydride.(24 mg, 0.38 mmol) was added, and the mixture was stirred at room temperature for 18 h then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated Na—HCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1.5% 35% ammonia:15% methanol:83.5% dichloromethane) to give a white solid identified as the title compound (107 mg, 75%).


Example E93
1-Propyl-piperidine-4-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

A solution of propionaldehyde (0.29 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) was added to a solution of piperidine-4-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide hydrochloride (Compound number 1109) (2.8 mg, 0.005 mmol) in 1,2-dichloroethane (0.05 ml) and DIEA (0.0026 ml). The mixture was stirred at room temperature for 1 h then a solution of sodium triacetoxyborohydride (1.59 mg, 0.0075 mmol) in DMF (0.05 ml) was added. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=521.4


Example E94
N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-2-(1-hexyl-piperidin-4-yl)-acetamide

A solution of 1-bromohexane (0.83 mg, 0.005 mmol) in DMF (0.05 ml) was added to a solution of N-[4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-2-piperidin-4-yl-acetamide hydrochloride (Compound number 1110) (2.82 mg, 0.005 mmol) in DMF (0.05 ml) and triethylamine (0.0021 ml). The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=575.7


Example E95
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzyl]-3-(1-propionyl-piperidin-4-yl)-propionamide

A solution of propionyl chloride (0.46 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzyl]-3-piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=577:4


Example E96
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzyl]-3-(1-ethanesulfonyl-piperidin-4-yl)-propionamide

A solution of ethanesulfonyl chloride (0.64 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzyl]-3-piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=613.4


Example E97
4-{2-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methylbenzylcarbamoyl]-ethyl}-piperidine-1-carboxylic acid 4-nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (1.08 mg, 0.005 mmol) in dichloromethane (0.05 ml) was added to a solution of N-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzyl]-3-piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97 mg, 0.005 mmol) in dichloromethane (0.05 ml) and triethylamine (0.0035 ml). The mixture was stirred at room temperature for 1 h then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+=700.5, 702.5


Example E98
Propane-1-sulfonic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide
Example E98.1
[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester

A mixture of 4-(tert-butoxycarbonylamino-methyl)-3-fluoro-benzoic acid from Example E3 (1.38 g, 5.1 mmol) and 3,6-dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E2 (1.0 g, 4.7 mmol) in dichloromethane (20 ml) at room temperature was treated with DIEA (2.44 ml, 14.0 mmol), DMAP (627 mg, 5.1 mmol) and WSCD (1.16 g, 6.1 mmol). The solution was heated at reflux for 2 days then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (1.29 g, 59%).


Example E98.2
(4-Aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester from Example E98.1 (1.29 g, 2.8 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (1.1 g, 99%).


Example E98.3
Propane-1-sulfonic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide

1-Propanesulfonyl chloride (0.016 ml, 0.14 mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E98.2 (50 mg, 0.12 mmol) in dichloromethane (2 ml) and triethylamine (0.038 ml, 0.27 mmol) at room temperature. The mixture was stirred for 1 h then concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (30 mg, 51%).


Example E99
N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-formamide

Formic acid (0.85 ml, 22.5 mmol) and acetic anhydride (1.4 ml, 13.5 mmol) were combined and stirred for 1 h at room temperature. (4-Aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E98.2 (113 mg, 0.3 mmol) was added and the mixture was stirred for 1 h. Water (20 ml) was added and the mixture was stirred for 1 h. It was diluted with chloroform, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield a white solid identified as the title compound (48 mg, 40%).


Example E100
Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide

DIEA (0.08 ml, 0.46 mmol) and cyclopropanecarbonyl chloride (0.013 ml, 0.14 mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E98.2 (57 mg, 0.14 mmol) in dichloromethane (10 ml) at 0° C. The mixture was stirred for 90 min at room temperature then diluted with dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (33 mg, 54%).


Example E101
Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide
Example E101.1
4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzonitrile

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (753 mg, 4.7 mmol) and thionyl chloride (1.02 ml, 14.0 mmol) in toluene (50 ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (45 ml) and a solution of 3,6-dimethyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E2 (1.0 g, 4.7 mmol) in dichloromethane (5 ml) and triethylamine (1.3 ml, 9.3 mmol) was added slowly. The mixture was stirred at room temperature for 20 h, washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (1.42 g, 85%).


Example E101.2
(4-Aminomethyl-3-methyl-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

A solution of 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzonitrile from Example E101.1 (1.42 g, 4.0 mmol) in methanol (50 ml),at 0° C. was treated with cobalt(II) chloride hexahydrate (1.90 g, 8.0 mmol). The mixture was stirred for 15 min at room temperature then sodium borohydride (1.51 g, 40.0 mmol) was added portionwise. The reaction mixture was stirred for 2 h then saturated NH4Cl was added. The mixture was stirred for 30 min then the solid was filtered off through Celite® filter agent and the filtrate concentrated in vacuo. The residue was redissolved in EtOAc and saturated NaHCO3. The layers were partitioned and the aqueous layer was extracted further with chloroform. Organics were combined, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (511 mg, 35%).


Example E101.3
Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide

Triethylamine (0.145 ml, 1.04 mmol) and cyclopropanecarbonyl chloride (0.041 ml, 0.45 mmol) were added to a solution of (4-aminomethyl-3-methyl-phenyl)-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone from Example E101.2 (150 mg, 0.41 mmol) in dichloromethane (10 ml) at room temperature. The mixture was stirred for 20 h then concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give an off-white solid identified as the title compound (91 mg, 51%).


Example E102
Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide
Example E102.1
[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester

A solution of 4-(tert-butoxycarbonylamino-methyl)-3-fluoro-benzoic acid from Example E3 (568 mg, 2.1 mmol) in dichloromethane (25 ml) at room temperature was treated with DMAP (256 mg, 2.1 mmol), DIEA (1.1 ml, 6.3 mmol) then WSCD (520 mg, 2.7 mmol). The mixture was stirred for 3 h then 6-chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E1 (450 mg, 1.9 mmol) was added. The mixture was stirred for 4 days then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (503 mg, 54%).


Example E102.2
(4-Aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester from Example E102.1 (503 mg, 1.03 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (440 mg, 100%).


Example E102.3
Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide

Cyclopropanecarbonyl chloride (0.045 ml, 0.5 mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E102.2 (210 mg, 0.5 mmol) in dichloromethane (40 ml) and DIEA (0.30 ml, 1.7 mmol) at 0° C. The mixture was stirred for 1 h at room temperature then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (134 mg, 59%).


Example E103
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-propionamide

DIEA (0.27 ml, 1.56 mmol) and propionyl chloride (0.048 ml, 0.55 mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E102.2 (220 mg, 0.52 mmol) in dichloromethane (6 ml) at room temperature. The mixture was stirred for 2 h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (129 mg, 56%).


Example E104
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-butyramide

DIEA (0.135 ml, 0.78 mmol) and butyryl chloride (0.027 ml, 0.27 mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E102.2 (110 mg, 0.26 mmol) in dichloromethane (3 ml) at room temperature. The mixture was stirred for 1 h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (77 mg, 65%).


Example E105
N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-isobutyramide

DIEA (0.135 ml, 0.78 mmol) and isobutyryl chloride (0.029 ml, 0.27 mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E102.2 (110 mg, 0.26 mmol) in dichloromethane (3 ml) at room temperature. The mixture was stirred for 1 h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (85 mg, 71%).


Example E106
Cyclopropanecarboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide
Example E106.1
[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-carbamic acid tert-butyl ester

A solution of 4-(tert-butoxycarbonylamino-methyl)-3-chloro-benzoic acid from Example E2b (568 mg, 2.0 mmol) in dichloromethane (25 ml) at room temperature was treated with DMAP (244 mg, 2.0 mmol), DIEA (1.0 ml, 6.0 mmol) then WSCD (500 mg, 2.6 mmol). The mixture was stirred for 3 h then 6-chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza-benzo[f]azulene from Example E1 (430 mg, 1.8 mmol) was added. The mixture was stirred for 4 days then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (570 mg, 63%).


Example E106.2
(4-Aminomethyl-3-chloro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride

[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-carbamic acid tert-butyl ester from Example E106.1 (570 mg, 1.13 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (490 mg, 100%).


Example E106.3
Cyclopropanecarboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

Cyclopropanecarbonyl chloride (0.045 ml, 0.5 mmol) was added to a solution of (4-aminomethyl-3-chloro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E106.2 (220 mg, 0.5 mmol) in dichloromethane (40 ml) and DIEA (0.30 ml, 1.7 mmol) at 0° C. The mixture was stirred for 1 h at room temperature then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (135 mg, 57%).


Example E107
N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-butyramide

Butyryl chloride (46 mg, 0.4 mmol) was added to a solution of (4-aminomethyl-3-chloro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E106.2 (161 mg, 0.4 mmol) in dichloromethane (10 ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 20 h, diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (110 mg, 58%).


Example E108
N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-isobutyramide

Isobutyryl chloride (46 mg, 0.4 mmol) was added to a solution of (4-aminomethyl-3-chloro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E106.2 (161 mg, 0.4 mmol) in dichloromethane (10 ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 18 h, diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (75 mg, 40%).


Example E109
{4-[(Cyclopropylmethyl-amino)-methyl]-3-methyl-phenyl}(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone

Cyclopropanecarboxaldehyde (26 mg, 0.34 mmol) was added to a solution of (4-Aminomethyl-3-methyl-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone (131 mg, 0.38 mmol) in MeOH/AcOH (99:1, 5 ml) and the mixture was stirred at room temperature for 30 min. Sodium cyanoborohydride (31 mg, 0.49 mmol) was added and the mixture was stirred at room temperature for 18 h. The solvents were removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with sat. aq. NaHCO3 and brine, then dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane to give a white solid identified as the title compound (70 mg, 51%).


Example E110
[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamino]-acetic acid methyl ester and
Example E111
{[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-methoxycarbonylmethyl-amino}-acetic acid methyl ester

Methyl bromoacetate (0.054 ml, 0.58 mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from example E102.2 (107 mg, 0.28 mmol) and DIEA (0.26 ml, 1.53 mmol) in THF (25 ml) and the mixture was stirred at room temperature for 2 h. A further amount of methyl bromoacetate (0.10 ml, 1.11 mmol) was added, and the mixture was stirred overnight at room temperature. The solution was quenched with water and diluted with EtOAc. The organic layer was washed with brine (×3), dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to yield two products. The faster eluting product was isolated as a white solid and identified as E111 (68 mg, 46%).


The slower eluting product was isolated as a white solid and identified as E110 (13 mg, 10%).


Example E112
(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-{3-fluoro-4-[(2-hydroxy-ethylamino)-methyl]-phenyl}-methanone

Lithium aluminium hydride (14.5 mg, 0.38 mmol) was added to a solution of [4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamino]-acetic acid methyl ester from example E110 (58.5 mg, 0.13 mmol) in THF (5 ml), and the mixture was stirred at room temperature for 30 min. Before being quenched with MeOH and extracted with EtOAc. The organic extract was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane then 20% methanol:80% dichloromethane) to give a pale yellow solid identified as the title compound (15 mg, 28%).


Example E113
{[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylcarbamoyl]-methyl}-carbamic acid tert-butyl ester

HBTU (165 mg, 0.44 mmol) was added to a solution of N-(tert-butoxycarbonyl)glycine (65 mg, 0.37 mmol) in DMF (10 ml) and the mixture was stirred for 30 min at room temperature. (4-Aminomethyl-3-fluoro-phenyl)-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl)-methanone hydrochloride from Example E102.2 (100 mg, 0.22 mmol) and DIEA (0.228 ml, 1.31 mmol) were added and the mixture was stirred for 24 h at room temperature. The solution was diluted with EtOAc, washed with water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane then 10% methanol:90% dichloromethane) to give a white solid identified as the title compound (123 mg, 100%).


Example E114
2-Amino-N-[4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-acetamide hydrochloride

{[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylcarbamoyl]-methyl}-carbamic acid tert-butyl ester from Example E113 (120 mg, 0.22 mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (95 mg, 83%).


Example E115
4-[(3-Chloro-benzoylamino)-methyl]-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide
Example E115.1
N-(4-Chloro-phenyl)-4-cyano-3,N-dimethyl-benzamide

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (3.4 g, 21 mmol) and thionyl chloride (10 ml, 137 mmol) in dichloromethane (50 ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (50 ml). (4-Chlorophenyl)-methyl amine (3.0 g, 21 mmol) and triethylamine (to pH9) were added and the mixture was stirred at room temperature for 20 h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with 1M KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 35% EtOAc:65% cyclohexane) to yield the title compound (5.1 g, 85%).


Example E115.2
4-Aminomethyl-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide

A solution of N-(4-chloro-phenyl)-4-cyano-3,N-dimethyl-benzamide from Example E115.1 (5.1 g, 17.9 mmol) in methanol (250 ml) was treated with cobalt(II) chloride hexahydrate (8.4 g, 35.8 mmol). The mixture was stirred for 15 min at room temperature then cooled down to 0° C. and sodium borohydride (6.7 g, 179 mmol) was added portionwise. The mixture was stirred for 1 h at room temperature, filtered through Celite® filter agent, washed with methanol and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:10% methanol:89% dichloromethane) to yield the title compound (3.6 g, 70%).


Example E115.3
4-[(3-Chloro-benzoylamino)-methyl]-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide

3-Chlorobenzoyl chloride (61 mg, 0.35=01) and triethylamine (to pH9) were added to a solution of 4-aminomethyl-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide from Example E115.2 (100 mg, 0.35 mmol) in dichloromethane (5 ml) at room temperature. The mixture was stirred for 1 h then concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (101 mg, 69%).


Example E116
1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-[(4-chloro-phenyl)-methyl-carbamoyl]-2-methyl-benzylamide

PyBroP (212 mg, 0.45 mmol) and 1-cyclopropylmethyl-piperidine-4-carboxylic acid from Example E15a (76 mg, 0.42 mmol) were added to a solution of 4-aminomethyl-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide from Example E115.2 (100 mg, 0.35 mmol) in dichloromethane (5 ml) and DMF (1 ml). The mixture was stirred at room temperature for 18 h then solvents were removed in vacuo and azeotroped with toluene. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (34 mg, 22%).


Example E117
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-[(4-chloro-phenyl)-methyl-carbamoyl]-2-methyl-benzylamide

HBTU (296 mg, 0.78 mmol) was added to a solution of 1-(3,3-dimethyl-butyl)-piperidine-4-carboxylic acid from Example E15 (182 mg, 0.73 mmol) in DMF (5 ml) and DIEA (0.272 ml, 1.56 mmol). The mixture was stirred at room temperature for 2 h then 4-aminomethyl-N-(4-chloro-phenyl)-3,N-dimethyl-benzamide from Example E115.2 (150 mg, 0.52 mmol) was added. The mixture was stirred for 2 h at room temperature then diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (209 mg, 83%).


Example E118
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-[methyl-(4-trifluoromethyl-phenyl)-carbamoyl]-benzylamide
Example E118.1
4-Cyano-3-methyl-N-(4-trifluoromethyl-phenyl)-benzamide

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (750 mg, 4.6 mmol) and thionyl chloride (1.02 ml, 14.0 mmol) in toluene (40 ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (25 ml) then 4-trifluoromethylaniline hydrochloride (1.11 g, 5.6 mmol) in dichloromethane (5 ml) and triethylamine (1.95 ml, 14.0 mmol) was added. The mixture was stirred at room temperature for 2 days, washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 20% EtOAc:80% cyclohexane) to yield the title compound (1.13 g, 80%).


Example E118.2
4-Cyano-3,N-dimethyl-N-(4-trifluoromethyl-phenyl)-benzamide

4-Cyano-3-methyl-N-(4-trifluoromethyl-phenyl)-benzamide from Example E118.1 (1.10 g, 3.6 mmol) was dissolved in DMF (10 ml) and cooled down to 0° C. Sodium hydride (60% dispersion in oil, 174 mg, 4.3 mmol) was added and the mixture was stirred for 30 min at room temperature. Methyl iodide (0.27 ml, 4.3 mmol) was added and the mixture was stirred for 20 h. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with brine, dried and concentrated in vacuo to yield the title compound (1.08 g, 94%).


Example E118.3
4-Aminomethyl-3,N-dimethyl-N-(4-trifluoromethyl-phenyl)-benzamide

A solution of 4-cyano-3,N-dimethyl-N-(4-trifluoromethyl-phenyl)-benzamide from Example E118.2 (1.08 g, 3.4 mmol) in methanol (40 ml) at room temperature was treated with cobalt(II) chloride hexahydrate (1.61 g, 6.8 mmol). The mixture was stirred for 10 min then sodium borohydride (1.28 g, 34 mmol) was added portionwise. The mixture was stirred for 20 h then saturated NH4Cl solution (10 ml) was added. The mixture was stirred for 30 min, filtered through glass-fibre paper and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (863 mg, 79%).


Example E118.4
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-[methyl-(4-trifluoromethyl-phenyl)-carbamoyl]-benzylamide

PyBroP (188 mg, 0.40 mmol) and 1-(3,3-dimethyl-butyl)-piperidine-4-carboxylic acid (82 mg, 0.38 mmol) were added to a solution of 4-aminomethyl-3,N-dimethyl-N-(4-trifluoromethyl-phenyl)-benzamide from Example E118.3 (100 mg, 0.31 mmol) in dichloromethane (5 ml) and DIEA (0.081 ml, 0.46 mmol). The mixture was stirred at room temperature for 2 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a off-white powder identified as the title compound (22 mg, 14%).


Example E119
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide
Example E119.1
[2-Methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzyl]-carbamic acid tert-butyl ester

A solution of 4-(tert-butoxycarbonylamino-methyl)-3-methyl-benzoic acid from Example E2h (400 mg, 1.5 mmol) in dichloromethane (20 ml) and triethylamine (to pH9) was treated with WSCD (573 mg, 3.0 mmol) and DMAP (183 mg, 1.5 mmol). The solution was stirred for 30 min at room temperature then 2-methyl-5,6-dihydro-4H-1-oxa-3,6-diaza-benzo[e]azulene from Example E6 (300 mg, 1.5 mmol) was added and the mixture was heated at reflux for 3 days. WSCD (287 mg, 1.5 mmol) was added and the mixture was heated at reflux for another 24 h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with 1N KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (62 mg, 9%).


Example E119.2
(4-Aminomethyl-3-methyl-phenyl)-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulen-6-yl)-methanone hydrochloride

[2-Methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzyl]-carbamic acid tert-butyl ester from Example E119.1 (62 mg, 0.14 mmol) in methanol (0.5 ml) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (53 mg, 100%).


Example E119.3
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide

Cyclopropanecarbonyl chloride (26 mg, 0.25 mmol) was added to a solution of (4-aminomethyl-3-methyl-phenyl)-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulen-6-yl)-methanone hydrochloride from Example E119.2 (85 mg, 0.22 mmol) in dichloromethane (5 ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 1 h then purified by flash chromatography on silica gel (eluant; 10% methanol:90% dichloromethane) to give a white solid identified as the title compound (62 mg, 67%).


Example E120
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide

(4-Aminomethyl-3-methyl-phenyl)-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulen-6-yl)-methanone hydrochloride from Example E119.2 (89 mg, 0.225 mmol) was dissolved in dichloromethane (10 ml) and triethylamine (to pH9) at room temperature. 1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid (53 mg, 0.25 mmol), DMAP (27 mg, 0.225 mmol) and PyBroP (165 mg, 0.36 mmol) were added and the mixture was heated at reflux for 18 h. The solution was diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to give a white solid identified as the title compound (84 mg, 69%).


Example E121
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzylamide
Example E121.1
4-(1-Benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzonitrile

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (557 mg, 3.4 mmol) and thionyl chloride (0.755 ml, 10.3 mmol) in toluene (100 ml) was heated at reflux for 2 h. After cooling to room temperature, solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (100 ml) and triethylamine (0.962 ml, 6.9 mmol) then 1-benzyl-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E5a (1.0 g, 3.4 mmol) was added. The mixture was stirred at room temperature for 2 h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc:50% pet. ether then EtOAc) to yield the title compound (844 mg, 56%).


Example E121.2
(4-Aminomethyl-3-methyl-phenyl)-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone

A solution of 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzonitrile from Example E121.1 (830 mg, 1.9 mmol) in methanol (10 ml) at room temperature was treated with cobalt(II) chloride hexahydrate (913 mg, 3.8 mmol). The mixture was stirred for 15 min then cooled down to 0° C. Sodium borohydride (726 mg, 19 mmol) was added portionwise and the reaction mixture was stirred for 2 h at room temperature. 35% Ammonia (5 ml) was added dropwise and the mixture was stirred for 30 min then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (680 mg, 81%).


Example E121.3
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzylamide

HBTU (175 mg, 0.46 mmol) was added to a solution of 1-(3,3-dimethyl-butyl)-piperidine-4-carboxylic acid (86 mg, 0.34 mmol) in DMF (5 ml). The mixture was stirred at room temperature for 2 h then (4-aminomethyl-3-methyl-phenyl)-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone from Example E121.2 (100 mg, 0.23 mmol) and DIEA (0.12 ml, 0.69 mmol) were added. The mixture was stirred at room temperature for 18 h then solvents were removed in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 5% methanol:95% dichloromethane then 10% methanol:90% dichloromethane) to give a yellow foam identified as the title compound (114 mg, 79%).


Example E122
1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-benzylamide

1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzylamide from Example E121 (110 mg, 0.17 mmol) was dissolved in absolute ethanol (5 ml) and placed under an inert atmosphere. 10% Palladium on carbon (110 mg) and cyclohexene (0.176 ml, 1.7 mmol) were added and the mixture was heated at 60° C. for 3 h. The catalyst was filtered off through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (45 mg, 48%).


Example E123
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-benzylamide
Example E123.1
Cyclopropanecarboxylic acid 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzylamide

DIEA (0.176 ml, 1.02 mmol) and cyclopropanecarbonyl chloride (0.033 ml, 0.36 mmol) were added to a solution of (4-aminomethyl-3-methyl-phenyl)-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone from Example E121.2 (150 mg, 0.34 mmol) in dichloromethane (5 ml) at room temperature. The mixture was stirred for 20 h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give the title compound (155 mg, 90%).


Example E123.2
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-benzylamide

Cyclopropanecarboxylic acid 4-(1-benzyl-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzylamide from Example E123.1 (155 mg, 0.31 mmol) was dissolved in absolute ethanol (10 ml) and placed under an inert atmosphere. 10% Palladium on carbon (155 mg) and cyclohexene (0.311 ml, 3.1 mmol) were added and the mixture was heated at 60° C. for 18 h. The catalyst was filtered off through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (67 mg, 53%).


Example E124
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide
Example E124.1
2-Methyl-4-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulene-6-carbonyl)-benzonitrile

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (147 mg, 0.91 mmol) was dissolved in dichloromethane (25 ml) and 2 drops of DMF and cooled down to 0° C. Oxalyl chloride (0.1 ml) was added slowly and the mixture was stirred for 2 h at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (10 ml) and cooled down to 0° C. Triethylamine (0.5 ml) and 2-methyl-5,6-dihydro-4H-3-thia-1,6-diaza-benzo[e]azulene from Example E7 (165 mg, 0.76 mmol) in dichloromethane (10 ml) were added and the mixture was stirred for 2 days at room temperature. Another 0.91 mmol of acid chloride was formed as previously and added to the mixture. The solution was stirred for 20 h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% EtOAc:90% cyclohexane then 20% EtOAc:80% cyclohexane) to yield the title compound (220 mg, 80%).


Example E124.2
(4-Aminomethyl-3-methyl-phenyl)-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulen-6-yl)-methanone

A solution of 2-methyl-4-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulene-6-carbonyl)-benzonitrile from Example E124.1 (190 mg, 0.53 mmol) in methanol (15 ml) at room temperature was treated with cobalt(II) chloride hexahydrate (275 mg, 1.15 mmol). The mixture was stirred for 20 min then cooled down to 0° C. Sodium borohydride (200 mg, 5.3 mmol) was added portionwise and the mixture was stirred for 20 h at room temperature. Saturated NH4Cl (2 ml) was added dropwise and the mixture was stirred for 30 min then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (100 mg, 52%).


Example E124.3
Cyclopropanecarboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide

DIEA (0.02 ml, 0.115 mmol) and cyclopropanecarbonyl chloride (0.008 ml, 0.088 mmol) were added to a solution of (4-aminomethyl-3-methyl-phenyl)-(2-methyl-4,5-dihydro-3-thia-1,6-diaza-benzo[e]azulen-6-yl)-methanone from E124.2 (20 mg, 0.055 mmol) in dichloromethane (5 ml) at 0° C. The mixture was stirred for 20 h at room temperature then concentrated in vacuo and purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white powder identified as the title compound (11 mg, 46%).


Example E125
N-[4-(9-Chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzyl]-isobutyramide
Example E125.1
4-[1-(4-Cyano-3-methyl-benzoyl)-9-chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl]-2-methyl-benzonitrile

A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (262 mg, 1.6 mmol) was dissolved in dichloromethane (20 ml) and 2 drops of DMF and cooled down to 0° C. Oxalyl chloride (0.6 ml) was added and the mixture was stirred for 0.5 h at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (10 ml) and added to a solution of 9-chloro-2-methyl-1,4,5,6-tetrahydro-1,3,6-triaza-benzo[e]azulene from Example E7 (190 mg, 0.8 mmol) and DIEA (0.5 ml) in dichloromethane (10 ml) and the mixture was stirred for 20 h. at room temperature. The solvents were removed in vacuo and the residue was taken up in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc:60% cyclohexane) to yield the title compound (124 mg, 30%).


Example E125.2
4-(9-Chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzonitrile

4-[1-(4-Cyano-3-methyl-benzoyl)-9-chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl]-2-methyl-benzonitrile from E125.1 (124 mg, 0.24 mmol) was dissolved in MeOH 5 ml). 2M NaOH (2 ml) was added, and the mixture was stirred for 1 h. at room temperature. The solvents were removed in vacuo, and azeotroped with toluene. The residue was taken up in EtOAc, was with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield the title compound (80 mg, 89%)


Example E125.3
(4-Aminomethyl-3-methyl-phenyl)-(9-chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone

A solution of 4-(9-chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzonitrile from E125.2 (80 mg, 0.2 mmol) in methanol (5 ml) at room temperature was treated with cobalt(II) chloride hexahydrate (101 mg, 0.4 mmol). The mixture was cooled to 0° C. then sodium borohydride (80 mg, 2.1 mmol) was added portionwise. The reaction mixture was stirred at 0° C. for 30 min. then for 2 h at room temperature then saturated NH4Cl was added. The mixture was stirred for 10 min then the solid was filtered off through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:9% methanol:90% dichloromethane) to yield the title compound (24 mg, 30%).


Example E125.4
N-[4-(9-Chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzyl]-isobutyramide

Isobutyryl chloride (0.07 ml, 0.07 mmol) was added to a solution of (4-aminomethyl-3-methyl-phenyl)-(9-chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulen-6-yl)-methanone from Example E125.3 (24 mg, 0.07 mmol) in dichloromethane (3 ml) and DIEA (0.10 ml, 0.57 mmol) at 0° C. The mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol:95% dichloromethane to 10% methanol:90% dichloromethane) to give a colourless oil identified as the title compound 24 mg, 85%).


Example A
In Vitro Testing

Compounds were assayed to determine their ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, the compounds of the invention cause significant inhibition of cellular activation at concentrations of 30 μM or less. Preferred compounds cause significant inhibition at concentrations of 300 nM.


Example B
Tablet for Oral Administration

Tablets containing 100 mg of the compound of Example E8 as the active agent may be prepared from the following:


















Compound of Example E8
200.0
g



Corn starch
71.0
g



Hydroxypropylcellulose
18.0
g



Carboxymethylcellulose calcium
13.0
g



Magnesium stearate
3.0
g



Lactose
195.0
g



Total
500.0
g









The materials are blended and then pressed to give 2000 tablets of 250 mg, each containing 100 mg of the compound of Example E8.


All the cited references are hereby incorporated in their entirety.


Schemes and Structures
Example E1



embedded image


Example E2



embedded image


Examples E2a-g
Example E2a
4-Aminomethyl-3-chloro-benzoic acid tert-butyl ester



embedded image


Example E2b
4-(tert-Butoxycarbonylamino-methyl)-3-chloro-benzoic acid



embedded image


Example E2c
4-(tert-Butoxycarbonylamino-methyl-3-nitro-benzoic acid



embedded image


Example E2d
4-Cyano-3-methyl-benzoic acid



embedded image


Example E2e
4-Cyano-2-methyl-benzoic acid



embedded image


Example E2f
4-(tert-Butoxycarbonylamino-methyl)-2-fluoro-benzoic acid



embedded image


Example E2g
4-Cyano-3,5-dimethyl-benzoic acid



embedded image


Example E2h



embedded image


Example E3



embedded image


Example E4



embedded image


Example E5



embedded image


Example E5a



embedded image


Example E6



embedded image


Example E7



embedded image


Example E8



embedded image


Example E9



embedded image


Example E10



embedded image


Example E11



embedded image


Example E12



embedded image


Example E13



embedded image


Example E14



embedded image


Example E15



embedded image


Example E15a



embedded image


Example E16



embedded image


Example E17



embedded image


Example E18



embedded image


Example E19



embedded image


Example E20



embedded image


Example E21



embedded image


Example E22



embedded image


Example E23



embedded image


Example E24



embedded image


Example E25



embedded image


Example E26



embedded image


Example E27



embedded image


Example E28



embedded image


Example E29



embedded image


Example E30



embedded image


Example E31



embedded image


Example E32



embedded image


Example E33



embedded image


Example E34



embedded image


Example E35



embedded image


Example E36



embedded image


Example E37



embedded image


Example E38



embedded image


Example E39



embedded image


Example E40



embedded image


embedded image


Example E41



embedded image


Example E41a



embedded image


Example E41b



embedded image


Example E41c



embedded image


Example E42



embedded image


Example E43



embedded image


Example E44



embedded image


Example E45



embedded image


Example E46



embedded image


Example E47



embedded image


Example E48



embedded image


Example E49



embedded image


Example E50



embedded image


Example E51



embedded image


Example E52



embedded image


Example E53



embedded image


Example E54



embedded image


Example E55



embedded image


Example E56



embedded image


Example E57



embedded image


Example E58



embedded image


Example E59



embedded image


Example E60



embedded image


Example E61



embedded image


Example E62



embedded image


Example E63



embedded image


Example E64



embedded image


Example E65



embedded image


Example E66



embedded image


Example E67



embedded image


Example E68



embedded image


embedded image


Example E69



embedded image


embedded image


Example E70



embedded image


embedded image


Example E71



embedded image


Example E72



embedded image


embedded image


Example E73



embedded image


Example E74



embedded image


Example E75



embedded image


Example E76



embedded image


Example E77



embedded image


Example E78



embedded image


Example E79



embedded image


Example E80



embedded image


Example E81



embedded image


Example E82



embedded image


Example E83



embedded image


Example E84



embedded image


Example E85



embedded image


Example E86



embedded image


embedded image


Example E87



embedded image


Example E88



embedded image


Example E89



embedded image


Example E90



embedded image


Example E91



embedded image


Example E92



embedded image


Example E93



embedded image


Example E94



embedded image


Example E95



embedded image


Example E96



embedded image


Example E97



embedded image


Example E98



embedded image


Example E99



embedded image


Example E100



embedded image


Example E101



embedded image


Example E102



embedded image


Example E103



embedded image


Example E104



embedded image


Example E105



embedded image


Example E106



embedded image


Example E107



embedded image


Example E108



embedded image


Example E109



embedded image


Example E110 and Example E111



embedded image


Example E112



embedded image


Example E113



embedded image


Example E114



embedded image


Example E115



embedded image


Example E116



embedded image


Example E117



embedded image


Example E118



embedded image


Example E119



embedded image


Example E120



embedded image


Example E121



embedded image


Example E122



embedded image


Example E123



embedded image


Example E124



embedded image


Example E125



embedded image


Example Tables

The following compounds were prepared using methods analogous to those described above.


Example E5 and Compound number 2 have particular utility as intermediates.














embedded image















Compound

MS



number
R8
(ESI)+: [M + H]+ =

1H NMR: δ (ppm)






1 E5
H




2
Cl
234.0, 236.0
2.43 (3H, s), 2.98 (2H, d,





J = 5.2 Hz), 3.34 (2H, t, J = 5.2 Hz),





6.59 (2H, d, J = 8.4 Hz), 6.90-6.95





(1H, m), 7.80-8.10 (1H, m)





















embedded image
















Compound



MS:


number
R1
R4
R7
[M + H]+





3 E8
F


embedded image


Me
562.4





 4
Me


embedded image


Me
558.4





 5
Me


embedded image


Me
528.4





 6
Me


embedded image


Me
514.3





 7
Me


embedded image


Me
544.4





 8
Me


embedded image


Me
556.6





 9
Me


embedded image


Cl
587.4, 580.4





10
Me


embedded image


Cl
548.3 550.3





11
F


embedded image


Me
532.3





12
F


embedded image


Cl
582.4, 584.4





13
F


embedded image


Cl
552.3, 554.3





14
F


embedded image


F
566.2





15
Cl


embedded image


Cl
598.3, 600.4





16
Cl


embedded image


Cl
568.1





17
Cl


embedded image


Me
578.4, 580.4





18
Cl


embedded image


Me
548.3, 550.3





19
Me


embedded image


Me
532.5





20
Me


embedded image


Me
622.4





21
Me


embedded image


Cl
576.4, 578.3





22
Me


embedded image


Cl
564.4, 566.4





23
Me


embedded image


Cl
534.3, 536.3





24
Me


embedded image


Cl
564.4, 566.4





25
Me


embedded image


Cl
550.4, 552.4





26
Me


embedded image


Cl
536.4, 538.1





27
Me


embedded image


Me
544.4





28
Me


embedded image


Me
530.8





29
Me


embedded image


Me
516.5





















embedded image


















Com-





MS:


pound





[M +


number
R1
R4
R7
R8
R9
H]+





30
Me


embedded image


H
Me
H
558.4





31
F


embedded image


Me
H
H
562.4





















embedded image
















Compound



MS:


number
R1
R4
R7
[M + H]+





32
Me


embedded image


Cl
527.1, 529.1





33
Me


embedded image


Me
507.4





















embedded image
















Compound



MS:


number
R1
R4
R7
[M + H]+





34
Me


embedded image


Me
493.4


35
Me


embedded image


Cl
513.1





















embedded image
















Compound



MS:


number
R1
R4
R9
[M + H]+





36
Me


embedded image


Me
491.8





















embedded image






















MS:


Compound




(ESI)+:


number
X2
R1
R4
R10
[M + H]+





37
NH
Me


embedded image


Cl
557.4





38
NH
Me


embedded image


Me
557.0





39
O
Me


embedded image


H
544.5





40
NH
Me


embedded image


H
543.4





















embedded image

















Compound




MS:


number
X2
R1
R4
R10
[M + H]+





41
S
Me


embedded image


Me
544.2





42
S
Me


embedded image


H
530.4





43
S
Me


embedded image


H
560.4





















embedded image
















Compound






number
R3
R4
R7
MS: [M + H]+





44
Me


embedded image


Me
558.4





45
Me


embedded image


Me
528.4





46
Me


embedded image


Cl
578.3, 580.3





47
Me


embedded image


Cl
548.3, 550.3





48
F


embedded image


Me
562.4





49
F


embedded image


Me
532.4





50
F


embedded image


Cl
582.4, 584.3





51
F


embedded image


Cl
552.3, 554.3





52
Cl


embedded image


Cl
598.3, 600.3





53
Cl


embedded image


Cl
568.3





54
Cl


embedded image


Me
578.3, 580.3





55
Cl


embedded image


Me
548.3, 550.3




















Compound



number

1H NMR: δ(ppm)








 3 E8
0.86 (9H, s), 1.33-1.39 (2H, m), 2.12 (3H, s), 2.27-2.38 (6H, m),



3.33-3.35 (4H, m), 3.68 (3H, s), 3.92, (1H, d, J = 14.3 Hz), 4.25 (2H, d,



J = 5.4 Hz), 5.45 (1H, t, J = 5.4 Hz), 5.79 (1H, d, J = 14.3 Hz), 6.43 (1H, d,



J = 8.0 Hz), 6.53 (1H, d, J = 8.0 Hz), 6.79-7.00 (4H, m), 7.17 (1H, s), 7.31



(1H, s)


 4
0.88 (9H, s), 1.34-1.41 (2H, m), 2.09 (3H, s), 2.18 (3H, s), 2.29-2.36 (2H, m),



2.40 (4H, t, J = 4.7 Hz), 3.37 (4H, t, J = 4.7 Hz), 3.75 (3H, s), 3.94 (1H, d,



J = 14.4 Hz), 4.24 (2H, d, J = 5.2 Hz), 4.95 (1H, t), 5.85 (1H, d, J = 14.4 Hz),



6.53 (1H, q, J = 7.9 Hz), 6.76 (1H, d, J = 5.7 Hz), 6.90 (1H, s), 7.02-7.11



(3H, m), 7.58 (1H, s)


 5
0.05-0.09 (2H, m), 0.47-0.54 (2H, m), 0.81-0.86 (1H, m), 2.08 (3H, s),



2.16 (3H, s), 2.24 (2H, d, J = 6.4 Hz), 2.47-2.49 (4H, m), 3.38-3.44 (4H, m),



3.67 (3H, s), 3.92 (1H, d, J = 14.3 Hz), 4.22 (2H, m), 4.92 (1H, m), 5.85



(1H, d, J = 14.3 Hz), 6.43-6.56 (2H, m), 6.66-6.85 (3H, m), 7.07-7.24 (3H, m)


 6
0.45-0.47 (4H, m), 1.64 (1H, m), 2.05 (3H, s), 2.13 (3H, s), 2.56 (4H, m),



3.32 (4H, m), 3.65 (3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.18 (2H, m), 5.21



(1H, m), 5.82 (1H, d, J = 14.6 Hz), 6.43 (1H, d, J = 8.0 Hz), 6.53 (1H, d,



J = 8.0 Hz), 6.80-6.85 (3H, m), 6.93 (1H, s), 7.04 (1H, s), 7.16 (1H, s)


 7
0.84 (3H, s), 0.86 (3H, s), 1.28-1.37 (2H, m), 1.48-1.60 (1H, m), 2.01 (3H, s),



2.10 (3H, s), 2.22-2.35 (2H, m), 2.32 (4H, br t), 3.34 (4H, br t), 3.59



(3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.16 (2H, d, J = 4.9 Hz), 5.15 (1H, t,



J = 5.2 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.40 (1H, d, J = 7.9 Hz), 6.51 (1H, d,



J = 7.9 Hz), 6.69-6.83 (3H, m), 7.01 (1H, s), 7.11 (1H, s), 7.14 (1H, s)


 8
1.06-1.23 (2H, m), 1.38-1.59 (4H, m), 1.63-1.78 (2H, m), 1.98-2.05 (1H, m),



2.07 (3H, s), 2.15 (3H, s), 2.22 (2H, d, J = 7.4 Hz), 2.35 (4H, t, J = 4.7 Hz),



3.33 (4H, t, J = 4.7 Hz), 3.67 (3H, s), 3.91 (1H, d, J = 14.6 Hz), 4.22 (2H, d,



J = 5.2 Hz), 4.84 (1H, br t), 5.84 (1H, d, J = 14.6 Hz), 6.43 (1H, d, J = 8.2 Hz),



6.54 (1H, d, J = 8.2 Hz), 6.67 (1H, s), 6.76 (1H, s), 6.77-6.88 (2H, m), 7.07



(1Hs), 7.18 (1H, s)


 9
0.88 (9H, s), 1.34-1.41 (2H, m), 2.09 (3H, s), 2.25-2.36 (2H, m), 2.36-2.41



(4H, m), 3.35-3.42 (4H, m), 3.72 (3H, s), 3.93 (1H, d, J = 14.6 Hz),



4.24 (2H, d, J = 4.45 Hz), 5.02 (1H, br t), 5.83 (1H, d, J = 14.6 Hz), 6.59



(1H, s), 6.88 (1H, s), 7.01-7.09 (3H, m), 7.56-7.63 (2H, m)


10
0.11 (2H, q, J = 4.7 Hz), 0.52 (2H, q, J = 4.7 Hz), 0.76-0.93 (1H, m), 2.10



(3H, s), 2.31 (2H, d, J = 6.4 Hz), 2.45-2.62 (4H, m), 3.39-3.53 (4H, m), 3.79



(3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.23-4.25 (2H, m), 5.27 (1H, s), 5.81 (1H,



d, J = 14.6 Hz), 6.58 (2H, s), 6.80-6.90 (2H, m), 7.07 (3H, s), 7.19 (1H, s)


11
0.05-0.11 (2H, m), 0.47-0.55 (2H, m), 0.75-0.89 (1H, m), 2.18 (3H, s),



2.24 (2H, d, J = 6.7 Hz), 2.47 (4H, m), 3.38 (4H, m), 3.75 (3H, s), 3.93 (1H,



d, J = 14.6 Hz), 4.31 (2H, d, J = 5.7 Hz), 5.13 (1H, t, J = 5.4 Hz), 5.82 (1H, d,



J = 14.6 Hz), 6.47-6.58 (2H, m), 6.72-6.80 (2H, m), 6.87-6.95 (2H, m),



7.00-7.04 (1H, m), 7.08-7.17 (1H, m)


12
0.86 (9H, s), 1.33-1.39 (2H, m), 2.28-2.38 (6H, m), 3.37 (4H, m), 3.66



(3H, m), 3.94 (1H, d, J = 14.6 Hz), 4.28 (2H, d, J = 5.5 Hz), 5.41 (1H, t,



J = 5.5 Hz), 5.78 (1H, d, J = 14.6 Hz), 6.56 (2H, s), 6.84-6.88 (2H, m), 7.00-



7.06 (2H, m), 7.18 (1H, s), 7.98 (1H, s)


13
0.27-0.29 (2H, m), 0.65-0.67 (2H, m), 0.94-1.10 (1H, m), 1.36-1.56 (2H, m),



2.59 (1H, d, J = 6.4 Hz), 2.76-2.89 (4H, m), 3.54-3.70 (4H, m), 3.83



(3H, s), 3.96 (1H, d, J = 14.6), 4.31-4.35 (2H, m), 5.81 (1H, d, J = 14.6 Hz),



6.63 (1H, s), 6.83-7.00 (1H, m), 7.11 (4H, s), 7.23-7.24 (1H, m), 7.70



(1H, s)


14
0.89 (9H, s), 1.37-1.43 (2H, m), 2.33-2.43 (6H, m), 3.35-3.39 (4H, m),



3.74 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.34 (2H, d, J = 5.0 Hz), 5.83 (1H, d,



J = 14.6 Hz), 6.35-6.41 (1H, m), 6.62-6.73 (2H, m), 6.80 (1H, s), 6.89-6.93



(2H, m), 7.06-7.12 (1H, m)


15
0.87 (9H, s), 1.33-1.39 (2H, m), 2.28-2.38 (6H, m), 3.37 (4H, m), 3.66



(3H, m), 3.94 (1H, d, J = 14.6 Hz), 4.31 (2H, d, J = 5.5 Hz), 5.45 (1H, t,



J = 5.5 Hz), 5.78 (1H, d, J = 14.6 Hz), 6.91 (1H, m), 7.03 (2H, m), 7.19



(2H, m), 7.84 (1H, s)


16
(CD3OD): 0.14-0.18 (2H, m), 0.52-0.59 (2H, m), 0.89 (1H, m), 2.28-2.30



(2H, m), 2.52-2.56 (4H, m), 3.43-3.47 (4H, m), 3.80 (3H, s), 3.97 (1H, d,



J = 14.6 Hz), 4.34 (2H, d, J = 4.5 Hz), 5.73 (1H, d, J = 14.6 Hz), 6.64-6.77



(2H, m), 7.08-7.17 (2H, m), 7.23-7.28 (3H, m)


17
0.87 (9H, s), 1.36 (2H, m), 2.12 (3H, s), 2.32 (6H, m), 3.39 (4H, m), 3.66



(3H, s), 3.92 (1H, d, J = 14.3 Hz), 4.28 (2H, m), 5.43 (1H, m), 5.78 (1H, d,



J = 14.3 Hz), 6.48 (1H, d, J = 7.9 Hz), 6.52 (1H, d, J = 7.9 Hz), 6.78 (1H, s),



6.88-6.98 (2H, m), 7.05 (1H, s), 7.17 (1H, m)


18
0.06-0.08 (2H, m), 0.48-0.51 (2H, m), 0.76-0.89 (1H, m), 2.15 (3H, s),



2.21-2.29 (2H, m), 2.44-2.48 (4H, m), 3.36-3.38 (4H, m), 3.68 (3H, s),



3.93 (1H, d, J = 14.6 Hz), 4.30 (2H, d, J = 6.0 Hz), 5.33 (1H, m), 5.80 (1H, d,



J = 14.6 Hz), 6.48-6.55 (2H, m), 6.77-7.00 (4H, m), 7.19-7.21 (2H, m)


19
CD3OD: 2.18 (3H, s), 2.22 (3H, s), 3.05-3.09 (4H, m), 3.47 (2H, s), 3.58-



3.62 (4H, m), 3.79 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.25 (2H, s), 5.75 (1H,



d, J = 14.6 Hz), 6.47 (1H, d, J = 8.0 Hz), 6.59 (1H, d, J = 8.0 Hz), 6.97-7.06



(4H, m), 7.21 (1H, s)


20
2.02 (3H, s), 2.11 (3H, s), 2.39-2.50 (4H, m), 3.22 (2H, s), 3.32-3.43 (4H, m),



3.60 (3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.16 (2H, d, J = 5.0 Hz), 5.12 (2H, s),



5.25 (1H, t, J = 5.0 Hz), 5.80 (1H, d, J = 14.6 Hz), 6.41 (1H, d, J = 7.9 Hz),



6.51 (1H, d, J = 7.9 Hz), 6.76-6.83 (3H, m), 7.02 (1H, s), 7.12-7.14 (2H, m),



7.28-7.31 (5H, m)


21
1.11-1.18 (2H, m), 1.45-1.56 (4H, m), 1.67-1.72 (2H, m), 1.98-2.01, (1H,



m), 2.04 (3H, s), 2.22 (2H, d, J = 7.2 Hz), 2.29-2.50 (4H, m), 3.30-3.41 (4H,



m), 3.62 (3H, s), 3.91 (1H, d, J = 14.6 Hz), 4.19-4.21 (2H, m), 5.04-5.06



(1H, m), 5.80 (1H, d, J = 14.6 Hz), 6.53-6.54 (2H, m), 6.80-6.84 (2H, m),



7.01-7.03 (2H, m), 7.16 (1H, s), 7.72 (1H, s)


22
0.84 (9H, s), 2.05 (2H, s), 2.12 (3H, s), 2.41-2.54 (4H, m), 3.27-3.39 (4H, m),



3.72 (3H, s), 3.92 (1H, d, J = 14.6 Hz), 4.26-4.27 (2H, m), 4.66-4.68



(1H, m), 5.85 (1H, d, J = 14.6 Hz), 6.58-6.59 (2H, m), 6.88-6.92 (2H, m),



6.98-7.00 (2H, m), 7.09 (1H, s), 7.21 (1H, s)


23
0.38-0.44 (4H, m), 1.57-1.58 (1H, m), 2.04 (3H, s), 2.53 (4H, m), 3.31



(4H, m), 3.62 (3H, s), 3.91 (1H, d, J = 14.6 Hz), 4.20 (2H, m), 5.08 (1H, m),



5.80 (1H, d, J = 14.6 Hz), 6.54-6.58 (2H, m), 6.80-6.86 (2H, m), 7.01-7.03



(2H, m), 7.16 (1H, s), 7.71 (1H, s)


24
0.85 (6H, d, J = 6.4 Hz), 1.23-1.36 (2H, m), 1.49-1.56 (1H, m), 2.01 (3H, s),



2.23-2.35 (6H, m), 3.36 (4H, m), 3.62 (3H, s), 3.91 (1H, d, J = 14.6 Hz),



4.18 (2H, m), 5.29 (1H, m), 5.78 (1H, d, J = 14.6 Hz), 6.48-6.56 (2H, m),



6.80-6.86 (2H, m), 6.98-7.02 (2H, m), 7.15 (1H, s), 8.12 (1H, s)


25
0.85 (6H, d, J = 6.4 Hz) 1.73 (1H, m), 2.05 (5H, m), 2.26-2.31 (4H, m), 3.34



(4H, m), 3.62 (3H, s), 3.91 (1H, d, J = 14.6 Hz), 4.21 (2H, m), 5.02 (1H, m),



5.80 (1H, d, J = 14.6 Hz), 6.54 (2H, m), 6.84-6.87 (2H, m), 7.02 (2H, m),



7.16 (1 H, s), 7.72 (1H, s)


26
0.85 (3H, t, J = 7.2 Hz), 1.40-1.49 (2H, m), 2.01 (3H, s), 2.22-2.28 (2H, m),



2.34 (4H, m) 3.35 (4H, m), 3.58 (3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.18 (2H,



m), 5.21 (1H, m), 5.77 (1H, d, J = 14.6 Hz), 6.51-6.55 (2H, m), 6.81-6.85



(2H, m), 7.00 (2H, m), 7.13 (1H, s), 7.88 (1H, s)


27
0.84 (9H, s), 2.04 (2H, s), 2.11 (3H, s), 2.18 (3H, s), 2.45 (4H, t, J = 4.7 Hz),



3.30 (4H, t, J = 4.7 Hz), 3.71 (3H, s), 3.92 (1H, d, J = 14.6 Hz), 4.24 (2H, d,



J = 5.2 Hz), 4.66 (1H, br t), 5.86 (1H, d, J = 14.6 Hz), 6.41 (1H, s), 6.46



(1H, d, J = 7.9 Hz), 6.56 (1H, d, J = 7.9 Hz), 6.75 (1H, s),



6.88 (2H, s), 7.10 (1H, s), 7.20 (1H, s)


28
0.86 (6H, d, J = 6.7 Hz), 1.68-1.81 (1H, m), 2.05 (2H, d, J = 7.4 Hz), 2.09



(3H, s), 2.17 (3H, s), 2.32 (4H, t, J = 4.7 Hz), 3.33 (4H, t, J = 4.7 Hz),



3.69 (3H, s), 3.92 (1H, d, J = 14.6 Hz), 4.23 (2H, d, J = 4.9 Hz), 4.78 (1H,



t, J = 4.9 Hz), 5.85 (1H, d, J = 14.6 Hz), 6.46 (1H, d, J = 7.9 Hz), 6.55 (1H,



d, J = 7.9 Hz), 6.57 (1H, s), 6.76 (1H, s), 6.86 (2H, s), 7.08 (1 H, s),



7.19 (1H, s)


29
0.88 (3H, t, J = 7.4 Hz), 1.43-1.54 (2H, m), 2.12 (3H, s), 2.19 (3H, s),



2.28 (2H, t, J = 7.4 Hz), 2.38 (4H, t, J = 4.9 Hz), 3.35 (4H, t, J = 4.9 Hz),



3.73 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.25 (2H, d, J = 5.2 Hz), 4.66 (1H,



br t), 5.87 (1H, d, J = 14.6 Hz), 6.29 (1H, s), 6.47 (1H, d, J = 7.7 Hz),



6.56 (1H, d, J = 7.7 Hz), 6.74 (1H, s), 6.89 (2H, s), 7.11 (1H, s), 7.21



(1H, s)


30
0.88 (9H, s), 1.32-1.42 (2H, m), 2.02 (3H, s), 2.14 (3H, s), 2.28-2.46



(6H, m), 3.30-3.42 (4H, m), 3.75 (3H, s), 3.94 (1H, d, J = 14.4 Hz),



4.26-4.32 (2H, m), 4.48-4.56 (1H, m), 5.87 (1H, d, J = 14.4 Hz), 6.07



(1H, s), 6.52 (1H, s), 6.78-6.97 (4H, m), 7.13 (1H, s)


31
0.88 (9H, s), 1.35-1.41 (2H, m), 2.28-2.42 (8H, m), 3.27-3.40 (4H, m),



3.82 (3H, s), 3.96 (1H, d, J = 14.4 Hz), 4.33 (2H, d, J = 5.4 Hz), 4.68-4.79



(1H, m), 5.80 (1H, s), 5.89 (1H, d, J = 14.4 Hz), 6.58-6.70 (2H, m), 6.88-



6.95 (2H, m), 6.96-7.12 (3H, m), 7.65 (1H, s)


32
0.88 (9H, s), 1.35-1.41 (2H, m), 2.00-2.18 (2H, m), 2.27-2.35 (2H, m),



2.36-2.43 (4H, m), 3.34-3.41 (4H, m), 3.44 (2H, s), 4.29 (2H, d, J = 5.2 Hz),



4.58-4.63 (1H, m), 6.48-6.61 (1H, m), 6.62-6.75 (1H, m), 6.88-7.03 (2H, m),



7.07-7.11 (2H, m)


33
0.87 (9H, s), 1.35-1.41 (2H, m), 2.16 (3H, s), 2.22 (3H, s), 2.23-2.36



(2H, m), 2.40 (4H, t, J = 4.7 Hz), 3.35 (4H, t, J = 4.7 Hz), 4.28-4.30 (2H, m),



4.50 (1H, br s), 6.52 (2H, br s), 6.88 (1H, s), 6.95 (2H, s), 7.11 (1H, s)


34
0.89 (9H, s), 1.36-1.43 (2H, m), 2.23 (3H, s), 2.31 (3H, s), 2.31-2.41



(2H, m), 2.43 (4H, t, J = 4.9 Hz), 3.40 (4H, t, J = 4.9 Hz), 3.95 (2H, t,



J = 4.7 Hz), 4.31 (2H, t, J = 4.7 Hz), 4.41-4.44 (2H, m), 4.55-4.60 (1H,



m), 6.47-6.51 (1H, m), 6.70 (1H, s), 6.81-7.00 (1H, m), 7.21-7.27 (2H,



m), 7.34 (1H, s)


35
0.89 (9H, s), 1.36-1.43 (2H, m), 2.31 (3H, s), 2.32-2.39 (2H, m), 2.44



(4H, t, J = 4.9 Hz), 3.40 (4H, t, J = 4.9 Hz), 3.94 (2H, t, J = 4.4 Hz), 4.31



(2H, t, J = 4.4 Hz), 4.42 (2H, d, J = 5.4 Hz), 4.62 (1H, t, J = 5.2 Hz), 6.64-



6.73 (1H, m), 6.91 (1H, d, J = 2.2 Hz), 7.00-7.15 (1H, m), 7.24 (3H, d,



J = 3.0 Hz)


36
0.88 (9H, s), 0.89 (3H, s), 1.32-1.42 (2H, m), 1.65-2.20 (4H, m), 2.30-2.45



(7H, m), 2.49 (2H, t, J = 5.2 Hz), 2.80-2.90 (1H, m), 3.36 (4H, br s),



3.60 (2H, t, J = 4.9 Hz), 4.25-4.40 (1H, m), 6.80-7.40 (6H, m), 7.84 (1H, s)


37
0.92 (9H, s), 1.42-1.49 (2H, m), 2.09 (3H, s), 2.48 (3H, s) 2.50-2.58



(4H, m), 2.80-3.03 (2H, m), 3.13-3.33 (1H, m), 3.40-3.53 (4H, m),



4.17-4.33 (2H, m), 4.90-5.08 (1H, m), 5.67-5.78 (1H, m), 6.54-6.58



(2H, m), 6.79-6.90 (2H, m), 7.10 (2H, s), 7.68 (2H, s), 8.13 (1H, d,



J = 2.0 Hz)


38
0.89 (9H, s), 1.37-1.43 (2H, m), 2.13 (3H, s), 2.29 (3H, s), 2.30-2.47



(8H, m), 2.49 (3H, s), 2.76-2.88 (1H, m), 2.90-3.07 (1H, m), 3.31-3.42



(4H, m), 4.26 (2H, d, J = 4.2 Hz), 4.70-4.80 (1H, m), 4.96-5.08 (1H, m),



6.51 (1H, d, J = 7.9 Hz), 6.65 (2H, d, J = 7.4 Hz), 6.85 (1H, d, J = 7.7 Hz),



7.06 (1H, s), 7.86-7.97 (1H, m)


39
0.87 (9H, s), 1.33-1.39 (2H, m), 2.12 (3H, s), 2.27-2.36 (2H, m), 2.36-



2.43 (4H, m), 2.54 (3H, s), 2.82-2.91 (1H, m), 2.91-2.98 (1H, m),



3.20-3.27 (1H, m), 3.31-3.35 (4H, m), 4.27 (2H, t, J = 4.0 Hz), 4.54 (1H,



t, J = 4.9 Hz), 5.11-5.16 (1H, m), 6.62-6.72 (2H, m), 6.88-6.98 (2H, m),



6.99 (1H, s), 7.15-7.23 (1H, m), 7.75-7.80 (1H, m)


40
0.82 (9H, s), 1.31-1.37 (2H, m), 2.20 (3H, s), 2.25-2.42 (6H, m), 3.32-



3.42 (4H, m), 3.55 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.06-4.11 (2H, m),



5.53 (1H, m), 5.77 (1H, d, J = 14.6 Hz), 6.49-6.57 (2H, m), 6.64-6.73



(2H, m), 6.80-6.94, (3H, m), 7.16 (1H, s), 7.67 (1H, s)


41
0.07-0.13 (2H, m), 0.49-0.55 (2H, m), 0.83-0.88 (1H, m), 2.17 (3H, s),



2.28 (2H, d, J = 6.4 Hz), 2.33 (3H, s), 2.49-2.53 (4H, m), 2.73 (3H, s),



3.02-3.17 (2H, m), 3.36-3.41 (4H, m), 4.27-4.31 (2H, m), 4.51 (1H, s),



5.11-5.18 (1H, m), 6.55 (1H, d, J = 7.9 Hz), 6.67 (1H, d, J = 7.0 Hz), 6.77



(1H, d, J = 7.0 Hz), 6.86 (1H, d, J = 7.9 Hz), 7.15 (1H, s), 8.15 (1H, s)


42
0.07-0.09 (2H, m), 0.46-0.54 (2H, m), 0.80-0.85, (1H, m), 2.15 (3H, s),



2.23-2.27 (2H, m), 2.45-2.49 (4H, m), 2.73 (3H, s), 3.10-3.18 (2H, m),



3.35-3.37 (4H, m), 3.48-3.68 (1H, m), 4.25-4.29 (2H, m), 4.48 (1H, m),



5.16 (1H, m), 6.67 (2H, m), 6.86 (1H, d, J = 7.9 Hz), 6.92-6.98 (1H, m),



7.12 (1H, s) 7.20 (1H, m) 8.36 (1H, d, J = 7.9 Hz)


43
0.88 (9H, s), 1.34-1.40 (2H, m), 2.14 (3H, s), 2.29-2.49 (6H, m), 2.72



(3H, s), 3.03-3.18 (2H, m), 3.31-3.35 (4H, m), 3.47-3.67 (1H, m),



4.21-4.31 (2H, m), 4.51-4.54 (1H, m), 5.12-5.19 (1H, m), 6.67 (2H, m),



6.85 (1H, d, J = 7.9 Hz), 6.92-6.97 (1H, m), 7.06-7.22 (2H, m), 8.36



(1H, dd, J = 1.2, 7.9 Hz)


44
0.85 (9H, s), 1.31-1.39 (2H, m), 1.99 (3H, s), 2.19 (3H, s), 2.24-2.40



(6H, m), 3.33-3.38 (4H, m), 3.53 (3H, s), 3.90 (1H, d, J = 14.6 Hz),



4.10-4.12 (2H, m), 5.56 (1H, m), 5.75 (1H, d, J = 14.6 Hz), 6.33-6.35



(1H, m), 6.52-6.56 (2H, m), 6.66-7.11 (3H, m), 7.14 (1H, s), 7.48 (1H, s)


45
0.01-0.06 (2H, m), 0.42-0.49 (2H, m), 0.75-0.81 (1H, m), 1.98 (3H, s),



2.17-2.25 (5H, m), 2.38-2.48 (4H, m), 3.32-3.41 (4H, m), 3.50 (3H, s),



3.89 (1H, d, J = 14.6 Hz), 4.11 (2H, m), 5.54 (1H, m), 5.75 (1H, d,



J = 14.6 Hz), 6.34 (1H, dd, J = 1.0, 8.0 Hz), 6.50-6.54 (2H, m), 6.66-7.07



(3H, m), 7.13 (1H, s) 7.37 (1H, s)


46
0.88 (9H, s), 1.33-1.42 (2H, m), 2.24 (3H, s), 2.27-2.45 (6H, m), 3.35-



3.43 (4H, m), 3.68 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.20 (2H, d,



J = 5.4 Hz), 5.01-5.07 (1H, m), 5.79 (1H, d, J = 14.6 Hz), 6.54 (1H, dd,



J = 2.2, 8.4 Hz), 6.61-7.02 (5Hm), 7.05 (1H, d, J = 1.0 Hz), 7.53 (1H, d,



J = 4.7 Hz)


47
0.01-0.06 (2H, m), 0.42-0.47 (2H, m), 0.76-0.80 (1H, m), 2.15-2.23



(5H, m), 2.41-2.46 (4H, m), 3.35-3.48 (4H, m), 3.54 (3H, s), 3.90 (1H,



d, J = 14.6 Hz), 4.11 (2H, m), 5.46 (1H, m), 5.72 (1H, d, J = 14.6 Hz),



6.46 (1H, dd, J = 1.5, 8.5 Hz), 6.54-6.61 (2H, m), 6.67-6.73 (1H, m),



6.81-7.09 (2H, m), 7.13 (1H, s), 7.99 (1H, s)


48
0.84 (9H, s), 1.31-1.37 (2H, m), 1.99 (3H, s), 2.24-2.33 (6H, m), 3.34



(4H, m), 3.57 (3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.08 (2H, m), 5.70 (1H,



d, J = 14.6 Hz), 6.01 (1Hm), 6.34 (1H, m), 6.53-6.60 (2H, m), 6.70 (1H, s),



6.82-6.91 (2H, m), 7.10 (1H, s), 7.49 (1H, s)


49
0.02-0.08 (2H, m), 0.44-0.51 (2H, m), 0.77-0.82 (1H, m), 2.02 (3H, s),



2.16-2.24 (2H, m), 2.42-2.44 (4H, m), 3.36-3.42 (4H, m), 3.57 (3H, s),



3.92 (1H, d, J = 14.6 Hz), 4.11 (2H, m), 5.72 (1H, d, J = 14.6 Hz), 5.86



(1H, m), 6.36 (1H, dd, J = 1.0, 8.0 Hz), 6.54-6.89 (5H, m), 7.12 (1H, s),



7.27 (1H, s)


50
0.87 (9H, s), 1.33-1.40 (2H, m), 2.27-2.40 (6H, m), 3.34-3.42 (4H, m),



3.60 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.16 (2H, d, J = 5.2 Hz), 5.72 (1H,



d, J = 14.6 Hz), 5.81 (1H, t, J = 5.4, 11.1 Hz), 6.50 (1H, dd, J = 2.2, 8.4 Hz),



6.60-6.73 (3H, m), 6.91-7.02 (3H, m), 8.00 (1H, s)


51
0.02-0.08 (2H, m), 0.44-0.48 (2H, m), 0.77-0.81 (1H, m), 2.20-2.24,



(2H, m), 2.43 (4H, m), 3.37-3.47 (4H, m), 3.57 (3H, s), 3.93 (1H, d,



J = 14.6 Hz), 4.14 (2H, m), 5.70 (1H, d, J = 14.6 Hz), 5.82 (1H, m), 6.48



(1H, dd, J = 2.0, 8.5 Hz), 6.58-6.72 (3H, m), 6.89-7.00 (2H, m), 7.14 (1H, s),



7.92 (1H, s)


52
0.89 (9H, s), 1.34-1.42 (2H, m), 2.29-2.46 (6H, m), 3.35-3.44 (4H, m),



3.66 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.21 (2H, d, J = 5.4 Hz), 5.14-5.24



(1H, m), 5.76 (1H, d, J = 14.6 Hz), 6.58 (1H, dd, J = 2.2, 8.4 Hz), 6.74-7.00



(4H, m), 7.07 (1H, s), 7.22 (1H, s)


53
0.02-0.07 (2H, m), 0.43-0.48 (2H, m), 0.77-0.81 (1H, m), 2.19-2.24



(2H, m), 2.42-2.47 (4H, m), 3.37-3.41 (4H, m), 3.56 (3H, s), 3.95 (1H,



d, J = 14.6 Hz), 4.10 (2H, m), 5.68 (1H, d, J = 14.6 Hz), 5.89 (1H, m),



6.49 (1H, dd, J = 2.0, 8.5 Hz), 6.68-6.96 (5H, m), 7.14 (1H, s), 7.93



(1H, s)


54
0.82 (9H, s), 1.33-1.41 (2H, m), 1.99 (3H, s), 2.28-2.38 (6H, m), 3.36-



3.37 (4H, m), 3.60 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.07 (2H, m), 5.69



(1H, d, J = 14.6 Hz), 6.06 (1H, m), 6.37 (1H, m), 6.61-6.82 (3H, m),



6.94 (2H, m), 7.14 (1H, s), 7.46 (1H, s)


55
0.02-0.07 (2H, m), 0.43-0.50 (2H, m), 0.76-0.81 (1H, m), 1.97 (3H, s),



2.16-2.23 (2H, m), 2.41-2.45 (4H, m), 3.36-3.44, (4H, m), 3.54 (3H, s),



3.93 (1H, d, J = 14.6 Hz), 4.05 (2H, m), 5.68 (1H, d, J = 14.6 Hz), 6.00



(1H, m), 6.34 (1H, m), 6.58-6.79 (4H, m), 6.90 (1H, s), 7.11 (1H, s), 7.35



(1H, s)





















embedded image
















Compound






number
R3
R1

1H NMR: δ (ppm)

MS





109 E10
Cl


embedded image


0.42-0.90 (6H, m), 1.28 (6H, m), 1.78-1.80 (2H, m), 2.08 (1H, m), 2.95- 3.01 (2H, m), 3.66 (3H, s), 3.76 (1H, d, J = 14.6 Hz), 5.55 (1H, d, J = 14.6 Hz), 5.95 (1H, m), 6.97 (1H, dd, J = 8.4, 2.1 Hz), 7.03 (1H, s), 7.07 (1H, d, J = 8.4 Hz), 7.09 (1H, d, J = 2.1 Hz), 7.14 (1H, s)
(ESI)+: [M + H]+ = 442.3, 444.3





110
Me


embedded image


0.58-0.90 (6H, m), 1.23- 2.13 (9H, m), 2.33 (3H, s), 2.95-3.03 (2H, m), 3.68 (3H, s), 3.76 (1H, d, J = 14.6 Hz), 5.59 (1H, d, J = 14.6 Hz), 5.80 (1H, m), 6.15 (1H, s), 6.81-6.83 (2H, m), 6.97-7.00 (1H, m), 7.14 (1H, s)
(ESI)+: [M + H]+ = 422.4





111
H


embedded image


0.58-0.81 (6H, m), 1.31- 1.74 (6H, m), 1.69-1.80 (2H, m), 2.09-2.16 (1H, m), 2.89-2.98 (2H, m), 3.64 (3H, s), 3.80 (1H, d, J = 14.6 Hz), 5.58 (1H, d, J = 14.6 Hz), 6.49 (1H, m), 6.95-7.23 (5H, m), 7.39 (1H, s)
(APCI)+: [M + H]+ = 408.3





112
Me
CH3







113
Me


embedded image



(ESI)+: [M + H]+ = 458.7





114
Me


embedded image



(ESI)+: [M + H]+ = 492.2, 494.2





115
Me


embedded image



(ESI)+: [M + H]+ = 492.6, 494.2





116
Me


embedded image



(ESI)+: [M + H]+ = 492.2, 494.2





117
Me


embedded image



(ESI)+: [M + H]+ = 488.7





118
Me


embedded image



(ESI)+: [M + H]+ = 472.7





119
Me


embedded image



(ESI)+: [M + H]+ = 472.7





120
Me


embedded image



(ESI)+: [M + H]+ = 493.2





121
Me


embedded image



(ESI)+: [M + H]+ = 459.2





122
Me


embedded image



(ESI)+: [M + H]+ = 459.2





123
Me


embedded image



(ESI)+: [M + H]+ = 464.6





124
Me


embedded image



(ESI)+: [M + H]+ = 498.1





125
Me


embedded image



(ESI)+: [M + H]+ = 464.2





126
Me


embedded image



(ESI)+: [M + H]+ = 476.6





127
Me


embedded image



(ESI)+: [M + H]+ = 448.6





128
Me


embedded image



(ESI)+: [M + H]+ = 449.6





129
Me


embedded image



(ESI)+: [M + H]+ = 539.3





130
Me
CH2CH3

(ESI)+: [M + H]+ = 410.7


131
Me
CH2CH2CH3

(ESI)+: [M + H]+ = 424.7


132
Me
C(CH3)3

(ESI)+: [M + H]+ = 438.3





133
Me


embedded image



(ESI)+: [M + H]+ = 464.7





134
Me
CH2(CH2)3CH3

(ESI)+: [M + H]+ = 452.8


135
Me
CH(CH2CH3)CH2CH2CH2CH3

(ESI)+: [M + H]+ = (ESI)+: [M + H]+ = 480.4





136
Me


embedded image



(ESI)+: [M + H]+ = 532.3





137
Me


embedded image



(ESI)+: [M + H]+ = 472.7





138
Me


embedded image



(ESI)+: [M + H]+ = 486.7





139
Me


embedded image



(ESI)+: [M + H]+ = 498.7





140
Me


embedded image



(ESI)+: [M + H]+ = 478.6





141
Me


embedded image



(ESI)+: [M + H]+ = 488.7





142
Me


embedded image



(ESI)+: [M + H]+ = 502.7





143
Me
CH2CO2CH2CH3

(ESI)+: [M + H]+ = 468.2


144
Me
CH2CH2CO2CH3

(ESI)+: [M + H]+ = 468.2


145
Me
CH2(CH2)2CO2CH2CH3

(ESI)+: [M + H]+ = 496.7







text missing or illegible when filed




















embedded image





















MS



Compound



(ESI):



number
R1
R3
X
[M + H]+ =

1H NMR: δ (ppm)






146


embedded image


Cl
S
458.4, 460.4
0.51-0.98 (6H, m), 1.11- 1.99 (7H, m), 2.30-2.41 (1H, m), 2.67 (3H, s), 2.83-3.08 (4H, m), 3.42- 3.62 (1H, m), 5.55 (1H, s), 7.10 (1H, d, J = 8.4 Hz), 7.25 (1H, d d, J = 2.5, 8.4 Hz), 8.38 (1H, d, J = 2.5 Hz)





147


embedded image


Me
S
438.2
0.55-0.62 (1H, m), 0.62- 0.72 (2H, m), 0.72-0.85 (1H, m), 0.85-1.00 (2H, m), 1.10-1.45 (4H, m), 1.45-1.95 (4H, m), 2.35- 2.50 (1H, m), 2.43 (3H, s), 2.68 (3H, s), 2.85- 3.10 (4H, m), 3.45-3.65 (1H, m), 4.75-4.85 (1H, m), 5.45-5.65 (1H, m), 7.00-7.15 (2H, m), 8.14 (1H, s)





















embedded image
















Compound

MS



number
R3
(ESI)+: [M + H]+ =






148 E10.2
Cl




149
Me
354.2



150
H
340.2





















embedded image
















Compound

MS



number
R8
(ESI)+: [M + H]+ =






151 E12
CH(CH3)2
396.4



152
CH2CH3
396.4






153


embedded image


430.4






154


embedded image


444.4






155


embedded image


436.1






156


embedded image


464.2, 466.2






157


embedded image


464.3, 466.3






158
CH2CH2CH2CH3
410.4






159


embedded image


394.4






160


embedded image


458.4






161
CH2CH(CH3)2
410.4






162


embedded image


410.3






163


embedded image


431.1






164


embedded image


472.4






165


embedded image


446.4






166


embedded image


431.4






167


embedded image


436.3






168
CH2CF3
436.3






169


embedded image


434.4






170


embedded image


444.4






171


embedded image


444.3






172


embedded image


444.2






173


embedded image


454.2






174


embedded image


454.4






175


embedded image


498.3






176


embedded image


520.4






177


embedded image


488.4





















embedded image
















Com-

MS



pound

(ESI)+:



number
R1
[M + H]+ =







178 E13


embedded image


533.3







179


embedded image


522.2, 524.2







180


embedded image


536.4







181


embedded image


519.7







182


embedded image


438.2







183


embedded image


504.7







184


embedded image


436.7







185


embedded image


474.7







186


embedded image


508.6







187


embedded image


488.7







188


embedded image


454.7







189


embedded image


426.2







190


embedded image


556.2, 558.2







191
CH3
412.2







192


embedded image


424.2







193


embedded image


532.3






















embedded image
















Com-

MS



pound
R1
(ESI)+:



number

[M + H]+ =







194
CH2CH2CH2CH2CH3
458.4



E14





195
CH2CH3
416.4, 418.4



196
(CH2)2CN
441.5, 443.5







197


embedded image


484.4, 486.4







198


embedded image


482.4, 484.4







199


embedded image


520.6, 522.6







200


embedded image


548.5, 550.5







201


embedded image


522.6, 524.6







202


embedded image


464.5, 466.5







203


embedded image


470.5, 472.5







204
CH2OH
418.3, 420.3



205
CO2CH(CH3)2
474.4, 476.4







206


embedded image


600.6, 602.6







207
CH2CH(CH3)2
444.5, 446.5



208
CH2CH2OH
432.5



209
CN
413.4, 415.5







210


embedded image


446.5, 448.5







211


embedded image


434.3, 436.3







212


embedded image


509.5, 511.5







213


embedded image


428.4, 430.4







214


embedded image


514.6, 516.6







215


embedded image


414.4, 416.5







216


embedded image


490.6, 492.6







217


embedded image


540.6, 542.6







218


embedded image


472.3, 474.4







219


embedded image


489.4, 491.4







220


embedded image


530.5, 532.5







221
COC(CH3)3
472.5, 474.5



222
CONH2
431.5, 533.5







223


embedded image


499.5, 501.5







224


embedded image


506.6, 508.6






















embedded image

















Compound







number
R3
e
R8
MS

1H NMR: δ (ppm)






225
H
0
CH2CH2C(CH3)3
(ESI)+: [M + H]+ = 535.5
0.45-0.80 (2H, m), 0.88 (9H, s), 1.20-1.62 (7H, m), 1.62-2.19


E16




(10H, m), 2.33-2.46 (2H, m), 3.72 (3H, s), 3.79 (1H, d, J = 14.6







Hz), 5.61 (1H, d, J = 14.6 Hz), 5.63-5.70 (1H, m), 6.10 (1H, s),







7.02 (2H, t, J = 8.4 Hz), 7.10-7.19 (3H, m), 7.26-7.28 (2H, m)


226
Cl
2
CO2C(CH3)3
(ESI)+: [M + H]+ = 613.4, 615.4
0.43-0.62 (1H, m), 0.64-0.83 (1H, m), 0.91-1.14 (2H, m),







1.22-1.81 (11H, m), 1.44 (9H, s), 1.98-2.07 (2H, m), 2.16 (2H,







t, J = 7.7 Hz), 2.61 (2H, brs), 2.98 (2H, d, J = 5.4 Hz), 3.70 (3H,







s), 3.75 (1H, d, J = 14.6 Hz), 4.02 (2H, d, J = 12.4 Hz), 5.55







(1H, d, J = 14.6 Hz), 5.95 (1H, t, J = 5.2 Hz), 6.96 (1H, dd,







J = 2.0, 8.4 Hz), 7.04 (1H, d, J = 8.4 Hz), 7.09-7.13 (2H, m),







7.35 (1H, s)


227
H
0
CO2C(CH3)3

d4-MeOH δ 0.46-0.80 (2H, m), 1.13-1.84 (11H, m), 1.44 (9H,







s), 2.13-2.37 (2H, m), 2.74 (2H, brs), 2.89 (2H, t, J = 6.2 Hz),







3.72 (3H, s), 3.80 (1H, d, J = 14.6 Hz), 4.07 (2H, d, J = 13.4







Hz), 5.47 (1H, d, J = 14.6 Hz), 7.01-7.09 (1H, m), 7.14 (1H, s),







7.16-7.22 (1H, m), 7.26-7.37 (2H, m), 7.82-7.92 (2H, m)


228
Me
1
CO2C(CH3)3

0.48-0.61 (1H, m), 0.63-1.81 (1H, m), 0.92-1.14 (2H, m),







1.16-1.30 (2H, m), 1.42 (9H, s), 1.50-2.21 (10H, m), 2.31 (3H,







s), 2.53-2.72 (2H, m), 2.95 (2H, t, J = 5.9 Hz), 3.31-3.53 (1H,







m), 3.67 (3H, s), 3.75 (1H, d, J = 14.6 Hz), 3.98-4.03 (2H, m),







5.53 (1H, d, J = 14.6 Hz), 6.10 (1H, brt), 6.71 (1H, s), 6.80 (1H,







d, J = 7.9 Hz), 6.86 (1H, s), 6.97 (1H, d, J = 7.9 Hz), 7.10 (1H,







s)





229
H
0


embedded image


(ESI)+: [M + H]+ = 505.5
0.19 (2H, d, J = 4.7 Hz), 0.41-0.80 (4H, m), 0.80-0.99 (2H, m), 1.06-1.60 (6H, m), 1.61-1.93 (4H, m), 2.18-2.30 (2H, m), 2.30-2.45 (2H, m), 2.48 (2H, d, J = 6.7 Hz), 2.91 (2H, t, J = 6.4 Hz), 3.16-3.30 (2H, m), 3.68 (3H, s), 3.78 (1H, d, J = 14.6 Hz), 5.54 (1H, d, J = 14.6 Hz), 6.42-6.74 (1H, m), 6.95-7.18 (4H, m), 7.20-7.30 (2H, m)





230
Cl
0
CH2CH2C(CH3)3
(APCI)+: [M + H]+ = 569.5, 571.5
0.42-0.82 (2H, m), 0.86 (9H, s), 1.19-2.14 (17H, m), 2.28-2.34







(2H, m), 2.86-3.00 (4H, m), 3.65 (3H, s), 3.76 (1H, d, J = 14.6







Hz), 5.52 (1H, d, J = 14.6 Hz), 6.01-6.03 (1H, m), 6.94 (1H, dd,







J = 2.2, 8.4 Hz), 7.03 (1H, d, J = 8.4 Hz), 7.10-7.11 (2H, m),







7.72 (1H, s)





231
Cl
0


embedded image


(APCI)+: [M + H]+ = 539.4, 541.4
d4-MeOH: 0.37-0.43 (2H, m), 0.57-0.80 (4H, m), 1.05-2.01 (12H, m), 2.15-2.24 (1H, m), 2.44-2.52 (1H, m), 2.91-3.04 (6H, m), 3.61-3.69 (2H, m), 3.71 (3H, s), 3.80 (1H, d, J = 14.6 Hz), 5.43 (1H, d, J = 14.6 Hz), 7.03 (1H, dd, J = 2.2, 8.4 Hz), 7.15 (1H, s), 7.20 (1H, d, J = 8.4 Hz), 7.33 (1H, d, J = 2.2 Hz)





232
Me
0
CH2CH2C(CH3)3
(APCI)+: [M + H]+ = 549.5
0.51-0.82 (2H, m), 0.86 (9H, s), 1.12-1.84 (13H, m), 1.91-2.11







(4H, m), 2.20-2.36 (5H, m), 2.94-3.02 (4H, m), 3.66 (3H, s),







3.75 (1H, d, J = 14.6 Hz), 5.55 (1H, d, J = 14.6 Hz), 6.53 (1H,







s), 6.80 (1H, d, J = 7.9 Hz), 6.85 (1H, s), 6.97 (1H, d, J = 7.9







Hz), 7.12 (1H, s)





233
Me
0


embedded image


(APCI)+: [M + H]+ = 519.4
d4-MeOH: 0.39-0.76 (6H, m), 1.05-2.02 (16H, m), 2.20-2.26 (1H, m), 2.34 (3H, s), 2.44-2.50 (1H, m), 2.88-3.00 (4H, m), 3.69 (3H, s), 3.75 (1H, d, J = 14.6 Hz), 5.43 (1H, d, J = 14.6 Hz), 6.86-6.89 (1H, m), 7.03-7.13 (3H, m), 7.79 (1H, t, J = 5.9 Hz), 7.85 (1H, s)





















embedded image

















Com-







pound







num-







ber
R3
R8
X
MS

1H NMR: δ (ppm)






234
Cl
CH2CH2C(CH3)3
S
 585.5,
0.50-0.56 (1H, m),






587.6
0.88 (9H, s),







1.11-1.19 (2H, m),







1.35-1.49 (4H, m),







1.56-2.10 (9H, m),







2.28-2.34 (3H, m),







2.67 (3H, s),







2.83-3.12 (6H, m),







3.42-3.60 (2H, m),







4.76-4.83 (1H, m),







5.39-5.44 (1H, m),







7.10 (1H, d,







J = 8.4 Hz), 7.26







(1H, dd, J = 2.5,







8.4 Hz), 8.38 (1H,







d, J = 2.5 Hz)


235
Me
CH2CH2C(CH3)3
S
565.4
0.42-0.62 (1H, m),







0.72-0.84 (1H, m),







0.87 (9H, s),







1.08-1.20 (2H, m),







1.30-1.50 (4H, m),







1.56-1.75 (6H, m),







1.75-1.95 (5H, m),







1.96-2.10 (1H, m),







2.25-2.35 (1H, m),







2.43 (3H, s), 2.69







(3H, s), 2.85-3.05







(6H, m), 3.40-3.65







(1H, m), 4.75-4.85







(1H, m), 5.35-5.45







(1H, m), 7.00-7.15







(2H, m), 8.15 (1H,







s)





















embedded image
















Com-






pound






num-






ber
R3
e
MS

1H NMR: δ (ppm)






236
Me
1
(APCI)+:
0.44-0.68 (1H, m), 0.69-0.87


E17


[M + H]+ = 579.5
(1H, m), 1.19-2.32 (15H, m),






2.40 (3H, s), 2.88-3.03 (4H,






m), 3.28-3.43 (4H, m),






3.52-3.75 (1H, m), 3.84 (1H,






d, J = 14.6 Hz), 3.96 (3H, s),






5.50 (1H, d, J = 14.6 Hz),






7.07 (1H, d, J = 7.9 Hz),






7.22 (1H, d, J = 7.9 Hz),






7.28 (1H, s), 7.96 (1H, s)


237
Cl
2
(ESI)+:
CD3OD δ 0.54-0.70 (1H, m),





[M + H]+ =
0.72-0.89 (1H, m), 1.12-1.98





513.4, 515.4
(14H, m), 2.20-2.29 (3H, m),






2.89-2.98 (4H, m), 3.30-3.39






(2H, m), 3.87 (1H, d,






J = 14.6 Hz), 3.98 (3H, s),






5.51 (1H, d, J = 14.6 Hz),






7.24 (1H, dd, J = 2.2, 8.4






Hz), 7.37 (1H, d, J = 8.4






Hz), 7.56 (1H, d, J = 2.2






Hz), 7.91 (1H, s), 8.00 (1H,






s)


238
H
0
(ESI)+:
CD3OD δ 0.44-0.63 (1H, m),





[M + H]+ = 451.3
0.66-0.83 (1H, m), 1.10-2.03






(11H, m), 2.21-2.31 (1H, m),






2.47-2.61 (1H, m), 2.89-2.92






(2H, m), 2.98-3.14 (2H, m),






3.34-3.42 (2H, m), 3.87 (1H,






d, J = 14.6 Hz), 3.99 (3H, s),






5.53 (1H, d, J = 14.6 Hz),






7.24 (1H, dd, J = 2.0, 8.4






Hz), 7.32 (1H, d, J = 8.4






Hz), 7.38-7.53 (2H, m), 7.98






(1H, s)





















embedded image



















MS



Compound


(ESI)+:



number
R1
R3
[M + H]+ =

1H NMR: δ (ppm)






239
Me
Me
432.1



E18






240
CH(CH3)2
Me
460.2






241


embedded image


Me
508.2






242


embedded image


Me
(494.2






243


embedded image


Me
562.2






244


embedded image


Me
528.2, 530.2






245


embedded image


Me
528.2, 530.2






246


embedded image


Me
528.2, 530.2






247


embedded image


Me
524.2






248


embedded image


Me
508.7
0.50-0.80 (2H, m), 1.20-1.80 (7H, m), 2.05-2.20 (1H, m), 2.35 (3H, s), 2.40 (3H, s), 2.67 (2H, t, J = 6.4 Hz), 3.71 (3H, s), 3.75 (1H, d, J = 14.5 Hz), 4.29 (1H, t, J = 6.5 Hz), 6.59 (1H, d, J = 14.5 Hz), 5.71 (1H, s), 6.79 (1H, s), 6.79-6.89 (1H, m), 6.99 (1H, d, J = 7.9 Hz), 7.23-7.31 (2H, m), 7.66 (2H, d, J = 8.2 Hz)





249


embedded image


Me
519.7






250


embedded image


Me
562.2






251


embedded image


Me
551.3






252


embedded image


Me
534.1, 536.1






253


embedded image


Me
498.2






254
CH2CF3
Me
500.2






255


embedded image


Me
607.1, 609.1






256


embedded image


Me
542.2






257
CH2CH3
Me
446.1
0.55-0.90 (2H, m), 1.20-1.90 (10H, m),






2.08-2.20 (1H, m), 2.36 (3H, s), 2.86 (2H,






tJ = 6.0 Hz) 2.95-3.15 (2H, m), 3.71 (3H,






s), 3.75 (1H, d, J = 14.6 Hz), 4.12-4.16






(1H, m), 5.60 (1H, d, J = 14.6 Hz), 5.77






(1H, s), 6.80 (1H, s), 6.83 (1H, d, J = 7.9






Hz), 7.01 (1H, d, J = 7.9 Hz), 7.17 (1H, s)


258
CH2CH2CH3
Me
460.6



259
CH2CH2CH2CH3
Me
474.2



260
CH2CH2CH2CH3
Cl
494.2, 496.2
0.55-0.85 (2H, m), 0.92 (3H, t, J = 7.3






Hz), 1.25-1.85 (11H, m), 2.05-2.20 (1H,






m), 2.80-3.00 (4H, m), 3.72 (3H, s), 3.76






(1H, d, J = 14.6 Hz), 4.10-4.20 (1H, m),






5.59 (1H, d, J = 14.6 Hz), 5.91 (1H, s),






7.00-7.10 (3H, m), 7.19 (1H, s)





261


embedded image


Cl
528.1, 530.1
0.50-0.80 (2H, m), 1.20-1.80 (7H, m), 2.00-2.15 (1H, m), 2.40 (3H, s), 2.60-2.75 (2H, m), 3.71 (3H, s), 2.60-2.75 (2H, m), 3.71 (3H, s), 3.75 (1H, d, J = 14.6 Hz), 4.64 (1H, t, J = 6.5 Hz), 5.57 (1H, d, J = 14.6 Hz), 6.29 (1H, s), 6.95-7.10 (3H, m), 7.16 (1H, s), 7.25-7.35 (2H, m), 7.71 (2H, d, J = 8.2 Hz)





262


embedded image


H
446.2
0.50-0.80 (1H, m), 1.30 (6H, d, J = 6.7 Hz), 1.32-1.48 (4H, m), 1.50-1.90 (5H, m), 2.10-2.20 (1H, m) 2.75-3.00 (2H, m), 3.72 (3H, s), 3.81 (1H, d, J = 14.6 Hz), 4.25-4.45 (1H, m), 5.62 (1H, d, J = 14.6 Hz), 6.21 (1H, s), 6.95-7.10 (2H, m), 7.10-7.20 (2H, m), 7.25-7.30 (1H, m)





263


embedded image


H
510.1
0.45-0.75 (1H, m), 1.20-1.85 (8H, m), 2.00-2.15 (1H, m), 2.60-2.70 (2H, m), 3.73 (3H, s), 3.79 (1H, d, J = 14.6 Hz), 3.84 (3H, s), 4.30-4.40 (1H, m), 5.60 (1H, d, J = 14.6 Hz), 5.90 (1H, s), 6.90-7.10 (4H, m), 7.10-7.20 (2H, m), 7.25-7.30 (1H, m), 7.70-7.80 (2H, m)





















embedded image














Com-




pound




num-




ber
R12
MS





264
Me
(ESI)+:


E19

[M + H]+ = 557.4


265
CH(CH3)2
(ESI)+:




[M + H]+ = 585.4





266


embedded image


(ESI)+: [M + H]+ = 633.6





267


embedded image


(ESI)+: [M + H]+ = 619.5





268


embedded image


(ESI)+: [M + H]+ = 687.4, 689.4





269


embedded image


(ESI)+: [M + H]+ = 653.4, 655.4





270


embedded image


(ESI)+: [M + H]+ = 653.5, 655.5





271


embedded image


(ESI)+: [M + H]+ = 653.5, 655.5





272


embedded image


(ESI)+: [M + H]+ = 649.6





273


embedded image


(ESI)+: [M + H]+ = 633.5





274


embedded image


(ESI)+: [M + H]+ = 644.5





275


embedded image


(ESI)+: [M + H]+ = 687.5





276


embedded image


(ESI)+: [M + H]+ = 676.5





277


embedded image


(ESI)+: [M + H]+ = 659.4, 661.4





278


embedded image


(ESI)+: [M + H]+ = 623.5





279
CH2CF3
(ESI)+:




[M + H]+ = 625.5





280


embedded image


(ESI)+: [M + H]+ = 732.4, 734.4





281


embedded image


(ESI)+: [M + H]+ = 667.5





282
CH2CH3
(ESI)+:




[M + H]+ = 571.4


283
CH2CH2CH3
(ESI)+:




[M + H]+ = 585.5


284
CH2CH2CH2CH3
(ESI)+:




[M + H]+ = 599.5





















embedded image














Com-




pound




number
R12
MS





285
Me
(ESI)+:


E20

[M + H]+ =




521.5





286


embedded image


(ESI)+: [M + H]+ = 583.4





287


embedded image


(ESI)+: [M + H]+ = 617.5, 619.5





288


embedded image


(ESI)+: [M + H]+ = 617.5, 619.5





289


embedded image


(ESI)+: [M + H]+ = 617.3, 619.3





290


embedded image


(ESI)+: [M + H]+ = 613.5





291


embedded image


(ESI)+: [M + H]+ = 597.5





292


embedded image


(ESI)+: [M + H]+ = 618.5, 620.5





293


embedded image


(ESI)+: [M + H]+ = 584.4





294


embedded image


(ESI)+: [M + H]+ = 589.3





295


embedded image


(ESI)+: [M + H]+ = 623.5, 625.5





296


embedded image


(ESI)+: [M + H]+ = 589.2





297


embedded image


(ESI)+: [M + H]+ = 601.5





298


embedded image


(ESI)+: [M + H]+ = 573.4





299


embedded image


(ESI)+: [M + H]+ = 574.4





300


embedded image


(ESI)+: [M + H]+ = 664.6





301
CH2CH3
(ESI)+:




[M + H]+ =




535.3


302
CH2CH2CH3
(ESI)+:




[M + H]+ =




549.4





303


embedded image


(ESI)+: [M + H]+ = 547.4





304
C(CH3)3
(ESI)+:




[M + H]+ =




563.5





305


embedded image


(ESI)+: [M + H]+ = 589.5





306
CH2(CH2)3CH3
(ESI)+:




[M + H]+ =




577.5


307
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+:




[M + H]+ =




605.6





308


embedded image


(ESI)+: [M + H]+ = 657.6





309


embedded image


(ESI)+: [M + H]+ = 597.4





310


embedded image


(ESI)+: [M + H]+ = 611.5





311


embedded image


(ESI)+: [M + H]+ = 623.6





312


embedded image


(ESI)+: [M + H]+ = 603.5





313


embedded image


(ESI)+: [M + H]+ = 613.5





314


embedded image


(ESI)+: [M + H]+ = 627.6





315
CH2CH2CO2CH3
(ESI)+:




[M + H]+ =




593.4


316
CH2(CH2)2CO2CH2CH3
(ESI)+:




[M + H]+ =




621.6





















embedded image














Compound




number
R8
MS





317

(ESI)+: [M + H]+ = 507.4


E21




318
CH2CH2CH3
(ESI)+: [M + H]+ = 493.5





319


embedded image


(ESI)+: [M + H]+ = 541.5





320


embedded image


(ESI)+: [M + H]+ = 555.5





321


embedded image


(ESI)+: [M + H]+ = 547.4





322
CH2CH2CH2CH2CH3
(ESI)+: [M + H]+ = 521.5





323


embedded image


(ESI)+: [M + H]+ = 569.4





324
CH2CH2CH(CH3)2
(ESI)+: [M + H]+ = 521.5





325


embedded image


(ESI)+: [M + H]+ = 542.4





326


embedded image


(ESI)+: [M + H]+ = 547.4





327
CH2CH2CF3
(ESI)+: [M + H]+ = 547.3





328


embedded image


(ESI)+: [M + H]+ = 545.5





329
CH2CH2OH
(ESI)+: [M + H]+ = 495.6





330


embedded image


(ESI)+: [M + H]+ = 555.5





331


embedded image


(ESI)+: [M + H]+ = 555.3





332


embedded image


(ESI)+: [M + H]+ = 566.4





333


embedded image


(ESI)+: [M + H]+ = 566.4





334


embedded image


(ESI)+: [M + H]+ = 566.5





335


embedded image


(ESI)+: [M + H]+ = 631.5





336


embedded image


(ESI)+: [M + H]+ = 609.5





337


embedded image


(ESI)+: [M + H]+ = 631.6





















embedded image














Com-




pound




num-




ber
R8
MS





338

(ESI)+:


E22

[M + H]+ =




597.6, 599.6


339
CH2CH2CH3
(ESI)+:




[M + H]+ =




555.6, 557.6


340
CH2(CH2)2CN
(ESI)+:




[M + H]+ =




580.7, 582.7





341


embedded image


(ESI)+: [M + H]+ = 631.8, 633.8





342


embedded image


(ESI)+: [M + H]+ = 623.6, 625.6





343


embedded image


(ESI)+: [M + H]+ = 621.6, 623.6





344


embedded image


(ESI)+: [M + H]+ = 659.8, 661.8





345


embedded image


(ESI)+: [M + H]+ = 687.7, 689.7





346


embedded image


(ESI)+: [M + H]+ = 661.8, 663.8





347


embedded image


(ESI)+: [M + H]+ = 603.7, 605.7





348
CH2CH2OH
(ESI)+:




[M + H]+ =




557.5, 559.5


349
CH2CO2CH(CH3)2
(ESI)+:




[M + H]+ =




613.6, 615.6


350
CH2CH2CH(CH3)2
(ESI)+:




[M + H]+ =




583.6, 585.6


351
CH2CH2CH2OH
(ESI)+:




[M + H]+ =




571.6, 573.6


352
CH2CN
(ESI)+:




[M + H]+ =




552.6, 554.6





353


embedded image


(ESI)+: [M + H]+ = 648.7, 650.7





354


embedded image


(ESI)+: [M + H]+ = 567.7, 569.6





355


embedded image


(ESI)+: [M + H]+ = 653.8, 655.8





356


embedded image


(ESI)+: [M + H]+ = 553.6, 555.6





357


embedded image


(ESI)+: [M + H]+ = 629.8, 631.8





358


embedded image


(ESI)+: [M + H]+ = 679.8, 681.8





359


embedded image


(ESI)+: [M + H]+ = 611.6, 613.6





360


embedded image


(ESI)+: [M + H]+ = 628.7, 630.7





361
CH2COC(CH3)3
(ESI)+:




[M + H]+ =




611.7, 613.7


362
CH2CONH2
(ESI)+:




[M + H]+ =




570.6, 572.6





363


embedded image


(ESI)+: [M + H]+ = 638.8, 640.8





364


embedded image


(ESI)+: [M + H]+ = 645.8, 647.8





















embedded image














Compound




number
R12
MS





365 E23


embedded image


(ESI)+: [M + H]+ = 658.5





366


embedded image


(ESI)+: [M + H]+ = 647.5





367


embedded image


(ESI)+: [M + H]+ = 661.7





368


embedded image


(ESI)+: [M + H]+ = 644.5





369


embedded image


(ESI)+: [M + H]+ = 563.5





370


embedded image


(ESI)+: [M + H]+ = 629.6





371


embedded image


(ESI)+: [M + H]+ = 561.4





372


embedded image


(ESI)+: [M + H]+ = 599.4





373


embedded image


(ESI)+: [M + H]+ = 633.5





374


embedded image


(ESI)+: [M + H]+ = 613.5





375


embedded image


(ESI)+: [M + H]+ = 579.5





376


embedded image


(ESI)+: [M + H]+ = 551.5





377


embedded image


(ESI)+: [M + H]+ = 683.5





378
CH3
(ESI)+:




[M + H]+ = 537.4





379


embedded image


(ESI)+: [M + H]+ = 549.4





380


embedded image


(ESI)+: [M + H]+ = 657.6





















embedded image
















Compound






number
R3
R9
MS

1H NMR: δ (ppm)






  381 E24
Me
CH2CH2C(CH3)3
(APCI)+:
0.41-0.82 (2H, m), 0.86 (9H, s),





[M + H]+ =
1.33-1.50 (7H, m), 1.73 (2H, m),





550.4
2.12 (1H, m), 2.27-2.39 (6H, m),






2.29 (3H, s), 2.90-2.93 (2H, m),






3.31-3.35 (4H, m), 3.64 (3H, s),






3.74 (1H, d, J = 14.6 Hz), 4.78






(1H, m), 5.54 (1H, d, J = 14.6 Hz),






6.77 (1H, dd, J = 1.0, 8.0 Hz),






6.88 (1H, s), 6.95 (1H, d, J = 8.0






Hz), 7.03 (1H, d, J = 1.0 Hz),






7.11 (1H, s)


382
Me
CH2CH2CH2SCH3
(ESI)+:






[M + H]+ =






554.6



383
Me
CH2CH2OCH3
(ESI)+:






[M + H]+ =






524.7



384
Me
CH2CH2CH2CF3
(ESI)+:






[M + H]+ =






576.6



385
Me
CH2CH2N(CH2CH3)2
(ESI)+:






[M + H]+ =






565.6



386
Me
CH2CH2CH2F
(ESI)+:






[M + H]+ =






526.6



387
Me
CH2CH2CH2OH
(ESI)+:






[M + H]+ =






524.6



388
Me
CH2C(CH3)3
(ESI)+:
0.55-0.84 (2H, m), 0.84 (9H, s), 1.18-





[M + H]+ =
1.75 (7H, m), 2.04-2.16 (3H, m),





536.5
2.34 (3H, s), 2.44-2.48 (4H, m),






2.93-2.97 (2H, m), 3.26-3.29 (4H,






m), 3.70 (3H, s), 3.75 (1H, d, J =






14.6 Hz), 4.35-4.39 (1H, bs), 5.58






(1H, d, J = 14.6 Hz), 5.84 (1H, s),






6.79-6.83 (2H, m), 6.98 (1H, m),






7.16 (1H, s)





389
Me


embedded image


(APCI)+: [M + H]+ = 548.5
0.46-0.71 (2H, m), 1.11-1.27 (4H, m), 1.37-1.59 (7H, m), 1.69-1.78 (4H, m), 1.95-2.17 (2H, m), 2.21 (2H, d, J = 7.4 Hz), 2.30 (3H, s),






2.32-2.36 (4H, m), 2.85-2.98 (2H,






m), 3.29-3.32 (4H, m), 3.64 (3H,






s), 3.74 (1H, d, J = 14.6 Hz), 4.67-






4.71 (1H, m), 5.55 (1H, d, J = 14.6






Hz), 6.78 (1H, d, J = 8.0 Hz), 6.87-






6.88 (2H, m), 6.95 (1H, d, J = 8.0






Hz), 7.11 (1H, s)





390
Me
CH2CH2CH(CH3)2
(APCI)+:
0.48-0.72 (2H, m), 0.86 (6H, t, J =





[M + H]+ =
6.4 Hz), 1.18-1.38 (5H, m), 1.46-





536.5
1.60 (3H, m), 1.68-1.79 (2H, m),






2.07-2.18 (1H, m), 2.28-2.38 (9H,






m), 2.88-2.96 (2H, m), 3.31-3.34






(4H, m), 3.65 (3H, s), 3.75 (1H, d,






J = 14.6 Hz), 4.71-4.75 (1H, m),






5.55 (1H, d, J = 14.6 Hz), 6.78 (1H,






d, J = 7.9 Hz), 6.88 (1H, s), 6.96 (1H,






d, J = 7.9 Hz), 7.04 (1H, dd, J = 1.2,






7.9 Hz), 7.12 (1H, s)


391
Me
CH2CH(CH3)2
(APCI)+:
0.46-0.71 (2H, m), 0.85





[M + H]+ =
(6H, t, J = 6.4 Hz), 1.19-1.27





522.4
(2H, m), 1.37-1.54 (3H, m),






1.68-1.78 (3H, m), 2.04






(2H, d, J = 7.4 Hz), 2.05-2.17






(1H, m) 2.29 (3H, s), 2.29-






2.33 (4H, m), 2.87-2.98






(2H, m), 3.28-3.32 (4H, m),






3.64 (3H, s), 3.74 (1H, d,






J = 14.6 Hz), 4.68-4.72 (1H,






m), 5.55 (1H, d, J = 14.6 Hz),






6.78 (1H, d, J = 8.0 Hz), 6.88






(1H, s), 6.93 (1H, s), 6.95






(1H, d, J = 8.0 Hz), 7.11 (1H, s)


392
Me
CH2CH2CH3
(APCI)+:
0.47-0.89 (2H, m), 0.87





[M + H]+ =
(3H, t, J = 7.2 Hz), 1.18-1.27





508.4
(2H, m), 1.37-1.54 (5H, m),






1.68-1.78 (2H, m), 2.07-






2.17 (1H, m), 2.23-2.26






(2H, m), 2.29 (3H, s), 2.34-






2.38 (4H, m), 2.87-2.97






(2H, m), 3.30-3.34 (4H, m),






3.64 (3H, s), 3.74 (1H, d,






J = 14.6 Hz), 4.72-4.76 (1H,






m), 5.54 (1H, d, J = 14.6 Hz),






6.78 (1H, d, J = 8.0 Hz) 6.87-






6.88 (2H, m), 6.95 (1H, d,






J = 8.0 Hz), 7.11 (1H, s)


393
Cl


embedded image


(APCI)+: [M + H]+ = 568.4, 570.4
0.41-0.56 (1H, m), 0.60- 0.75 (1H, m), 0.78 (1H, d, J = 6.4 Hz), 0.94-1.14 (2H, m), 1.14-1.55 (9H, m),






1.57-1.72 (4H, m), 1.83-






2.00 (2H, m), 2.18 (2H, d,






J = 6.9 Hz), 2.29 (4H, t,






J = 4.9 Hz), 2.70-2.90 (2H,






m), 3.22 (4H, t, J = 4.9 Hz),






3.58 (3H, s), 3.66 (1H, d,






J = 14.6 Hz), 5.17 (1H, t,






J = 5.4 Hz), 5.38 (1H, d,






J = 14.6 Hz), 6.86 (1H, d,






J = 2.2 Hz), 6.91 (1H, s),






7.03 (1H, s), 7.12 (1H, d, J = 2.2 Hz)





394
Cl
CH2CH2CH(CH3)2
(APCI)+:
0.40-0.59 (1H, m), 0.60-





[M + H]+ =
0.80 (1H, m), 0.86 (6H, d,





556.4, 558.4
J = 6.7 Hz), 1.09-1.65 (9H,






m), 1.65-1.81 (2H, m),






2.01-2.17 (1H, m), 2.30-






2.41 (2H, m), 2.41 (4H, t,






J = 4.9 Hz) 2.92 (2H, t,






J = 5.9 Hz), 3.38 (4H, t,






J = 4.9 Hz), 3.70 (3H, s),






3.77 (1H, d, J = 14.6 Hz),






5.07 (1H, t, J = 5.4 Hz) 5.52






(1H, d, J = 14.6 Hz), 6.94






(1H, d, J = 2.2 Hz), 7.02 (1H,






s), 7.12 (1H, s), 7.32 (1H,






d, J = 2.2 Hz)


395
Cl
CH2CH(CH3)2
(APCI)+:
0.38-0.60 (1H, m), 0.60-





[M + H]+ =
0.78 (1H, m), 0.82 (6H, d,





542.4, 544.4
J = 6.7 Hz), 1.10-1.40 (2H,






m), 1.40-1.56 (2H, m),






1.63-1.80 (4H, m), 2.03






(2H, d, J = 7.4 Hz), 2.12 (2H,






s), 2.31 (4H, t, J = 4.9 Hz),






2.85-2.94 (2H, m), 3.30






(4H, t, J = 4.9 Hz), 3.64 (3H,






s), 3.72 (1H, d, J = 14.6 Hz),






4.75 (1H, t, J = 5.7 Hz), 5.49






(1H, d, J = 14.6 Hz), 6.93






(1H, d, J = 2.2 Hz), 6.98 (1H,






s), 7.11 (1H, s), 7.15 (1H,






d, J = 2.2 Hz)


396
Cl
CH2CH2CH3
(APCI)+:
0.39-0.60 (1H, m), 0.60-





[M + H]+ =
0.83 (1H, m), 0.88 (3H, t,





528.3, 530.3
J = 7.4 Hz), 1.17-1.63 (9H,






m), 1.64-1.83 (2H, m),






2.00-2.15 (1H, m), 2.25-






2.35 (2H, m), 2.40 (4H, t,






J = 4.9 Hz), 2.90-3.00 (2H,






m), 3.35 (4H, t, J = 4.9 Hz),






3.72 (3H, s), 4.59 (1H, t,






J = 5.7 Hz), 5.54 (1H, d,






J = 14.6 Hz), 6.90-7.04 (2H,






m), 7.10-7.19 (2H, m)





397
Cl


embedded image


(APCI)+: [M + H]+ = 540.3, 542.3
d6-DMSO: 0.02-0.04 (2H, m), 0.41-0.47 (2H, m), 0.80-1.75 (10H, m), 2.03






(1H, m), 2.14 (2H, d,






J = 6.5 Hz), 2.30-2.34 (4H,






m), 2.74 (2H, m), 3.20-3.28






(4H, m), 3.67 (3H, s), 3.70






(1H, d, J = 14.6 Hz), 5.34






(1H, d, J = 14.6 Hz), 6.29






(1H, m), 7.02 (1H, dd,






J = 2.5, 8.0 Hz), 7.08 (1H, s),






7.25 (1H, d, J = 8.0 Hz), 7.42






(1H, d, J = 2.5 Hz)





398
Me


embedded image


(APCI)+: [M + H]+ = 520.4
0.06-0.08 (2H, m), 0.46- 0.53 (2H, m), 0.81 (1H, m), 1.13-1.79 (9H, m), 2.09






(1H, m), 2.23 (2H, m), 2.30






(3H, s), 2.45-2.49 (4H, m),






2.92 (2H, m), 3.33-3.37






(4H, m), 3.65 (3H, s), 3.74






(1H, d, J = 14.6 Hz), 4.69






(1H, m), 5.54 (1H, d,






J = 14.6 Hz), 6.67 (1H, s),






6.78 (1H, dd, J = 1.0,






8.0 Hz), 6.86 (1H, d,






J = 1.0 Hz), 6.96 (1H, d,






J = 8.0 Hz), 7.11 (1H, s)





399
Cl
CH2CH2C(CH3)3
(APCI)+:
0.42-0.81 (2H, m), 0.87





[M + H]+ =
(9H, s), 1.22-1.40 (7H, m),





570.3, 572.3
1.74-1.78 (2H, m), 2.08






(1H, m), 2.28-2.40 (6H, m),






2.87-2.92 (2H, m), 3.33-






3.37 (4H, m), 3.63 (3H, s),






3.74 (1H, d, J = 14.6 Hz),






4.89 (1H, m), 5.51 (1H, d,






J = 14.6 Hz), 6.93 (1H, dd,






J = 2.2, 8.4 Hz), 7.03 (1H, d,






J = 8.4 Hz), 7.10 (1H, s),






7.20 (1H, d, J = 2.2 Hz), 8.10 (1H, s)


400
H
CH2CH2C(CH3)3
(APCI)+:
0.40-0.46 (1H, m), 0.63-





[M + H]+ =
0.68 (1H, m), 0.82 (9H, s),





536.4
1.26-1.67 (7H, m), 1.73-






1.79 (2H, m), 2.03-2.08






(1H, m), 2.34-2.37 (6H, m),






2.82-2.94 (2H, m), 3.32






(4H, m), 3.64 (3H, s), 3.77






(1H, d, J = 14.6 Hz), 4.80






(1H, t, J = 5.4 Hz), 5.56 (1H,






d, J = 14.6 Hz), 6.95 (1H, m),






7.05-7.12 (3H, m), 7.19






(1H, m), 7.32 (1H, s)


401
H


embedded image


(ESI)+: [M + H]+ = 506.3
0.04-0.11 (2H, m), 0.46- 0.53 (2H, m), 0.61-0.72 (1H, m), 0.72-0.89 (1H, m),






1.20-1.59 (6H, m), 1.69-






1.81 (2H, m), 2.04-2.17






(1H, m), 2.23 (2H, d,






J = 6.4 Hz), 2.46 (4H, t,






J = 4.9 Hz), 2.81-3.05 (2H,






m), 3.35 (4H, t, J = 4.9 Hz),






3.69 (3H, s), 3.79 (1H, d,






J = 14.6 Hz), 4.56 (1H, t,






J = 5.6 Hz), 5.60 (1H, d,






J = 14.6 Hz), 6.67 (1H, s),






6.96-7.26 (4H, m), 7.15 (1H, s)





402
H


embedded image


(ESI)+: [M + H]+ = 520.3






















embedded image

















Compound





1H NMR:



number
R3
R9
X
MS
δ (ppm)















403
Cl
CH2CH2C(CH3)3
S
(ESI)+:
0.49-0.60 (1H, m), 0.88






[M + H]+ =
(9H, s), 1.11-1.24 (2H, m),






586.6, 588.6
1.34-1.41 (4H, m), 1.47-1.87







(5H, m), 2.28-2.41 (5H, m),







2.67 (3H, s), 2.82-3.18







(4H, m), 3.29-3.33 (4H, m),







3.37-3.59 (1H, m), 4.34-4.38







(1H, m), 4.76-4.83 (1H, m),







7.10 (1H, d, J, = 8.4 Hz),







7.25 (1H, dd, J = 2.5, 8.4 Hz),







8.38 (1H, d, J = 2.5 Hz)





404
Me


embedded image


S
(ESI)+: [M + H]+ = 536.3
0.05-0.15 (2H, m), 0.40-0.60 (3H, m), 0.70-0.90 (2H, m), 1.10-1.20 (2H, m), 1.45-







1.95 (5H, m), 2.24 (2H, d, J =







6.7 Hz), 2.35-2.55 (8H, m), 2.69







(3H, s), 2.85-3.05 (4H, m),







3.30-3.40 (4H, m), 3.46-







3.65 (1H, m), 4.32-4.38 (1H, m),







4.74-4.86 (1H, m), 7.00-7.15







(2H, m), 8.14(1H, s)





















embedded image

















Compound





1H NMR:



number
R3
R9
X
MS
δ (ppm)















405
Me
CH2CH2C(CH3)3
NH

0.45-0.55 (1H, m), 0.75-0.90 (10H, m),







1.10-1.20 (1H, m), 1.20-1.90 (8H, m),







2.30-2.45 (13H, m), 2.65-3.00 (4H, m),







3.30-3.40 (5H, m), 4.35-4.45 (1H, m), 4.70-







4.80 (1H, m), 6.95-7.15 (2H, m), 7.95-







8 05 (1H, m)





















embedded image

















Compound







number
R1
R3
R8
MS

1H NMR: δ (ppm)
















406 E49
F
H
H
(APCI)+:
d4 MeOH 2.29-2.36 (2H, m),






[M + H]+ =
3.47 (2H, t, J = 7.7 Hz), 3.50-






465.3
3.78 (8H, m), 4.02 (3H, s),







4.03 (1H, d), 4.16 (2H, t,







J = 5.4 Hz), 5.87 (1H, d,







J = 15.0 Hz), 6.88-7.05 (4H, m),







7.24-7.31 (1H, m), 7.39-7.43







(1H, m), 8.02 (1H, s)


407
H
F
Cl
(APCI)+:







[M + H]+ =







499.4, 501.4



408
Me
H
H
(APCI)+:
d4-MeOH 2.07 (3H, s), 2.25-






[M + H]+ =
2.35 (2H, m), 3.43-3.49 (2H,






461.4
m), 3.52-3.73 (8H, m), 4.03







(3H, s), 3.98-4.07 (3H, m),







5.90 (1H, d, J = 14.6 Hz), 6.71







(1H, d, J = 8.9 Hz), 6.81-6.88







(2H, m), 7.04-7.07 (2H, m),







7.22-7.29 (1H, m), 7.40 (1H,







d, J = 7.7 Hz), 8.02 (1H, s)





















embedded image


















Compound








number
R1
R3
R8
R12
MS

1H NMR: δ (ppm)






409 E50
F
H
H
CH2CH2C(CH3)3
(APCI)+:
(9H, s), 1.35-1.46 (2H, m), 1.90-1.95







[M + H]+ =
(2H, m), 2.42-2.70 (11H, m), 2.95-







549.4
3.08 (1H, m), 3.47-3.59 (1H, m), 3.79








(3H, s), 3.90-4.03 (2H, m), 5.87 (1H,








d, J = 14.8 Hz), 6.31 (1H, s), 6.70 (3H,








s), 6.89-7.04 (3H, m), 7.04-7.13 (1H,








m), 7.21 (1H, s)


410
H
Cl
H
CH2CH(CH3)2
(APCI)+:
0.84-0.88 (6H, m), 1.69-2.08 (5H, m),







[M + H]+ =
2.37-2.53 (10H, m), 3.68 (3H, s),







537.4, 539.3
3.83-4.03 (3H, m), 4.33-4.42 (1H,








brs), 5.81 (1H, d, J = 14.6 Hz), 6.40-








6.44 (2H, m), 6.54-7.34 (5H, m), 7.21








(1H, s)


411
H
Cl
H
CH2CH2CH3
(APCI)+:
0.84-0.90 (3H, m), 1.41-1.54 (2H, m),







[M + H]+ =
1.80-2.00 (2H, m), 2.24-2.54 (12H,







523.3, 525.4
m), 3.68 (3H, s), 3.81-4.01 (3H, m),








4.33-4.42 (1H, brs), 5.80 (1H, d,








J = 14.6 Hz), 6.40-7.34 (7H, m), 7.21








(1H, s)





412
Me
H
Me


embedded image


(APCI)+: [M + H]+ = 557.5
1.06-1.26 (3H, m), 1.40-1.63 (6H, m), 1.63-1.78 (2H, m), 1.78-1.96 (1H, m), 1.96-2.10 (4H, m),2.10-2.29 (6H, m), 2.30-2.60 (8H, m), 3.76 (3H, s), 3.81-








4.00 (3H, m), 5.89 (1H, d, J = 14.6 Hz),








6.00 (1H, s), 6.40-6.62 (2H, m), 6.73








(1H, s), 6.98 (1H, d, J = 7.9 Hz), 7.12








(1H, brs), 7.20 (1H, brs)





413
Me
H
Me
CH2C(CH3)3
(ESI)+:
0.85 (9H, s), 1.95-2.01 (3H, m), 2.01-







[M + H]+ =
2.11 (1H, m), 2.16 (2H, s), 2.19 (3H,







545.4
s), 2.70-2.82 (6H, m), 2.85-3.07 (6H,








m), 3.73-3.85 (5H, m), 3.90 (1H, d,








J = 14.6 Hz), 5.83 (1H, d, J = 14.6 Hz),








6.39 (1H, d, J = 8.7 Hz), 6.43-








6.56 (2H, m), 6.88 (1H, s), 6.92 (1H,








s), 6.95-7.10 (1H, m), 7.12 (1H, s),








7.18 (1H, s)


414
Me
H
Me
CH2CH(CH2CH3)2
(ESI)+:
0.83 (6H, t, J = 7.4 Hz), 1.20-







[M + H]+ =
1.40 (7H, m), 1.40-1.52 (1H, m), 1.90-







559.5
2.10 (8H, m), 2.19 (3H, s), 2.41 (2H,








d, J = 6.7 Hz), 2.70-2.85 (3H, m), 2.85-








2.92 (3H, m), 3.79 (3H, s), 3.80-3.90








(2H, m), 5.83 (1H, d, J = 14.6 Hz),








6.37-6.60 (2H, m), 6.80 (1H, s), 6.87-








6.97 (2H, m), 7.13 (2H, d, J = 16.1 Hz)


415
Me
H
Me
CH2CH2CH(CH3)2
(APCI)+:
0.86 (6H, d, J = 6.7 Hz), 1.33-







[M + H]+ =
1.45 (2H, m), 1.46-1.62 (1H, m), 1.82-







545.5
1.93 (2H, m), 2.01 (3H, s), 2.10-2.25








(2H, m), 2.29-2.40 (2H, m), 2.40-2.59








(8H, m), 2.79-2.91 (1H, m), 3.48-3.60








(1H, m), 3.60-3.80 (3H, m), 3.80-3.96








(3H, m), 3.98-4.10 (1H, m), 5.88 (1H,








d, J = 14.6 Hz), 6.19 (1H, s), 6.41-6.52








(2H, m), 6.52-6.60 (1H, m), 6.75 (1H,








s), 6.97 (1H, d, J = 7.7 Hz) 7.12 (1H,








s), 7.19 (1H, s)


416
Me
H
Me
CH2CH(CH3)2
(APCI)+:
0.90 (6H, d, J = 6.7 Hz), 1.28







[M + H]+ =
(2H, t, J = 7.4 Hz), 1.72-1.88 (1H, m),







531.2
1.90-2.07 (7H, m), 2.19 (3H, s), 2.26








(2H, d, J = 7.2 Hz), 2.61-2.88 (8H, m),








3.45 (1H, s), 3.78 (2H, s), 3.81-3.91








(2H, m), 5.86 (1H, d, J = 14.6 Hz),








6.40-6.60 (3H, m), 6.83 (1H, s), 6.95








(1H, d, J = 8.2 Hz), 7.13-7.19 (2H, m)


417
Me
H
Me
CH2CH2CH3
(APCI)+:
0.88 (3H, t, J = 7.4 Hz), 1.39-







[M + H]+ =
1.60 (2H, m), 1.80-1.95 (2H, m), 1.96-







517.4
2.06 (2H, m), 2.19(3H, s), 2.29-2.38








(2H, m), 2.39-2.64 (12H, m), 3.75








(3H, s), 3.80-3.96 (3H, m), 5.88 (1H,








d, J = 14.6 Hz), 6.23 (1H, s), 6.40-6.60








(2H, m), 6.76 (1H, s), 6.98 (1H, d,








J = 7.7 Hz), 7.04-7.20 (2H, m)


418
F
H
H
CH2CH(CH3)2
(APCI)+:
0.85 (6H, d, J = 6.4 Hz), 1.71-







[M + H]+ =
1.76 (1H, m), 1.89-1.95 (2H, m), 2.04







521.4
(2H, d, J = 7.2 Hz), 2.43 (10H, m),








3.74 (3H, s), 3.93-3.98 (3H, m), 5.86








(1H, d, J = 14.6 Hz), 6.67-6.72 (4H, m),








6.91-7.08 (4H, m), 7.20 (1H, s)





419
F
H
H


embedded image


(APCI)+: [M + H]+ = 547.5
1.10-1.17 (2H, m), 1.44-1.58 (4H, m), 1.64-1.73 (2H, m), 1.87-2.03 (3H, m), 2.22 (2H, d, J = 7.2 Hz), 2.42 (10H, m), 3.72 (3H, s), 3.92-3.97








(3H, m), 5.86 (1H, d, J = 14.6 Hz),








6.66-6.72 (3H, m), 6.76 (1H, s), 6.87-








7.07 (4H, m), 7.19 (1H, s)





420
F
H
H
CH2CH(CH2CH3)2
(APCI)+:
0.81 (6H, t, J = 7.3 Hz), 1.21-







[M + H]+ =
1.37 (5H, m), 1.88-1.93 (2H, m), 2.10







549.5
(2H, d, J = 6.7 Hz), 2.41 (10H, m),








3.73 (3H, s), 3.93-3.98 (3H, m), 5.87








(1H, d, J = 14.6 Hz), 6.67-6.72 (4H, m),








6.87-7.07 (4H, m), 7.20 (1H, s)


421
F
H
H
CH2CH2CH(CH3)2
(APCI)+:
0.83 (6H, d, J = 6.4 Hz), 1.27-







[M + H]+ =
1.35 (2H, m), 1.50 (1H, m), 1.85-1.94







535.4
(2H, m), 2.24-2.40 (12H, m), 3.69








(3H, s), 3.90-3.95 (3H, m), 5.84 (1H,








d, J = 14.6 Hz), 6.63-6.69 (3H, m),








6.86 (1H, d, J = 11.9 Hz), 6.97-








7.02 (4H, m), 7.16 (1H, s)


422
F
H
H
CH2C(CH3)3
(ESI)+:
0.83 (9H, s), 1.92-2.00 (2H, m), 2.03







[M + H]+ =
(2H, s), 2.47-2.54 (10H, m), 3.79







535.4
(3H, s), 3.93-3.98 (3H, m), 5.88 (1H,








d, J = 14.6 Hz), 6.20 (1H, s), 6.67-6.70








(3H, m), 6.91-6.96 (2H, m), 7.03-7.13








(2H, m), 7.21-7.22 (1H, m)


423
F
H
H
CH2CH2CH3
(APCI)+:
0.85 (3H, t, J = 7.4 Hz), 1.47







[M + H]+ =
(2H, m), 1.90 (2H, m), 2.25 (2H, m),







507.4
2.43 (10H, m), 3.73 (3H, s), 3.95








(3H, m), 5.86 (1H, d, J = 14.6 Hz),








6.67-6.72 (4H, m), 6.87-7.08 (4H, m),








7.20 (1H, s)





424
Me
H
H


embedded image


(ESI)+: [M + H]+ = 515.3
0.07-0.13 (2H, m), 0.47-0.54 (2H, m), 0.81-0.92 (1H, m), 1.87-1.96 (3H, brt), 2.01 (3H, s), 2.27 (2H, d,








J = 6.7 Hz), 2.42-2.64 (10H, m),








3.78 (3H, s), 3.86-4.01 (3H, m), 5.92








(1H, d, J = 14.8 Hz), 6.06 (1H, s), 6.48








(1H, brd, J = 9.6 Hz), 6.70








(2H, s), 6.92 (1H, d, J = 7.4 Hz), 6.94-








7.11 (3H, m), 7.22 (1H, s)





425
F
H
H


embedded image


(ESI)+: [M + H]+ = 519.3
0.05-0.12 (2H, m), 0.46-0.53 (2H, m), 0.81-0.87 (1H, m), 1.87-1.98 (2H, m), 2.25 (2H, d, J = 6.7 Hz), 2.38-








2.62 (10H, m), 3.78 (3H, s), 3.98








(2H, t, J = 5.7 Hz), 3.96 (1H, d,








J = 14.6 Hz), 5.88 (1H, d, J = 14.6 Hz),








6.21 (1H, s), 6.68-6.74 (3H, m), 6.89-








6.96 (2H, m), 7.03-7.13 (2H, m), 7.22








(1H, s)





426
H
Cl
Me
CH2CH2C(CH3)3
(APCI)+:
0.89 (9H, s), 1.38-1.50 (2H, m), 1.79-







[M + H]+ =
1.91 (2H, m), 2.16 (3H, s), 2.43-2.60







579.4, 581.4
(8H, m), 2.60-2.79 (4H, m), 3.46 (3H,








s), 3.74 (2H, s), 3.86 (2H, t,








J = 5.9 Hz), 5.78 (1H, d, J = 14.6 Hz),








6.26 (1H, s), 6.47 (1H, d, J = 6.7 Hz),








6.67-6.84 (4H, m), 7.21 (1H, s)


427
H
Cl
Cl
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.35 (1H, d, J = 6.7 Hz),







[M + H]+ =
1.37-1.47 (2H, m), 1.83-1.90 (1H, m),







599.3
2.42-2.78 (10H, m), 3.46 (3H, s),








3.74 (2H, s), 3.88 (2H, t, J = 6.2 Hz),








3.94-4.00 (1H, m), 5.77 (1H, d,








J = 14.6 Hz), 6.50 (1H, dd, J = 2.2,








8.7 Hz), 6.61 (1H, dd, J = 2.2, 8.7 Hz),








6.73 (1H, d, J = 2.2 Hz), 6.81








(1H, s), 6.83 (1H, s), 6.84-7.00 (2H,








m), 7.22 (1H, s)


428
H
F
Cl
CH2CH2C(CH3)3
(APCI)+:
0.87 (9H, s), 1.26 (1H, d, J = 5.2 Hz),







[M + H]+ =
1.32-1.41 (2H, m), 1.88-1.91 (1H, m),







583.4, 585.4
2.30-2.41 (2H, m), 2.42-2.63 (8H, m),








3.44 (3H, s), 3.69 (2H, s), 3.82-3.93








(2H, m), 5.78 (1H, d, J = 14.8 Hz), 6.33








(1H, dd, J = 2.2, 14.1 Hz), 6.43-6.51








(1H, m), 6.54-6.70 (2H, m), 6.86 (1H,








s), 6.97 (1H, d, J = 2.2 Hz), 7.02-








7.10 (2H, m), 7.19 (1H, s)


429
Cl
H
Cl
CH2CH2C(CH3)3
(ESI)+:
0.88 (9H, s), 1.35-1.41 (2H, m), 1.88-







[M + H]+ =
2.12 (4H, m), 2.29-2.35 (2H, m), 2.38-







599.4
2.57 (8H, m), 3.46 (3H, s), 3.72-3.76








(2H, m), 3.92-4.08 (2H, m), 5.85 (1H,








d, J = 14.6 Hz), 6.43 (1H, s), 6.56-6.74








(2H, m), 6.98 (1H, s), 7.08 (1H, d,








J = 8.7 Hz), 7.21 (1H, s), 7.27 (1H, s)


430
F
H
Cl
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.36-1.42 (2H, m), 1.84-







[M + H]+ =
2.03 (4H, m), 2.31-2.39 (2H, m), 2.40-







583.4, 585.4
2.62 (8H, m), 3.46 (3H, s), 3.76 (2H,








s), 3.92-4.04 (2H, m), 5.85 (1H, d,








J = 14.1 Hz), 6.52 (1H, s), 6.57-6.80








(3H, m), 6.95-7.06 (2H, m), 7.21 (1H, s)


431
H
F
Me
CH2CH2C(CH3)3
(APCI)+:
0.89 (9H, s), 1.35-1.41 (2H, m), 1.88-







[M + H]+ =
1.97 (2H, m), 2.05-2.13 (1H, m), 2.21







563.5
(3H, s), 2.28-2.34 (2H, m), 2.34-2.54








(9H, m), 3.37 (3H, s), 3.68 (3H, s),








3.91 (2H, t, J = 6.4 Hz), 5.96-








6.01 (1H, m), 6.24-6.28 (1H, m), 6.33-








6.42 (1H, m), 6.42-6.48 (1H, m), 6.54-








6.60 (1H, m), 6.72 (1H, d, J = 7.9 Hz),








7.48-7.51 (1H, m)


432
Me
H
Me
CH2CH2C(CH3)3
(ESI)+:
0.88 (9H, t, J = 12.9 Hz), 1.35-







[M + H]+ =
1.42 (2H, m), 1.72-2.00 (2H, m), 2.02







559.5
(3H, s), 2.22 (3H, s), 2.28-2.35 (2H,








m), 2.37-2.62 (10H, m), 3.77








(3H, s), 3.88-3.96 (3H, m), 5.89 (1H,








d, J = 11.6 Hz), 6.45-6.62 (3H, m),








6.73 (1H, s), 6.94-7.01 (1H, m), 7.13








(1H, s), 7.19-7.22 (1H, m)


433
Me
H
Cl
CH2CH2C(CH3)3
(ESI)+:
0.88 (9H, t, J = 12.9 Hz), 1.36-







[M + H]+ =
1.43 (2H, m), 1.91-2.02 (2H, m), 2.05







579.4, 581.5
(3H, s), 2.30-2.37 (2H, m), 2.39-2.63








(10H, m), 3.75 (3H, s), 3.82-3.98








(3H, m), 5.87 (1H, d, J = 14.6 Hz), 6.25








(1H, s), 6.53-6.70 (2H, m), 6.96 (2H,








s), 7.13-7.23 (2H, m)


434
Cl
H
Me
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.32-1.43 (2H, m), 1.61-







[M + H]+ =
1.82 (1H, m), 1.89-2.02 (2H, m), 2.23







579.4, 581.4
(3H, s), 2.28-2.37 (2H, m), 2.37-2.68








(9H, m), 3.78 (3H, s), 3.96-4.01 (3H,








m), 5.86 (1H, d, J = 14.6 Hz), 6.00








(1H, s), 6.48-6.61 (2H, m), 6.61-6.70








(2H, m), 6.75 (1H, s), 7.14 (1H, d,








J = 8.2 Hz), 6.22 (1H, s)


435
F
H
Me
CH2CH2C(CH3)3
(APCI)+:
0.87 (9H, s), 1.35-1.41 (2H, m), 1.88-







[M + H]+ =
1.97 (2H, m), 2.05-2.13 (1H, m), 2.21







563.4
(3H, s), 2.28-2.34 (2H, m), 2.34-2.54








(9H, m), 3.76 (3H, s), 3.90-4.04 (3H,








m), 5.85 (1H, d, J = 12.1 Hz), 6.18








(1H, s), 6.47-6.60 (2H, m), 6.67-6.79








(2H, m), 6.91 (1H, d, J = 9.3 Hz), 7.05








(1H, d, J = 9.3 Hz), 7.20 (1H, s)


436
Cl
H
H
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.29 (2H, d, J = 6.7 Hz),







[M + H]+ =
1.31-1.42 (2H, m), 1.59-1.82 (2H, m),







565.4, 567.4
1.92-1.97 (2H, m), 2.29-2.35 (2H, m),








2.35.2.67 (9H, m), 3.80 (3H, s), 3.91-








4.04 (2H, m), 5.89 (1H, d, J = 15 Hz),








6.03 (1H, s), 6.60-6.80 (2H, m), 6.94








(1H, d, J = 7.9 Hz), 7.07-7.19 (2H, m),








7.23 (1H, s)


437
H
Cl
H
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.32-1.43 (2H, m), 1.80-







[M + H]+ =
1.93 (2H, m), 2.27-2.38 (2H, m), 2.38-







565.5, 567.4
2.58 (9H, m), 3.61 (1H, s), 3.77 (3H,








s), 3.86 (1H, t, J = 6.2 Hz), 4.02








(1H, s), 5.85 (1H, d, J = 14.8 Hz), 6.02








(1H, s), 6.45 (1H, dd, J = 2.2, 8.4 Hz),








6.67-6.69 (1H, m), 6.69-6.91 (2H, m),








6.91-7.12 (2H, m)


438
H
F
H
CH2CH2C(CH3)3
(APCI)+:
0.88 (9H, s), 1.35-1.46 (2H, m), 1.80-







[M + H]+ =
1.94 (2H, m), 2.30-2.41 (2H, m), 2.41-







549.4
2.62 (9H, m), 3.57 (1H, s), 3.76 (3H,








s), 3.87 (2H, t, J = 6.4 Hz), 3.99








(1H, d, J = 14.6 Hz), 5.85 (1H, d,








J = 14.6 Hz), 6.16 (1H, s), 6.39 (1H,








dd, J = 2.2, 21.8 Hz), 6.62-6.75








(1H, m), 6.77 (1H, d, J = 6.7 Hz), 6.87








(1H, d, J = 6.7 Hz), 6.97-7.12 (2H, m),








7.23 (1H, s)


439
Me
H
H
CH2CH2C(CH3)3
(ESI)+:
0.88 (9H, s), 1.38-1.53 (2H, m), 1.82-







[M + H]+ =
1.96 (2H, m), 1.96-2.06 (3H, s), 2.53-







545.4
2.69 (4H, m), 2.69-2.80 (2H, m), 2.80-








2.96 (2H, m), 3.73 (3H, s), 3.82-3.93








(2H, m), 5.90 (1H, d, J = 14.3 Hz), 6.37








(1H, s), 6.46 (1H, d, J = 7.7 Hz), 6.69








(2H, s), 6.90-7.01 (2H, m), 7.02-7.13








(2H, m), 7.14-7.27 (2H, m), 7.83-8.13








(3H, m)





















embedded image


















Com-








pound
R1
R8
R9
R10
MS

1H NMR: δ (ppm)






440
Me
H
H
Me
(APCI)+:
0.88 (9H, s), 1.35-1.50







[M + H]+ =
(2H, m), 1.60-1.85 (2H,







559.6
m), 1.90-2.05 (8H, m),








2.35-2.40 (2H, m), 2.40-








2.70 (8H, m), 3.79 (3H,








s), 3.85-3.95 (2H, m),








4.00-4.10 (2H, m), 5.85-








5.96 (1H, m), 6.41-7.28








(7H, m)


441
Me
H
Me
H
(APCI)+:
0.88 (9H, s), 1.36-1.42







[M + H]+ =
(2H, m), 1.60-1.70 (2H,







559.6
m), 1.85-2.15 (10H, m),








2.25-2.60 (8H, m), 3.77








(3H, s), 3.90-3.92 (3H,








m), 5.80-6.00 (2H, m),








6.45-6.55 (2H, m), 6.75-








7.22 (5H, m)


442
F
Me
H
H
(ESI)+:
0.92 (9H, s), 1.49-1.56







[M + H]+ =
(2H, m), 1.85-2.03 (2H,







563.4
m), 2.41 (3H, s), 2.50-








2.97 (13H, m), 3.83 (3H,








s), 3.88-4.03 (3H, m),








5.78-5.99 (2H, m), 6.57-








6.75 (3H, m), 6.92-7.08








(3H, m)





















embedded image



















Compound









number
R1
R3
R8
R12
X
a
MS





443 E51
Me
H
Me
CH2CH(CH3)2
CH
3
(ESI)+: [M + H]+ = 530.5


444
Me
H
Me
CH2CH2CH3
CH
3
(ESI)+: [M + H]+ = 516.5





445
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 564.5





446
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 570.5





447
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 578.5





448
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 570.5





449
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 598.4





450
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 598.5





451
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 598.5





452
Me
H
Me
CH2CH2CH2CH2CH3
CH
3
(ESI)+: [M + H]+ = 544.5





453
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 528.5





454
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 592.5





455
Me
H
Me
CH2CH2CH(CH3)2
CH
3
(ESI)+: [M + H]+ = 544.5





456
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 554.4





457
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 584.5





458
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 565.5





459
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 553.4





460
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 606.6





461
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 580.5





462
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 565.4





463
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 565.4





464
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 570.4





465
Me
H
Me
CH2CH2CF3
CH
3
(ESI)+: [M + H]+ = 570.4





466
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 568.5





467
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 567.5





468
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 578.5





469
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 578.5





470
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 578.5





471
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 589.5





472
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 589.5





473
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 589.5





474
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 632.5





475
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 654.6





476
Me
H
Me


embedded image


CH
3
(ESI)+: [M + H]+ = 622.6





477
Me
H
Me
CH2CH(CH3)2
N
2
(ESI)+: [M + H]+ = 517.5


478
Me
H
Me
CH2CH2CH3
N
2
(ESI)+: [M + H]+ = 503.5





479
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 551.4





480
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 565.5





481
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 557.3





482
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 585.4





483
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 585.4





484
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 585.4





485
Me
H
Me
CH2CH2CH2CH2CH3
N
2
(ESI)+: [M + H]+ = 531.4





486
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 515.5





487
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 579.5





488
Me
H
Me
CH2CH2CH(CH3)2
N
2
(ESI)+: [M + H]+ = 531.5


489
Me
H
Me
CH2C(CH3)3
N
2
(ESI)+: [M + H]+ = 531.4





490
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 541.4





491
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 571.5





492
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 552.4





493
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 540.4





494
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 593.5





495
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 567.4





496
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 552.4





497
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 552.5





498
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 557.4





499
Me
H
Me
CH2CH2CF3
N
2
(ESI)+: [M + H]+ = 557.4





500
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 555.5





501
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 565.4





502
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 565.4





503
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 565.4





504
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 576.5





505
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 576.4





506
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 576.4





507
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 619.4





508
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 641.5





509
Me
H
Me


embedded image


N
2
(ESI)+: [M + H]+ = 609.5





510
H
F
H
CH2CH(CH3)2
N
2
(ESI)+: [M + H]+ = 507.4


511
H
F
H
CH2CH2CH3
N
2
(ESI)+: [M + H]+ = 493.4





512
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 541.4





513
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 555.4





514
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 547.3





515
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 575.3





516
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 575.3





517
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 575.3





518
H
F
H
CH2CH2CH2CH2CH3
N
2
(ESI)+: [M + H]+ = 521.4





519
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 505.4





520
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 569.4





521
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 531.3





522
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 561.4





523
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 583.4





524
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 557.3





525
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 547.3





526
H
F
H
CH2CH2OH
N
2
(ESI)+: [M + H]+ = 495.3





527
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 555.3





528
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 566.3





529
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 566.4





530
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 566.3





531
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 629.4





532
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 609.3





533
H
F
H


embedded image


N
2
(ESI)+: [M + H]+ = 599.4





















embedded image
















Com-






pound






number
R8
R12
X
MS





534 E52
Cl
CH2CH2CH2CH2CH2CH3
N
(ESI)+: [M + H]+ =






583.6


535
Cl
CH2(CH2)2CH3
N
(ESI)+: [M + H]+ =






555.6


536
Cl
CH2(CH2)2CN
N
(ESI)+: [M + H]+ =






566.5





537
Cl


embedded image


N
(ESI)+: [M + H]+ = 617.7





538
Cl


embedded image


N
(ESI)+: [M + H]+ = 609.8





539
Cl


embedded image


N
(ESI)+: [M + H]+ = 607.7





540
Cl


embedded image


N
(ESI)+: [M + H]+ = 645.8





541
Cl


embedded image


N
(ESI)+: [M + H]+ = 673.7





542
Cl


embedded image


N
(ESI)+: [M + H]+ = 647.7





543
Cl


embedded image


N
(ESI)+: [M + H]+ = 589.6





544
Cl


embedded image


N
(ESI)+: [M + H]+ = 595.6





545
Cl
CH2CO2CH(CH3)2
N
(ESI)+: [M + H]+ =






599.7


546
Cl
CH2CH2CH(CH3)2
N
(ESI)+: [M + H]+ =






569.6


547
Cl
CH2CH2CN
N
(ESI)+: [M + H]+ =






552.5


548
Cl
CH2CH2CH2OH
N
(ESI)+: [M + H]+ =






557.6


549
Cl
CH2CN
N
(ESI)+: [M + H]+ =






538.5


550
Cl
CH2CH2OCH2CH3
N
(ESI)+: [M + H]+ =






571.5


551
Cl
CH2CH2CH2F
N
(ESI)+: [M + H]+ =






559.6





552
Cl


embedded image


N
(ESI)+: [M + H]+ = 634.8





553
Cl


embedded image


N
(ESI)+: [M + H]+ = 553.5





554
Cl


embedded image


N
(ESI)+: [M + H]+ = 639.8





555
Cl


embedded image


N
(ESI)+: [M + H]+ = 539.6





556
Cl


embedded image


N
(ESI)+: [M + H]+ = 615.7





557
Cl


embedded image


N
(ESI)+: [M + H]+ = 665.6





558
Cl


embedded image


N
(ESI)+: [M + H]+ = 597.6





559
Cl


embedded image


N
(ESI)+: [M + H]+ = 614.7





560
Cl
CH2COC(CH3)3
N
(ESI)+: [M + H]+ =






597.6


561
Cl
CH2CONH2
N
(ESI)+: [M + H]+ =






556.5





562
Cl


embedded image


N
(ESI)+: [M + H]+ = 624.6





563
Cl


embedded image


N
(ESI)+: [M + H]+ = 631.6





564
H
CH2(CH2)4CH3
CH
(ESI)+: [M + H]+ =






548.6


565
H
CH2(CH2)2CH3
CH
(ESI)+: [M + H]+ =






520.6


566
H
CH2(CH2)3OH
CH
(ESI)+: [M + H]+ =






536.6





567
H


embedded image


CH
(ESI)+: [M + H]+ = 582.5





568
H


embedded image


CH
(ESI)+: [M + H]+ = 574.6





569
H


embedded image


CH
(ESI)+: [M + H]+ = 572.5





570
H


embedded image


CH
(ESI)+: [M + H]+ = 610.7





571
H


embedded image


CH
(ESI)+: [M + H]+ = 638.7





572
H


embedded image


CH
(ESI)+: [M + H]+ = 612.6





573
H


embedded image


CH
(ESI)+: [M + H]+ = 554.5





574
H


embedded image


CH
(ESI)+: [M + H]+ = 560.1





575
H
CH2CO2CH(CH3)2
CH
(ESI)+: [M + H]+ =






564.6


576
H
CH2CH2CH(CH3)2
CH
(ESI)+: [M + H]+ =






534.6


577
H
CH2CH2CN
CH
(ESI)+: [M + H]+ =






517.5


578
H
CH2CN
CH
(ESI)+: [M + H]+ =






503.5


579
H
CH2CH2OCH2CH3
CH
(ESI)+: [M + H]+ =






536.6


580
H
CH2CH2CH2F
CH
(ESI)+: [M + H]+ =






524.6





581
H


embedded image


CH
(ESI)+: [M + H]+ = 599.6





582
H


embedded image


CH
(ESI)+: [M + H]+ = 518.6





583
H


embedded image


CH
(ESI)+: [M + H]+ = 604.6





584
H


embedded image


CH
(ESI)+: [M + H]+ = 504.5





585
H


embedded image


CH
(ESI)+: [M + H]+ = 580.5





586
H


embedded image


CH
(ESI)+: [M + H]+ = 630.7





587
H


embedded image


CH
(ESI)+: [M + H]+ = 562.5





588
H


embedded image


CH
(ESI)+: [M + H]+ = 579.5





589
H
CH2COC(CH3)3
CH
(ESI)+: [M + H]+ =






562.6


590
H
CH2CONH2
CH
(ESI)+: [M + H]+ =






521.5





591
H


embedded image


CH
(ESI)+: [M + H]+ = 589.5





592
H


embedded image


CH
(ESI)+: [M + H]+ = 596.6





















embedded image
















Com-






pound






number
X
R8
R19
MS





593 E53
N
H
Me
(ESI)+: [M + H]+ =






503.2





594
N
H


embedded image


(ESI)+: [M + H]+ = 565.3





595
N
H


embedded image


(ESI)+: [M + H]+ = 599.3





596
N
H


embedded image


(ESI)+: [M + H]+ = 599.3





597
N
H


embedded image


(ESI)+: [M + H]+ = 599.3





598
N
H


embedded image


(ESI)+: [M + H]+ = 595.3





599
N
H


embedded image


(ESI)+: [M + H]+ = 579.3





600
N
H


embedded image


(ESI)+: [M + H]+ = 579.3





601
N
H


embedded image


(ESI)+: [M + H]+ = 600.3





602
N
H


embedded image


(ESI)+: [M + H]+ = 566.3





603
N
H


embedded image


(ESI)+: [M + H]+ = 571.3





604
N
H


embedded image


(ESI)+: [M + H]+ = 571.3





605
N
H


embedded image


(ESI)+: [M + H]+ = 583.3





606
N
H


embedded image


(ESI)+: [M + H]+ = 555.3





607
N
H


embedded image


(ESI)+: [M + H]+ = 556.3





608
N
H


embedded image


(ESI)+: [M + H]+ = 646.4





609
N
H
CH2CH3
(ESI)+: [M + H]+ =






517.3


610
N
H
CH2CH2CH3
(ESI)+: [M + H]+ =






531.3





611
N
H


embedded image


(ESI)+: [M + H]+ = 529.3





612
N
H
C(CH3)3
(ESI)+: [M + H]+ =






545.3





613
N
H


embedded image


(ESI)+: [M + H]+ = 571.3





614
N
H
CH2(CH2)3CH3
(ESI)+: [M + H]+ =






559.3


615
N
H
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+: [M + H]+ =






587.4





616
N
H


embedded image


(ESI)+: [M + H]+ = 639.4





617
N
H


embedded image


(ESI)+: [M + H]+ = 579.3





618
N
H


embedded image


(ESI)+: [M + H]+ = 593.3





619
N
H


embedded image


(ESI)+: [M + H]+ = 605.4





620
N
H


embedded image


(ESI)+: [M + H]+ = 585.3





621
N
H


embedded image


(ESI)+: [M + H]+ = 595.3





622
N
H


embedded image


(ESI)+: [M + H]+ = 609.4





623
N
H
CH2CH2CO2CH3
(ESI)+: [M + H]+ =






575.3


624
N
H
CH2CH2CH2CO2CH2CH3
(ESI)+: [M + H]+ =






603.4


625
CH
Me
CH3
(ESI)+: [M + H]+ =






516.4





626
CH
Me


embedded image


(ESI)+: [M + H]+ = 578.4





627
CH
Me


embedded image


(ESI)+: [M + H]+ = 612.4





628
CH
Me


embedded image


(ESI)+: [M + H]+ = 612.4





629
CH
Me


embedded image


(ESI)+: [M + H]+ = 612.4





630
CH
Me


embedded image


(ESI)+: [M + H]+ = 608.5





631
CH
Me


embedded image


(ESI)+: [M + H]+ = 592.4





632
CH
Me


embedded image


(ESI)+: [M + H]+ = 592.4





633
CH
Me


embedded image


(ESI)+: [M + H]+ = 613.4





634
CH
Me


embedded image


(ESI)+: [M + H]+ = 579.4





635
CH
Me


embedded image


(ESI)+: [M + H]+ = 579.4





636
CH
Me


embedded image


(ESI)+: [M + H]+ = 584.4





637
CH
Me


embedded image


(ESI)+: [M + H]+ = 584.4





638
CH
Me


embedded image


(ESI)+: [M + H]+ = 596.4





639
CH
Me


embedded image


(ESI)+: [M + H]+ = 568.4





640
CH
Me


embedded image


(ESI)+: [M + H]+ = 569.4





641
CH
Me


embedded image


(ESI)+: [M + H]+ = 659.5





642
CH
Me
CH2CH2CH3
(ESI)+: [M + H]+ =






544.4





643
CH
Me


embedded image


(ESI)+: [M + H]+ = 542.4





644
CH
Me
C(CH3)3
(ESI)+: [M + H]+ =






558.4





645
CH
Me


embedded image


(ESI)+: [M + H]+ = 584.4





646
CH
Me
CH2(CH2)3CH3
(ESI)+: [M + H]+ =






572.4


647
CH
Me
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+: [M + H]+ =






600.5





648
CH
Me


embedded image


(ESI)+: [M + H]+ = 652.5





649
CH
Me


embedded image


(ESI)+: [M + H]+ = 592.5





650
CH
Me


embedded image


(ESI)+: [M + H]+ = 606.5





651
CH
Me


embedded image


(ESI)+: [M + H]+ = 618.5





652
CH
Me


embedded image


(ESI)+: [M + H]+ = 598.4





653
CH
Me


embedded image


(ESI)+: [M + H]+ = 608.5





654
CH
Me


embedded image


(ESI)+: [M + H]+ = 622.5





655
CH
Me
CH2CH2CH2CO2CH2CH3
(ESI)+: [M + H]+ =






616.5





















embedded image
















Compound






number
X
R8
R19
MS





656 E54
N
H
Me
(ESI)+: [M + H]+ =






539.2


657
N
H
CH(CH3)2
(ESI)+: [M + H]+ =






567.3





658
N
H


embedded image


(ESI)+: [M + H]+ = 615.3





659
N
H


embedded image


(ESI)+: [M + H]+ = 601.3





660
N
H


embedded image


(ESI)+: [M + H]+ = 669.3





661
N
H


embedded image


(ESI)+: [M + H]+ = 635.3





662
N
H


embedded image


(ESI)+: [M + H]+ = 635.3





663
N
H


embedded image


(ESI)+: [M + H]+ = 635.3





664
N
H


embedded image


(ESI)+: [M + H]+ = 631.3





665
N
H


embedded image


(ESI)+: [M + H]+ = 615.3





666
N
H


embedded image


(ESI)+: [M + H]+ = 626.3





667
N
H


embedded image


(ESI)+: [M + H]+ = 669.3





668
N
H


embedded image


(ESI)+: [M + H]+ = 658.4





669
N
H


embedded image


(ESI)+: [M + H]+ = 641.3





670
N
H


embedded image


(ESI)+: [M + H]+ = 605.3





671
N
H
CH2CF3
(ESI)+: [M + H]+ =






607.3





672
N
H


embedded image


(ESI)+: [M + H]+ = 716.2





673
N
H


embedded image


(ESI)+: [M + H]+ = 649.3





674
N
H
CH2CH3
(ESI)+: [M + H]+ =






553.3


675
N
H
CH2CH2CH3
(ESI)+: [M + H]+ =






567.3


676
N
H
CH2CH2CH2CH3
(ESI)+: [M + H]+ =






581.3


677
CH
Me
CH3
(ESI)+: [M + H]+ =






552.3


678
CH
Me
CH(CH3)2
(ESI)+: [M + H]+ =






580.4





679
CH
Me


embedded image


(ESI)+: [M + H]+ = 628.5





680
CH
Me


embedded image


(ESI)+: [M + H]+ = 614.4





681
CH
Me


embedded image


(ESI)+: [M + H]+ = 682.4





682
CH
Me


embedded image


(ESI)+: [M + H]+ = 648.4





683
CH
Me


embedded image


(ESI)+: [M + H]+ = 648.4





684
CH
Me


embedded image


(ESI)+: [M + H]+ = 648.4





685
CH
Me


embedded image


(ESI)+: [M + H]+ = 644.5





686
CH
Me


embedded image


(ESI)+: [M + H]+ = 628.5





687
CH
Me


embedded image


(ESI)+: [M + H]+ = 639.5





688
CH
Me


embedded image


(ESI)+: [M + H]+ = 682.4





689
CH
Me


embedded image


(ESI)+: [M + H]+ = 671.5





690
CH
Me


embedded image


(ESI)+: [M + H]+ = 654.4





691
CH
Me


embedded image


(ESI)+: [M + H]+ = 618.5





692
CH
Me


embedded image


(ESI)+: [M + H]+ = 729.2





693
CH
Me


embedded image


(ESI)+: [M + H]+ = 662.4





694
CH
Me
CH2CH3
(ESI)+: [M + H]+ =






566.3


695
CH
Me
CH2CH2CH3
(ESI)+: [M + H]+ =






580.4


696
CH
Me
CH2CH2CH2CH3
(ESI)+: [M + H]+ =






594.4





















embedded image


















Compound








number
R1
R10
R12
X2
MS
1H NMR





697
F
Cl


embedded image


S
(ESI)+: [M + H]+ = 569.5, 571.3
0.05-0.15 (2H, m), 0.45-0.55 (2H, m), 0.80-0.90 (1H, m), 1.90-2.00 (2H, m), 2.24 (2H, d, J = 6.4 Hz), 2.35-2.70 (10H, m), 2.73 (3H, s) 2.95-3.25 (2H, m), 3.45-3.55 (1H, m), 3.99 (2H, t, J = 6.4 Hz), 5.15-5.25 (1H, m), 6.60-6.75 (3H, m), 6.90-7.05 (2H, m), 8.41 (1H, d, J = 2.5 Hz)





698
Cl
Me


embedded image


S
(ESI)+: [M + H]+ = 643.3, 645.4
1.22 (6H, d, J = 6.9 Hz), 1.87-1.99 (2H, m), 2.34 (3H, s), 2.45-2.52 (10H, m), 2.74 (3H, s), 2.87 (1H, septet, J = 6.9 Hz), 3.03-3.18 (2H, m), 3.45 (2H, s), 3.45-3.54 (1H, m), 3.95 (2H, t, J = 6.2 Hz), 5.13-5.19 (1H, m), 6.52 (1H, d, J = 8.6 Hz), 6.57 (1H, d, J = 8.2 Hz), 6.75 (1H, dd, J = 2.2, 8.6 Hz), 6.81 (1H, d, J = 8.2 Hz), 7.15 (2H, d, J = 8.2 Hz), 7.21 (2H, d, J = 8.2 Hz), 7.38 (1H, d, J = 2.2 Hz), 8.18 (1H, s)





699
Cl
Me


embedded image


S
(ESI)+: [M + H]+ = 595.4, 597.4
0.89 (9H, s), 1.38- 1.44 (2H, m), 1.89- 1.99 (2H, m), 2.34, (3H, s), 2.35-2.41 (2H, m), 2.47-2.56 (10H, m), 2.73 (3H, s), 3.01-3.18 (2H, m), 3.45-3.57 (1H, m), 3.95 (2H, t, J = 6.4 Hz), 5.12-5.19, (1H, m), 6.52 (1H, d, J = 8.6 Hz), 6.57 (1H, d, J = 8.4 Hz), 6.75 (1H, dd, J = 2.2, 8.4 Hz), 6.80 (1H, d, J = 8.6 Hz), 7.38 (1H, d, J = 2.2 Hz), 8.17 (1H, s)





















embedded image















Compound





number
R4


1H NMR: δ (ppm)






700


embedded image


(ESI)+: [M + H]+ = 543.6
0.85 (9H, s), 1.30- 1.41 (4H, m), 2.10 (3H, s), 2.28-2.45 (6H, m), 2.71-2.82 (2H, m), 3.25-3.34 (2H, m), 3.52-3.65 (2H, m), 3.71 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 5.85 (1H, d, J = 14.6 Hz), 6.65 (1H, s), 6.75- 7.01 (5H, m), 7.07- 7.17 (3H, m)





701


embedded image


(ESI)+: [M + H]+ = 472.7
2.17 (3H, s), 2.29 (2H, t, J = 5.7 Hz), 2.40 (2H, t, J = 5.7 Hz), 2.53 (2H, t, J = 7.2 Hz), 2.87 (2H, t, J = 7.2 Hz), 3.52 (2H, brs), 3.79 (3H, s), 3.77-3.83 (2H, m), 3.95 (1H, d, J = 14.6 Hz), 5.89 (1H, d, J = 14.6 Hz), 6.19 (1H, s), 6.62- 6.74 (2H, m), 6.81- 6.94 (3H, m), 7.02- 7.08 (1H, m), 7.16 (1H, s)





702


embedded image


(ESI)+: [M + H]+ = 527.7
1.61-1.68 (2H, m), 1.68-1.91 (3H, m), 1.92-2.08 (2H, m), 2.14 (3H, s), 2.28- 2.51 (4H, m), 2.72- 2.89 (2H, m), 2.93- 3.08 (2H, m), 3.21- 3.34 (2H, m), 3.46- 3.69 (4H, m), 3.80 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 5.87 (1H, d, J = 14.6 Hz), 6.51 (1H, s), 6.68 (2H, s), 6.74-6.89 (2H, m), 6.94-7.08 (2H, m), 7.13 (1H, s)





703


embedded image


(ESI)+: [M + H]+ = 499.7






704


embedded image


(ESI)+: [M + H]+ = 556.7






705


embedded image


(ESI)+: [M + H]+ = 632.0 (MeCN adduct)






706


embedded image


(ESI)+: [M + H]+ = 444.3






707


embedded image


(ESI)+: [M + H]+ = 516.4






708


embedded image


(ESI)+: [M + H]+ = 506.3






709


embedded image


(ESI)+: [M + H]+ = 486.4






710 E56


embedded image


(ESI)+: [M + H]+ = 553.4






711


embedded image


(ESI)+: [M + H]+ = 458.3






712


embedded image


(ESI)+: [M + H]+ = 472.4






713


embedded image


(ESI)+: [M + H]+ = 460.4






714


embedded image


(ESI)+: [M + H]+ = 558.4






715


embedded image


(ESI)+: [M + H]+ = 473.3






716


embedded image


(ESI)+: [M + H]+ = 512.4






717


embedded image


(ESI)+: [M + H]+ = 512.4






718


embedded image


(ESI)+: [M + H]+ = 476.3






719


embedded image


(ESI)+: [M + H]+ = 462.3






720


embedded image


(ESI)+: [M + H]+ = 530.4






721


embedded image


(ESI)+: [M + H]+ = 502.4






722


embedded image


(ESI)+: [M + H]+ = 502.4






723


embedded image


(ESI)+: [M + H]+ = 487.3






724


embedded image


(ESI)+: [M + H]+ = 593.4






725


embedded image


(ESI)+: [M + H]+ = 553.4






726


embedded image


(ESI)+: [M + H]+ = 530.4






727


embedded image


(ESI)+: [M + H]+ = 603.4






728


embedded image


(ESI)+: [M + H]+ = 603.4






729


embedded image


(ESI)+: [M + H]+ = 565.4






730


embedded image


(ESI)+: [M + H]+ = 548.4






731


embedded image


(ESI)+: [M + H]+ = 527.5






732


embedded image


(ESI)+: [M + H]+ = 550.3






733


embedded image


(ESI)+: [M + H]+ = 492.4






734


embedded image


(ESI)+: [M + H]+ = 506.4






735


embedded image


(ESI)+: [M + H]+ = 508.4






736


embedded image


(ESI)+: [M + H]+ = 509.3






737


embedded image


(ESI)+: [M + H]+ = 536.4






738


embedded image


(ESI)+: [M + H]+ = 515.4






739


embedded image


(ESI)+: [M + H]+ = 501.4






740


embedded image


(ESI)+: [M + H]+ = 501.4






741


embedded image


(ESI)+: [M + H]+ = 557.5






742


embedded image


(ESI)+: [M + H]+ = 488.4






















embedded image















Com-





pound





num-





ber
R15
R16





743
H


embedded image


(ESI)+: [M + H]+ = 466.1





744
H


embedded image


(ESI)+: [M + H]+ = 494.2





745
H


embedded image


(ESI)+: [M + H]+ = 550.3





746
H


embedded image


(ESI)+: [M + H]+ = 510.3





747
H


embedded image


(ESI)+: [M + H]+ = 566.3





748
H


embedded image


(ESI)+: [M + H]+ = 509.3





749
H


embedded image


(ESI)+: [M + H]+ = 467.2





750
H


embedded image


(ESI)+: [M + H]+ = 467.2





751
H


embedded image


(ESI)+: [M + H]+ = 593.3





752
H


embedded image


(ESI)+: [M + H]+ = 549.3





753
H


embedded image


(ESI)+: [M + H]+ = 498.3





754
H
CH3
(ESI)+:





[M + H]+ =





404.2


755
H
CH2CH3
(ESI)+:





[M + H]+ =





418.2


756
H
CH2CH(CH3)3
(ESI)+:





[M + H]+ =





446.2


757
H
CH2CH2CH3
(ESI)+:





[M + H]+ =





432.2





758
H


embedded image


(ESI)+: [M + H]+ = 430.2





759
H
CH2(CH2)4CH3
(ESI)+:





[M + H]+ =





474.3





760
H


embedded image


(ESI)+: [M + H]+ = 458.2





761
H


embedded image


(ESI)+: [M + H]+ = 486.3





762
H
C(CH3)2CH2CH3
(ESI)+:





[M + H]+ =





460.2


763
H
CH(CH2CH3)2
(ESI)+:





[M + H]+ =





460.3


764
H
CH2CH2CH(CH3)2
(ESI)+:





[M + H]+ =





460.2





765
H


embedded image


(ESI)+: [M + H]+ = 506.3





766
H


embedded image


(ESI)+: [M + H]+ = 506.3





767
H


embedded image


(ESI)+: [M + H]+ = 486.3





768
H


embedded image


(ESI)+: [M + H]+ = 480.2





769
H


embedded image


(ESI)+: [M + H]+ = 564.2





770
H


embedded image


(ESI)+: [M + H]+ = 548.2





771
H


embedded image


(ESI)+: [M + H]+ = 510.3





772
H


embedded image


(ESI)+: [M + H]+ = 548.2





773
H


embedded image


(ESI)+: [M + H]+ = 494.3





774
H


embedded image


(ESI)+: [M + H]+ = 528.2





775
H


embedded image


(ESI)+: [M + H]+ = 508.2





776
H


embedded image


(ESI)+: [M + H]+ = 524.3





777
H


embedded image


(ESI)+: [M + H]+ = 481.2





778
H


embedded image


(ESI)+: [M + H]+ = 481.2





779
H


embedded image


(ESI)+: [M + H]+ = 495.3





780
H


embedded image


(ESI)+: [M + H]+ = 486.2





781
H


embedded image


(ESI)+: [M + H]+ = 470.2





782
H
CH2CH2F
(ESI)+:





[M + H]+ =





436.2


783
H
CH2CH2OH
(ESI)+:





[M + H]+ =





434.2


784
H
CH2CH2CH2OH
(ESI)+:





[M + H]+ =





448.2


785
H
CH2(CH2)3OH
(ESI)+:





[M + H]+ =





462.2


786
H
CH2(CH2)4OH
(ESI)+:





[M + H]+ =





476.2





787
H


embedded image


(ESI)+: [M + H]+ = 462.2





788
H


embedded image


(ESI)+: [M + H]+ = 502.2





789
H
CH2(CH2)2SCH3
(ESI)+:





[M + H]+ =





478.2





790
H


embedded image


(ESI)+: [M + H]+ = 503.2





791
H
CH2CH2N(CH3)2
(ESI)+:





[M + H]+ =





461.2





792
H


embedded image


(ESI)+: [M + H]+ = 531.4





793
H
CH2(CH2)2N(CH3)2
(ESI)+:





[M + H]+ =





475.2





794
H


embedded image


(ESI)+: [M + H]+ = 563.3





795
H
CH2CH2NHCOCH3
(ESI)+:





[M + H]+ =





475.2





796
H


embedded image


(ESI)+: [M + H]+ = 545.3





797
H
CH2CO2CH3
(ESI)+:





[M + H]+ =





462.2





798
H


embedded image


(ESI)+: [M + H]+ = 558.4





799
H
CH2CO2CH(CH3)2
(ESI)+:





[M + H]+ =





490.3





800
H


embedded image


(ESI)+: [M + H]+ = 590.3





801
H
CH2CONH2
(ESI)+:





[M + H]+ =





447.1


802
H
CH2CN
(ESI)+:





[M + H]+ =





429.2


803
H
CH2CH2CN
(ESI)+:





[M + H]+ =





443.2


804
H
CH2(CH2)4CN
(ESI)+:





[M + H]+ =





485.3


805
H
CH2CF3
(ESI)+:





[M + H]+ =





472.2





806
CH3


embedded image


(ESI)+: [M + H]+ = 494.4





807
CH2CH2CH3


embedded image


(ESI)+: [M + H]+ = 567.4





808
CH3
CH2CH3
(ESI)+:





[M + H]+ =





432.3





809
CH2CH3


embedded image


(ESI)+: [M + H]+ = 509.4





810
CH2CH2CN


embedded image


(ESI)+: [M + H]+ = 534.3





811
CH2CO2CH2CH3


embedded image


(ESI)+: [M + H]+ = 566.4





812
CH3


embedded image


(ESI)+: [M + H]+ = 544.4





813
CH3
CH2CH2CH2CH3
(ESI)+:





[M + H]+ =





460.3


814
CH3
CH2(CH2)4CH3
(ESI)+:





[M + H]+ =





488.4





815
CH(CH3)2


embedded image


(ESI)+: [M + H]+ = 514.5





816
CH2CH3
CH2CH3
(ESI)+:





[M + H]+ =





446.2


817
CH(CH3)2
CH(CH3)2
(ESI)+:





[M + H]+ =





474.4





818
CH3


embedded image


(ESI)+: [M + H]+ = 509.4





819
CH2CH3


embedded image


(ESI)+: [M + H]+ = 550.4





820
CH(CH3)2
CH2CH2OCH3
(ESI)+:





[M + H]+ =





490.4





821
CH3


embedded image


(ESI)+: [M + H]+ = 508.4





822
CH2CH2OCH3
CH2CH2OCH3
(ESI)+:





[M + H]+ =





506.3


823
CH3
C6H5
(ESI)+:





[M + H]+ =





480.3


824
CH2CH2OH
C6H5
(ESI)+:





[M + H]+ =





510.4





825
CH3


embedded image


(ESI)+: [M + H]+ = 514.4





826
CH3


embedded image


(ESI)+: [M + H]+ = 481.4





827
CH3


embedded image


(ESI)+: [M + H]+ = 481.3





828
CH2CH3


embedded image


(ESI)+: [M + H]+ = 502.4





829
CH3
CH3
(ESI)+:





[M + H]+ =





418.3





830
CH3


embedded image


(ESI)+: [M + H]+ = 538.3





831
CH3


embedded image


(ESI)+: [M + H]+ = 484.3





832
CH3
CH2CO2H
(ESI)+:





[M + H]+ =





460.4


833
CH3
CH2CH2CH2CO2H
(ESI)+:





[M + H]+ =





490.4


834
CH3
CH2CN
(ESI)+:





[M + H]+ =





443.3


835
CH3
CH2CH2CN
(ESI)+:





[M + H]+ =





457.3





836
CH2CH2N(CH3)2


embedded image


(ESI)+: [M + H]+ = 551.5





837
CH2CH2OH


embedded image


(ESI)+: [M + H]+ = 524.4





838
CH2CN


embedded image


(ESI)+: [M + H]+ = 519.4





















embedded image














Compound




number
R4
MS





839 E57


embedded image








840


embedded image








841


embedded image























embedded image
















Com-






pound




1H



number
R13
R14
MS
NMR





842 E58
Me
CH2CH2CH2CH3
(ESI)+:






[M + H]+ =






557.6






843
H


embedded image


(ESI)+: [M + H]+ = 660.7






844
H
CH2C6H5
(ESI)+:






[M + H]+ =






577.6



845
H
CH2CH2C6H5
(ESI)+:






[M + H]+ =






591.7






846
H


embedded image


(ESI)+: [M + H]+ = 595.7






847
H


embedded image


(ESI)+: [M + H]+ = 555.6






848
H
CH2CH(CH3)2
(ESI)+:






[M + H]+ =






543.6





















embedded image















Com-





pound



1H



number
R4
MS
NMR





849


embedded image


(ESI)+: [M + H]+ = 603.7






850


embedded image


(ESI)+: [M + H]+ = 573.6






















embedded image
















Compound






number
R13
R14
MS

1H NMR






851 E59
H


embedded image


(ESI)+: [M + H]+ = 586.6






852
H
CH2C6H5
(ESI)+:






[M + H]+ =






563.6






853
H


embedded image


(ESI)+: [M + H]+ = 569.6






















embedded image














Compound




number
R12
MS





868 E60
CH2CH2CH2CH2CH2CH3
(ESI)+:




[M + H]+ =




543.4


869
CH2CH2CH3
(ESI)+:




[M + H]+ =




501.4


870
CH2(CH2)3OH
(ESI)+:




[M + H]+ =




531.3


871
CH2(CH2)2CN
(ESI)+:




[M + H]+ =




526.4





872


embedded image


(ESI)+: [M + H]+ = 569.4





873


embedded image


(ESI)+: [M + H]+ = 567.3





874


embedded image


(ESI)+: [M + H]+ = 605.5





875


embedded image


(ESI)+: [M + H]+ = 633.5





876


embedded image


(ESI)+: [M + H]+ = 607.4





877


embedded image


(ESI)+: [M + H]+ = 549.4





878
CH2CH2OH
(ESI)+:




[M + H]+ =




503.3


879
CH2CO2CH(CH3)2
(ESI)+:




[M + H]+ =




559.3


880
CH2CH2CH(CH3)2
(ESI)+:




[M + H]+ =




529.4


881
CH2CH2CH2OH
(ESI)+:




[M + H]+ =




517.4


882
CH2CN
(ESI)+:




[M + H]+ =




498.4


883
CH2CH2OCH2CH3
(ESI)+:




[M + H]+ =




531.4





884


embedded image


(ESI)+: [M + H]+ = 594.4





885


embedded image


(ESI)+: [M + H]+ = 599.4





886


embedded image


(ESI)+: [M + H]+ = 499.4





887


embedded image


(ESI)+: [M + H]+ = 575.4





888


embedded image


(ESI)+: [M + H]+ = 625.5





889
CH2COC(CH3)3
(ESI)+:




[M + H]+ =




557.4


890
CH2CONH2
(ESI)+:




[M + H]+ =




516.4





891


embedded image


(ESI)+: [M + H]+ = 584.4





892


embedded image


(ESI)+: [M + H]+ = 591.4





















embedded image














Compound




number
R12
MS





893
CH2CH2CH3
(ESI)+:




[M + H]+ =




515.5


894
CH2CH(CH3)2
(ESI)+:




[M + H]+ =




529.5





895


embedded image


(ESI)+: [M + H]+ = 563.4





896


embedded image


(ESI)+: [M + H]+ = 569.4





897


embedded image


(ESI)+: [M + H]+ = 577.5





898


embedded image


(ESI)+: [M + H]+ = 597.4





899


embedded image


(ESI)+: [M + H]+ = 597.4





900


embedded image


(ESI)+: [M + H]+ = 597.5





901
CH2CH2CH2CH2CH3
(ESI)+:




[M + H]+ =




543.4





902


embedded image


(ESI)+: [M + H]+ = 527.4





903


embedded image


(ESI)+: [M + H]+ = 591.5





904
CH2CH2CH(CH3)2
(ESI)+:




[M + H]+ =




543.5





905


embedded image


(ESI)+: [M + H]+ = 553.4





906


embedded image


(ESI)+: [M + H]+ = 583.5





907


embedded image


(ESI)+: [M + H]+ = 564.4





908


embedded image


(ESI)+: [M + H]+ = 552.4





909


embedded image


(ESI)+: [M + H]+ = 605.5





910


embedded image


(ESI)+: [M + H]+ = 564.4





911


embedded image


(ESI)+: [M + H]+ = 564.4





912


embedded image


(ESI)+: [M + H]+ = 569.3





913


embedded image


(ESI)+: [M + H]+ = 567.5





914
CH2CH2OH
(ESI)+:




[M + H]+ =




517.4





915


embedded image


(ESI)+: [M + H]+ = 577.5





916


embedded image


(ESI)+: [M + H]+ = 577.5





917


embedded image


(ESI)+: [M + H]+ = 577.4





918


embedded image


(ESI)+: [M + H]+ = 588.5





919


embedded image


(ESI)+: [M + H]+ = 588.5





920


embedded image


(ESI)+: [M + H]+ = 588.5





921


embedded image


(ESI)+: [M + H]+ = 653.5





922


embedded image


(ESI)+: [M + H]+ = 631.5





923


embedded image


(ESI)+: [M + H]+ = 653.6





924


embedded image


(ESI)+: [M + H]+ = 621.6





















embedded image

















Compound






number
R8
R19
MS







925 E62
Cl
Me
(ESI)+:






[M + H]+ =






535.5







926
Cl


embedded image


(ESI)+: [M + H]+ = 597.5







927
Cl


embedded image


(ESI)+: [M + H]+ = 631.5







928
Cl


embedded image


(ESI)+: [M + H]+ = 631.5







929
Cl


embedded image


(ESI)+: [M + H]+ = 631.5







930
Cl


embedded image


(ESI)+: [M + H]+ = 627.6







931
Cl


embedded image


(ESI)+: [M + H]+ = 611.5







932
Cl


embedded image


(ESI)+: [M + H]+ = 611.6







933
Cl


embedded image


(ESI)+: [M + H]+ = 632.5







934
Cl


embedded image


(ESI)+: [M + H]+ = 598.5







935
Cl


embedded image


(ESI)+: [M + H]+ = 598.5







936
Cl


embedded image


(ESI)+: [M + H]+ = 603.5







937
Cl


embedded image


(ESI)+: [M + H]+ = 603.4







938
Cl


embedded image


(ESI)+: [M + H]+ = 615.6







939
Cl


embedded image


(ESI)+: [M + H]+ = 587.5







940
Cl


embedded image


(ESI)+: [M + H]+ = 588.5







941
Cl


embedded image


(ESI)+: [M + H]+ = 678.6







942
Cl
CH2CH3
(ESI)+:






[M + H]+ =






549.4



943
Cl
CH2CH2CH3
(ESI)+:






[M + H]+ =






563.5







944
Cl


embedded image


(ESI)+: [M + H]+ = 561.5







945
Cl
C(CH3)3
(ESI)+:






[M + H]+ =






577.5







946
Cl


embedded image


(ESI)+: [M + H]+ = 603.6







947
Cl
CH2(CH2)3CH3
(ESI)+:






[M + H]+ =






591.5



948
Cl
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+:






[M + H]+ =






619.6







949
Cl


embedded image


(ESI)+: [M + H]+ = 671.6







950
Cl


embedded image


(ESI)+: [M + H]+ = 611.6







951
Cl


embedded image


(ESI)+: [M + H]+ = 625.6







952
Cl


embedded image


(ESI)+: [M + H]+ = 637.6







953
Cl


embedded image


(ESI)+: [M + H]+ = 617.5







954
Cl


embedded image


(ESI)+: [M + H]+ = 627.6







955
Cl


embedded image


(ESI)+: [M + H]+ = 641.6







956
Cl
CH2CH2CH2CO2CH2CH3
(ESI)+:






[M + H]+ =






635.6







957
Me


embedded image


(ESI)+: [M + H]+ = 577.4







958
Me


embedded image


(ESI)+: [M + H]+ = 611.3







959
Me


embedded image


(ESI)+: [M + H]+ = 611.3







960
Me


embedded image


(ESI)+: [M + H]+ = 611.3







961
Me


embedded image


(ESI)+: [M + H]+ = 607.4







962
Me


embedded image


(ESI)+: [M + H]+ = 591.4







963
Me


embedded image


(ESI)+: [M + H]+ = 591.3







964
Me


embedded image


(ESI)+: [M + H]+ = 612.3







965
Me


embedded image


(ESI)+: [M + H]+ = 578.3







966
Me


embedded image


(ESI)+: [M + H]+ = 583.3







967
Me


embedded image


(ESI)+: [M + H]+ = 617.3







968
Me


embedded image


(ESI)+: [M + H]+ = 583.3







969
Me


embedded image


(ESI)+: [M + H]+ = 595.3







970
Me


embedded image


(ESI)+: [M + H]+ = 567.3







971
Me


embedded image


(ESI)+: [M + H]+ = 568.3







972
Me


embedded image


(ESI)+: [M + H]+ = 658.4







973
Me
CH2CH3
(ESI)+:






[M + H]+ =






529.3



974
Me
CH2CH2CH3
(ESI)+:






[M + H]+ =






543.4







975
Me


embedded image


(ESI)+: [M + H]+ = 541.3







976
Me
C(CH3)3
(ESI)+:






[M + H]+ =






557.3







977
Me


embedded image


(ESI)+: [M + H]+ = 583.4







978
Me
CH2(CH2)3CH3
(ESI)+:






[M + H]+ =






571.4



979
Me
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+:






[M + H]+ =






599.5







980
Me


embedded image


(ESI)+: [M + H]+ = 651.4







981
Me


embedded image


(ESI)+: [M + H]+ = 591.3







982
Me


embedded image


(ESI)+: [M + H]+ = 605.4







983
Me


embedded image


(ESI)+: [M + H]+ = 617.4







984
Me


embedded image


(ESI)+: [M + H]+ = 597.3







985
Me


embedded image


(ESI)+: [M + H]+ = 607.4







986
Me


embedded image


(ESI)+: [M + H]+ = 621.4







987
Me
CH2N(CH3)2
(ESI)+:






[M + H]+ =






558.3



988
Me
CH2CH2CH2CO2CH2CH3
(ESI)+:






[M + H]+ =






615.4






















embedded image















Compound





number
R8
R19
MS





989 E63
Me
Me
(ESI)+:





[M + H]+ =





551.3


990
Me
CH(CH3)2
(ESI)+:





[M + H]+ =





579.4





 991
Me


embedded image


(ESI)+: [M + H]+ = 627.4





 992
Me


embedded image


(ESI)+: [M + H]+ = 613.3





 993
Me


embedded image


(ESI)+: [M + H]+ = 681.3





 994
Me


embedded image


(ESI)+: [M + H]+ = 647.3





 995
Me


embedded image


(ESI)+: [M + H]+ = 647.3





 996
Me


embedded image


(ESI)+: [M + H]+ = 643.3





 997
Me


embedded image


(ESI)+: [M + H]+ = 627.4





 998
Me


embedded image


(ESI)+: [M + H]+ = 638.4





 999
Me


embedded image


(ESI)+: [M + H]+ = 681.3





1000
Me


embedded image


(ESI)+: [M + H]+ = 670.4





1001
Me


embedded image


(ESI)+: [M + H]+ = 653.3





1002
Me
CH2CF3
(ESI)+:





[M + H]+ =





619.3





1003
Me


embedded image


(ESI)+: [M + H]+ = 728.3





1004
Me


embedded image


(ESI)+: [M + H]+ = 661.3





1005
Me
CH2CH3
(ESI)+:





[M + H]+ =





565.3


1006
Me
CH2CH2CH3
(ESI)+:





[M + H]+ =





579.3


1007
Me
CH2CH2CH2CH3
(ESI)+:





[M + H]+ =





593.3


1008
Cl
CH3
(ESI)+:





[M + H]+ =





571.4


1009
Cl
CH(CH3)2
(ESI)+:





[M + H]+ =





599.5





1010
Cl


embedded image


(ESI)+: [M + H]+ = 647.6





1011
Cl


embedded image


(ESI)+: [M + H]+ = 633.6





1012
Cl


embedded image


(ESI)+: [M + H]+ = 701.4





1013
Cl


embedded image


(ESI)+: [M + H]+ = 667.5





1014
Cl


embedded image


(ESI)+: [M + H]+ = 667.5





1015
Cl


embedded image


(ESI)+: [M + H]+ = 667.5





1016
Cl


embedded image


(ESI)+: [M + H]+ = 663.6





1017
Cl


embedded image


(ESI)+: [M + H]+ = 647.6





1018
Cl


embedded image


(ESI)+: [M + H]+ = 658.5





1019
Cl


embedded image


(ESI)+: [M + H]+ = 701.5





1020
Cl


embedded image


(ESI)+: [M + H]+ = 690.5





1021
Cl


embedded image


(ESI)+: [M + H]+ = 673.4





1022
Cl


embedded image


(ESI)+: [M + H]+ = 637.5





1023
Cl
CH2CF3
(ESI)+:





[M + H]+ =





639.5





1024
Cl


embedded image


(ESI)+: [M + H]+ = 748.5





1025
Cl


embedded image


(ESI)+: [M + H]+ = 687.5





1026
Cl
CH2CH3
(ESI)+:





[M + H]+ =





585.4


1027
Cl
CH2CH2CH3
(ESI)+:





[M + H]+ =





599.5


1028
Cl
CH2CH2CH2CH3
(ESI)+:





[M + H]+ =





613.6





















embedded image















Com-





pound





num-





ber
R12


1H NMR: δ (ppm)






1029
CH2CH2C(CH3)3
(ESI)+:
0.88 (9H, s), 1.33-1.41


E64

[M +
(2H, m), 1.74-1.82 (2H,




H]+ =
m), 2.14 (3H, s) 2.15-




557.6
2.28 (2H, m), 2.29-2.38





(6H, m), 2.42-2.54 (2H,





m), 3.31-3.39 (2H, m),





3.54-3.63 (2H, m), 3.79





(3H, s), 3.95 (1H, d,





J = 14.6 Hz), 5.91 (1H, d,





J = 14.6 Hz), 6.16 (1H, s),





6.62-6.71 (2H, m), 6.79-





6.91 (3H, m), 7.01-7.13





(2H, m)





1030


embedded image


(ESI)+: [M + H]+ = 541.5
1.61-2.11 (8H, m), 2.12 (3H, s), 2.14-2.26 (1H, m), 2.27-2.41 (8H, m), 2.50 (2H, t, J = 7.0 Hz), 3.32 (2H, brs), 3.56 (2H, brs), 3.76 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 5.90 (1H, d, J = 14.6 Hz), 6.42 (1H, s), 6.63-6.67 (2H, m), 6.74-7.23 (5H, m)





















embedded image















Com-





pound





num-





ber
R4
MS

1H NMR






1031 E65


embedded image


(APCI)+: [M + H]+ = 413.4
1.38-1.60 (1H, m), 1.84-2.00 (2H, m), 2.00-2.14 (1H, m), 2.38 (2H, t, J = 7.7 Hz), 2.64-2.77 (1H, m), 2.77-2.91 (1H, m), 2.87 (2H, t, J = 7.7 Hz), 2.95- 3.08 (1H, m), 4.32- 4.36 (2H, m), 4.99 (1H, d, J = 13.6 Hz), 5.61 (1H, s), 6.58 (1H, d, J = 7.7 Hz), 6.80- 6.87 (1H, m), 6.91-6.95 (2H, m), 7.01-7.12 (3H, m), 7.14-7.21 (3H, m), 7.25-7.35 (3H, m)





1032
NHCH2(CH2)3OH







1033


embedded image









1034


embedded image

























embedded image















Compound





number
G


1H NMR: δ (ppm)






1035 E66


embedded image


(ESI)+: [M + H]+ = 542.5
0.88 (9H, s), 1.34-1.40 (2H, m), 2.13 (3H, s), 2.28-2.40 (8H, m), 2.44 (3H, s), 2.77-2.87 (3H, m), 2.87-3.05 (2H, m), 3.28-3.41 (3H, m), 3.52-3.67 (2H, m), 5.08 (1H, dd, J = 4.2, 12.9 Hz), 6.64 (2H, d, J = 7.9 Hz), 6.75 (1H, d, J = 7.9 Hz), 6.85 (1H, t, J = 7.4 Hz), 7.06 (1H, s), 7.17 (1H, t, J = 7.6 Hz), 8.00- 8.17 (1H, m)





1036


embedded image


(APCI)+: [M + H]+ = 559.4
0.88 (9H, s), 1.23-1.40 (4H, m), 2.16 (3H, s), 2.34-2.37 (6H, m), 2.73 (3H, s), 2.78-2.84 (2H, m), 3.09-3.57 (7H, m), 5.15-5.20 (1H, m), 6.67 (2H, m), 6.77 (1H, d, J = 7.9 Hz), 6.96 (1H, m), 7.12 (1H, s), 7.23 (1H, m), 8.37 (1H, dd, J = 1.5, 8.2 Hz)





1037


embedded image


(ESI)+: [M + H]+ = 559.4
0.88 (9H, s), 1.36-1.43 (2H, m), 2.15 (3H, s), 2.23 (3H, s), 2.35-2.46 (8H, m), 2.83 (2H, t, J = 7.4 Hz), 3.31-3.39 (2H, m), 3.37 (3H, s), 3.48 (3H, s), 3.63 (2H, t, J = 4.4 Hz), 5.70 (1H, s), 5.74 (1H, s), 6.49-6.56 (1H, m), 6.65- 6.72 (1H, m), 6.83-6.94 (2H, m), 7.01-7.08 (2H, m), 7.19 (1H, s)





1038


embedded image


(ESI)+: [M + H]+ = 547.5
0.88 (9H, s), 1.03-1.40 (8H, m), 1.58- 1.83 (3H, m), 1.94-2.08 (2H, m), 2.15 (3H, s), 2.26-2.45 (8H, m), 2.81 (2H, t, J = 7.4 Hz), 3.24 (3H, s), 3.29 (2H, t, J = 4.4 Hz), 3.58 (2H, t, J = 4.4 Hz), 3.91 (1H, d, J = 8.2 Hz), 6.37-6.43 (1H, m), 6.61-6.70 (2H, m), 6.85 (1H, d, J = 7.9 Hz), 7.01-7.06 (2H, m), 7.20 (1H, s)





1039


embedded image


(APCI)+: [M + H]+ = 505.2
0.28-0.38 (2H, m), 0.49-0.59 (2H, m), 0.73-0.81 (1H, m), 0.88 (9H, s), 1.34- 1.40 (2H, m), 2.15 (3H, s), 2.25-2.45 (8H, m), 2.82 (2H, t, J = 7.7 Hz), 3.24 (3H, s), 3.31 (2H, t, J = 5.2 Hz), 3.59 (2H, t, J = 5.2 Hz), 4.44 (1H, s), 6.49- 6.55 (1H, m), 6.73 (1H, d, J = 6.7 Hz), 6.84 (1H, d, J = 7.9 Hz), 6.94-7.02 (2H, m), 7.07-7.15 (2H, m)





1040


embedded image


(ESI)+: [M + H]+ = 510.3, 512.4
0.51-0.54 (2H, m), 0.80-0.89 (2H, m), 0.88 (9H, s), 1.35-1.41 (2H, m), 1.53- 1.62 (1H, m), 2.23 (3H, s), 2.29-2.43 (5H, m), 2.44-2.50 (2H, m), 2.85-2.91 (2H, m), 3.14-3.24 (1H, m), 3.31-3.38 (2H, m), 3.56-3.63 (2H, m), 6.93-7.02 (4H, m), 7.18-7.25 (3H, m)





1041


embedded image


(ESI)+: [M + H]+ = 491.5
0.88 (9H, s), 1.99 (1H, d, J = 6.4 Hz), 1.34-1.40 (2H, m), 1.80 (1H, s), 2.26 (3H, s), 2.28-2.40 (4H, m), 2.49-2.55 (2H, m), 2.90-2.97 (2H, m), 3.39 (2H, t, J = 4.7 Hz), 3.62 (2H, t, J = 4.7 Hz), 4.55 (2H, s), 6.72-6.83 (2H, m), 6.90- 6.96 (1H, m), 7.01-7.12 (3H, m), 7.25 (1H, s), 9.20 (1H, s)





1042


embedded image


(ESI)+: [M + H]+ = 506.8
0.89 (9H, s), 1.34-1.40 (2H, m), 1.93- 2.08 (2H, m), 2.26 (3H, s), 2.26-2.43 (6H, m), 2.46-2.53 (2H, m), 2.79 (2H, t, J = 6.7 Hz), 2.88-2.94 (2H, m), 3.37 (2H, t, J = 4.9 Hz), 3.62 (2H, t, J = 4.9 Hz), 3.73 (3H, s), 3.83 (2H, t, J = 6.4 Hz), 6.40-6.48 (1H, m), 6.66 (1H, d, J = 3.0 Hz), 6.67-6.81 (1H, m), 6.99 (2H, s), 7.23 (1H, s)





1043


embedded image


(ESI)+: [M + H]+ = 510.8
0.89 (9H, m), 1.36-1.42 (2H, m), 1.97-2.07 (2H, m), 2.28 (3H, s), 2.28- 2.44 (6H, m), 2.46-2.54 (2H, m), 2.80 (2H, t, J = 6.7 Hz), 3.33-3.42 (2H, m), 3.58-3.70 (2H, m), 3.84 (2H, t, J = 6.7 Hz), 6.76 (1H, d, J = 8.9 Hz), 6.87 (1H, dd, J = 2.2, 8.7 Hz), 7.02 (2H, s), 7.12 (1H, d, J = 2.2 Hz), 7.25 (1H, s)





1044


embedded image


(ESI)+: [M + H]+ = 490.8
0.89 (9H, s), 1.34-1.41 (2H, m), 1.92- 1.99 (2H, m), 2.06 (3H, s), 2.25 (3H, s), 2.28-2.43 (6H, m), 2.43-2.52 (2H, m), 2.70-2.81 (2H, m), 2.88-2.96 (2H, m), 3.35-3.43 (2H, m), 3.56-3.68 (2H, m), 3.80-3.90 (2H, m), 6.64 (1H, s), 6.77-6.89 (2H, m), 6.92-7.06 (3H, m)





1045


embedded image


(ESI)+: [M + H]+ = 518.4
0.88 (9H, s), 1.34-1.41 (2H, m), 2.23 (3H, s), 2.28-2.42 (6H, m), 2.43-2.51 (2H, m), 2.85-2.91 (2H, m), 3.36 (2H, t, J = 4.9 Hz), 3.43 (3H, s), 3.61 (2H, t, J = 4.9 Hz), 6.83 (1H, dd, J = 2.5, 8.7 Hz), 6.94 (2H, s), 7.20-7.27 (3H, m)





1046


embedded image


(ESI)+: [M + H]+ = 518.4
0.88 (9H, s), 1.34-1.40 (2H, m), 2.20 (3H, s), 2.26-2.39 (6H, m), 2.45 (2H, t, J = 7.9 Hz), 2.85 (2H, t, J = 7.9 Hz), 3.31 (3H, s), 3.24-3.33 (2H, m), 3.59 (2H, d, J = 3.2 Hz), 6.82-7.03 (3H, m), 7.06-7.14 (1H, m), 7.19 (1H, s), 7.38 (1H, s)





1047


embedded image


(ESI)+: [M + H]+ = 491.6
0.88 (9H, s), 1.34-1.40 (2H, m), 2.15 (3H, s), 2.28-2.46 (8H, m), 2.82 (2H, t, J = 7.9 Hz), 3.31 (2H, t, J = 4.7 Hz), 3.59 (2H, t, J = 4.7 Hz), 6.48-6.62 (2H, m), 6.75 (1H, d, J = 7.2 Hz), 6.83 (1H, d, J = 7.2 Hz), 6.90-6.98 (2H, m), 7.11 (1H, s)





1048


embedded image


(APCI)+: [M + H]+ = 528.1, 530.3
0.87 (9H, s), 1.32-1.39 (2H, m), 2.16 (3H, s), 2.24-2.46 (8H, m), 2.81 (2H, t, J = 7.2 Hz), 3.28 (2H, t, J = 4.4 Hz), 3.33 (3H, s), 3.57 (2H, t, J = 4.4 Hz), 6.85 (1H, d), 6.94-7.07 (3H, m), 7.11- 7.19 (2H, m), 7.52 (1H, d, J = 7.7 Hz)





1049


embedded image


(ESI)+: [M + H]+ = 538.7
0.87 (9H, s), 1.33-1.39 (2H, m), 2.11 (3H, s), 2.25-2.43 (8H, m), 2.75-2.88 (4H, m), 3.28 (2H, t, J = 4.9 Hz), 3.58 (2H, t, J = 4.9 Hz), 3.83-3.91 (1H, m), 4.60-4.71 (1H, m), 6.69-6.82 (3H, m), 6.90 (1H, s), 7.06 (1H, t, J = 7.2 Hz), 7.25-7.52 (6H, m)





1050


embedded image


(ESI)+: [M + H]+ = 540.7
0.87 (9H, s), 1.33-1.40 (2H, m), 2.19 (3H, s), 2.26-2.49 (8H, m), 2.85 (2H, t, J = 7.7 Hz), 3.32 (2H, t, J = 4.7 Hz), 3.59 (2H, t, J = 4.7 Hz), 5.07-5.23 (2H, m), 6.71-6.81 (2H, m), 6.83-6.93 (2H, m), 6.98-7.09 (2H, m), 7.11-7.28 (5H, m)





1051


embedded image


(ESI)+: [M + H]+ = 539.7
0.87 (9H, s), 1.33-1.40 (2H, m), 2.15 (3H, s), 2.24-2.46 (8H, m), 2.81 (2H, t, J = 8.2 Hz), 3.30 (2H, t, J = 4.4 Hz), 3.59 (2H, t, J = 4.4 Hz), 4.08-4.24 (2H, m), 5.68-5.89 (1H, m), 6.48-6.59 (3H, m), 6.72-6.93 (4H, m), 6.95-7.23 (4H, m)





1052


embedded image


(ESI)+: [M + H]+ = 538.7
0.87 (9H, s), 1.33-1.40 (2H, m), 2.20 (3H, s), 2.27-2.39 (6H, m), 2.42-2.47 (2H, m), 2.85 (2H, t, J = 7.4 Hz), 3.32 (2H, t, J = 4.7 Hz), 3.59 (2H, t, J = 4.7 Hz), 4.02-4.48 (4H, m), 6.78- 7.34 (11H, m)





1053 E67


embedded image


(ESI)+: [M + H]+ = 490.7
0.89 (9H, s), 1.34-1.41 (2H, m), 1.94- 2.03 (2H, m), 2.23 (3H, s), 2.26 (3H, s), 2.28-2.40 (6H, m), 2.47-2.53 (2H, m), 2.78 (2H, t, J = 6.7 Hz), 2.88-2.94 (2H, m), 3.36 (2H, t, J = 4.7 Hz), 3.61 (2H, t, J = 4.7 Hz), 3.84 (2H, t, J = 6.4 Hz), 6.68 (2H, s), 6.93 (1H, s), 6.99 (3H, s)





1054


embedded image


(APCI)+: [M + H]+ = 526.1, 528.2
0.92 (9H, s), 1.34-1.45 (5H, m), 1.47- 1.54 (5H, m), 1.55-1.78 (2H, m), 2.00-2.13 (1H, m), 2.20 (3H, s), 2.42- 2.53 (2H, m), 2.70-2.81 (1H, m), 2.82-2.93 (2H, m), 3.03-3.13 (2H, m), 3.58-3.72 (2H, m), 6.51-6.61 (1H, m), 6.68-6.77 (1H, m), 6.90 (2H, s), 7.09 (2H, d, J = 2.2 Hz) ppm.





1055


embedded image


(ESI)+: [M + H]+ = 617.5
0.88 (9H, s), 1.29-1.42 (2H, m), 2.24- 2.43 (12H, m), 2.47-2.60 (2H, m), 2.88-3.02 (2H, m), 3.37-3.58 (2H, m), 3.59-3.71 (2H, m), 3.93 (1H, dd, J = 7.2, 13.4 Hz), 4.31 (1H, dd, J = 3.2, 13.4 Hz), 4.51-4.78 (2H, m), 4.79-4.82 (1H, m), 6.80-6.90 (1H, m), 7.01-7.06 (2H, m), 7.12-7.16 (1H, m), 7.17-7.23 (1H, m), 7.28-7.39 (2H, m) ppm.





1056


embedded image


(ESI)+: [M + H]+ = 496.5
0.89 (9H, s), 1.35-1.41 (2H, m), 2.32 (3H, s), 2.36-2.42 (6H, m), 2.51-2.57 (2H, m), 2.93-3.00 (2H, m), 3.40 (2H, t, J = 4.7 Hz), 3.63 (2H, t, J = 4.4 Hz), 3.95 (2H, t, J = 4.4 Hz), 4.31 (2H, t, J = 4.4 Hz), 6.42-6.48 (1H, m), 6.62 (1H, dd, J = 3.0, 9.6 Hz), 7.11-7.19 (1H, m), 7.22-7.24 (1H, m), 7.31 (1H, s) ppm.





















embedded image















Compound





number
G


1H NMR






1057


embedded image


(ESI)+: [M + H]+ = 513.6
CDCl3 δ 0.05-0.09 (2H, m), 0.42- 0.52 (2H, m), 0.71-0.89 (1H, m), 2.13 (3H, s), 2.17-2.22 (2H, m), 2.28-2.52 (6H, m), 2.79-2.86 (2H, m), 3.22-3.35 (2H, m), 3.56-3.72 (2H, m), 3.74 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 5.89 (1H, d, J = 14.6 Hz), 6.58-6.71 (2H, m), 6.75-6.90 (2H, m), 6.91-7.06 (2H, m), 7.08-7.22 (2H, m) ppm.





1058


embedded image


(ESI)+: [M + H]+ = 510.7
CDCl3 δ 0.03-0.08 (2H, m), 0.43- 0.50 (2H, m), 0.77-0.86 (1H, m), 2.19 (3H, s), 2.18-2.21 (2H, m), 2.36-2.47 (6H, m), 2.84 (2H, t, J = 7.4 Hz), 3.32 (2H, t, J = 4.9 Hz), 3.60 (2H, t, J = 4.9 Hz), 5.03-5.26 (2H, m), 6.74-6.78 (1H, m), 6.82- 6.91 (2H, m), 6.98-7.07 (2H, m), 7.11-7.18 (2H, m), 7.19-7.24 (4H, m) ppm.





1059


embedded image


(ESI)+: [M + H]+ = 509.7
CDCl3 δ 0.03-0.08 (2H, m), 0.45- 0.50 (2H, m), 0.71-0.89 (1H, m), 2.15 (3H, s), 2.19-2.22 (2H, m), 2.34-2.45 (6H, m), 2.83 (2H, t, J = 7.2 Hz), 3.31 (2H, brs), 3.60 (2H, brs), 4.03-4.34 (2H, m), 5.62-5.97 (1H, m), 6.48-6.59 (3H, m), 6.72-6.93 (5H, m), 6.97-7.03 (1H, m), 7.07-7.16 (2H, m) ppm.





1060


embedded image


(ESI)+: [M + H]+ = 508.7
CDCl3 δ 0.06-0.10 (2H, m), 0.47- 0.54 (2H, m), 0.72-0.89 (1H, m), 2.21 (3H, s), 2.19-2.24 (2H, m), 2.38-2.49 (6H, m), 2.85 (2H, t, J = 7.4 Hz), 3.34 (2H, t, J = 4.9 Hz), 3.62 (2H, t, J = 4.9 Hz), 4.00-4.50 (4H, m), 6.73-7.31 (11H, m) ppm.





















embedded image



















Compound









number
R1
R3
R8
R13
n
MS

1H NMR: δ (ppm)






1061 E90
H
F
H


embedded image


0
(APCI)+: [M + H]+ = 517.4
0.03-0.12 (3H, m), 0.45-0.54 (3H, m), 0.77-0.91 (2H, m), 1.70-1.82 (3H, m), 1.88-2.03 (2H, m), 2.03-2.17 (1H, m), 2.22 (2H, d, J = 4.9 Hz), 2.98- 3.17 (2H, m), 3.65 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.10-4.30 (2H, m), 5.80 (1H, d, J = 14.6 Hz), 6.53- 6.79 (4H, m), 6.88-7.00 (3H, m), 7.21 (1H, s)





1062
F
H
F
CH2CH2CH3
0
(ESI)+:
d4-MeOH 0.95








[M + H]+ =
(9H, s), 1.50-1.56








565.3
(2H, m), 1.80-1.91









(4H, m), 2.35-2.41









(1H, m), 2.52-2.58









(1H, m), 2.74-2.81









(2H, m), 3.30-3.33









(3H, m), 3.81 (3H,









s), 4.00 (1H, d,









J = 14.6 Hz), 4.32









(2H, s), 5.73 (1H,









d, J = 14.6 Hz),









6.39-6.46 (1H, m),









6.77-6.83 (1H, m),









6.93-7.01 (3H, m),









7.12-7.18 (1H, m),









7.24 (1H, s)


1063
H
Me
Cl
CO2C(CH3)3
2
(APCI)+:
1.44 (9H, s), 1.34-








[M + H]+ =
1.71 (5H, m),








621.5,
2.12-2.30 (2H, m),








623.5
2.32 (3H, s), 2.53-









2.72 (4H, m), 3.80









(3H, s), 3.94 (1H,









d, J = 14.6 Hz),









3.93-4.04 (2H, m),









4.19-4.42 (2H, m),









5.81 (1H, d,









J = 14.6 Hz), 6.17









(1H, s), 6.57-7.20









(7H, m), 7.38 (1H,









s)


1064
Cl
H
H
CO2C(CH3)3
0
(APCI)+:
1.43 (9H, s), 1.47-








[M −
1.62 (2H, m),








Boc + H]+ =
1.65-1.78 (2H, m),








479.4,
2.16-2.31 (1H, m),








481.4
2.57-2.72 (2H, m),









3.77 (3H, s), 3.98









(1H, d, J = 14.6 Hz),









4.00-4.13 (2H, m),









4.33-4.36 (2H, m),









5.86 (1H, d,









J = 14.6 Hz), 6.18-









6.24 (1H, m), 6.51









(1H, s), 6.67-6.70









(2H, m), 6.89-6.98









(3H, m), 7.04-7.11









(1H, m), 7.21-7.27









(2H, m)


1065
F
H
Me
CO2C(CH3)3
1
(APCI)+:
1.43 (9H, s), 1.50-








[M −
1.63 (2H, m),








Boc + H]+ =
1.82-2.00 (2H, m),








492.2
2.01-2.11 (2H, m),









2.13-2.23 (1H, m),









2.20 (3H, s), 2.53-









2.71 (3H, m), 3.79









(3H, s), 3.94 (1H,









d, J = 14.6 Hz),









3.96-4.04 (3H, m),









4.19-4.42 (1H, m),









5.83 (1H, d,









J = 14.6 Hz), 6.31-









6.42 (1H, m),









6.43-6.58 (2H, m),









6.78-6.83 (2H, m),









6.85-6.96 (2H, m),









7.21 (1H, s)


1066
Me
H
H
CO2C(CH3)3
2
(APCI)+:
0.91-1.12 (2H, m),








[M −
1.30-1.64 (6H, m),








Boc + H]+ =
1.43 (9H, s), 2.11








487.5
(3H, s), 2.22 (2H,









t, J = 7.2 Hz), 2.48-









2.64 (2H, m), 3.79









(3H, s), 3.93-4.09









(3H, m), 4.929-4.44









(1H, m), 5.87 (1H,









d, J = 14.6 Hz), 6.11









(1H, brs), 6.65-









6.68 (2H, m),









6.70-6.84 (3H, m),









6.85-6.92 (1H, m),









6.99-7.05 (1H, m)









7.15 (1H, s), 7.21









(1H, s)


1067
Me
H
H
CO2C(CH3)3
1
(APCI)+:
0.91-1.11 (2H, m),








[M −
1.44 (9H, s), 1.49-








Boc + H]+ =
1.72 (4H, m),








473.5
1.84-2.06 (2H, m),









2.09 (3H, s), 2.58-









2.74 (2H, m), 3.76









(3H, s), 3.93-4.06









(3H, m), 4.17-4.31









(1H, m), 5.87 (1H,









d, J = 14.6 Hz), 6.25









(1H, brs), 6.64-









6.67 (2H, m),









6.74-6.76 (3H, m),









6.94-6.98 (1H, m),









7.01-7.08 (1H, m),









7.12 (1H, s), 7.21









(1H, s)


1068
Cl
H
H
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.34-








[M + H]+ =
1.40 (2H, m),








563.4,
1.65-1.95 (5H, m),








565.4
2.08-2.14 (2H, m),









2.27-2.33 (2H, m),









2.93-2.97 (2H, m),









3.73 (3H, s), 3.97









(1H, d, J = 14.6 Hz),









4.33 (1H, d,









J = 5.9 Hz), 5.85









(1H, d, J = 14.6 Hz),









6.20-6.22 (1H, m),









6.66-6.71 (3H, m),









6.91-6.98 (4H, m),









7.03-7.07 (1H, m),









7.22 (1H, s)





1069
Cl
H
H


embedded image


0
(APCI)+: [M + H]+ = 533.4, 535.2
0.04-0.10 (2H, m), 0.46-0.53 (4H, m), 0.78-0.85 (1H, m), 1.64-1.77 (4H, m), 1.93-2.16 (2H, m), 2.23 (2H, d, J = 6.7 Hz), 2.33- 2.40 (1H, m), 3.05-3.10 (2H, m), 3.73 (3H, s), 3.98 4.33 (2H, d, J = 5.9 Hz), 5.85 (1H, d, J = 14.6 Hz), 6.30-6.32 (1H, m), 6.66-6.67 (2H, m), 6.83 (1H, s), 6.90- 7.08 (3H, m), 7.22 (1H, s)





1070
H
F
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.86 (9H, s), 1.34-








[M + H]+ =
1.40 (2H, m),








581.4,
1.72-1.76 (4H, m),








583.4
1.88-1.95 (2H, m),









2.10-2.14 (1H, m),









2.28-2.34 (2H, m),









2.94-2.98 (2H, m),









3.64 (3H, s), 3.97









(1H, d, J = 14.6 Hz),









4.22 (2H, d,









J = 5.7 Hz), 5.76









(1H, d, J = 14.6 Hz),









6.54 (1H, dd,









J = 2.2, 8.4 Hz),









6.58-6.76 (4H, m),









6.96-7.03 (2H, m),









7.20 (1H, s)





1071
H
F
Cl


embedded image


0
(APCI)+: [M + H]+ = 551.3, 553.3
0.07-0.09 (2H, m), 0.46-0.51 (2H, m), 0.80-0.84 (1H, m), 1.73-1.78 (4H, m), 1.93-1.99 (2H, m), 2.10-2.15 (1H, m), 2.24 (2H, d, J = 6.4 Hz), 2.51- 2.53 (1H, brs), 3.07-3.11 (2H, m), 3.66 (3H, s), 3.97 (1H, d, J = 14.6 Hz), 4.24 (2H, d, J = 5.9 Hz), 5.77 (1H, d, J = 14.6 Hz), 6.55-6.77 (5H, m), 6.96-7.04 (2H, m), 7.21 (1H, s)





1072
H
F
Me
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.35-








[M + H]+ =
1.41 (2H, m),








561.4
1.73-1.81 (4H, m),









1.89-2.02 (2H, m),









2.10-2.14 (4H, m),









2.29-2.35 (2H, m),









2.94-2.98 (2H, m),









3.68 (3H, s), 3.95









(1H, d, J = 14.6 Hz),









4.20-4.25 (2H, m),









5.79 (1H, d,









J = 14.6 Hz), 6.42









(1H, dd, J = 1.2,









8.2 Hz), 6.52-7.00









(6H, m), 7.20 (1H,









s)





1073
H
F
Me


embedded image


0
(APCI)+: [M + H]+ = 531.4
0.05-0.10 (2H, m), 0.46-0.53 (2H, m), 0.79-0.83 (1H, m), 1.72-1.79 (4H, m), 1.95-2.04 (2H, m), 2.08-2.14 (4H, m), 2.22-2.26 (2H, m), 2.90-2.92 (1H, brs), 3.06-3.10 (2H, m), 3.66 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.18- 4.23 (2H, m), 5.76 (1H, d, J = 14.6 Hz), 6.43 (1H, dd, J = 1.2, 8.2 Hz), 6.57-6.97 (6H, m), 7.18 (1H, s)





1074
F
H
Me


embedded image


0
(APCI)+: [M + H]+ = 531.4
0.09-0.15 (2H, m), 0.49-0.57 (2H, m), 0.79-0.92 (1H, m), 1.72-1.84 (4H, m), 1.99-2.19 (3H, m), 2.21 (3H, s), 2.26- 2.33 (2H, m), 3.10-3.16 (2H, m), 3.77 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.33 (2H, d, J = 5.9 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.24 (1H, brs), 6.36 (1H, s), 6.48- 6.58 (2H, m), 6.79 (1H, s), 6.87-7.01 (3H, m), 7.21 (1H, s)





1075
F
H
Me
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.36-








[M + H]+ =
1.43 (2H, m),








561.4
1.62-1.81 (4H, m),









1.96-1.17 (3H, m),









2.20 (3H, s), 2.33-









2.40 (2H, m),









2.97-3.02 (2H, m),









3.76 (3H, s), 3.94









(1H, d, J = 14.6 Hz),









4.32 (2H, d,









J = 5.7 Hz), 5.83









(1H, d, J = 14.6 Hz),









6.19 (1H, brs),









6.39 (1H, s), 6.47-









6.57 (2H, m), 6.78









(1H, s), 6.86-7.00









(3H, m), 7.21 (1H,









s)


1076
H
F
H
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.34-








[M + H]+ =
1.40 (2H, m),








547.4
1.68-1.77 (4H, m),









1.97-2.03 (2H, m),









2.03-2.19 (1H, m),









2.28-2.38 (2H, m),









2.52 (2H, s), 2.90-









3.00 (2H, m), 3.65









(3H, s), 3.98 (1H,









d, J = 14.6 Hz), 4.18









(1H, t, J = 6.2 Hz),









5.79 (1H, d,









J = 14.6 Hz), 6.57-









6.72 (4H, m), 6.75









(1H, s), 6.90-7.02









(4H, m)





1077
H
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 533.5, 535.5
0.35-0.45 (3H, m), 0.68-0.80 (3H, m), 0.98-1.15 (2H, m), 1.81-2.10 (4H, m), 2.46-2.55 (1H, m), 2.91-3.00 (4H, m), 3.60-3.75 (3H, m), 3.78 (3H, s), 4.02 (1H, d, J = 14.6 Hz), 5.69 (1H, d, J = 14.6 Hz), 6.59- 6.70 (1H, m), 6.91-7.20 (6H, m), 7.25 (1H, s)





1078
H
Cl
H
CH2CH2C(CH3)3
0
(ESI)+:
0.87 (9H, s), 1.31-








[M + H]+ =
1.48 (3H, m),








563.5,
1.67-1.82 (4H, m),








565.7
1.93-2.22 (2H, m),









2.28-2.47 (3H, m),









2.90-3.10 (3H, m),









3.67 (3H, s), 4.03









(1H, d, J = 14.6 Hz),









4.10-4.21 (2H, m),









5.78 (1H, d,









J = 14.6 Hz), 6.56-









6.70 (2H, m),









6.70-6.85 (1H, m),









6.85-6.95 (4H, m),









7.22 (1H, s)





1079
H
Me
H


embedded image


0
(ESI)+: [M + H]+ = 513.5
0.05-0.07 (3H, m), 0.48-0.51 (3H, m), 0.83-0.85 (2H, m), 1.61-2.00 (7H, m), 2.22 (2H, d, J = 6.4 Hz), 2.31 (3H, s), 3.00-3.15 (2H, m), 3.71 (3H, s), 4.03 (1H, d, J = 14.6 Hz), 4.22 (2H, d, J = 5.7 Hz), 5.85 (1H, d, J = 14.6 Hz), 6.42 (1H, s), 6.60-6.87 (4H, m), 6.90-7.10 (2H, m) ppm.





1080
H
Me
H
CH2CH2C(CH3)3
0
(ESI)+:
δ 0.93 (9H, s),








[M + H]+ =
1.28-1.37 (5H, m),








543.5
1.43-1.52 (2H, m),









1.71-1.91 (3H, m),









2.29 (3H, s), 2.30-









2.40 (2H, m),









2.60-2.68 (2H, m),









3.12-3.23 (2H, m),









3.62-3.73 (1H, m),









3.78 (3H, s), 4.00









(1H, d, J = 14.6 Hz),









5.73 (1H, d,









J = 14.6 Hz), 6.59-









6.66 (1H, m),









6.78-6.85 (2H, m),









6.90-7.00 (2H, m),









7.01-7.15 (1H, m),









7.24 (1H, s), 7.25-









7.30 (1H, m)





1081
H
Cl
Cl


embedded image


0
(APCI)+: [M + H]+ = 567.3
0.04-0.09 (2H, m), 0.46-0.51 (2H, m), 0.74-0.89 (1H, m), 1.63-1.84 (2H, m), 1.89-2.04 (2H, m), 2.05-2.21 (1H, m), 2.23 (2H, d, J = 6.4 Hz), 3.04- 3.15 (4H, m), 3.61 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.10-4.19 (2H, m), 4.31-4.38 (1H, m), 5.71 (1H, d, J = 14.6 Hz), 6.53 (1H, dd, J = 2.0, 8.4 Hz), 6.70-6.84 (3H, m), 6.96-7.11 (2H, m), 7.17 (1H, s), 7.73 (1H, s)





1082
H
Me
Cl


embedded image


0
(APCI)+: [M + H]+ = 547.4, 549.4
0.03-0.09 (2H, m), 0.44-0.49 (2H, m), 0.78-0.84 (1H, m), 1.68-1.85 (4H, m), 1.94-2.10 (2H, m), 2.10-2.24 (1H, m), 2.22 (3H, s), 2.23 (2H, d, J = 8.2 Hz), 3.04-3.13 (2H, m), 3.61(3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.17 (2H, d, J = 5.7 Hz), 4.38 (1H, d, J = 5.7 Hz), 5.76 (1H, d, J = 14.6 Hz), 6.49- 6.65 (3H, m), 6.71-6.83 (2H, m), 6.87-7.02 (1H, m), 7.19 (1H, s), 7.57 (1H, s)





1083
H
Cl
Me


embedded image


0
(APCI)+: [M + H]+ = 547.3, 549.3
d4-MeOH: 0.30- 0.36 (2H, m), 0.65-0.71 (2H, m), 0.96-1.10 (1H, m), 1.82-2.04 (4H, m), 2.15 (3H, s), 2.38- 2.49 (1H, m), 2.68-2.84 (4H, m), 3.49 (2H, brd, J = 12.6 Hz), 3.76 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.22 (2H, s), 5.67 (1H, d, J = 14.6 Hz), 6.46 (1H, dd, J = 1.5, 8.2 Hz), 6.83 (1H, d, J = 8.2 Hz), 6.94- 7.11 (3H, m), 7.16 (1H, s), 7.22 (1H, s)





1084
H
Me
Me


embedded image


0
(APCI)+: [M + H]+ = 527.4
0.05-0.09 (2H, m), 0.45-0.52 (2H, m), 0.72-0.86 (1H, m), 1.62-1.84 (4H, m), 1.97-2.11 (2H, m), 2.05 (3H, s), 2.11- 2.24 (1H, m), 2.25 (2H, d, J = 5.7 Hz), 2.26 (3H, s), 3.06- 3.17 (2H, m), 3.66 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.17 (2H, d, J = 5.7 Hz), 4.37 (1H, d, J = 5.7 Hz), 5.78 (1H, d, J = 14.6 Hz), 6.31-6.83 (7H, m), 7.19 (1H, s)





1085
H
Cl
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.33-








[M + H]+ =
1.41 (2H, m),








597.3
1.63-1.98 (6H, m),









2.07-2.17 (1H, m),









2.26-2.32 (2H, m),









2.92-2.96 (2H, m),









3.61 (3H, s), 3.98









(1H, d,









J = 14.6 Hz), 4.08-









4.23 (2H, m),









4.34-4.37 (1H, m),









5.71 (1H, d,









J = 14.6 Hz), 6.52









(1H, dd, J = 2.0,









8.4 Hz), 6.70-6.98









(5H, m), 7.17 (1H,









s), 7.73 (1H, s)


1086
H
Me
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.33-








[M + H]+ =
1.41 (2H, m),








577.4,
1.68-1.98 (6H, m),








579.3
2.03-2.17 (1H, m),









2.22 (3H, s), 2.27-









2.33 (2H, m),









2.93-2.97 (2H, m),









3.61 (3H, s), 3.95









(1H, d, J = 14.6 Hz),









4.17-4.19 (2H, m),









4.37-4.39 (1H, m),









5.77 (1H, d,









J = 14.6 Hz), 6.40-









7.17 (6H, m), 7.19









(1H, s), 7.47 (1H,









s) ppm.


1087
H
Cl
Me
CH2CH2C(CH3)3
0
(APCI)+:
δ 0.88 (9H, s),








[M + H]+ =
1.34-1.42 (2H, m),








577.4,
1.67-2.22 (7H, m),








579.4
2.07 (3H, s), 2.27-









2.33 (2H, m),









2.93-2.97 (2H, m),









3.65 (3H, s), 3.98









(1H, d, J = 14.6 Hz),









4.13-4.20 (2H, m),









4.34-4.37 (1H, m),









5.75 (1H, d,









J = 14.6 Hz), 6.43









(1H, dd, J = 1.2,









8.2 Hz), 6.67-6.80









(5H, m), 6.92-6.93









(1H, m), 7.19 (1H,









s)


1088
H
Me
Me
CH2CH2C(CH3)3
0
(APCI)+:
0.87 (9H, s), 1.33-








[M + H]+ =
1.41 (2H, m),








557.4
1.65-2.04 (7H, m),









2.07 (3H, s), 2.22-









2.34 (5H, m),









2.92-3.00 (2H, m),









3.62 (3H, s), 3.94









(1H, d, J = 14.6 Hz),









4.16-4.19 (2H, m),









4.36-4.39 (1H, m),









5.80 (1H, d,









J = 14.6 Hz), 6.34-









7.14 (7H, m), 7.19









(1H, s)





1089
F
H
H


embedded image


0
(ESI)+: [M + H]+ = 517.5
d4-MeOH: 0.14- 0.19 (2H, m), 0.53-0.59 (2H, m), 0.87-0.90 (1H, m), 1.73-1.81 (4H, m), 2.14-2.24 (3H, m), 2.35-2.37 (2H, m), 3.16-3.21 (2H, m), 3.79 (3H, s), 3.97 (1H, d, J = 14.6 Hz), 4.29 (2H, s), 5.75 (1H, d, J = 14.6 Hz), 6.65-6.77 (2H, m), 6.90-7.00 (2H, m), 7.07-7.15 (2H, m), 7.20-7.24 (2H, m)





1090
F
H
H
CH2CH2C(CH3)3
0
(ESI)+:
0.86 (9H, s), 1.32-








[M + H]+ =
1.39 (2H, m),








547.5
1.69-1.92 (3H, m),









2.04-2.10 (2H, m),









2.25-2.31 (1H, m),









2.58 (1H, m),









2.90-2.94 (2H, m),









3.67 (3H, s), 3.97









(1H, d, J = 14.6 Hz),









4.25-4.28 (2H, m),









5.83 (1H, d,









J = 14.6 Hz), 6.37-









6.39 (1H, m), 6.65









(2H, m), 6.83-7.03









(5H, m), 7.14 (1H,









s), 7.20 (1H, s)





1091
Cl
H
Me


embedded image


0
(ESI)+: [M + H]+ = 547.4, 549.4
d4-MeOH: 0.14- 0.20 (2H, m), 0.52-0.60 (2H, m), 0.90 (1H, m), 1.76-1.84 (4H, m), 2.16-2.32 (6H, m), 2.36-2.39 (2H, m), 3.18-3.22 (2H, m), 3.78 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.32 (2H, s), 5.73 (1H, d, J = 14.6 Hz), 6.50 (1H, dd, J = 1.0, 8.0 Hz), 6.62 (1H, d, J = 8.0 Hz), 7.04 (1H, d, J = 1.0 Hz), 7.11 (2H, s), 7.20- 7.23 (2H, m)





1092
Cl
H
Me
CH2CH2C(CH3)3
0
(APCI)+:
0.86 (9H, s), 1.33-








[M + H]+ =
1.40 (2H, m),








577.3,
1.70-1.92 (6H, m),








579.3
2.12-2.14 (4H, m),









2.28-2.34 (2H, m),









2.93-2.96 (2H, m),









3.70 (3H, s), 3.93









(1H, d, J = 14.6 Hz),









4.28-4.32 (2H, m),









5.79 (1H, d,









J = 14.6 Hz), 6.45-









6.54 (2H, m),









6.79-6.89 (4H, m),









7.17 (1H, s), 7.22









(1H, s)


1093
Cl
H
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.86 (9H, s), 1.33-








[M + H]+ =
1.39 (2H, m),








597.2
1.68-1.90 (6H, m),









2.13 (1H, m),









2.26-2.32 (2H, m),









2.93-2.97 (2H, m),









3.67 (3H, s), 3.94









(1H, d, J = 14.6 Hz),









4.32 (2H, m), 5.78









(1H, d, J = 14.6 Hz),









6.56 (2H, s), 6.87-









6.97 (2H, m), 7.02









(1H, s), 7.18 (1H,









s), 7.21 (1H, d,









J = 1.2 Hz), 7.64









(1H, s)


1094
F
H
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.85 (9H, s), 1.35-








[M + H]+ =
1.41 (2H, m), 1.76








581.3,
(4H, m), 2.01-2.14








583.3
(3H, m), 2.34-2.40









(2H, m), 2.97-3.01









(2H, m), 3.68 (3H,









s), 3.94 (1H, d,









J = 14.6 Hz), 4.27









(2H, m), 5.76 (1H,









d, J = 14.6 Hz), 6.54









(2H, s), 6.81-6.97









(3H, m), 7.05 (1H,









s), 7.17 (1H, s),









8.08 (1H, s)





1095
Me
H
Cl


embedded image


0
(APCI)+: [M + H]+ = 547.4, 549.4
d6-DMSO: 0.15- 0.24 (2H, m), 0.48-0.59 (2H, m), 0.84-1.03 (1H, m), 1.61-1.88 (4H, m), 2.14 (3H, s), 2.20- 2.80 (4H, m), 3.16-3.46 (3H, m), 3.77 (3H, s), 3.90 (1H, d, J = 14.6 Hz), 4.06-4.23 (2H, m), 5.63 (1H, d, J = 14.6 Hz), 6.67 (1H, dd, J = 2.0, 8.4 Hz), 6.74 (1H, d, J = 8.4 Hz), 6.84 (1H, d, J = 7.8 Hz), 6.94 (1H, d, J = 7.8 Hz), 7.05 (1H, s), 7.18 (1H, s), 7.40 (1H, d, J = 2.0 Hz), 8.26 (1H, s), 8.82 (1H, s)





1096
Cl
H
Cl


embedded image


0
(ESI)+: [M + H]+ = 567.2
d6-DMSO: 0.15- 0.22 (2H, m), 0.50-0.52 (2H, m), 0.89 (1H, m), 1.60-1.82 (6H, m), 2.13-2.34 (3H, m), 3.09-3.18 (2H, m), 3.76 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.25 (2H, m), 5.62 (1H, d, J = 14.6 Hz), 6.71 (1H, dd, J = 2.2, 8.4 Hz), 6.84 (1H, d, J = 8.4 Hz), 7.03- 7.11 (2H, m), 7.20 (2H, s), 7.38 (1H, d, J = 2.2 Hz), 8.34 (1H, m), 8.82 (1H, s)





1097
F
H
Cl


embedded image


0
(ESI)+: [M + H]+ = 551.3, 553.3
d6-DMSO: 0.04- 0.06 (2H, m), 0.43-0.45 (2H, m), 0.78-0.81 (1H, m), 1.53-1.66 (5H, m), 1.90 (1H, m), 2.07-2.16 (3H, m), 2.98 (2H, m), 3.76 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.19 (2H, m), 5.61 (1H, d, J = 14.6 Hz), 6.69 (1H, dd, J = 2.2, 8.4 Hz), 6.82 (1H, d, J = 8.4 Hz), 6.90- 6.94 (2H, m), 7.05-7.11 (1H, m), 7.19 (1H, s), 7.37 (1H, d, J = 2.2 Hz), 8.25 (1H, m), 8.80 (1H, s)





1098
Me
H
Me


embedded image


0
(APCI)+: [M + H]+ = 527.4
d4-MeOH: 0.32- 0.45 (2H, m), 0.68-0.80 (2H, m), 1.01-1.19 (1H, m), 1.78-2.15 (4H, m), 2.17 (3H, s), 2.24 (3H, s), 2.81-3.20 (4H, m), 3.51-3.78 (3H, m), 3.93 (1H, d, J = 14.6 Hz), 3.96 (3H, s), 4.26 (2H, s), 5.78 (1H, d, J = 14.6 Hz), 6.52- 6.71 (2H, m), 6.99-7.13 (4H, m), 7.61 (1H, s)





1099
Me
H
Cl
CH2CH2C(CH3)3
0
(APCI)+:
0.88 (9H, s), 1.38-








[M + H]+ =
1.45 (2H, m),








577.4,
1.72-1.94 (4H, m),








579.4
2.01-2.18 (2H, m),









2.11 (3H, s), 2.39-









2.45 (2H, m),









2.96-3.05 (2H, m),









3.09-3.22 (1H, m),









3.76 (3H, s), 3 .93









(1H, d, J = 14.6 Hz),









4.26 (2H, d,









J = 4.5 Hz), 5.83









(1H, d, J = 14.6 Hz),









6.13 (1H, brs),









6.57-6.61 (2H, m),









6.80-6.84 (3H, m),









7.03 (1H, s), 7.08









(1H, s), 7.21 (1H,









s)


1100
Me
H
Me
CH2CH2C(CH3)3
0
(APCI)+:
0.88 (9H, s), 1.38-








[M + H]+ =
1.45 (2H, m),








557.5
1.67-1.83 (4H, m),









1.94-2.23 (2H, m),









2.07 (3H, s), 2.19









(3H, s), 2.35-2.44









(2H, m), 2.93-3.15









(3H, m), 3.74 (3H,









s), 3.93 (1H, d,









J = 14.6 Hz), 4.19-









4.25 (2H, m), 5.83









(1H, d, J = 14.6 Hz)









6.19 (1H, brs),









6.45-6.55 (3H, m),









6.77-6.83 (3H, m),









7.06 (1H, s), 7.19









(1H, s)























embedded image














Compound




number
MS

1H NMR: δ (ppm)






1101
(ESI)+:
1.41(9H, s), 3.13-3.30(2H, m), 3.73



[M + H]+ =
(2H, s), 3.80-4.15 (6H, m), 4.18-4.34



569.2
(2H, m), 5.77 (1H, m), 6.58 (2H, s),




6.73-6.87 (2H, m), 6.87-6.99 (1H,




m), 7.08 (1H, s), 7.19 (1H, s), 7.82




(1H, s)





















embedded image


















Com-








pound








number
R1
R8
R9
R10
MS

1H NMR: δ (ppm)






1102
Me
Me
H
H
(ESI)+:
0.89 (9H, s), 1.46-1.56 (2H,







[M + H]+ =
m), 1.78-2.06 (7H, m),







557.6
2.20-2.62 (8H, m), 3.10-








3.20 (2H, m), 3.88 (3H, s),








3.95 (1H, d, J = 14.6 Hz),








4.22 (2H, m), 5.90 (1H, d,








J = 14.6 Hz), 6.28-6.40 (1H,








m), 6.55-6.68 (2H, m),








6.79-6.88 (2H, m), 6.90-








7.04 (2H, m), 7.25 (1H, s)


1103
Me
H
Me
H
(ESI)+:
0.88 (9H, s), 1.36-1.46 (2H,







[M + H]+ =
m), 1.68-1.90 (4H, m), 2.03







557.4
(3H, s), 2.12 (3H, s), 2.26-








2.43 (4H, m), 2.95-3.05








(2H, m), 3.65-3.75 (1H, m),








3.78 (3H, s), 3.95 (1H, d,








J = 14.7 Hz), 4.25-4.35 (2H,








m), 5.86 (1H, d, J = 14.7 Hz),








6.02-6.12 (1H, m), 6.51








(1H, s), 6.82 (1H, s), 6.82-








6.94 (4H, m), 7.12 (1H, s)


1104
F
Me
H
H
(ESI)+:
0.91 (9H, s), 1.79-2.00 (2H,







[M + H]+ =
m), 2.10-2.34 (1H, m), 2.42







561.4
(3H, s), 2.50-2.73 (1H, m),








2.83-2.97 (2H, m), 2.98-








3.12 (3H, m), 3.13-3.33








(1H, m), 3.35-3.52 (1H, m),








3.53-3.70 (2H, m), 3.85








(3H, s), 3.95 (1H, d,








J = 14.6 Hz), 4.14-4.42 (2H,








m), 5.81 (1H, d, J = 14.6 Hz),








6.08 (1H, s), 6.40-6.70 (2H,








m), 6.72-7.06 (4H, m), 7.43








(1H, s)





















embedded image
















Compound






number
b
R11
MS

1H NMR: δ (ppm)






1105
3
Me
585.4
0.88 (9H, s), 0.97 (3H, t, J = 7.3 Hz), 1.03-1.05






(4H, m), 1.07-1.95 (6H, m), 2.00-2.25 (5H, m),






2.35-2.50 (2H, m), 3.00-3.12 (3H, m), 3.97






(1H, d, J = 14.6 Hz), 4.06 (2H, t, J = 6.8






Hz), 4.26 (2H, d, J = 4.7 Hz) 5.90 (1H, d,






J = 14.6 Hz) 5.95-6.05 (1H, m) 6.24,






(1H, s), 6.67-6.73 (2H, m), 6.80-6.98 (3H,






m), 7.05-7.15 (2H, m)


1106
1
Me
557.4
0.87 (9H, s), 1.36-1.52 (5H, m),






1.68-1.90 (4H, m), 1.92-2.16 (6H,






m), 2.32-2.42 (2H, m), 2.96-3.06






(2H, m), 3.97 (1H, d, J = 14.5 Hz),






4.09 (2H, q, J = 7.0 Hz), 4.46 (2H, d,






J = 4.9 Hz), 5.80-5.90 (1H, m), 5.90






(1H, d, J = 14.5 Hz), 6.63-6.74 (2H,






m), 6.79-7.00 (3H, m), 7.02-7.12






(2H, m), 7.13 (1H, s), 7.24 (1H, s)





















embedded image


















Compound








number
R1
R3
R8
n
MS

1H NMR: δ (ppm)






1107 E 91
Me
H
H
1
(APCI)+: [M + H]+ = 473.5
d4-MeOH 1.35-1.54 (3H, m), 1.89 (2H, d, J = 13.6 Hz), 1.92- 2.11 (1H, m), 2.18 (3H, s), 2.18-2.24 (1H, m), 2.92-3.02 (2H, m), 3.29-3.39 (2H, m), 3.99-4.04 (1H, m), 4.04 (3H, s), 4.27 (2H, s), 5.88 (1H, d, J = 14.6 Hz), 6.84-6.86 (2H, m), 6.98-7.07 (3H, m), 7.20-7.27 (1H, m), 7.40 (1H, d, J = 8.2 Hz), 8.03 (1H, s)


1108
H
Me
Cl
2
(APCI)+: [M + H]+ = 521.6, 523.5
d4-MeOH 1.28-1.41 (1H, m), 1.42-1.67 (2H, m), 1.85-1.91 (2H, m), 2.20-2.33 (2H, m), 2.27 (3H, s), 2.78-2.94 (1H, m), 3.27-3.39 (5H, m), 3.79 (3H, s), 3.99 (1H, d, J = 14.6 Hz), 4.22 (2H, s), 5.71 (1H, d, J = 14.6 Hz), 6.53-6.61 (1H, m), 6.74-6.81 (1H, m), 6.83-6.94 (2H, m), 7.00-7.04 (1H, m), 7.22-7.25 (2H, m)


1109
Cl
H
H
0
(APCI)+: [M + H]+ = 479.4, 481.4
d4-MeOH 1.78-2.07 (2H, m), 2.52-2.71 (1H, m), 2.96-3.12 (2H, m), 3.19-3.32 (2H, m), 3.35-3.43 (2H, m), 4.04 (1H, d, J = 14.6 Hz), 4.05 (3H, s), 4.35 (2H, s), 5.87 (1H, d, J = 14.6 Hz), 6.86-6.90 (2H, m), 7.11-7.19 (2H, m), 7.22-7.28 (2H, m), 7.42-7.45 (1H, m), 8.05 (1H, s)


1110
F
H
Me
1
(ESI)+: [M + H]+ = 491.6
d4-MeOH 1.34-1.53 (2H, m), 1.85-1.91 (2H, m), 1.93-2.17 (1H, m), 2.20-2.23 (2H, m), 2.28 (3H, s), 2.91-3.02 (2H, m), 3.30-3.38 (2H, m), 3.99 (1H, d, J = 14.6 Hz), 4.02 (3H, s), 4.32 (2H, s), 5.84 (1H, d, J = 14.6 Hz), 6.67-6.78 (2H, m), 6.95-7.03 (2H, m), 7.12-7.23 (2H, m), 8.01 (1H, s)


1111
Me
H
H
2
(APCI)+: [M + H]+ = 487.4
d4-MeOH: 1.29-1.48 (2H, m), 1.50-1.64 (3H, m), 1.82-1.98 (2H, m), 2.18 (3H, s), 2.18-2.31 (2H, m), 2.85-2.99 (2H, m), 3.30-3.38 (2H, m), 3.94-4.05 (1H, m), 4.05 (3H, s), 4.26 (2H, s), 5.88 (1H, d, J = 14.6 Hz), 6.85 (2H, s), 7.00-7.09 (3H, m), 7.19-7.28 (1H, m), 7.40-7.43 (1H, m), 8.04 (1H, s)





















embedded image














Compound




number
MS

1H NMR: δ (ppm)






1112
(ESI)+: [M + H]+ = 469.2, 471.2
d4-MeOH 3.57-3.72 (1H, m), 3.98 (3H, s), 4.04 (1H, d, J = 15.3 Hz), 4.17 (4H, d, J = 8.2 Hz), 4.36-4.42 (2H, m), 5.83 (1H, d, J = 15.3 Hz), 6.82-6.92 (2H, m), 6.96-7.08 (2H, m), 7.18- 7.32 (1H, m), 7.41 (1H, s), 7.92 (1H, s), 8.56-8.64





















embedded image



















Com-









pound









number
R1
R3
R8
R13
n
MS

1H NMR: δ (ppm)






1113 E92
Me
H
H
CH2CH2C(CH3)3
1
(APCI)+: [M + H]+ = 557.5
0.86 (9H, s), 1.11-1.29 (2H, m), 1.34- 1.41 (2H, m), 1.58-1.64 (2H, m), 1.65- 1.86 (1H, m), 1.89-2.01 (2H, m), 2.04 (3H, s), 2.29-2.36 (2H, m), 2.80-2.91 (4H, m), 3.64 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.19 (2H, d, J = 4.0 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.51- 6.68 (3H, m), 6.75-6.81 (2H, m), 6.91- 7.02 (3H, m), 7.10-7.17 (2H, m)


1114
Me
H
H
CH2CH2C(CH3)3
2
(APCI)+: [M + H]+ = 571.5
0.87 (9H, s), 1.13-1.28 (3H, m), 1.34- 1.40 (2H, m), 1.43-1.68 (4H, m), 1.78- 1.89 (2H, m), 2.06 (3H, s), 2.15 (2H, t, J = 7.4 Hz), 2.23-2.30 (2H, m), 2.88 (2H, d, J = 10.9 Hz), 3.66 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.22 (2H, d, J = 5.2 Hz), 5.87 (1H, d, J = 14.6 Hz), 6.08 (1H, t, J = 5.2 Hz), 6.61-6.68 (2H, m), 6.76-6.87 (3H, m), 6.95-7.05 (2H, m), 7.07 (1H, s), 7.20 (1H, s)


1115
Me
H
H
CH2CH2C(CH3)3
0
(ESI)+: [M + H]+ = 543.4
0.88 (9H, s), 1.35-1.42 (2H, m), 1.57- 2.00 (6H, m), 2.12 (3H, s), 2.29-2.32 (2H, m), 2.92-3.03 (2H, m), 3.14-3.15 (1H, m), 3.80 (3H, s), 3.97 (1H, d, J = 14.6 Hz), 4.28 (2H, d, J = 5.2 Hz), 5.58-5.72 (1H, m), 5.90 (1H, d, J = 14.6 Hz), 6.11 (1H, s), 6.70 (2H, d, J = 4.2 Hz), 6.82-6.96 (3H, m), 7.03- 7.14 (1H, m), 7.14 (1H, s)





1116
Me
H
H


embedded image


0
(ESI)+: [M + H]+ = 513.3
0.12-0.14 (2H, m), 0.53-0.56 (2H, m), 0.78-0.97 (1H, m), 1.48-2.01 (6H, m), 2.17 (3H, s), 2.18-2.24 (2H, m), 2.32 (2H, d, J = 6.7 Hz), 3.12-3.16 (2H, m), 3.80 (3H, s), 3.96 (1H, d, J = 15.1 Hz) 5.88 (1H, d, J = 15.1 Hz), 6.05- 6.18 (1H, m), 6.42-6.43 (1H, m), 6.68 (2H, d, J = 4.0 Hz), 6.80-6.89 (2H, m), 6.97-7.02 (1H, m), 7.03-7.13 (2H, m)





















embedded image














Compound




number
R13
MS





1117 E93
CH2CH2CH3
(ESI)+: [M + H]+ = 521.4





1118


embedded image


(ESI)+: [M + H]+ = 569.3





1119


embedded image


(ESI)+: [M + H]+ = 583.4





1120


embedded image


(ESI)+: [M + H]+ = 603.3





1121


embedded image


(ESI)+: [M + H]+ = 603.4





1122
CH2CH2CH2CH2CH3
(ESI)+: [M + H]+ = 549.4





1123


embedded image


(ESI)+: [M + H]+ = 597.4





1124
CH2CH2CH(CH3)2
(ESI)+: [M + H]+ = 549.4


1125
CH2C(CH3)3
(ESI)+: [M + H]+ = 549.4





1126


embedded image


(ESI)+: [M + H]+ = 589.4





1127


embedded image


(ESI)+: [M + H]+ = 570.3





1128


embedded image


(ESI)+: [M + H]+ = 575.3





1129


embedded image


(ESI)+: [M + H]+ = 573.4





1130


embedded image


(ESI)+: [M + H]+ = 583.3





1131


embedded image


(ESI)+: [M + H]+ = 583.4





1132


embedded image


(ESI)+: [M + H]+ = 583.4





1133


embedded image


(ESI)+: [M + H]+ = 594.4





1134


embedded image


(ESI)+: [M + H]+ = 594.4





1135


embedded image


(ESI)+: [M + H]+ = 594.2





1136


embedded image


(ESI)+: [M + H]+ = 659.4





1137


embedded image


(ESI)+: [M + H]+ = 659.5





















embedded image

















Compound







number
R1
R8
R13
n
MS





1138 E94
F
Me
CH2(CH2)4CH3
1
(ESI)+: [M + H]+ = 575.7


1139
Cl
H
CH2(CH2)4CH3
0
(ESI)+: [M + H]+ = 563.3


1140
Cl
H
CH2(CH2)2CH3
0
(ESI)+: [M + H]+ = 535.3


1141
Cl
H
CH2(CH2)3OH
0
(ESI)+: [M + H]+ = 551.3


1142
Cl
H
CH2(CH2)2CN
0
(ESI)+: [M + H]+ = 546.3





1143
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 597.3





1144
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 589.3





1145
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 587.3





1146
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 625.4





1147
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 653.3





1148
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 627.3





1149
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 575.3





1150
Cl
H
CH2CO2CH(CH3)2
0
(ESI)+: [M + H]+ = 579.3


1151
Cl
H
CH2CH2CN
0
(ESI)+: [M + H]+ = 532.2


1152
Cl
H
CH2CH2CH2OH
0
(ESI)+: [M + H]+ = 537.3


1153
Cl
H
CH2CN
0
(ESI)+: [M + H]+ = 518.2





1154
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 614.3





1155
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 619.3





1156
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 519.2





1157
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 595.3





1158
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 645.4





1159
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 577.3


1160
Cl
H
CH2COC(CH3)3
0
(ESI)+: [M + H]+ = 577.3


1161
Cl
H
CH2CONH2
0
(ESI)+: [M + H]+ = 536.2





1162
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 604.3





1163
Cl
H


embedded image


0
(ESI)+: [M + H]+ = 611.3





1164
F
Me
CH2(CH2)2CH3
1
(ESI)+: [M + H]+ = 547.6


1165
F
Me
CH2(CH2)3OH
1
(ESI)+: [M + H]+ = 563.7


1166
F
Me
CH2(CH2)2CN
1
(ESI)+: [M + H]+ = 558.8





1167
F
Me


embedded image


1
(ESI)+: [M + H]+ = 609.8





1168
F
Me


embedded image


1
(ESI)+: [M + H]+ = 601.8





1169
F
Me


embedded image


1
(ESI)+: [M + H]+ = 599.7





1170
F
Me


embedded image


1
(ESI)+: [M + H]+ = 637.9





1171
F
Me


embedded image


1
(ESI)+: [M + H]+ = 665.7





1172
F
Me


embedded image


1
(ESI)+: [M + H]+ = 639.8





1173
F
Me


embedded image


1
(ESI)+: [M + H]+ = 581.7





1174
F
Me


embedded image


1
(ESI)+: [M + H]+ = 587.8


1175
F
Me
CH2CO2CH(CH3)2
1
(ESI)+: [M + H]+ = 591.7


1176
F
Me
CH2CH2CH(CH3)2
1
(ESI)+: [M + H]+ = 561.6


1177
F
Me
CH2CH2CH2OH
1
(ESI)+: [M + H]+ = 549.6


1178
F
Me
CH2CH2OCH2CH3
1
(ESI)+: [M + H]+ = 563.5


1179
F
Me
CH2CH2CH2F
1
(ESI)+: [M + H]+ = 551.5





1180
F
Me


embedded image


1
(ESI)+: [M + H]+ = 626.8





1181
F
Me


embedded image


1
(ESI)+: [M + H]+ = 545.6





1182
F
Me


embedded image


1
(ESI)+: [M + H]+ = 631.8





1183
F
Me


embedded image


1
(ESI)+: [M + H]+ = 607.7





1184
F
Me


embedded image


1
(ESI)+: [M + H]+ = 657.7





1185
F
Me


embedded image


1
(ESI)+: [M + H]+ = 589.7





1186
F
Me


embedded image


1
(ESI)+: [M + H]+ = 606.8





1187
F
Me
CH2COC(CH3)3
1
(ESI)+: [M + H]+ = 589.7


1188
F
Me
CH2CONH2
1
(ESI)+: [M + H]+ = 548.5





1189
F
Me


embedded image


1
(ESI)+: [M + H]+ = 616.7





1190
F
Me


embedded image


1
(ESI)+: [M + H]+ = 623.6





















embedded image














Compound number
R16
MS





1191 E95
CH2CH3
(ESI)+: [M + H]+ = 577.4





1192


embedded image


(ESI)+: [M + H]+ = 660.7





1193


embedded image


(ESI)+: [M + H]+ = 660.4





1194


embedded image


(ESI)+: [M + H]+ = 659.5





1195


embedded image


(ESI)+: [M + H]+ = 655.5





1196


embedded image


(ESI)+: [M + H]+ = 660.6





1197


embedded image


(ESI)+: [M + H]+ = 626.3





1198


embedded image


(ESI)+: [M + H]+ = 631.4





1199


embedded image


(ESI)+: [M + H]+ = 643.3





1200
CH2CH2CH3
(ESI)+: [M + H]+ = 591.3





1201


embedded image


(ESI)+: [M + H]+ = 589.4





1202
C(CH3)3
(ESI)+: [M + H]+ = 605.2


1203
CH2(CH2)3CH3
(ESI)+: [M + H]+ = 619.3


1204
CH(CH2CH3)CH2CH2CH2CH3
(ESI)+: [M + H]+ = 648.7





1205


embedded image


(ESI)+: [M + H]+ = 639.4





1206


embedded image


(ESI)+: [M + H]+ = 665.5





1207


embedded image


(ESI)+: [M + H]+ = 645.3





1208


embedded image


(ESI)+: [M + H]+ = 655.4





1209
CH2CH2CH2CO2CH2CH3
(ESI)+: [M + H]+ = 663.5





















embedded image














Compound




number
R16
MS





1210 E96
CH2CH3






1211


embedded image


(ESI)+: [M + H]+ = 661.2





1212


embedded image


(ESI)+: [M + H]+ = 686.2





1213


embedded image


(ESI)+: [M + H]+ = 729.3





1214


embedded image


(ESI)+: [M + H]+ = 718.4





1215


embedded image


(ESI)+: [M + H]+ = 701.2





1216


embedded image


(ESI)+: [M + H]+ = 776.4





1217
CH2CH2CH2CH3
(ESI)+: [M + H]+ = 641.4





















embedded image














Compound




number
R16
MS





1218 E97


embedded image








1219


embedded image


(ESI)+: [M + H]+ = 689.4, 691.4





1220


embedded image


(ESI)+: [M + H]+ = 703.6, 705.6





1221


embedded image


(ESI)+: [M + H]+ = 686.3, 688.3





1222


embedded image


(ESI)+: [M + H]+ = 605.4, 607.4





1223


embedded image


(ESI)+: [M + H]+ = 671.3





1224


embedded image


(ESI)+: [M + H]+ = 603.4, 605.4





1225


embedded image


(ESI)+: [M + H]+ = 641.5





1226


embedded image


(ESI)+: [M + H]+ = 675.4, 677.4





1227


embedded image


(ESI)+: [M + H]+ = 655.5, 657.5





1228


embedded image


(ESI)+: [M + H]+ = 621.3, 623.3





1229


embedded image


(ESI)+: [M + H]+ = 593.4





1230


embedded image


(ESI)+: [M + H]+ = 725.4,





1231
CH3
(ESI)+: [M + H]+ = 579.4, 581.4





1232


embedded image


(ESI)+: [M + H]+ = 591.1





1233


embedded image


(ESI)+: [M + H]+ = 699.5, 701.5





















embedded image


















Compound number
R1
R3
R4
R8
MS

1H NMR: δ (ppm)






1234 E98
F
H
CH2CH2CH3
Me
(APCI)+: [M + H]+ = 472.4
0.96 (3H, t, J = 7.4 Hz), 1.65-1.78 (2H, m), 2.21 (3H, s), 2.83 (2H, t, J = 7.7 Hz), 3.75 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.21 (2H, d, J = 6.2 Hz), 4.90 (1H, brs), 5.83 (1H, d, J = 14.6 Hz), 6.24 (1H, s), 6.48-6.58 (2H, m), 6.77 (1H, s), 6.93-7.02 (2H, m), 7.06- 7.12 (1H, m), 7.21 (1H, s)


1235
Cl
H
CH2CH2CH3
Cl
(APCI)+: [M + H]+ = 508.3
0.97 (3H, t, J = 7.4 Hz), 1.68- 1.83 (2H, m), 2.86 (2H, t, J = 7.4 Hz), 3.69 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.26 (2H, d, J = 6.4 Hz), 5.56 (1H, t, J = 6.4 Hz), 5.80 (1H, d, J = 14.6 Hz), 6.58-6.62 (2H, m), 6.94 (1H, dd, J = 1.5, 7.9 Hz), 7.04 (1H, s), 7.09 (1H, s), 7.16-7.20 (2H, m), 7.33 (1H, d, J = 1.5 Hz)


1236
F
H
CH2CH2CH3
Cl
(APCI)+: [M + H]+ = 492.3, 494.3
0.97 (3H, t, J = 7.4 Hz), 1.68-1.79 (2H, m), 2.85, (2H, t, J = 7.4 Hz), 3.77 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.25 (2H, d, J = 6.2 Hz), 4.80 (1H, t, J = 6.2 Hz), 5.84 (1H, d, J = 14.6 Hz), 6.38 (1H, s), 6.60-6.66 (2H, m), 6.94-7.03 (3H, m), 7.17-7.24 (2H, m)





















embedded image


















Compound








number
R1
R3
R4
R8
MS

1H NMR: δ (ppm)






1237 E99
F
H
H
Me
(ESI)+: [M + H]+ = 394.2
2.20 (3H, s), 3.75 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.30-4.40 (2H, m), 5.82 (1H, d, J = 14.6 Hz), 6.31- 6.42 (1H, m), 6.46 (1H, s), 6.47-6.59 (2H, m), 6.78 (1H, s), 6.88-7.03 (3H, m), 7.21 (1H, s), 8.16 (1H, s)


1238
Cl
H
H
Cl
(ESI)+: [M + H]+ = 430.2
3.69 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.40-4.55 (2H, m), 5.83 (1H, d, J = 14.6 Hz), 6.28-6.41 (1H, m), 6.56- 6.68 (2H, m), 6.78 (1H, s), 6.90-7.14 (3H, m), 7.23 (1H, s), 7.30 (1H, s), 8.20 (1H, s)


1239
F
H
H
Cl
(ESI)+: [M + H]+ = 414.2, 416.2
3.72 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.33-4.40 (2H, m), 5.81 (1H, d, J = 14.6 Hz), 6.52-6.56 (1H, m), 6.61 (2H, s), 6.87-6.94 (2H, m), 7.01-7.07 (2H, m), 7.13 (1H, s), 7.21 (1H, s), 8.16 (1H, s)





















embedded image


















Compound number
R1
R3
R4
R8
MS

1H NMR: δ (ppm)






1240 E100
F
H


embedded image


Me
(APCI)+: [M + H]+ = 434.2
0.65-0.69 (2H, m), 0.85-0.88 (2H, m), 1.37-1.43 (1H, m), 2.08 (3H, s), 3.64 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.28-4.31 (2H, m), 5.81 (1H, d, J = 14.6 Hz), 6.46 (1H, d, J = 8.4 Hz), 6.53 (1H, d, J = 7.9 Hz), 6.78-6.96 (4H, m), 7.15 (1H, s), 7.17 (1H, s)





1241 E101
Me
H


embedded image


Me
(ESI)+: [M + H]+ = 430.4
0.62-0.71 (2H, m), 0.81-0.89 (2H, m), 1.39-1.50 (1H, m), 2.04 (3H, s), 2.12 (3H, s), 3.66 (3H, s), 3.91 (1H, d, J = 14.6 Hz), 4.22 (2H, d, J = 2.0 Hz), 5.82 (1H, d, J = 14.6 Hz), 6.46 (2H, q, J = 7.9 Hz), 6.68-6.87 (4H, m), 7.06 (2H, s)





1242 E102
F
H


embedded image


Cl
(APCI)+: [M + H]+ = 454.2, 456.2
0.62-0.80 (2H, m), 0.88-1.00 (2H, m), 1.31-1.47 (1H, m), 3.69 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.35 (2H, d, J = 5.4 Hz), 5.82 (1H, d, J = 14.6 Hz), 6.51 (1H, t, J = 5.4 Hz), 6.61 (2H, s), 6.82- 7.08 (4H, m), 7.17 (1H, s), 7.21 (1H, s)





1243 E103
F
H
CH2CH3
Cl
(ESI)+: [M + H]+ = 442.1, 444.2
1.12 (3H, t, J = 7.7 Hz), 2.21 (2H, q, J = 7.7 Hz), 3.76 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.37 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 5.94 (1H, t, J = 5.7 Hz), 6.58-6.67 (3H, m), 6.89-7.00 (3H, m), 7.07 (1H, t, J = 7.4 Hz), 7.23 (1H, s)


1244 E104
F
H
CH2CH2CH3
Cl
(APCI)+: [M + H]+ = 456.3, 458.3
0.88 (3H, t, J = 7.4 Hz), 1.56-1.69 (2H, m), 2.15 (2H, t, J = 7.2 Hz), 3.71 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.35 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.23 (1H, t, J = 5.7 Hz), 6.59-6.64 (2H, m), 6.87-6.94 (2H, m), 7.01-7.06 (2H, m), 7.19 (1H, s), 7.22 (1H, s)


1245 E105
F
H
CH(CH3)2
Cl
(APCI)+: [M + H]+ = 456.3, 458.2
1.11 (6H, d, J = 6.9 Hz), 2.29-2.42 (1H, m), 3.73 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.35 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.06 (1H, t, J = 5.7 Hz), 6.60-6.63 (2H, m), 6.88-7.08 (5H, m), 7.22 (1H, s)





1246 E106
Cl
H


embedded image


Cl
(APCI)+: [M + H]+ = 470.2
0.71-0.74 (2H, m), 0.90- 0.91 (2H, m), 1.40-1.43 (1H, m), 3.67 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.38 (2H, d, J = 5.4 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.56 (3H, m), 6.90-7.04 (4H, m), 7.21 (1H, s), 7.26 (1H, s)





1247 E107
Cl
H
CH2CH2CH3
Cl
(APCI)+: [M + H]+ = 472.3
0.87 (3H, t, J = 7.4 Hz), 1.60-1.65 (2H, m), 2.16 (2H, t, J = 7.7 Hz), 3.67 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.36 (2H, t, J = 3.5 Hz), 5.79 (1H, d, J = 14.6 Hz), 6.59 (2H, s), 6.91 (1H, d, J = 7.7 Hz), 6.98 (1H, d, J = 7.7 Hz), 7.03 (2H, s), 7.20 (1H, s), 7.23 (1H, s), 7.60 (1H, s)


1248 E108
Cl
H
CH(CH3)2
Cl
(APCI)+: [M + H]+ = 472.3
1.09-1.13 (6H, m), 2.30- 2.50 (1H, m), 3.70 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.37 (2H, d, J = 4.0 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.25 (1H, t, J = 5.9 Hz), 6.60 (2H, s), 6.85-7.04 (3H, m), 7.22 (1H, s), 7.26 (2H, s)


1249
Me
H
CH(CH3)2
Cl
(ESI)+: [M + H]+ = 452.2, 454.2
1.14 (6H, d, J = 6.7 Hz), 2.14 (3H, s), 2.27-2.42 (1H, m), 3.74 (3H, s), 3.94 (1H, d, J = 14.5 Hz), 4.30 (2H, d, J = 5.2 Hz), 5.70 (1H, s), 5.87 (1H, d, J = 14.5 Hz), 6.57-6.67, (3H, m), 6.88 (2H, s), 6.98 (2H, s), 7.13 (1H, s)


1250
Me
H
CH2CH2CH3
Cl
(ESI)+: [M + H]+ = 452.2, 454.2
0.92 (3H, t, J = 7.3 Hz), 1.64 (2H, q, J = 7.3 Hz), 2.12-2.24 (5H, m), 3.75 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.32 (2H, d, J = 5.0 Hz), 5.64 (1H, s), 5.87 (1H, d, J = 14.6 Hz), 6.40 (1H, s), 6.62 (2H, s), 6.89 (2H, s), 6.97 (2H, s), 7.14 (1H, s)


1251
Me
H
CH2CH3
Cl
(ESI)+: [M + H]+ = 438.2, 440.2
1.14 (3H, t, J = 7.3 Hz), 2.15 (3H, s), 2.23 (2H, q, J = 7.3 Hz), 3.74 (3H, s), 3.93 (1H, d, J = 14.9 Hz), 4.31 (2H, d, J = 5.2 Hz), 5.71 (1H, s), 5.87 (1H, d, J = 14.9 Hz), 6.55 (1H, s), 6.62 (2H, s), 6.88 (2H, s), 6.98 (2H, s), 7.13 (1H, s)


1252
Me
H
CH2CH2CH3
Me
(ESI)+: [M + H]+ = 433.2
0.91 (3H, t, J = 7.4 Hz), 1.65 (2H, q, J = 7.4 Hz), 2.13 (3H, s), 2.11-2.30 (2H, m), 2.21 (3H, s), 3.76 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.29 (2H, d, J = 5.2 Hz), 5.55-5.70 (1H, m), 5.87 (1H, d, J = 14.6 Hz), 6.09 (1H, s), 6.52 (2H, q, J = 7.7 Hz), 6.74 (1H, s), 6.80-6.93 (2H, m), 7.14 (1H, s), 7.23 (1H, s)


1253
Me
H
CH(CH3)2
Me
(ESI)+: [M + H]+ = 433.2
1.12 (6H, d, J = 6.7 Hz), 2.13 (3H, s), 2.21 (3H, s), 2.25-2.42 (1H, m), 3.76 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.29 (2H, d, J = 5.4 Hz), 5.55-5.70 (1H, m), 5.88 (1H, d, J = 14.6 Hz), 6.10 (1H, s), 6.52 (2H, q, J = 7.9 Hz), 6.74 (1H, s), 6.75-6.93 (2H, m), 7.14 (1H, s), 7.23 (1H, s)


1254
Me
H
CH2CH3
Me
(ESI)+: [M + H]+ = 418.2
1.13 (3H, t, J = 7.4 Hz), 2.12 (3H, s), 2.18-2.28 (5H, m), 3.76 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.29 (2H, d, J = 5.2 Hz), 5.57- 5.70 (1H, m), 5.87 (1H, d, J = 14.6 Hz), 6.07 (1H, s), 6.52 (2H, q, J = 7.9 Hz), 6.74 (1H, s), 6.80-6.92 (2H, m), 7.14 (1H, s), 7.23 (1H, s)


1255
Me
H
CH2CH3
F
(APCI)+: [M + H]+ = 422.4
1.13 (3H, t, J = 7.4 Hz), 2.12 (3H, s), 2.20 (2H, q, J = 7.4 Hz), 3.70 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.28 (1H, d, J = 5.2 Hz), 5.83 (1H, s), 5.85 (1H, d, J = 14.6 Hz), 6.33-6.39 (1H, m), 6.61-6.70 (2H, m), 6.77-6.86 (3H, m), 7.10 (1H, s), 7.23 (1H, s)


1256
Me
H
CH2CH2CH3
F
(APCI)+: [M + H]+ = 436.4
0.91 (3H, t, J = 7.4 Hz), 1.59-1.68 (2H, m), 2.10- 2.20 (5H, m), 3.71 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.29 (2H, d, J = 5.2 Hz), 5.79 (1H, s), 5.86 (1H, d, J = 14.6 Hz), 6.33-6.42 (1H, m), 6.61-6.72 (3H, m), 6.83-6.88 (2H, m), 7.11 (1H, s), 7.23 (1H, s)


1257
Me
H
CH(CH3)2
F
(APCI)+: [M + H]+ = 436.4
1.12 (6H, d, J = 6.4 Hz), 2.12 (3H, s), 2.30-2.41 (1H, m), 3.71 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.28 (2H, d, J = 5.2 Hz), 5.75 (1H, s), 5.86 (1H, d, J = 14.6 Hz), 6.33-6.39 (1H, m), 6.62-6.73 (3H, m), 6.80-6.92 (2H, m), 7.10 (1H, s), 7.23 (1H, s)





1258
Me
H


embedded image


F
(APCI)+: [M + H]+ = 434.4
0.71-0.74 (2H, m), 0.91- 0.96 (2H, m), 1.35-1.37 (1H, m), 2.13 (3H, s), 3.70 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.30 (2H, d, J = 5.2 Hz), 5.86 (1H, d, J = 14.6 Hz), 5.99 (1H, s), 6.34-6.40 (1H, m), 6.62- 6.70 (3H, m), 6.83-6.91 (2H, m), 7.11 (1H, s)





1259
F
H


embedded image


F
(APCI)+: [M + H]+ = 438.4
0.71-0.75 (2H, m), 0.91- 0.95 (2H, m), 1.31-1.37 (1H, m), 3.74 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.38 (2H, d, J = 5.7 Hz), 5.84 (1H, d, J = 14.6 Hz), 6.14 (1H, s), 6.37-6.43 (1H, m), 6.64-6.69 (3H, m), 6.89-6.95 (2H, m), 7.04- 7.10 (1H, m)





1260
F
H
CH(CH3)2
F
(APCI)+: [M + H]+ = 440.4
1.11 (6H, d, J = 6.7 Hz), 2.34 (1H, septet, J = 6.7 Hz), 3.76 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.36 (2H, d, J = 5.9 Hz), 5.84 (1H, d, J = 14.6 Hz), 5.87 (1H, s), 6.37-6.43 (1H, m), 6.51 (1H, s), 6.64-6.69 (2H, m), 6.91- 6.95 (2H, m), 7.04-7.10 (1H, m)


1261
F
H
CH2CH2CH3
F
(APCI)+: [M + H]+ = 440.4
0.88 (3H, t, J = 7.2 Hz), 1.58-1.66 (2H, m), 2.14 (2H, t, J = 7.4 Hz), 3.74 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.36 (2H, d, J = 5.2 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.01 (1H, s), 6.36-6.41 (1H, m), 6.63- 6.71 (2H, m), 6.79 (1H, s), 6.91-6.94 (2H, m), 7.03- 7.09 (1H, m)


1262
F
H
CH2CH3
F
(APCI)+: [M + H]+ = 426.4
1.12 (3H, t, J = 7.4 Hz), 2.20 (2H, q, J = 7.4 Hz), 3.76 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.37 (2H, d, J = 5.4 Hz), 5.83 (1H, d, J = 14.6 Hz), 5.87 (1H, s), 6.37-6.47 (2H, m), 6.64- 6.69 (2H, m), 6.92-6.95 (2H, m), 7.05-7.11 (1H, m)





1263
F
H


embedded image


Me
(APCI)+: [M + H]+ = 448.4
1.72-1.91 (3H, m), 2.05- 2.28 (4H, m), 2.92-3.06 (1H, m), 3.46 (2H, s), 3.72 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.31 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.05 (1H, t, J = 5.7 Hz), 6.47 (1H, d, J = 7.7 Hz), 6.54 (1H, d, J = 7.7 Hz), 6.68 (1H, s), 6.78 (1H, s), 6.82-7.00 (3H, m), 7.20 (1H, s)





1264
F
H


embedded image


Me
(APCI)+: [M + H]+ = 476.4
1.10-1.48 (5H, m), 1.60- 1.70 (1H, m), 1.70-1.84 (4H, m), 2.00-2.14 (1H, m), 2.19 (3H, s), 3.74 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.32 (2H, d, J = 5.9 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.03 (1H, t, J = 6.0 Hz), 6.44-6.59 (3H, m), 6.77 (1H, s), 6.88- 7.02 (3H, m), 7.21 (1H, s)





1265
F
H
CH2CH2CH3
Me
(APCI)+: [M + H]+ = 436.4
0.86 (3H, t, J = 7.4 Hz), 1.53-1.68 (2H, m), 2.13 (2H, q, J = 7.4 Hz), 2.17 (3H, s), 3.71 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.31 (2H, d, J = 5.4 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.29 (1H, t, J = 6.7 Hz), 6.47 (1H, d, J = 8.2 Hz), 6.55 (1H, d, J = 8.2 Hz), 6.76 (2H, d, J = 6.4 Hz), 6.87- 6.97 (3H, m), 7.20 (1H, s)


1266
F
H
Me
Me
(APCI)+: [M + H]+ = 408.4
1.92 (3H, s), 2.17 (3H, s), 3.70 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.29 (2H, d, J = 5.4 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.42-6.61 (3H, m), 6.85 (2H, d, J = 6.9 Hz), 6.87-7.00 (3H, m), 7.20 (1H, s)


1267
F
H
CH(CH3)2
Me
(APCI)+: [M + H]+ = 436.4
1.08-1.11 (6H, m), 2.16 (3H, s), 2.28-2.42 (1H, m), 3.71 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.31 (2H, d, J = 4.2 Hz), 5.82 (1H, d, J = 14.6 Hz), 6.23 (1H, t, J = 5.9 Hz), 6.47(1H, d, J = 7.9 Hz), 6.55 (1H, d, J = 7.9 Hz), 6.77 (2H, d, J = 2.5 Hz), 6.85-7.03 (3H, m), 7.20 (1H, s)


1268
F
H
C(CH3)3
Me
(APCI)+: [M + H]+ = 450.4
1.15 (9H, s), 2.16 (3H, s), 3.71 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.32 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.10-6.23 (1H, m), 6.46 (1H, d, J = 7.9 Hz), 6.55 (1H, d, J = 7.9 Hz), 6.68 (1H, s), 6.76 (1H, s), 6.85-7.05 (3H, m), 7.20 (1H, s)





1269
Cl
H


embedded image


Cl
(APCI)+: [M + H]+ = 484.3
1.78-2.04 (2H, m), 2.04- 2.32 (4H, m), 2.92-3.10 (1H, m), 3.73 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.39 (2H, d, J = 3.2 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.01 (1H, t, J = 5.7 Hz), 6.62 (2H, s), 6.85-7.10 (4H, m), 7.23 (1H, s), 7.27 (1H, s)





1270
Cl
H


embedded image


Cl
(APCI)+: [M + H]+ = 512.4
1.23 (2H, t, J = 7.2 Hz), 1.26-1.50 (3H, m), 1.59- 1.71 (1H, m), 1.71-1.83 (5H, m), 2.12-2.28 (1H, m), 3.79 (3H, s), 3.97 (1H, d, J = 14.6 Hz), 4.33 (2H, d, J = 1.5 Hz), 5.74 (1H, d, J = 14.6 Hz), 6.63-6.68 (2H, m), 7.08-7.13 (2H, m), 7.20 (1H, s), 7.21-7.23 (2H, m)





1271
Cl
H


embedded image


Cl
(APCI)+: [M + H]+ = 498.3
1.43-1.58 (1H, m), 1.58- 1.78 (5H, m), 1.58-1.90 (2H, m), 2.46-2.60 (1H, m), 3.72 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.30-4.50 (2H, m), 5.83 (1H, d, J = 14.6 Hz), 6.12 (1H, t, J = 5.9 Hz), 6.61 (2H, s), 6.84-7.11 (4H, m), 7.22 (1H, s), 7.27 (1H, s)





1272
Cl
H
Me
Cl
(APCI)+: [M + H]+ = 444.3
1.97 (3H, s), 3.67 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.33 (2H, t, J = 5.2 Hz), 5.79 (1H, d, J = 14.6 Hz), 6.59 (2H, s), 6.60-6.70 (1H, m), 6.90 (1H, d, J = 7.9 Hz), 6.97 (1H, d, J = 7.9 Hz), 7.04 (1H, s), 7.19 (1H, s), 7.23 (1H, s), 7.58 (1H, s)





1273
F
H


embedded image


Me
(APCI)+: [M + H]+ = 462.4
1.41-1.84 (8H, m), 2.13 (3H, s), 2.46-2.57 (1H, m), 3.67 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.28 (2H, d, J = 5.2 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.43-6.55 (3H, m), 6.79 (1H, s), 6.83- 6.96 (3H, m), 7.12 (1H, s), 7.17 (1H, s)


1274
F
H
CH2CH3
Me
(APCI)+: [M + H]+ = 422.4
1.08 (3H, t, J = 7.7 Hz), 2.15 (3H, s), 2.17 (2H, q, J = 7.7 Hz), 3.69 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.30 (2H, d, J = 5.2 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.38-6.57 (3H, m), 6.80- 6.98 (5H, m), 7.19 (1H, s)


1275
Cl
H
C(CH3)3
Cl
(APCI)+: [M + H]+ = 486.3
1.17 (9H, s), 3.72 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.38 (2H, d, J = 5.9 Hz), 5.82 (1H, d, J = 14.6 Hz), 6.21 (1H, t, J = 5.7 Hz), 6.61 (2H, s), 6.85-7.08 (4H, m), 7.22-7.27 (2H, m)


1276
Cl
H
CH2CH3
Cl
(APCI)+: [M + H]+ = 458.2
1.11 (3H, t, J = 7.7 Hz), 2.22 (2H, q, J = 7.7 Hz), 3.45 (1H, d, J = 5.2 Hz), 3.67 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.23-4.45 (2H, m), 5.80 (1H, d, J = 14.6 Hz), 6.53 (1H, t, J = 5.9 Hz), 6.59 (2H, s), 6.85-6.92 (1H, m), 6.98 (1H, s), 6.99-7.04 (1H, m), 7.20 (1H, s), 7.59 (1H, s)





1277
F
H


embedded image


Cl
(APCI)+: [M + H]+ = 496.3, 498.3
1.17-1.25 (2H, m), 1.25- 1.42 (2H, m), 1.65-1.81 (6H, m), 2.02-2.18 (1H, m), 3.73 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.34 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.08 (1H, t, J = 5.7 Hz), 6.59-6.64 (2H, m), 6.87-6.94 (2H, m), 7.00-7.04 (2H, m), 7.06 (1H, s), 7.22 (1H, s)





1278
F
H


embedded image


Cl
(APCI)+: [M + H]+ = 468.3, 470.3
1.80-2.02 (2H, m), 2.03- 2.31 (4H, m), 2.95-3.08 (1H, m), 3.71 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.34 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.06 (1H, t, J = 5.7 Hz), 6.59- 6.63 (2H, m), 6.87-6.94 (2H, m), 6.99-7.06 (2H, m), 7.22 (2H, s)





1279
F
H
Me
Cl
(APCI)+: [M + H]+ = 428.2, 430.2
1.96 (3H, s), 3.73 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.35 (2H, d, J = 5.7 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.23 (1H, t, J = 5.7 Hz), 6.58-6.66 (2H, m), 6.87- 7.05 (5H, m), 7.22 (1H, s)


1280
F
H
C(CH3)3
Cl
(APCI)+: [M + H]+ = 470.3, 472.3
1.16 (9H, s), 3.74 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.36 (2H, d, J = 5.7 Hz), 5.84 (1H, d, J = 14.6 Hz), 6.07 (1H, t, J = 5.7 Hz), 6.60-6.64 (2H, m), 6.79 (1H, s), 6.90-6.98 (3H, s), 7.02-7.08 (1H, m), 7.23 (1H, s)





1281
F
H


embedded image


Cl
(ESI)+: [M + H]+ = 482.2, 484.2
1.31-1.88 (8H, m), 2.48- 2.58 (1H, m), 3.72 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.34 (2H, d, J = 5.7 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.25 (1H, t, J = 5.7 Hz), 6.59 (2H, s), 6.87-6.93 (2H, m), 7.01 (1H, t, J = 7.4 Hz), 7.08 (1H, s), 7.21 (1H, s), 7.44 (1H, s)





1282
H
Cl


embedded image


Me
(APCI)+: [M + H]+ = 450.2, 452.3
0.70-0.74 (2H, m), 0.91- 0.94 (2H, m), 1.39 (1H, m), 2.13 (3H, s), 3.70 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.25 (2H, m), 5.79 (1H, d, J = 14.6 Hz), 6.32 (1H, s), 6.45-6.49 (2H, m), 6.65 (1H, s), 6.74-6.83 (3H, m), 7.04 (1H, s), 7.23 (1H, s)





1283
H
Me


embedded image


Cl
(APCI)+: [M + H]+ = 450.2, 452.2
0.68-0.73 (2H, m), 0.90- 0.94 (2H, m) 1.31-1.43 (1H, m), 2.25 (3H, s), 3.63 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.23 (2H, d, J = 5.6 Hz), 4.41 (1H, d, J = 5.6 Hz), 5.80 (1H, d, J = 14.6 Hz), 6.39-6.46 (1H, m), 6.56-7.23 (7H, m)





1284
H
Me


embedded image


Me
(APCI)+: [M + H]+ = 430.2
0.69-0.74 (2H, m), 0.93- 0.96 (2H, m), 1.28-1.36 (1H, m), 2.15 (3H, s), 2.31 (3H, s), 3.47 (2H, d, J = 5.6 Hz), 3.72 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.27 (1H, d, J = 5.6 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.11 (1H, s), 6.41-6.46 (1H, m), 6.58-6.91 (6H, m)





1285
H
Cl


embedded image


Cl
(APCI)+: [M + H]+ = 470.2
0.68-0.76 (2H, m), 0.88- 0.97 (2H, m), 1.42 (1H, m), 3.60 (3H, s), 3.98 (1H, d, J = 14.6 Hz), 4.19 (2H, m), 4.38 (1H, m), 5.73 (1H, d, J = 14.6 Hz), 6.52- 6.56 (1H, m), 6.71-7.18 (6H, m), 7.60 (1H, brs)





1286
H
F


embedded image


Cl
(APCI)+: [M + H]+ = 454.2, 456.3
0.69-0.75 (2H, m), 0.91- 0.94 (2H, m), 1.32-1.44 (1H, m), 3.66 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.28 (2H, d, J = 5.9 Hz), 5.80 (1H, d, J = 14.6 Hz), 6.51- 6.62 (2H, m), 6.69 (2H, t, J = 8.4, 18.3 Hz), 6.79 (1H, d, J = 6.4 Hz), 6.92 (2H, s), 6.98-7.09 (1H, m), 7.22 (1H, s)





1287
H
F


embedded image


Me
(APCI)+: [M + H]+ = 434.2
0.69-0.74 (2H, m), 0.91- 0.96 (2H, m), 1.31-1.42 (1H, m), 2.15 (3H, s), 3.69 (3H, s), 3.96 (1H, d, J = 14.6 Hz), 4.27 (2H, t, J = 5.7, 11.1 Hz), 5.81 (1H, d, J = 14.6 Hz), 6.32 (1H, s), 6.42-6.47 (2H, m), 6.62-6.79 (3H, m), 7.02 (1H, t, J = 7.4, 14.8 Hz), 7.21 (1H, s)





1288
Cl
H


embedded image


Me
(APCI)+: [M + H]+ = 450.3, 452.4
0.94 (2H, m), 1.37-1.46 (1H, m), 2.15 (3H, s), 3.68 (3H, s), 3.95 (1H, d, J = 14.6 Hz), 4.24-4.42 (2H, m), 5.81 (1H, d, J = 14.6 Hz), 6.47 (1H, d, J = 8.2 Hz), 6.54 (1H, d, J = 8.2 Hz), 6.74-6.79 (2H, m), 6.90-6.96 (2H, m), 7.19-7.23 (1H, m)





1289
Me
H


embedded image


Cl
(ESI)+: [M + H]+ = 450.3, 452.4
0.66-0.78 (2H, m), 0.82- 0.94 (2H, m), 1.34-1.46 (1H, m), 2.08 (3H, s), 3.63 (3H, s), 3.93 (1H, d, J = 14.6 Hz), 4.26 (2H, d, J = 4.0 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.47-6.62 (2H, m), 6.78-6.86 (2H, m), 7.01-7.08 (1H, m), 7.19 (1H, s), 7.39 (1H, s)





















embedded image



















Com-









pound









num-









ber
R1
R4
R8
R9
R10
MS

1H NMR: δ (ppm)






1290
Me
CH(CH3)2
Me
H
H
(ESI)+:
1.13 (6H, d, J = 6.5 Hz),








[M +
2.15 (3H, s), 2.26-








H]+ =
2.38 (1H, m), 2.39








433.2
(3H, s), 3.82 (3H, s),









3.95 (1H, d,









J = 14.6 Hz, 4.29 (2H,









d, J = 5.2 Hz), 5.43 (1H,









s), 5.77 (1H, s), 5.93









(1H, d, J = 14.6 Hz),









6.62 (2H, s), 6.87 (2H,









s), 6.96-7.06 (1H, m),









7.16 (1H, s), 7.25 (1H,









s)


1291
Me
CH2CH2CH3
Me
H
H
(ESI)+:
0.91 (3H, t, J = 7.2 Hz),








[M +
1.56-1.74 (2H, m),








H]+ =
2.09 (3H, s), 2.10-








433.2
2.20 (2H, m), 2.39









(3H, s), 3.81 (3H, s),









3.94 (1H, d,









J = 14.6 Hz), 4.25 (2H,









d, J = 4.7 Hz), 5.65 (1H,









s), 5.85-6.05 (2H, m),









6.60-6.63 (2H, m),









6.82 (2H, s), 7.00 (1H,









d, J = 5.7 Hz), 7.07 (1H,









s), 7.20 (1H, s)


1292
Me
CH2CH3
Me
H
H
(ESI)+:
1.34 (3H, t, J = 7.4 Hz),








[M +
2.12 (3H, s), 2.20 (2H,








H]+ =
q, J = 7.4 Hz), 2.39 (3H,








418.2
s), 3.82 (3H, s), 3.94









(1H, d, J = 14.7 Hz),









4.27 (2H, d, J = 5.2 Hz),









5.52 (1H, s), 5.85 (1H,









s) 5.92 (1H, d,









J = 14.7 Hz), 6.56-6.68









(2H, m), 6.86 (2H, s),









7.00 (1H, d, J = 5.7 Hz),









7.12 (1H, s), 7.25 (1H,









s)


1293
Me
CH(CH3)2
H
Me
H
(ESI)+:
1.08-1.24 (6H, m),








[M +
2.02 (3H, s), 2.13 (3H,








H]+ =
s), 2.26-2.44 (1H, m)








433.2
3.74 (3H, s), 3.94 (1H,









d, J = 14.4 Hz), 4.28









(2H, d, J = 5.2 Hz), 5.62









(1H, s), 5.88 (1H, d,









J = 14.4 Hz), 6.12 (1H,









s), 6.52 (1H, s), 6.78-









6.96 (4H, m), 7.14









(1H, s), 7.22 (1H, s)


1294
Me
CH2CH2CH3
H
Me
H
(ESI)+:
0.88-1.02 (3H, m),








[M +
2.02 (3H, s), 2.08-








H]+ =
2.22 (7H, m), 3.72








433.2
(3H, s), 3.93 (1H, d,









J = 14.5 Hz), 4.28 (2H,









d, J = 5.2 Hz), 5.73 (1H,









s), 5.86 (1H, d,









J = 14.5 Hz), 6.21 (1H,









s), 6.51 (1H, s), 6.79-









6.96 (4H, m), 7.12









(1H, s), 7.22 (1H, s)


1295
Me
CH2CH3
H
Me
H
(ESI)+:
1.12 (3H, t, J = 7.4 Hz),








[M +
2.02 (3H, s), 2.12 (3H,








H]+ =
s), 2.19 (2H, q,








418.2
J = 7.4 Hz), 3.73 (3H,









s), 3.94 (1H, d,









J = 14.4 Hz), 4.28 (2H,









d, J = 5.0 Hz), 5.68 (1H,









s), 5.87 (1H, d,









J = 14.4 Hz), 6.15 (1H,









s), 6.51 (1H, s), 6.78-









6.98 (4H, m), 7.13









(1H, s), 7.22 (1H, s)





1296
Me


embedded image


H
H
Me
(ESI)+: [M + H]+ = 430.1
0.69-0.79 (2H, m), 0.91-1.03 (2H, m), 1.32-1.41 (1H, m), 1.97 (3H, s), 2.07 (3H, s), 3.71 (3H, s), 3.86 (1H, d, J = 14.6 Hz), 4.26 (2H, d, J = 5.5 Hz), 5.89 (1H, d, J = 14.6 Hz), 5.99-6.08 (1H, m), 6.64 (1H, d, J = 7.4 Hz), 6.69-6.83 (2H, m), 6.90-7.03 (2H, m), 7.13 (1H, s), 7.23 (1H, s)





1297
Me
CH(CH3)2
H
H
Me
(ESI)+:
1.10-1.21 (6H, m),








[M +
1.99 (3H, s), 2.10 (3H,








H]+ =
s), 2.33-2.42 (1H, m),








432.2
3.76 (3H, s), 3.86 (1H,









d, J = 14.6 Hz), 4.27









(2H, d, J = 5.5 Hz), 5.61









(1H, s), 5.89 (1H, d,









J = 14.6 Hz), 6.65 (1H,









d, J = 7.4 Hz), 6.76-6.85









(2H, m), 6.94-7.04









(2H, m), 7.17 (1H, s),









7.22 (1H, s)


1298
Me
CH2CH2CH3
H
H
Me
(ESI)+:
0.87-0.99 (3H, m),








[M +
1.56-1.72 (2H, m),








H]+ =
1.98 (3H, s), 2.10 (3H,








432.2
s), 2.13-2.25 (2H, m),









3.76 (3H, s), 3.86 (1H,









d, J = 14.6 Hz), 4.27









(2H, d, J = 5.7 Hz), 5.66









(1H, s), 5.90 (1H, d,









J = 14.6 Hz), 6.65 (1H,









d, J = 7.4 Hz), 6.76-6.85









(3H, m), 6.94-7.04









(3H, m), 7.16 (1H, s)


1299
Me
CH2CH3
H
H
Me
(ESI)+:
1.09-1.22 (3H, m),








[M +
1.98 (3H, s), 2.08 (3H,








H]+ =
s), 2.14-2.29 (2H, m)








418.2
3.74 (3H, s), 3.86 (1H,









d, J = 14.6 Hz), 4.26









(2H, d, J = 5.5 Hz), 5.75









(1H, s), 5.89 (1H, d,









J = 14.6 Hz), 6.61-6.66









(1H, m), 6.74-6.83









(2H, m), 6.94-7.04









(2H, m), 7.15 (1H, s),









7.22 (1H, s)





1300
Me


embedded image


H
Me
H
(ESI)+: [M + H]+ = 430.2
0.68-0.79 (2H, m), 0.90-0.98 (2H, m), 1.30-1.40 (1H, m), 2.03 (3H, s), 2.12 (3H, s), 3.73 (3H, s), 3.94 (1H, d, J = 14.6 Hz), 4.27-4.33 (2H, m), 5.87 (1H, d, J = 14.6 Hz), 5.90-5.97 (1H, m), 6.24 (1H, s), 6.51 (1H, s), 6.79- 6.94 (4H, m), 7.13 (1H, s)





1301
Me


embedded image


Me
H
H
(ESI)+: [M + H]+ = 430.3
0.68-0.80 (2H, m), 0.90-1.02 (2H, m), 1.28-1.40 (1H, m), 2.14 (3H, s), 2.39 (3H, s), 3.82 (3H, m), 3.95 (1H, d, J = 14.6 Hz), 4.30 (2H, d, J = 5.4 Hz), 5.69 (1H, brs), 5.82 (1H, s), 5.93 (1H, d, J = 14.6 Hz), 6.58-6.70 (2H, m), 6.85-6.96 (2H, m), 6.96-7.08 (1H, m), 7.14 (1H, s)





















embedded image

















Com-


















pound








num-








ber
R1
R4
R8

b

R11
MS
















1302
F
CH2CH2CH3
F
0


embedded image


(ESI)+: [M + H]+ = 502.4





1303
F
CH(CH3)2
F
0


embedded image


(ESI)+: [M + H]+ = 502.2





1304
F


embedded image


F
0


embedded image


(ESI)+: [M + H]+ = 500.2





1305
F
CH2CH3
F
0


embedded image


(ESI)+: [M + H]+ = 488.2





1306
F
CH2CH2CH3
F
1
CH3
(ESI)+: [M +








H]+ = 454.3


1307
F
CH(CH3)2
F
1
CH3
(ESI)+: [M +








H]+ = 454.3





1308
F


embedded image


F
1
CH3
(ESI)+: [M + H]+ = 452.3





1309
F
CH2CH3
F
1
CH3
(ESI)+: [M +








H]+ = 440.3


1310
Me
CH2CH2CH3
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 478.4


1311
Me
CH2CH3
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 464.4


1312
Me
CH(CH3)2
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 478.4





1313
Me


embedded image


F
0
C(CH3)3
(ESI)+: [M + H]+ = 476.4





1314
F
CH2CH2CH3
F
0


embedded image


(ESI)+: [M + H]+ = 508.3





1315
F
CH2CH3
F
0


embedded image


(ESI)+: [M + H]+ = 494.2





1316
F
CH(CH3)2
F
0


embedded image


(ESI)+: [M + H]+ = 508.3





1317
F


embedded image


F
0


embedded image


(ESI)+: [M + H]+ = 506.2





1318
F
CH2CH2CH3
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 482.2


1319
F
CH2CH3
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 468.2


1320
F
CH(CH3)2
F
0
C(CH3)3
(ESI)+: [M +








H]+ = 482.2





1321
F


embedded image


F
0
C(CH3)3
(ESI)+: [M + H]+ = 480.2





1322
F
CH(CH3)2
Cl
1
CH3
(ESI)+: [M +








H]+ = 436.4


1323
F
CH2CH2CH3
Cl
1
CH3
(ESI)+: [M +








H]+ = 436.4


1324
F
CH2CH3
Cl
1
CH3
(ESI)+: [M +








H]+ = 422.4





1325
F


embedded image


Cl
1
CH3
(ESI)+: [M + H]+ = 434.4





1326
Me
CH2CH3
H
2
CH2CH3
(ESI)+: [M +








H]+ = 446.3


1327
Me
CH2CH2CH3
H
2
CH2CH3
(ESI)+: [M +








H]+ = 460.3


1328
Me
CH(CH3)2
H
2
CH2CH3
(ESI)+: [M +








H]+ = 460.2





1329
Me


embedded image


H
2
CH2CH3
(ESI)+: [M + H]+ = 458.2





1330
F
CH2CH3
H
2
CH2CH3
(ESI)+: [M +








H]+ = 450.2


1331
F
CH2CH2CH3
H
2
CH2CH3
(ESI)+: [M +








H]+ = 464.2


1332
F
CH(CH3)2
H
2
CH2CH3
(ESI)+: [M +








H]+ = 464.2





1333
F


embedded image


H
2
CH2CH3
(ESI)+: [M + H]+ = 462.4





1334
F


embedded image


Cl
0


embedded image


(ESI)+: [M + H]+ = 517.2, 519.2





1335
F
CH(CH3)2
Cl
0


embedded image


(ESI)+: [M + H]+ = 519.2, 521.2





1336
F
CH2CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 519.2, 521.2





1337
F
CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 505.2, 507.2





1338
Me
CH(CH3)2
H
1
CH3
(ESI)+: [M +








H]+ = 433.2


1339
Me
CH2CH2CH3
H
1
CH3
(ESI)+: [M +








H]+ = 433.2


1340
Me
CH2CH3
H
1
CH3
(ESI)+: [M +








H]+ = 418.2





1341
Me


embedded image


H
1
CH3
(ESI)+: [M + H]+ = 430.2





1342
F
CH2CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 524.3, 526.3





1343
F
CH(CH3)2
Cl
0


embedded image


(ESI)+: [M + H]+ = 524.3, 526.3





1344
F


embedded image


Cl
0


embedded image


(ESI)+: [M + H]+ = 522.2, 524.2





1345
F
CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 510.3, 512.3





1346
F
CH2CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 518.3, 520.3





1347
F


embedded image


Cl
0


embedded image


(ESI)+: [M + H]+ = 530.2, 532.2





1348
F
CH2CH3
Cl
0


embedded image


(ESI)+: [M + H]+ = 504.2, 506.2





1349
F
CH(CH3)2
Cl
0


embedded image


(ESI)+: [M + H]+ = 518.2, 520.2





1350
F
CH2CH2CH3
Cl
0
C(CH3)3
(ESI)+: [M +








H]+ =








498.2, 500.2





1351
F


embedded image


Cl
0
C(CH3)3
(ESI)+: [M + H]+ = 510.4, 512.4





1352
F
CH2CH3
Cl
0
C(CH3)3
(ESI)+: [M +








H]+ =








484.4, 486.4


1353
F
CH(CH3)2
Cl
0
C(CH3)3
(ESI)+: [M +








H]+ =








498.4, 500.4


1354
F
CH2CH2CH3
Cl
1
CH3
(ESI)+: [M +








H]+ =








470.3, 472.3





1355
F


embedded image


Cl
1
CH3
(ESI)+: [M + H]+ = 482.3, 484.3





1356
F
CH2CH3
Cl
1
CH3
(ESI)+: [M +








H]+ =








456.2, 458.2


1357
F
CH(CH3)2
Cl
1
CH3
(ESI)+: [M +








H]+ =








470.2, 472.2


1358
F
CH2CH2CH3
Cl
2
CH2CH3
(ESI)+: [M +








H]+ =








498.3, 500.3





1359
F


embedded image


Cl
2
CH2CH3
(ESI)+: [M + H]+ = 510.3, 512.3





1360
F
CH2CH3
Cl
2
CH2CH3
(ESI)+: [M +








H]+ =








484.3, 486.3


1361
F
CH(CH3)2
Cl
2
CH2CH3
(ESI)+: [M +








H]+ =








498.3, 500.3





1362
F


embedded image


Cl
0


embedded image


(ESI)+: [M + H]+ = 516.2, 518.2





1363
F


embedded image


Cl
0
C(CH3)3
(ESI)+: [M + H]+ = 496.2, 498.2





1364
F


embedded image


Cl
1
CH3
(ESI)+: [M + H]+ = 468.1, 470.2





1365
F


embedded image


Cl
2
CH2CH3
(ESI)+: [M + H]+ = 496.3, 498.3





















embedded image
















Compound





number
R4
MS














1366 E109


embedded image


(ESI)+: [M + H]+ = 402.4






1367


embedded image


(APCI)+: [M + H]+ = 522.3





















embedded image















Com-





pound





num-





ber

c

R12
MS













1368
1
NHCO2C(CH3)3
(ESI)+: [M + H]+ = 543.2, 545.2


E113





1369
1
N(CH3)2
(ESI)+: [M + H]+ = 471.2


1370
1
N(CH3)CO2C(CH3)3
(ESI)+: [M + H]+ = 557.1, 559.1


1371
1
NH2
(ESI)+: [M + H]+ = 443.0


E114





1372
1
NHCH3
(ESI)+: [M + H]+ = 457.1





















embedded image














Compound




number
R4
MS












1373 E115


embedded image


(ESI)+: [M + H]+ = 427.2





1374


embedded image


(APCI)+: [M + H] = 357.3, 359.3





1375


embedded image


(APCI)+: [M + H]+ = 413.2, 415.2





1376


embedded image


(APCI)+: [M + H]+ = 399.2, 401.2





1377
CH2CH2CH2CH2CH3
(APCI)+: [M + H]+ = 387.2, 389.2





1378


embedded image


(APCI)+: [M + H]+ = 427.1, 429.1





1379


embedded image


(APCI)+: [M + H]+ = 427.1, 429.1





1380


embedded image


(APCI)+: [M + H]+ = 393.2, 395.2





















embedded image

















Com-







pound







number
R1
R10
R13
X2
MS















1381
Me
Me


embedded image


S
(ESI)+: [M + H]+ = 573.3





















embedded image

















Com-







pound







number
R1
R10
R13
X2
MS















1382 E122
Me
H


embedded image


NH
(APCI)+: [M + H]+ = 542.4





1383
Me
Cl


embedded image


NH
(ESI)+: [M + H]+ = 576.4





1384
Me
Me


embedded image


NH
(ESI)+: [M + H]+ = 556.4





















embedded image

















Compound







number
R1
R4
R10
X2
MS





1385 E124
Me


embedded image


H
S
(APCI)+: [M + H]+ = 432.3





1386
Cl


embedded image


Me
S
(ESI)+: [M + H]+ = 446.2





















embedded image


















Compound








number
R1
R3
R4
R10
X2
MS





1387
H
F
CH2CH2CH3
Me
NH
(ESI)+: [M +








H]+ = 435.2






















Compound



number

1H NMR: δ (ppm)






1314
0.89 (3H, t, J = 7.4 Hz), 1.20-1.53 (3H, m), 1.54-1.70 (2H, m), 1.71-



1.82 (1H, m), 1.80-2.10 (6H, m), 2.14 (2H, t, J = 7.4 Hz), 2.77-3.93



(1H, m), 3.97 (1H, d, J = 14.6 Hz), 4.38 (2H, d, J = 6.2 Hz), 5.70-5.79



(1H, m), 5.86 (1H, d, J = 14.6 Hz), 6.10 (1H, s), 6.34-6.46 (1H, m),



6.62-6.75 (2H, m), 6.95 (2H, d, J = 8.6 Hz), 7.11 (1H, t, J = 7.4 Hz),



7.28 (1H, s)


1315
1.13 (3H, t, J = 7.4 Hz), 1.30-1.54 (3H, m), 1.72-1.80 (1H, m), 1.89-



2.11 (6H, m), 2.19 (2H, q, J = 7.4 Hz), 3.78-3.92 (1H, m), 3.97 (1H,



d, J = 14.6 Hz), 4.38 (2H, d, J = 5.7 Hz), 5.69-5.80 (1H, m), 5.87 (1H,



d, J = 14.6 Hz), 6.07 (1H, s), 6.38-6.48 (1H, m), 6.62-6.71 (2H, m),



6.94 (2H, d, J = 8.6 Hz), 7.11 (1H, t, J = 7.2 Hz), 7.28 (1H, s)


1316
1.11 (6H, d, J = 6.9 Hz), 1.30-1.49 (3H, m), 1.74-1.80 (1H, m), 1.94-



1.99 (6H, m), 2.31-2.36 (1H, m), 3.79-3.92 (1H, m), 3.97 (1H, d,



J = 14.8 Hz), 4.37 (2H, d, J = 5.9 Hz), 5.70-5.81 (1H, m), 5.87 (1H, d,



J = 14.8 Hz), 6.10 (1H, s), 6.36-6.43 (1H, m), 6.62-6.70 (2H, m),



6.95 (2H, d, J = 8.9 Hz), 7.10 (1H, t, J = 7.4 Hz), 7.28 (1H, s)


1317
0.72-0.77 (2H, m), 0.92-1.00 (2H, m), 1.25-1.50 (4H, m), 1.74-1.80



(1H, m), 1.95-2.00 (6H, m), 3.78-3.90 (1H, m), 3.97 (1H, d,



J = 14.8 Hz), 4.40 (2H, d, J = 5.7 Hz), 5.84-5.94 (2H, m), 6.04 (1H, s),



6.36-6.45 (1H, m), 6.64-6.70 (2H, m), 6.95 (2H, d, J = 8.9 Hz), 7.12



(1H, t, J = 7.7 Hz), 7.28 (1H, s)


1318
0.89 (3H, t, J = 7.4 Hz), 1.59-1.64 (2H, m), 1.74 (9H, s), 2.14 (2H, t,



J = 7.7 Hz), 3.97 (1H, d, J = 14.6 Hz), 4.38 (2H, d, J = 5.7 Hz), 5.62-



5.77 (1H, m), 5.85 (1H, d, J = 14.6 Hz), 6.36-6.48 (2H, m), 6.58-6.70



(2H, m), 6.92-7.00 (2H, m), 7.13 (1H, t, J = 7.7 Hz), 7.21 (1H, s)


1319
1.13 (3H, t, J = 7.4 Hz), 1.74 (9H, s), 2.18 (2H, q, J = 7.4 Hz), 3.97



(1H, d, J = 14.6 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.63-5.75 (1H, m), 5.85



(1H, d, J = 14.6 Hz), 6.37-6.45 (2H, m), 6.60-6.70 (2H, m), 6.90-7.00



(2H, m), 7.12 (1H, t, J = 7.4 Hz), 7.22 (1H, s)


1320
1.11 (6H, d, J = 6.7 Hz), 1.74 (9H, s), 2.22-2.40 (1H, m), 3.97 (1H, d,



J = 14.8 Hz), 4.38 (2H, d, J = 5.7 Hz), 5.65-5.73 (1H, m), 5.85 (1H, d,



J = 14.8 Hz), 6.34-6.48 (2H, m), 6.56-6.70 (2H, m), 6.90-7.00 (2H,



m), 7.12 (1H, t, J = 7.7 Hz), 7.22 (1H, s)


1321
0.68-0.81 (2H, m), 0.92-1.01 (2H, m), 1.24-1.35 (1H, m), 1.74 (9H,



s), 3.97 (1H, d, J = 14.4 Hz), 4.40 (2H, d, J = 6.2 Hz), 5.77-5.95 (2H,



m), 6.36 (1H, s), 6.37-6.48 (1H, m), 6.58-6.70 (2H, m), 6.90-7.03



(2H, m), 7.13 (1H, t, J = 7.2 Hz), 6.22 (1H, s)


1322
1.11 (6H, d, J = 6.9 Hz), 1.47 (3H, t, J = 7.2 Hz), 2.32 (1H, septet,



J = 6.9 Hz), 3.99 (1H, d, J = 14.6 Hz), 4.09 (2H, q, J = 7.2 Hz), 4.34 (2H,



d, J = 5.9 Hz) 5.79 (1H, s), 5.88 (1H, d, J = 14.6 Hz), 6.14 (1H, s),



6.69-6.71, (2H, m), 6.91-7.11 (5H, m), 7.25-7.26 (1H, m)


1323
0.89 (3H, t, J = 7.4 Hz), 1.48 (3H, t, J = 7.2 Hz), 1.57-1.60, (2H, m),



2.13 (2H, q, J = 7.6 Hz), 3.99 (1H, d, J = 14.6 Hz), 4.09 (2H, q,



J = 7.2 Hz), 4.36 (2H, d, J = 5.9 Hz), 5.74 (1H, s), 5.87 (1H, d,



J = 14.6 Hz), 6.05 (1H, s), 6.69-6.71 (2H, m), 6.90-6.97 (3H, m),



7.03-7.12 (2H, m), 7.25-7.26 (1H, m)


1324
1.11 (3H, t, J = 7.7 Hz), 1.46 (3H, t, J = 7.2 Hz), 2.18 (2H, q, J = 7.7 Hz),



3.99 (1H, d, J = 14.6 Hz), 4.09 (2H, q, J = 7.2 Hz), 4.35 (2H, d,



J = 5.9 Hz), 5.82 (1H, s), 5.88 (1H, d, J = 14.6 Hz), 6.19 (1H, s), 6.69-



6.71 (2H, m), 6.91-7.13 (5H, m), 7.25-7.26 (1H, m)


1325
0.70-0.74 (2H m), 0.91 -0.95 (2H, m), 1.25-1.35 (1H, m), 1.48 (3H,



t, J = 7.2 Hz), 3.98 (1H, d. J = 14.6 Hz), 4.09 (2H, q, J = 7.2 Hz), 4.37



(2H, d. J = 5.9 Hz), 5.89 (1H, d, J = 14.6 Hz), 5.96 (1H, s), 6.10 (1H,



s), 6.70-6.72, (2H, m), 6.90-7.12 (5H, m), 7.25-7.26 (1H, m)


1326
0.96 (3H, t, J = 7.4 Hz), 1.12 (3H, t, J = 7.4 Hz), 1.33-1.44 (2H, m),



1.79-1.88 (2H, m), 2.10-2.25 (5H, m), 3.95-4.04 (3H, m), 4.27 (2H,



d, J = 5.4 Hz), 5.67 (1H, s), 5.90 (1H, d, J = 14.6 Hz), 6.21 (1H, s),



6.68-6.70 (2H, m), 6.83-7.12 (5H, m), 7.24 (1H, s)


1327
0.87-0.99 (6H, m), 1.33-1.44 (2H, m), 1.58-1.67 (2H, m), 1.77-1.87



(2H, m), 2.10-2.16 (5H, m), 3.95-4.04 (3H, m), 4.27 (2H, d,



J = 5.7 Hz), 5.65 (1H, s), 5.90 (1H, d, J = 14.6 Hz), 6.18 (1H, s), 6.68-



6.70 (2H, m), 6.86-7.12 (5H, m), 7.24 (1H, s)


1328
0.97 (3H, t, J = 7.2 Hz), 1.12 (6H, d, J = 6.2 Hz), 1.37-1.45 (2H, m),



1.78-1.87 (2H, m), 2.13 (3H, s), 2.30-2.36 (1H, m), 3.95-4.06 (3H,



m), 4.28 (2H, d, J = 5.4 Hz), 5.53 (1H, s), 5.91 (1H, d, J = 14.6 Hz),



6.05 (1H, s), 6.68-6.70 (2H, m), 6.85-7.14 (5H, m), 7.24 (1H, s)


1329
0.70-0.74 (2H, m), 0.94-1.00 (5H, m), 1.30-1.45 (3H, m), 1.81-1.87



(2H, m), 2.13 (3H, s), 3.95-4.05 (3H, m), 4.30 (2H, d, J = 5.7 Hz),



5.74 (1H, s), 5.91 (1H, d, J = 14.6 Hz), 6.06 (1H, s), 6.70-6.72 (2H,



m), 6.89-6.93 (3H, m), 7.03-7.14 (2H, m), 7.24 (1H, s)


1330
0.96 (3H, t, J = 7.4 Hz), 1.10 (3H, t, J = 7.4 Hz), 1.35-1.44 (2H, m),



1.77-1.85 (2H, m), 2.17 (2H, q, J = 7.4 Hz), 3.96-4.06 (3H, m), 4.33



(2H, d, J = 5.4 Hz), 5.87 (1H, d, J = 14.6 Hz), 5.90 (1H, s), 6.26 (1H,



s), 6.68 = 6.70 (2H, m), 6.86-7.10 (5H, m), 7.24 (1H, s)


1331
0.87 (3H, t, J = 7.4 Hz), 0.95 (3H, t, J = 7.4 Hz), 1.35-1.43 (2H, m),



1.56-1.64 (2H, m), 1.76-1.84 (2H, m), 2.09-2.15 (2H, m), 3.96-4.05



(3H, m), 4.33 (2H, d, J = 5.7 Hz), 5.87 (1H, d, J = 14.6 Hz), 5.93 (1H,



s), 6.28 (1H, s), 6.68-6.70 (2H, m), 6.86-7.10 (5H, m), 7.24 (1H, s)


1332
0.96 (3H, t, J = 7.2 Hz), 1.09 (6H, d, J = 6.2 Hz), 1.32-1.46 (2H, m),



1.77-1.88 (2H, m), 2.27-2.37 (1H, m), 3.96-4.06 (3H, m), 4.32 (2H,



d, J = 5.4 Hz), 5.87 (1H, d, J = 14.6 Hz), 5.90 (1H, s), 6.27 (1H, s),



6.68-6.70 (2H, m), 6.85-7.10 (5H, m), 7.24 (1H, s)


1333
0.70-0.74 (2H, m), 0.94-1.01 (5H, m), 1.29-1.45 (3H, m), 1.78-1.87



(2H, m), 3.96-4.05 (3H, m), 4.36 (2H, d, J = 5.7 Hz), 5.88 (1H, d,



J = 14.6 Hz), 5.97 (1H, s), 6.06 (1H, s), 6.70-6.72 (2H, m), 6.89-6.97



(3H, m), 7.03-7.09 (2H, m), 7.24 (1H, s)


1334
0.63-0.80 (2H, m), 0.80-1.08 (2H, m), 1.21-1.45 (1H, m), 4.00 (1H,



d, J = 15.1 Hz), 4.40 (2H, d, J = 5.7 Hz), 5.80-5.94 (2H, m), 6.55-6.70



(2H, m), 6.89-7.21 (5H, m), 7.46 (1H, s), 7.80-7.90 (1H, m), 8.04



(1H, d, J = 8.7 Hz), 8.44 (1H, d, J = 4.5 Hz), 11.26 (1H, s)


1335
1.11 (6H, d, J = 6.7 Hz), 2.32 (1H, sept, J = 6.7 Hz), 4.00 (1H, d,



J = 14.6 Hz), 4.38 (2H, d, J = 5.7 Hz), 5.62-5.78 (1H, m), 5.92 (1H, d,



J = 14.6 Hz), 6.50-6.70 (2H, m), 6.90-7.21 (5H, m), 7.46 (1H, s),



7.83-7.89 (1H, m), 8.04 (1H, d, J = 8.4 Hz), 8.44 (1H, d, J = 4.2 Hz),



11.26 (1H, s)


1336
0.89 (3H, t, J = 7.4 Hz), 1.62 (2H, m), 2.14 (2H, t, J = 7.7 Hz), 4.00



(1H, d, J = 14.6 Hz), 4.39 (2H, d, J = 5.7 Hz), 5.50-5.65 (1H, m), 5.92



(1H, d, J = 14.6 Hz), 6.50-6.70 (2H, m), 6.91 -7.21 (5H, m), 7.46 (1H,



s), 7.82-7.91 (1H, m), 8.05 (1H, d, J = 8.4 Hz), 8.44 (1H, d,



J = 4.2 Hz), 11.26 (1H, s)


1337
1.12 (3H, t, J = 7.5 Hz), 2.18 (2H, q, J = 7.5 Hz), 4.00 (1H, d,



J = 14.8 Hz), 4.39 (2H, d, J = 5.7 Hz), 5.60-5.85 (1H, m), 5.92 (1H, d,



J = 14.8 Hz), 6.58-6.69 (2H, m), 6.98-7.20 (5H, m), 7.46 (1H, s),



7.83-7.90 (1H, m), 8.04 (1H, d, J = 8.7 Hz), 8.44 (1H, d, J = 4.7 Hz),



11.26 (1H, s)


1338
1.12 (6H, d, J = 6.7 Hz), 1.47 (3H, t, J = 7.0 Hz), 2.13 (3H, s), 2.33



(1H, sept, J = 6.7 Hz), 3.98 (1H, d, J = 14.9 Hz), 4.08 (2H, q,



J = 7.0 Hz), 4.28 (2H, d, J = 5.2 Hz), 5.50-5.60 (1H, m), 5.92 (1H, d,



J = 14.9 Hz), 6.10 (1H, s), 6.62-6.76 (2H, m), 6.82-7.00 (3H, m),



7.02-7.10 (1H, m), 7.14 (1H, s)


1339
0.90 (3H, t, J = 7.3 Hz), 1.46 (3H, t, J = 7.2 Hz), 1.54-1.71 (2H, m),



2.06-2.20 (5H, m), 3.97 (1H, d, J = 14.6 Hz), 4.07 (2H, q, J = 7.2 Hz),



4.28 (2H, d, J = 4.9 Hz), 5.56-5.66 (1H, m), 5.86 (1H, d, J = 14.6 Hz),



6.17 (1H, s), 6.62-6.74 (2H, m), 6.84-6.98 (3H, m), 7.02-7.12 (1H,



m), 7.13 (1H, s)


1340
1.13 (3H, t, J = 7.7 Hz), 1.47 (3H, t, J = 7.1 Hz), 2.13 (3H, s), 2.19



(2H, q, J = 7.7 Hz), 3.97 (1H, d, J = 14.9 Hz), 4.08 (2H, q, J = 7.1 Hz),



4.28 (2H, d, J = 5.4 Hz), 5.54-5.64 (1H, m), 5.91 (1H, d, J = 14.9 Hz),



6.14 (1H, s), 6.66-6.76 (2H, m), 6.82-6.98 (3H, m), 7.02-7.12 (1H,



m), 7.14 (1H, s)


1341
0.68-0.78 (2H, m), 0.94 (2H, s), 1.26-1.38 (1H, m), 1.46 (3H, t,



J = 7.2 Hz), 2.13 (3H, s), 3.97 (1H, d, J = 14.6 Hz), 4.07 (2H, q,



J = 7.2 Hz), 4.29 (2H, d, J = 5.2 Hz), 5.76-5.86 (1H, m), 5.92 (1H, d,



J = 14.6 Hz), 6.18 (1H, s), 6.64-6.74 (2H, m), 6.86-6.96 (3H, m),



7.02-7.12 (1H, m), 7.14 (1H, s)


1342
0.90 (3H, t, J = 7.4 Hz), 1.20-1.71 (5H, m), 1.70 (1H, m), 1.81-2.10



(6H, m), 2.15 (2H, t, J = 7.4 Hz), 3.76-3.90 (1H, m), 3.95 (1H, d,



J = 14.4 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.65-5.79 (1H, m), 5.87 (1H, d,



J = 14.4 Hz), 6.64 (2H, q, J = 7.2 Hz), 6.58-6.70 (3H, m), 7.12 (1H, t,



J = 7.7 Hz), 7.27 (1H, s)


1343
1.12 (6H, d, J = 6.7 Hz), 1.14-1.50 (3H, m), 1.77 (1H, m), 1.81-2.11



(6H, m), 2.28-2.40 (1H, m), 3.73-3.91 (1H, m), 3.95 (1H, d,



J = 14.6 Hz), 4.38 (2H, d, J = 6.2 Hz), 5.64-5.76 (1H, m), 5.98 (1H, d,



J = 14.6 Hz), 6.64 (2H, q, J = 6.9 Hz), 6.95-6.98 (3H, m), 7.12 (1H, t,



J = 7.9 Hz), 7.28 (1H, s)


1344
0.60-0.81 (2H, m), 0.90-1.00 (2H, m), 1.20-1.48 (4H, m), 1.76 (1H,



m), 1.82-2.10 (6H, m), 3.73-3.90 (1H, m), 3.95 (1H, d, J = 14.6 Hz),



4.41 (2H, d, J = 6.2 Hz), 5.84-5.90 (2H, m), 6.60-6.72 (2H, m), 6.88-



7.03 (3H, m), 7.12 (1H, t, J = 7.2 Hz), 7.28 (1H, s)


1345
1.13 (3H, t, J = 7.5 Hz), 1.16-1.63 (3H, m), 1.76 (1H, m), 1.85-2.13



(6H, m), 2.22 (2H, q, J = 7.5 Hz), 3.72-3.90 (1H, m), 3.95 (1H, d,



J = 15.1 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.66-5.80 (1H, m), 5.86 (1H, d,



J = 15.1 Hz), 6.60-6.87 (2H, m), 6.92-7.05 (3H, m), 7.12 (1H, t,



J = 7.2 Hz), 7.27 (1H, s)


1346
0.88-0.98 (3H, m), 1.60-1.71 (2H, m), 2.10-2.21 (2H, m), 4.08 (1H,



d, J = 14.6 Hz), 4.40 (2H, d, J = 5.4 Hz), 5.70 (1H, brs), 5.95 (1H, d,



J = 14.6 Hz), 6.27 (1H, s), 6.62-6.70 (2H, m), 6.80 (1H, s), 6.85-7.08



(2H, m), 7.12-7.19 (1H, m), 7.45-7.65 (6H, m)


1347
1.80-2.02 (2H, m), 2.08-2.30 (4H, m), 2.97 (1H, t, J = 9.2 Hz), 4.01



(1H, d, J = 14.9HZ), 4.39 (2H, d, J = 6.2 Hz), 5.60 (1H, brs), 5.96 (1H,



d, J = 14.9 Hz), 6.27 (1H, s), 6.62-6.72 (2H, m), 6.80 (1H, s), 6.96-



7.06 (2H, m), 7.10-7.20 (1H, m), 7.45-7.65 (6H, m)


1348
1.13 (3H, t, J = 7.5 Hz), 2.19 (2H, q, J = 7.5 Hz), 4.04 (1H, d,



J = 14.9 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.69 (1H, brs), 5.96 (1H, d,



J = 14.9 Hz), 6.27 (1H, s), 6.61-6.71 (2H, m), 6.80 (1H, s), 6.96-7.02



(2H, m), 7.10-7.18 (1H, m), 7.42-7.66 (6H, m)


1349
1.20 (6H, d, J = 6.7 Hz), 2.30-2.40 (1H, m), 4.05 (1H, d, J = 14.6 Hz),



4.39 (1H, d, J = 5.7 Hz), 5.72 (1H, brs), 5.96 (1H, d, J = 14.6 Hz), 6.29



(1H, s), 6.61-6.72 (2H, m), 6.72 (1H, s), 6.95-7.15 (2H, m), 7.10-



7.20 (1H, m), 7.45-7.70 (6H, m)


1350
0.88-1.00 (3H, m), 1.59-1.71 (2H, m), 1.74 (9H, s), 2.12-2.20 (2H,



m), 3.95 (1H, d, J = 14.6 Hz), 4.39 (2H, d, J = 5.2 Hz), 5.70 (1H, brs),



5.84 (1H, d, J = 14.6 Hz), 6.36 (1H, s), 6.58-6.62 (2H, m), 6.88-7.02



(3H, m), 7.10-7.20 (1H, m), 7.20-7.22 (1H, s)


1351
1.74 (9H, s), 1.82-2.03 (2H, m), 2.04-2.35 (4H, m), 2.90-3.05 (1H,



m), 3.95 (1H, d, J = 14.6 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.59 (1H, brs),



5.85 (1H, d, J = 14.6 Hz), 6.36 (1H, s), 6.60-6.72 (2H, m), 6.90-7.08



(3H, m), 7.10-7.20 (1H, m), 7.25 (1H, s)


1352
1.13 (3H, t, J = 7.4 Hz), 1.74 (9H, s), 2.19 (2H, q, J = 7.4 Hz), 3.98



(1H, d, J = 14.6 Hz), 4.40 (2H, d, J = 5.4 Hz), 5.70 (1H, brs), 5.88 (1H,



d, J = 14.6 Hz), 6.36 (1H, s), 6.58-6.70 (2H, m), 6.89-7.04 (3H, m),



7.10-7.20 (1H, m), 7.25 (1H, s)


1353
1.12 (6H, d, J = 6.7 Hz), 1.74 (9H, s), 2.33 (1H, q, J = 6.9 Hz), 3.95



(1H, d, J = 14.9 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.70 (1H, brs), 5.85 (1H,



d, J = 14.9 Hz), 6.36 (1H, s), 6.59-6.71 (2H, m), 6.90-7.05 (3H, m),



7.21 (1H, s), 7.25 (1H, s)


1354
0.89 (3H, t, J = 7.4 Hz), 1.48 (3H, t, J = 7.2 Hz), 1.56-1.68 (2H, m),



2.15 (2H, t, J = 7.4 Hz), 3.95 (1H, d, J = 14.8 Hz), 4.06 (2H, q,



J = 7.2 Hz), 4.39 (2H, d, J = 5.9 Hz), 5.72-5.80 (1H, m), 5.85 (1H, d,



J = 14.8 Hz), 6.11 (1H, s), 6.65 (2H, dd, J = 8.4, 14.1 Hz), 6.89-6.98



(3H, m), 7.12 (1H, t, J = 7.7 Hz), 7.27 (1H, s)


1355
1.45 (3H, t, J = 7.2 Hz), 1.75-2.03 (2H, m), 2.04-2.31 (4H, m), 2.88-



3.07 (1H, m), 3.95 (1H, d, J = 14.6 Hz), 4.07 (2H, q, J = 7.4 Hz), 4.38



(2H, d, J = 5.9 Hz), 5.58-5.72 (1H, m), 5.85 (1H, d, J = 14.6 Hz), 6.17



(1H, s), 6.65 (2H, dd, J = 8.4, 13.6 Hz), 6.88-6.98 (3H, m), 7.10 (1H,



t, J = 8.2 Hz), 7.26 (1H, s)


1356
1.13 (3H, t, J = 7.7 Hz), 1.47 (3H, t, J = 7.4 Hz), 2.21 (2H, q, J = 7.7 Hz),



3.98 (1H, d, J = 14.6 Hz), 4.07 (2H, q, J = 7.4 Hz), 4.39 (2H, d,



J = 7.4 Hz), 5.70-5.91 (2H, m), 6.17 (1H, s), 6.65 (2H, dd, J = 8.4,



14.1 Hz), 6.88-7.00 (3H, m), 7.11 (1H, t, J = 7.7 Hz), 7.26 (1H, s)


1357
1.12 (6H, d, J = 6.9 Hz), 1.47 (3H, t, J = 7.2 Hz), 2.25-2.43 (1H, m),



3.95 (1H, d, J = 14.6 Hz), 4.06 (2H, q, J = 7.2 Hz), 4.38 (2H, d,



J = 5.9 Hz), 5.73-5.92 (2H, m), 6.22 (1H, s), 6.64 (2H, dd, J = 8.1,



12.4 Hz), 6.88-6.99 (3H, m), 7.09 (1H, t, J = 7.7 Hz), 7.26 (1H, s)


1358
0.90 (3H, t, J = 7.4 Hz), 0.98 (3H, t, J = 7.4 Hz), 1.33-1.52 (1H, m),



1.56-1.70 (2H, m), 1.73-1.90 (2H, m), 2.15 (2H, t, J = 7.7 Hz), 3.88-



4.04 (3H, m), 4.39 (2H, d, J = 7.2 Hz), 5.69-5.80 (1H, m), 5.85 (1H,



d, J = 14.6 Hz), 6.06 (1H, s), 6.59-6.72 (2H, m), 6.89-7.01 (3H, m),



7.12 (1H, t, J = 7.4 Hz), 7.25 (1H, s)


1359
0.98 (3H, t, J = 7.2 Hz), 1.33-1.48 (2H, m), 1.56 (2H, s), 1.78-2.00



(4H, m), 2.03-2.30 (3H, m), 2.90-3.06 (1H, m), 3.88-4.05 (3H, m),



4.38 (2H, d, J = 5.7 Hz), 5.58-5.68 (1H, m), 5.85 (1H, d, J = 14.6 Hz)



6.06 (1H, s), 6.57-6.70 (2H, m), 6.90-7.02 (3H, m), 7.11 (1H, t,



J = 7.7 Hz)


1360
0.97 (3H, t, J = 7.4 Hz), 1.13 (3H, t, J = 7.4 Hz), 1.31-1.49 (2H, m),



1.72-1.91 (2H, m), 2.13-2.28 (2H, m), 3.00-3.15 (1H, m), 3.90-4.10



(3H, m), 4.38 (2H, d, J = 6.2 Hz), 5.83-5.90 (2H, m), 6.20 (1H, s),



6.56-6.70 (2H, m), 6.90-7.03 (3H, m), 7.07-7.14 (1H, m)


1361
0.98 (3H, t, J = 7.4 Hz), 1.12 (6H, d, J = 6.9 Hz), 1.33-1.48 (2H, m),



1.77-1.91 (2H, m), 2.28-2.41 (1H, m), 3.90-4.10 (3H, m), 4.38 (2H,



d, J = 5.9 Hz), 5.70-5.90 (2H, m), 6.14 (1H, s), 6.64 (2H, dd, J = 7.9,



12.1 Hz), 6.90-7.00 (3H, m), 7.10 (1H, t, J = 7.2 Hz), 7.25 (1H, s)


1362
0.66-0.78 (2H, m), 0.90-0.99 (2H, m), 1.28-1.52 (2H, m), 4.03 (1H,



d, J = 14.6 Hz), 4.40 (2H, d, J = 5.9 Hz), 5.90-6.00 (2H, m), 6.29 (1H,



s), 6.60-6.74 (2H, m), 6.80 (1H, d, J = 1.7 Hz), 6.91-7.03 (2H, m),



7.13 (1H, t, J = 7.7 Hz), 7.42-7.66 (5H, m)


1363
0.66-0.78 (2H, m), 0.91-1.00 (2H, m), 1.21-1.46 (2H, m), 1.74 (9H,



s), 3.95 (1H, d, J = 14.8 Hz), 4.40 (2H, d, J = 5.7 Hz), 5.85 (1H, d,



J = 14.8 Hz), 5.92-6.00 (1H, m), 6.39 (1H, s), 6.59-6.69 (2H, m),



6.89-7.02 (2H, m), 7.13 (1H, t, J = 7.4 Hz), 7.25 (1H, s)


1364
0.67-0.85 (2H, m), 0.94 (2H, s), 1.25-1.55 (5H, m), 3.95 (1H, d,



J = 14.6 Hz), 4.07 (2H, q, J = 7.2 Hz), 4.39 (2H, d, J = 5.7 Hz), 5.85 (1H,



d, J = 14.6 Hz), 6.11 (1H, s), 6.52 (1H, s), 6.65 (2H, dd,



J = 8.6, 13.3 Hz), 6.80-7.00 (3H, m), 7.09 (1H, t, J = 7.2 Hz)


1365
0.67-0.80 (2H, m), 0.86-1.06 (5H, m), 1.28-1.46 (4H, m), 1.75-1.90



(2H, m), 3.89-4.08 (3H, m), 4.39 (2H, d, J = 7.2 Hz), 5.85 (1H, d,



J = 14.6 Hz), 5.95-6.07 (1H, m), 6.25 (1H, s), 6.64 (2H, dd, J = 8.4,



13.1 Hz), 6.85-7.00 (3H, m), 7.05-7.15 (1H, m)


1366
0.37-0.11 (2H, m), 0.42-0.47 (2H, m), 0.87-1.10 (1H, m), 1.32-



1.69 (1H, m), 2.16 (3H, s), 2.37-2.43 (2H, m), 3.64 (2H, s), 3.77



(3H, s), 3.99 (1H, d, J = 14.6 Hz), 5.90 (1H, d, J = 14.6 Hz), 6.20-6.34



(1H, m), 6.58-6.72 (2H, m), 6.80-7.09 (4H, m), 7.16 (1H, s),



7.24(1H, d, J = 4.7 Hz)


1367
1.46-1.63 (2H, m), 2.15 (3H, s), 3.64 (2H, s), 3.79 (4H, s), 3.96



(1H, d, J = 14.6 Hz), 5.92 (1H, d, J = 14.6 Hz), 6.07 (1H, s), 6.61-6.73



(2H, m), 6.87-6.96 (2H, m), 6.99-7.10 (2H, m), 7.17 (1H, s), 7.20-



7.30 (4H, m), 7.36-7.48 (1H, m)


1368
1.38 (9H, s), 3.66 (3H, s), 3.70-3.80 (2H, m), 3.94 (1H, d,



J = 14.6 Hz), 4.28-4.38 (2H, m), 5.52-5.61 (1H, m), 5.78 (1H, d,



J = 14.6 Hz), 6.58 (2H, s), 6.82-7.20 (6H, m), 7.62 (1H, s)


1369
2.23 (6H, s), 2.96 (2H, s), 3.78 (3H, s), 3.95 (1H, d, J = 14.5 Hz),



4.41 (2H, d, J = 5.9 Hz), 5.85 (1H, d, J = 14.5 Hz), 6.44 (1H, s), 6.58-



6.70 (2H, m), 6.90-7.10 (3H, m), 7.11 (1H, t, J = 7.0 Hz), 7.51 (1H,



s)


1370
1.38 (9H, s), 2.85 (3H, s), 3.68 (3H, s), 3.84 (2H, s), 3.93 (1H, d,



J = 14.6 Hz), 4.30-4.41 (2H, m), 5.78 (1H, d, J = 14.6 Hz), 6.57 (2H,



s), 6.75-7.25 (6H, m), 7.70 (1H, s)


1371
3.30 (1H, s), 3.68 (2H, s), 4.00 (3H, s), 4.00-4.10 (1H, m), 4.41



(2H, s), 5.84 (1H, d, J = 15.1 Hz), 6.82-6.92 (2H, m), 7.00 (1H, d,



J = 8.9 Hz), 7.26 (1H, t, J = 7.5 Hz), 7.43 (1H, s), 7.95 (1H, s), 8.55-



8.65 (1H, m)


1372
2.70 (3H, s), 3.30 (1H, s), 3.79 (2H, s), 4.01 (3H, s), 4.01-4.10



(1H, m), 4.41 (2H, s), 5.84 (1H, d, J = 15.1 Hz), 6.82-6.96 (2H, m),



6.98-7.06 (2H, m), 7.26 (1H, t, J = 7.7 Hz), 7.44 (1H, s), 7.98 (1H, s),



8.70-8.80 (1H, m)


1373
2.21 (3H, s), 3.43 (3H, s), 4.51 (2H, d, J = 5.7 Hz), 6.40-6.52 (1H,



m), 6.87-6.98 (4H, m), 7.17-7.21 (3H, m), 7.28-7.38 (1H, m), 7.42-



7.48 (1H, m), 7.61-7.67 (1H, m), 7.76 (1H, s)


1374
0.68-0.79 (2H, m), 0.92-1.00 (2H, m), 1.27-1.40 (1H, m), 2.21 (3H,



s), 3.44 (3H, s), 4.36 (2H, d, J = 5.7 Hz), 5.61-5.68 (1H, m), 6.95-



7.04 (4H, m), 7.18-7.25 (3H, m)


1375
2.12 (3H, s), 3.42 (3H, s), 3.85 (2H, s), 4.31 (2H, d, J = 5.7 Hz),



5.72-5.77 (1H, m), 6.84-6.99 (6H, m), 7.12-7.25 (4H, m)


1376
2.27 (3H, s), 3.44 (3H, s), 4.52 (2H, d, J = 5.7 Hz), 6.00-6.16 (1H,



m), 6.92-6.99 (3H, m), 7.04-7.11 (2H, m), 7.21-7.30 (3H, m), 7.45-



7.48 (2H, m)


1377
0.85 (3H, t, J = 7.2 Hz), 1.20-1.37 (4H, m), 1.53-1.70 (2H, m), 2.12-



2.29 (2H, m), 2.21 (3H, s), 3.43 (3H, s), 4.34 (2H, d, J = 5.4 Hz),



5.44-5.54 (1H, m), 6.91-6.99 (4H, m), 7.17-7.24 (3H, m)


1378
2.28 (3H, s), 3.44 (3H, s), 4.57 (2H, d, J = 5.4 Hz), 6.19-6.30 (1H,



m), 6.92-7.01 (2H, m), 7.09-7.11 (1H, m), 7.11-7.29 (4H, m), 7.31-



7.42 (3H, m), 7.62-7.70 (1H, m)


1379
2.21 (3H, s), 3.42 (3H, s), 4.50 (2H, d, J = 5.4 Hz), 6.41-6.51 (1H,



m), 6.87-7.03 (4H, m), 7.13-7.22 (3H, m), 7.37 (2H, d, J = 6.7 Hz),



7.69 (2H, d, J = 6.7 Hz)


1380
2.23 (3H, s), 3.43 (3H, s), 4.53 (2H, d, J = 5.7 Hz), 6.29-6.42 (1H,



m), 6.89-7.07 (4H, m), 7.13-7.25 (3H, m), 7.37-7.50 (3H, m), 7.74-



7.77 (2H, m)


1381
0.87 (9H, s), 1.34-1.41 (2H, m), 1.68-2.10 (7H, m), 2.14 (3H, s),



2.27-2.32 (2H, m), 2.33 (3H, s), 2.74 (3H, s), 2.94-3.18 (4H, m),



3.48-3.55 (1H, m), 4.30 (2H, d, J = 5.4 Hz), 5.12-5.18 (1H, m), 5.51



(1H, s), 6.55 (1H, d, J = 7.9 Hz), 6.67 (1H, d, J = 7.9 Hz), 6.76-6.81



(2H, m), 7.16 (1H, s), 8.16 (1H, s)


1382
0.86 (9H, s), 1.33-1.40 (2H, m), 1.66-1.92 (6H, m), 2.04-2.11 (1H,



m), 2.08 (3H, s), 2.24-2.32 (2H, m), 2.45 (3H, s), 2.69-3.43 (5H,



m), 4.25 (2H, d, J = 4.4 Hz), 4.98-5.06 (1H, brd), 5.76-5.84 (1H,



brd), 6.62 (2H, t, J = 6.4, 13.6 Hz), 6.76-6.85 (2H, m), 7.06 (1H, s),



7.07-7.24 (1H, m), 8.11-8.23 (1H, m), 10.04-10.19 (1H, m)


1383
(CD3OD): 0.89-0.99 (10H, m), 1.48-1.54 (2H, m), 1.77-1.80 (1H,



m), 1.80-1.91 (4H, m), 2.15 (3H, s), 2.30-2.43 (1H, m), 2.43 (3H,



s), 2.44-2.50 (1H, m), 2.64-2.73 (1H, m), 2.91-3.10 (2H, m), 3.22-



3.39 (4H, m), 4.26, (2H, s), 4.95-5.08 (1H, m), 6.63-6.75 (2H, m),



6.78-6.87 (2H, m), 6.90-7.00 (2H, m), 7.95 (1H, s)


1384
0.75-0.98 (11H, m), 1.33-1.50 (2H, m), 1.51-1.67 (1H, m), 1.68-



1.90, (4H, m), 2.09 (3H, s), 2.11-2.33 (6H, m), 2.36-2.58 (4H, m),



2.77-2.92 (1H, m), 2.93-3.16 (2H, m), 3.17-3.30 (1H, m), 4.14-



4.30 (2H, m), 4.90-5.09 (1H, m), 6.36-6.53 (1H, m), 6.53-6.70



(1H, m), 6.70-6.78 (1H, m), 7.04 (1H, s), 7.20-7.30 (2H, m),



7.88(1Hs)


1385
0.69-0.73 (2H, m), 0.81-0.97 (2H, m), 1.23-1.28 (1H, m), 2.14



(3H, s), 2.73 (3H, s), 3.09-3.19 (2H, m), 3.48-3.60 (1H, m), 4.30



(2H, d, J = 5.4 Hz), 5.13-5.23 (1H, m), 5.72 (1H, brs), 6.67 (2H, m),



6.86 (1H, d, J = 7.9 Hz), 6.95 (1H, m), 7.12-7.24 (2H, m), 8.37 (1H,



dd, J = 1.5, 8.1 Hz)


1386
0.68-0.75 (2H, m), 0.93-0.98 (2H, m), 1.25-1.42 (1H, m), 2.16



(3H, s), 2.33 (3H, s), 2.74 (3H, s), 3.04-3.18 (2H, m), 3.48-3.57



(1H, m), 4.32 (2H, d, J = 5.4 Hz), 5.12-5.19 (1H, m), 5.64 (1H, s),



6.55 (1H, d, J = 7.9 Hz), 6.69 (1H, d, J = 7.6 Hz), 6.77 (1H, d,



J = 7.6 Hz), 6.86 (1H, d, J = 7.9 Hz), 7.16 (1H, s), 8.16(1H, s)


1387
0.90 (3H, t, J = 7.4 Hz), 1.56-1.70 (2H, m), 2.14 (2H, t, J = 7.2 Hz),



2.25 (3H, s), 2.46 (3H, s), 2.81-2.87 (1H, m), 2.98-3.10 (1H, m),



3.25-3.34 (1H, m), 4.28 (2H, d, J = 5.9 Hz), 4.93-5.00 (1H, m), 6.06



(1H, bs), 6.57-6.84 (6H. m), 7.82 (1H, bs)












Compound




number

1H NMR: δ(ppm)

MS





1388 E48
δ 0.32-0.47 (4H, m), 1.50-1.61 (1H, m), 1.83-2.00
(APCI)+:



(2H, m), 2.31-2.52 (4H, m), 2.52-2.73 (4H, m), 3.45
[M + H]+ =



(2H, s), 3.76 (3H, s), 3.89-4.06 (3H, m), 5.87 (1H, d,
505.4



J = 14.3 Hz), 6.37 (1H, s), 6.61-6.80 (3H, m), 6.86-



7.00 (2H, m), 7.00-7.13 (2H, m), 7.20 (1H, s) ppm.


1389 E55
δ 1.10-1.35 (4H, m), 1.62-1.82 (4H, m), 2.11 (3H, s),
(ESI)+:



2.36-2.50 (2H, m), 2.70-2.90 (2H, m), 3.73 (3H, s),
[M + H]+ =



3.80-4.00 (5H, m), 4.50-4.65 (2H, m), 5.87 (1H, d,
530.3



J = 14.6 Hz), 6.60-7.25 (9H, m) ppm.


1390 E68
δ 0.88 (9H, s), 1.22-1.46 (7H, m), 1.64-1.77 (4H, m),
(APCI)+:



1.93 (2H, t, J = 10.9 Hz), 2.02 (3H, s), 2.31-2.38 (2H,
[M + H]+ =



m), 2.95-2.99 (2H, m), 3.78 (3H, s), 3.78-3.92 (2H,
544.6



m), 3.95 (1H, d, J = 14.6 Hz), 5.91 (1H, d, J = 14.6 Hz),



6.16 (1H, s), 6.43-6.49 (1H, m), 6.68-6.73 (2H, m),



6.92-7.11 (4H, m), 7.21 (1H, s) ppm.


1391 E69
δ 0.86 (9H, s), 1.33-1.40 (2H, m), 1.84-1.94 (2H, m),
(APCI)+:



2.26-2.33 (2H, m), 2.42 (3H, s), 2.33-2.51 (10H, m),
[M + H]+ =



2.85 (1H, d, J = 15.6 Hz), 2.91-3.05 (1H, m), 3.26-
548.4



3.42 (1H, m), 3.91 (2H, t, J = 6.2 Hz), 5.06 (1H, dd,



J = 4.2, 12.6 Hz), 6.56 (1H, t, J = 8.2 Hz), 6.62-6.73



(2H, m), 6.83-6.94 (2H, m), 7.18 (1H, t, J = 7.4 Hz),



8.08-8.22 (1H, brs), 10.25-10.55 (1H, brs) ppm.


1392 E70
δ 0.87 (9H, s), 1.37-1.45 (2H, m), 1.83-1.94 (2H, m),
(APCI)+:



2.00 (3H, s), 2.29-2.40 (2H, m), 2.43 (3H, s), 2.44-
[M + H]+ =



2.63 (10H, m), 2.83 (1H, d, J = 15.3 Hz), 2.91-3.08
544.5



(1H, m), 3.22-3.41 (1H, m), 3.83 (2H, t, J = 5.9 Hz),



5.09 (1H, dd, J = 4.2, 12.9 Hz), 6.35 (1H, d, J = 8.4 Hz),



6.63-6.69 (2H, m), 6.85 (1H, t, J = 7.4 Hz), 7.07 (1H,



s), 7.16 (1H, t, J = 7.4 Hz), 8.10 (1H, d, J = 6.4 Hz)



ppm.


1393 E71
δ 0.89 (9H, s), 1.42-1.49 (2H, m), 1.88-2.02 (2H, m),
(APCI)+:



2.46-2.58 (4H, m), 2.58-2.78 (8H, m), 3.42 (3H, s),
[M + H]+ =



4.01 (2H, t, J = 6.2 Hz), 6.72 (1H, t, J = 8.4 Hz), 6.93-
490.3/492.3



6.99 (3H, m), 7.04 (1H, dd, J = 2.0, 11.6 Hz), 7.19-



7.25 (2H, m) ppm.


1394 E72
δ 0.89 (9H, s), 1.42-1.53 (2H, m), 1.58-1.82 (4H, m),
(APCI)+:



2.40-2.58 (3H, m), 2.58-2.79 (4H, m), 3.46 (3H, s),
[M + H]+ =



3.81 (3H, s), 3.88-3.97 (3H, m), 5.87 (1H, d,
563.4



J = 14.8 Hz), 6.55 (1H, s), 6.60-6.69 (4H, m), 6.93



(1H, d, J = 11.4 Hz) 6.99-7.12 (4H, m), 7.21 (1H, s)



ppm.


1395 E73
δ 0.88 (9H, s), 1.32-1.46 (2H, m), 1.47-1.83 (2H, m),
(ESI)+:



2.03 (3H, s), 2.30-2.40 (2H, m), 2.40-2.57 (2H, m),
[M + H]+ =



2.57-2.69 (2H, m), 2.80 (2H, t, J = 4.9 Hz), 3.80 (3H,
531.4



s), 3.95-4.08 (2H, m), 5.91-6.01 (2H, m), 6.50 (1H,



d, J = 7.7 Hz), 6.63-7.78 (2H, m), 6.92 (1H, d,



J = 7.9 Hz), 6.92-7.01 (1H, m), 7.06-7.18 (2H, m),



7.21-7.28 (3H, m) ppm.


1396 E74
δ 0.86 (9H, s), 1.33-1.39 (2H, m), 2.09 (3H, s), 2.24-
(ESI)+:



2.37 (6H, m), 3.50-3.60 (4H, m), 3.75 (3H, s), 3.95
[M + H]+ =



(1H, d, J = 14.6 Hz), 4.60 (2H, s), 5.91 (1H, d,
545.4



J = 14.6 Hz), 6.10 (1H, s), 6.51 (1H, d, J = 8.1 Hz), 6.70



(2H, s), 6.88-6.99 (2H, m), 7.01-7.10 (1H, m), 7.20-



7.24 (2H, m) ppm.


1397 E75
δ 0.88 (9H, s), 1.37 (2H, t, J = 8.4 Hz), 2.24-2.37 (6H,
(ESI)+:



m), 3.50-3.60 (4H, m), 3.75 (3H, s), 3.95 (1H, d,
[M + H]+ =



J = 14.6 Hz), 4.60 (2H, s), 5.93 (1H, d, J = 14.6 Hz),
531.5



6.39 (1H, s), 6.61-6.73 (4H, m), 6.93 (1H, d,



J = 7.9 Hz), 7.01-7.10 (1H, m), 7.20-7.24 (2H, m)



ppm.


1398 E76
δ 0.87 (9H, s), 1.30-1.36 (2H, m), 1.86-1.91 (2H,
(ESI)+:



m), 1.99 (3H, s), 2.22-2.28 (6H, m), 2.40-2.45 (2H,
[M + H]+ =



m), 3.34-3.39 (4H, m), 3.77 (3H, s), 3.84-3.90 (3H,
573.5



m), 5.68 (2H, d, J = 14.3 Hz), 6.63-6.69 (3H, m),



6.91 (1H, d, J = 8.4 Hz), 7.01 (1H, s), 7.13-7.16 (2H,



m), 7.30 (1H, d, J = 8.2 Hz), 8.60 (1H, s) ppm.


1399 E77
δ 1.18-1.38 (2H, m), 1.48-1.76 (2H, m), 1.87 (2H, t,
(ESI)+:



J = 10.6 Hz), 2.15 (3H, s), 2.42-2.48 (2H, m), 2.71-
[M + H]+ =



2.88 (4H, m), 2.91-3.01 (1H, m), 3.78 (3H, s), 3.86-
488.4



3.90 (2H, m), 3.95 (1H, d, J = 14.6 Hz), 5.90 (1H, d,



J = 14.6 Hz), 6.68 (2H, brs), 6.79-6.96 (3H, m), 7.02-



7.10 (1H, m), 7.13-7.24 (2H, m) ppm.


1400 E78
δ 2.15 (3H, s), 3.72 (3H, s), 3.75 (3H, s), 3.96 (1H,
(APCI)+:



d, J = 14.6 Hz), 4.50 (2H, s), 5.80 (1H, d, J = 14.6 Hz),
[M + H]+ =



6.12 (1H, s), 6.45-6.51 (2H, m), 6.64 (1H, s), 6.74-
441.2,



6.92, (3H, m), 7.23(1H, s)
443.2


1401 E79
δ 0.42-1.38 (3H, m), 2.16 (3H, s), 2.28-2.66 (4H, m),
(ESI)+:



2.71-3.01 (4H, m), 3.28-3.76 (4H, m), 3.78 (3H, s),
[M + H]+ =



3.96 (1H, d, J = 14.6 Hz), 4.60-4.73 (1H, m), 5.89
488.5



(1H, d, J = 14.6 Hz), 6.15 (1H, d, J = 9.1 Hz), 6.71 (2H,



s), 6.77-6.98 (3H, m), 7.01-7.21 (3H, m) ppm.


1402 E80
δ 0.88 (9H, s), 1.33-1.40 (2H, m), 2.17-2.58 (11H,
(ESI)+:



m), 2.79-2.98 (2H, m), 3.18-3.41 (5H, m), 3.60 (2H,
[M + H]+ =



brs), 3.87 (3H, s), 3.88-4.01 (1H, m), 5.92-6.11 (1H,
557.5



m), 6.78-7.42 (8H, m) ppm.


1403 E82
δ 0.89 (9H, s), 1.35-1.41 (2H, m), 1.64 (2H, brs),
(ESI)+:



1.74-1.84 (2H, m), 2.14 (3H, s), 2.23 (2H, t,
[M + H]+ =



J = 7.4 Hz), 2.28-2.38 (6H, m), 2.54 (2H, t, J = 7.4 Hz),
506.5



3.34 (2H, t, J = 4.9 Hz), 3.59 (2H, t, J = 4.9 Hz), 6.58-



6.78 (4H, m), 6.81-6.92 (1H, m), 7.04-7.09 (3H, m)



ppm.


1404 E83
δ 0.87 (9H, s), 1.30-1.70 (4H, m), 2.09 (3H, s), 2.20-
(ESI)+:



2.50 (10H, m), 3.41 (2H, brs), 3.58 (4H, brs), 3.74
[M + H]+ =



(3H, s), 3.88-3.98 (1H, m), 5.85-5.95 (1H, m), 6.60-
571.5



7.22 (9H, m) ppm.


1405 E84
δ 1.08-1.47 (2H, m), 1.61-1.86 (4H, m), 2.15 (3H, s),
(ESI)+:



2.35-2.48 (2H, m), 2.78-2.84 (2H, m), 2.94-3.11
[M + H]+ =



(2H, m), 3.44-3.62 (1H, m), 3.77 (3H, s), 3.72-3.88
474.5



(1H, m), 3.95 (1H, d, J = 14.6 Hz), 4.01-4.12 (1H, m),



5.89 (1H, d, J = 14.6 Hz), 6.34 (1H, d, J = 4.7 Hz), 6.66-



6.71 (2H, m), 6.76-6.94 (3H, m), 7.01-7.18 (2H, m)



ppm.


1406 E85
δ 1.36-1.55 (6H, m), 1.71-1.80 (2H, m), 1.82-1.96
(ESI)+:



(1H, m), 2.02-2.10 (4H, m), 2.68 (3H, s), 2.97-3.10
[M + H]+ =



(2H, m), 3.40-3.55 (4H, m), 3.63 (3H, s), 3.81 (1H,
513.8



d, J = 14.6 Hz), 5.83 (1H, d, J = 14.6 Hz), 6.42-6.56



(1H, m), 6.61-6.89 (2H, m), 6.95-7.05 (1H, m), 7.17-



7.25 (3H, m), 7.33 (1H, s) ppm.


1407 E86
δ 0.20-0.27 (2H, m), 0.31-0.42 (2H, m), 0.83-1.10
(ESI)+:



(2H, m), 1.44-1.83 (4H, m), 2.02-2.10 (1H, m), 2.13
[M + H]+ =



(3H, s), 2.29-2.58 (6H, m), 2.71-2.89 (2H, m), 3.55-
527.7



3.74 (2H, m), 3.75 (3H, s), 3.95 (1H, d, J = 14.6 Hz),



4.50-4.60 (1H, m), 5.90 (1H, d, J = 14.6 Hz), 6.48-



6.75 (3H, m), 6.79-7.22 (5H, m) ppm.


1408 E87
δ 0.55-0.64 (2H, m), 0.71-0.81 (2H, m), 1.11-1.24
(ESI)+:



(2H, m), 1.53-1.62 (2H, m), 1.70-1.91 (1H, m), 2.15
[M + H]+ =



(3H, s), 2.62-2.84 (4H, m), 3.12-3.25 (4H, m), 3.86
527.6



(3H, s), 3.90-4.15 (5H, m), 5.67 (1H, d, J = 14.6 Hz),



6.61-6.75 (2H, m), 6.76-6.94 (2H, m), 7.07-7.17



(2H, m), 7.35-7.43 (1H, m), 7.47 (1H, s) ppm.


1409 E110
δ 1.91-1.99 (1H, m), 3.32 (2H, s), 3.52-3.85 (8H,
(ESI)+:



m), 3.93 (1H, d, J = 14.6 Hz), 5.81 (1H, d, J = 14.6 Hz),
[M + H]+ =



6.59 (2H, s), 6.80-7.10 (4H, m), 7.10-7.38, (2H, m)
530.2,



ppm
532.2


1410 E111
δ 3.47 (4H, s), 3.67 (6H, s), 3.79 (3H, s), 3.87 (2H,
(ESI)+:



s), 3.95 (1H, d, J = 14.6 Hz), 5.85 (1H, d, J = 14.6 Hz),
[M + H]+ =



6.14 (1H, s), 6.60-6.70 (2H, m), 6.90-7.02 (3H, m),
458.1



7.20-7.38 (2H, m) ppm


1411 E112
δ 1.28 (1H, s), 2.71 (2H, t, J = 5.3 Hz), 3.64 (2H, t,
(ESI)+:



J = 5.3 Hz), 3.81 (3H, s), 3.95 (2H, s), 4.00 (1H, d,
[M + H]+ =



J = 14.7 Hz), 5.74 (1H, d, J = 14.7 Hz), 6.66 (1H, d,
430.1



J = 8.3 Hz), 6.78 (1H, d, J = 8.3 Hz), 7.02-7.10 (2H, m),



7.22-7.38(3H, m) ppm


1412 E116
(270 MHz, d4-MeOH): δ 0.37-0.48 (2H, m), 0.70-
(APCI)+:



0.81 (2H, m), 1.02-1.18 (1H, m), 1.86-2.11 (4H, m),
[M + H]+ =



2.22 (3H, s), 2.49-2.64 (1H, m), 3.01 (2H, d, J = 7.4
454.3/456.3



Hz), 3.17-3.30 (2H, m), 3.42 (3H, s), 3.49-3.76 (2H,



m), 4.30 (2H, s), 7.06-7.17 (5H, m), 7.23-7.27 (2H,



m)ppm.


1413 E117
δ 0.91 (9H, s), 1.48-1.58 (2H, m), 1.60-1.79 (4H,
(ESI)+:



m), 2.16 (3H, s), 2.22-2.35 (1H, m), 2.51-2.65 (2H,
[M + H]+ =



m), 2.71-2.82 (2H, m), 3.11-3.27 (2H, m), 3.43 (3H,
484.4/486.4



s), 4.25 (2H, d, J = 5.5 Hz), 6.52-6.63 (1H, m), 6.95-



7.09 (5H, m), 7.20 (2H, d, J = 8.6 Hz) ppm.


1414 E118
δ 0.87 (9H, s), 1.34-1.41 (2H, m), 1.62-1.96 (6H,
(APCI)+:



m), 2.04-2.19 (1H, m), 2.17 (3H, s), 2.26-2.33 (2H,
[M + H]+ =



m), 2.94-2.99 (2H, m), 3.48 (3H, s), 4.34 (2H, d,
518.4



J = 5.4 Hz), 6.95 (2H, d, J = 1.0 Hz), 7.14 (2H, d,



J = 8.2 Hz), 7.19 (1H, s), 7.49 (2H, d, J = 8.4 Hz) ppm.


1415 E119
δ 0.64-0.73 (2H, m), 0.90-1.00 (2H, m), 1.25-1.40
(ESI)+:



(1H, m), 2.12 (3H, s), 2.55 (3H, s), 2.80-2.90 (1H,
[M + H]+ =



m), 2.90-2.94 (1H, m), 3.45 (1H, s), 4.30 (2H, d,
416.3



J = 5.4 Hz), 5.09-5.22 (1H, m), 5.77-5.88 (1H, m),



6.60-6.73 (2H, m), 6.86-6.93 (2H, m), 7.01 (1H, s),



7.14-7.24 (1H, m), 7.76 (1H, dd, J = 1.2, 7.9 Hz) ppm.


1416 E120
δ 0.87 (9H, s), 1.36-1.45 (2H, m), 1.73-1.82 (2H, m),
(APCI)+:



1.90-2.07 (2H, m), 2.11 (3H, s), 2.36-2.42 (2H, m), 2.55
[M + H]+ =



(3H, s), 2.80-2.90 (1H, m), 2.90-2.98 (1H, m), 3.10-3.16
543.4



(2H, m), 4.28 (2H, d, J = 5.2 Hz), 5.11-5.19 (1H, m), 5.72-



5.82 (1H, m), 6.49 (2H, dd, J = 1.5, 6.7 Hz), 6.61-6.72 (2H,



m), 6.80-6.97 (2H, m), 7.00 (1H, s), 7.13-7.25 (1H, m),



7.77 (1H, dd, J = 1.5, 7.9 Hz), 8.15 (2H, dd, J = 1.7, 5.2 Hz)



ppm.


1417 E121
δ 0.88 (9H, s), 1.37-1.53 (5H, m), 1.63-1.70 (2H,
(APCI)+:



m), 2.11 (3H, s), 2.45 (3H, s), 2.63-3.46 (8H, m),
[M + H]+ =



2.87-2.94 (2H, m), 4.23 (2H, brd), 5.08 (2H, d,
632.4



J = 7.9 Hz), 4.96-5.11 (1H, m), 6.60 (2H, t, J = 7.9,



15.1 Hz), 6.81-6.86 (2H, m), 6.95 (2H, d, J = 7.9 Hz),



7.04 (1H, s), 7.12-7.33 (4H, m), 8.22 (1H, dd, J = 1.2,



7.9 Hz) ppm.


1418 E123
δ 0.64-0.71 (2H, m), 0.89-0.95 (2H, m), 1.33-1.39
(APCI)+:



(1H, m), 2.10 (3H, s), 2.43 (3H, s), 2.74-2.81 (1H,
[M + H]+ =



m), 2.92-3.04 (1H, m), 3.07-3.26 (1H, m), 4.18-4.34
415.3



(2H, m), 4.97-5.05 (1H, m), 6.60 (2H, d, J = 7.9 Hz),



6.79-6.84 (2H, m), 7.05 (1H, s), 7.11 (1H, t, J = 7.4,



14.8 Hz), 7.96-8.21 (1H, brs), 10.10-10.60 (1H, brs)



ppm.


1419 E125
δ 1.13 (6H, d, J = 6.9 Hz), 2.15 (3H, s), 2.30-2.40 (1H,
(ESI)+:



m), 2.48 (3H, s), 2.86-3.03 (2H, m), 3.20-3.38 (1H,
[M + H]+ =



m), 4.20-4.36 (2H, m), 5.04-5.11 (1H, m), 5.63 (1H,
451.2,



s), 6.53 (1H, d, J = 8.2 Hz), 6.62 (1H, d, J = 7.9 Hz),
453.2



6.70-6.90 (2H, m), 7.10 (1H, s), 8.21 (1H, s), 9.39



(1H, s) ppm.








Claims
  • 1-73. (canceled)
  • 74. A method of treatment of a disorder selected among dysmenorrhoea, pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure, comprising the administration to a person in need of such treatment of an effective amount of a compound according to general formula 1a, or a compound which is a tautomer or a pharmaceutically acceptable salt thereof,
  • 75. The method of claim 74, wherein G is selected among:
  • 76. The method of claim 74, wherein G is selected among:
  • 77. The method of claim 74, wherein at least one of R1, R2 and R3 is other than hydrogen.
  • 78. The method of claim 77, wherein one of R1, R2 and R3 is selected among methyl, chlorine and fluorine, and the others are hydrogen
  • 79. The method of claim 74, wherein W is NH.
  • 80. The method of claim 74, wherein R4 is alkyl.
  • 81. The method of claim 74, wherein d is 2 and e is 2.
  • 82. The method of claim 74, wherein R13 is alkyl.
  • 83. The method of claim 74, wherein n is 0.
  • 84. The method of claim 74, wherein R2 is H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(═O) and n is 0, as shown in formula 18a:
  • 85. The method of claim 74, wherein X is C(═O), n is 0 and R4 is a piperidine where d is 2 and e is 2, as shown in formula 19a:
  • 86. The method of claim 74, wherein R2 is H and W is NH as shown in formula 20a:
  • 87. The method of claim 74, wherein R2 is H, W is NH and X is C(═O) as shown in formula 21a:
  • 88. The method of claim 74, wherein X is C(═O) as shown in formula 22a:
  • 89. The method of claim 74, wherein R2 and R3 are both H, W is NH and X is C(═O) as shown in formula 23a:
  • 90. The method of claim 74, wherein R2 and R3 are both H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(═O) and n is 0 as shown in formula 24a:
  • 91. The method of claim 74, wherein the compound is selected among the group consisting of: 1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo-[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-(2-methyl-4,5-dihydro-1-oxa-3,6-diaza-benzo[e]azulene-6-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 3-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 3-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo-[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;1-(3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4-[(4-chloro-phenyl)-methyl-carbamoyl]-2-methyl-benzylamide;1-Cyclopropyl-methyl-piperidine-4-carboxylic acid 2-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;1-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-[(4-chloro-phenyl)-methyl-carbamoyl]-2-methyl-benzylamide;Cyclobutanecarboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclobutanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclobutanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclopentanecarboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclopentanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclopentanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclopropanecarboxylic acid 2-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclopropanecarboxylic acid 2-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclopropanecarboxylic acid 3-chloro-4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclopropanecarboxylic acid 3-chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;Cyclopropanecarboxylic acid 4-(3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-methyl-benzylamide;Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-fluoro-benzylamide;Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-3-methyl-benzylamide;N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-propionamide;N-[-2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-2,2-dimethyl-propionamide;N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-isobutyramide;N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-butyramide;N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-propionamide;N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-2,2-dimethyl-propionamide;N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-isobutyramide;N-[4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-butyramide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-propionamide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-2,2-dimethyl-propionamide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-isobutyramide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-acetamide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-butyramide;N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-formamide;N-[4-(6-Chloro-3-ethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzyl]-propionamide;Cyclopropane-carboxylic acid 4-(6-chloro-3-ethyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide;N-[2-Fluoro-4-(6-fluoro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-propionamide;N-[2-Fluoro-4-(6-fluoro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzyl]-isobutyramide;Cyclopropanecarboxylic acid 2-fluoro-4-(6-fluoro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; andN-[4-(9-Chloro-2-methyl-4,5-dihydro-1H-1,3,6-triaza-benzo[e]azulene-6-carbonyl)-2-methyl-benzyl]-isobutyramide.
Priority Claims (1)
Number Date Country Kind
04104062.7 Aug 2004 EP regional
Parent Case Info

Priority is claimed from EP patent application number 04104062 and U.S. patent application No. 60/603,557, both filed 24 Aug. 2004.

Provisional Applications (1)
Number Date Country
60603557 Aug 2004 US
Divisions (1)
Number Date Country
Parent 11659798 Jan 2008 US
Child 13329476 US